


**CUMULATIVE
SUPPLEMENT 8**
August 2023



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

43rd EDITION

Department of Health and Human Services
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

43rd EDITION

**Cumulative Supplement 8
August 2023**

CONTENTS

	<i>PAGE</i>
Contents	
1.0 INTRODUCTION.....	v
1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2 CUMULATIVE SUPPLEMENT CONTENT	vi
1.3 APPLICANT NAME CHANGES.....	vii
1.4 LEVOTHYROXINE SODIUM	viii
1.5 AVAILABILITY OF THE EDITION.....	ix
1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7 CUMULATIVE SUPPLEMENT LEGEND.....	xi
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Products Designations and Approvals List	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

43rd EDITION

**CUMULATIVE SUPPLEMENT 8
AUGUST 2023**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPRA) of any changes or corrections. The DOBPRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME (NEW ABBREVIATED NAME)</u>
ALEOR DERMACEUTICALS LTD (ALEOR DERMACEUTICALS)	ALEMBIC PHARMACEUTICALS LTD (ALEMBIC)
ALLERGAN (ALLERGAN)	ABBVIE INC (ABBVIE)
ALLERGAN HOLDINGS UNLTD CO (ALLERGAN HOLDINGS)	ABBVIE INC (ABBVIE)
ALLERGAN INC (ALLERGAN)	ABBVIE INC (ABBVIE)
ALLERGAN SALES LLC (ALLERGAN)	ABBIE (ABBVIE)

ALLERGAN SALES LLC (ALLERGAN)	ABBVIE INC (ABBVIE)
EMCURE PHARMACEUTICALS LTD (EMCURE PHARMS)	AVET LIFESCIENCES LTD (AVET LIFESCIENCES)
EMCURE PHARMACEUTICALS LTD (EMCURE PHARMS LTD)	AVET LIFESCIENCES LTD (AVET LIFESCIENCES)
EPIC PHARMA INC (EPIC PHARMA)	EPIC PHARMA LLC (EPIC PHARMA LLC)
EPIC PHARMA INC (EPIC PHARMA INC)	EPIC PHARMA LLC (EPIC PHARMA LLC)
HERITAGE PHARMA LABS INC (HERITAGE PHARMA)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
HERITAGE PHARMA LABS INC DBA AVET PHARMACEUTICALS LABS INC (HERITAGE PHARMA AVET)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
MAYNE PHARMA INC (MAYNE PHARMA INC)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)
MAYNE PHARMA INTERNATIONAL PTY LTD (MAYNE PHARMA)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)
MAYNE PHARMA INTERNATIONAL PTY LTD (MAYNE PHARMA INTL)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)
MAYNE PHARMA LLC (MAYNE PHARMA)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)
NEXUS PHARMACEUTICALS INC (NEXUS PHARMS)	NEXUS PHARMACEUTICALS LLC (NEXUS)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2,

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange

² Please consult the Active Section of the Orange Book for information on other strengths.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at

<http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of

product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2022	MAR 2023	JUN 2023	SEP 2023	DEC 2024
DRUG PRODUCTS	21983	22398	22632		
LISTED SINGLE SOURCE	2718 (12.4%)	2759 (12.3%)	2779 (12.3%)		
MULTISOURCE	19265 (87.6%)	19639 (87.7%)	19853 (87.7%)		
THERAPEUTICALLY EQUIVALENT	19165 (87.2%)	19554 (87.3%)	19781 (87.4%)		
NOT THERAPEUTICALLY EQUIVALENT	100 (0.5%)	85 (0.4%)	72 (0.3%)		
EXCEPTIONS ⁴	46 (0.2%)	46 (0.2%)	46 (0.2%)		
NEW MOLECULAR ENTITIES APPROVED	8	19	11		
NUMBER OF APPLICANTS	1211	1222	1217		

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABIRATERONE ACETATE

TABLET;ORAL
ABIRATERONE ACETATE

>A> AB	DR REDDYS	500MG	A208416	002	Sep 01, 2023	Aug NEWA
AB	FLORIDA	500MG	A215086	001	Mar 23, 2023	Mar NEWA
AB	TEVA PHARMS USA	500MG	A210726	001	Jan 26, 2023	Jan NEWA

>A> ABIRATERONE ACETATE; NIRAPARIB TOSYLATE

>A>	TABLET;ORAL					
>A>	AKEEGA					
>A>	+ JANSSEN BIOTECH	500MG;EQ 50MG BASE	N216793	001	Aug 11, 2023	Aug NEWA
>A>	+!	500MG;EQ 100MG BASE	N216793	002	Aug 11, 2023	Aug NEWA

ACARBOSE

TABLET;ORAL
ACARBOSE

@ DASH PHARMS	25MG	A091053	001	Jan 06, 2011	Feb CAHN
@	50MG	A091053	002	Jan 06, 2011	Feb CAHN
@	100MG	A091053	003	Jan 06, 2011	Feb CAHN

ACETAMINOPHEN

SOLUTION;INTRAVENOUS
ACETAMINOPHEN

AP	HQ SPCLT PHARMA	1GM/100ML (10MG/ML)	A215403	001	May 03, 2023	Apr NEWA
AP	WOCKHARDT BIO AG	1GM/100ML (10MG/ML)	A205746	001	Apr 18, 2023	Apr NEWA
@	ZYDUS PHARMS	1GM/100ML (10MG/ML)	A216467	001	Oct 25, 2022	Mar DISC

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET;ORAL
APADAZ

+ @ KVK TECH INC	325MG;EQ 4.08MG BASE	N208653	002	Jan 04, 2019	Mar DISC
+ @	325MG;EQ 6.12MG BASE	N208653	001	Feb 23, 2018	Mar DISC
+ @	325MG;EQ 8.16MG BASE	N208653	003	Jan 04, 2019	Mar DISC
+ @ ZEVRA THERAP	325MG;EQ 4.08MG BASE	N208653	002	Jan 04, 2019	Jun CAHN
+ @	325MG;EQ 6.12MG BASE	N208653	001	Feb 23, 2018	Jun CAHN
+ @	325MG;EQ 8.16MG BASE	N208653	003	Jan 04, 2019	Jun CAHN

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL
BUTALBITAL AND ACETAMINOPHEN

>D> AA	ALVOGEN	300MG;50MG	A207635	001	Jun 05, 2017	Aug DISC
>A>	@	300MG;50MG	A207635	001	Jun 05, 2017	Aug DISC
AA	SENORES PHARMS	300MG;50MG	A214088	001	Apr 07, 2022	Jan CAHN
AA		325MG;25MG	A214088	002	Apr 07, 2022	Jan CAHN
AA		325MG;50MG	A214088	003	Apr 07, 2022	Jan CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

@ NOSTRUM LABS INC	300MG;15MG	A088629	002	Mar 06, 1985	Apr DISC
@	300MG;30MG	A088629	003	Mar 06, 1985	Apr DISC
+ @	300MG;60MG	A088629	001	Mar 06, 1985	Apr DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>D> AA	VISTAPHARM	325MG/15ML;7.5MG/15ML	A200343	001	Jan 25, 2012	Aug DISC
>A>	@	325MG/15ML;7.5MG/15ML	A200343	001	Jan 25, 2012	Aug DISC

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ SUN PHARM INDs INC	325MG;5MG	A090118	001	Dec 23, 2008	Jun DISC
@	325MG;7.5MG	A090118	002	Dec 23, 2008	Jun DISC
@	325MG;10MG	A090118	003	Dec 23, 2008	Jun DISC

ACETAMINOPHEN; IBUPROFEN

>D>	TABLET;ORAL					
>D>	COMBOGESIC					
>D>	+! AFT PHARMS LTD	325MG;97.5MG	N 209471	001	Mar 01, 2023	Aug DISC
>A>	+ @	325MG;97.5MG	N 209471	001	Mar 01, 2023	Aug DISC
	+!	325MG;97.5MG	N 209471	001	Mar 01, 2023	Mar NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL					
OXYCODONE AND ACETAMINOPHEN					
@ DR REDDYS LABS SA	325MG;2.5MG	A 090177	001	Oct 20, 2008	Apr CAHN
@	325MG;5MG	A 090177	002	Oct 20, 2008	Apr CAHN
@	325MG;7.5MG	A 090177	003	Oct 20, 2008	Apr CAHN
@	325MG;10MG	A 090177	004	Oct 20, 2008	Apr CAHN
@	500MG;7.5MG	A 090177	005	Oct 20, 2008	Apr CAHN
@	650MG;10MG	A 090177	006	Oct 20, 2008	Apr CAHN
@ MAYNE PHARMA INC	325MG;2.5MG	A 090177	001	Oct 20, 2008	Apr DISC
@	325MG;5MG	A 090177	002	Oct 20, 2008	Apr DISC
@	325MG;7.5MG	A 090177	003	Oct 20, 2008	Apr DISC
@	325MG;10MG	A 090177	004	Oct 20, 2008	Apr DISC

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL					
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN					
AB ! AMNEAL PHARMS	325MG;37.5MG	A 090485	001	Dec 09, 2009	Mar CHRS
ULTRACET					
+ @ JANSSEN PHARMS	325MG;37.5MG	N 021123	001	Aug 15, 2001	Mar DISC

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL					
ACETAZOLAMIDE					
AB INDICUS PHARMA	500MG	A 090779	001	Jul 14, 2011	Feb CMFD
TABLET;ORAL					
ACETAZOLAMIDE					
AB AARKISH PHARMS NJ	125MG	A 217197	001	May 09, 2023	Apr NEWA
AB	250MG	A 217197	002	May 09, 2023	Apr NEWA
@ BRECKENRIDGE	125MG	A 207503	001	Apr 30, 2020	Jan DISC
@	250MG	A 207503	002	Apr 30, 2020	Jan DISC
AB ZYDUS	125MG	A 211069	001	Apr 04, 2023	Mar NEWA
AB	250MG	A 211069	002	Apr 04, 2023	Mar NEWA

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC					
ACETIC ACID					
@ CHARTWELL RX	2%	A 040166	001	Jul 26, 1996	Jan CAHN

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC					
HYDROCORTISONE AND ACETIC ACID					
@ COSETTE	2%;1%	A 040609	001	Feb 06, 2006	Jun DISC
AT +! TARO	2%;1%	A 088759	001	Mar 04, 1985	Jun CHRS
AT +	2%;1%	A 088759	001	Mar 04, 1985	Jun CRLD

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS					
ACETYLCYSTEINE					
AP STERISCIENCE	6GM/30ML (200MG/ML)	A 217182	001	Apr 19, 2023	Apr NEWA

ACYCLOVIR

CAPSULE;ORAL					
ACYCLOVIR					
@ AUROBINDO PHARMA USA	200MG	A 074727	001	Apr 22, 1997	May CAHN
CREAM;TOPICAL					
ACYCLOVIR					
AB ZYDUS LIFESCIENCES	5%	A 206770	001	Feb 28, 2023	Feb NEWA
SUSPENSION;ORAL					
ACYCLOVIR					
>A> AB CHARTWELL RX	200MG/5ML	A 212718	001	Apr 23, 2020	Aug CAHN
>D> AB HERITAGE PHARMS INC	200MG/5ML	A 212718	001	Apr 23, 2020	Aug CAHN
AB MSN	200MG/5ML	A 217393	001	Mar 09, 2023	Mar NEWA
AB ! NOVITIUM PHARMA	200MG/5ML	A 212252	001	Jul 10, 2020	May CHRS

SUSPENSION;ORAL

ZOVIRAX

+ @ MYLAN

200MG/5ML

N 019909 001 Dec 22, 1989 May DISC

TABLET;ORAL

ACYCLOVIR

@ AUROBINDO PHARMA USA

400MG

A 075211 001 Sep 28, 1998 Apr CAHN

@

800MG

A 075211 002 Sep 28, 1998 Apr CAHN

ADAPALENE

GEL;TOPICAL

ADAPALENE

AB

ENCUBE ETHICALS

0.3%

A 200298 001 Jun 14, 2012 Apr CMFD

ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

>D>

@ ENCUBE

0.1%;2.5%

A 206164 001 May 23, 2018 Aug CMFD

>A> AB

0.1%;2.5%

A 206164 001 May 23, 2018 Aug CMFD

ALBENDAZOLE

TABLET;ORAL

ALBENDAZOLE

@ CHARTWELL RX

200MG

A 211636 001 Jun 10, 2020 May CAHN

ALBUTEROL SULFATE

SOLUTION;INHALATION

ACCUNEB

+ @ MYLAN SPECIALITY LP

EQ 0.021% BASE

N 020949 002 Apr 30, 2001 Jun DISC

ALBUTEROL SULFATE

AN

! RITEDOSE CORP

EQ 0.021% BASE

A 214531 001 Dec 28, 2021 Jun CHRS

AN

SENTISS

EQ 0.5% BASE

A 074543 001 Jan 15, 1998 Jul CAHN

TABLET;ORAL

ALBUTEROL SULFATE

AB

DASH PHARMS NATCO

EQ 2MG BASE

A 072894 002 Jan 17, 1991 Feb CAHN

AB

!

EQ 4MG BASE

A 072894 001 Jan 17, 1991 Feb CAHN

ALBUTEROL SULFATE; BUDESONIDE

AEROSOL, METERED;INHALATION

AIRSUPRA

+! ASTRAZENECA

EQ 90MCG BASE/INH;80MCG/INH

N 214070 001 Jan 10, 2023 Feb CAHN

+! BOND

EQ 90MCG BASE/INH;80MCG/INH

N 214070 001 Jan 10, 2023 Jan NEWA

ALENDRONATE SODIUM

SOLUTION;ORAL

ALENDRONATE SODIUM

AA

! HIKMA

EQ 70MG BASE/75ML

A 090520 001 Feb 25, 2013 May CTEC

AA

NOVITIUM PHARMA

EQ 70MG BASE/75ML

A 214512 001 May 11, 2023 May NEWA

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

AB

ACCORD HLTHCARE

300MG

A 203154 002 May 06, 2013 Jul CHRS

AB

HETERO LABS LTD V

100MG

A 217748 001 Aug 03, 2023 Jul NEWA

AB

300MG

A 217748 002 Aug 03, 2023 Jul NEWA

AB

! UNICHEM

300MG

A 211820 002 Mar 12, 2019 Jul CHRS

ALVIMOPAN

CAPSULE;ORAL

ALVIMOPAN

>A> AB

HIKMA

12MG

A 217753 001 Aug 31, 2023 Aug NEWA

AB

PAR PHARM

12MG

A 216843 001 Jan 24, 2023 Jan NEWA

AB

! WATSON LABS TEVA

12MG

A 208295 001 Dec 19, 2019 Jun CHRS

ENTEREG

+ @ CUBIST PHARMS

12MG

N 021775 001 May 20, 2008 Jun DISC

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

AB

STRIDES PHARMA

100MG

A 209047 001 Jun 07, 2017 Feb CTEC

	SYRUP;ORAL AMANTADINE HYDROCHLORIDE				
AA	! AUROBINDO PHARMA USA 50MG/5ML	A074170	001	Oct 28, 1994	Jul CAHN
	TABLET;ORAL AMANTADINE HYDROCHLORIDE				
AB	STRIDES PHARMA 100MG	A209035	001	Jun 09, 2017	Feb CTEC
	<u>AMIFOSTINE</u>				
	INJECTABLE;INJECTION AMIFOSTINE				
@	SUN PHARM 500MG/VIAL	A077126	001	Mar 14, 2008	Jul DISC
	ETHYOL				
+!	CLINIGEN 500MG/VIAL	N020221	001	Dec 08, 1995	Jul CTEC
	<u>AMIKACIN SULFATE</u>				
	INJECTABLE;INJECTION AMIKACIN SULFATE				
!	HIKMA EQ 50MG BASE/ML	A063313	001	Apr 11, 1994	Feb CTEC
	<u>AMINO ACIDS</u>				
	INJECTABLE;INJECTION FREAMINE HBC 6.9%				
@	B BRAUN 6.9% (6.9GM/100ML)	N016822	006	May 17, 1983	Jan DISC
	FREAMINE III 10%				
@	B BRAUN 10% (10GM/100ML)	N016822	005		Jan DISC
	FREAMINE III 8.5%				
@	B BRAUN 8.5% (8.5GM/100ML)	N016822	004		Jan DISC
	HEPATAMINE 8%				
@	B BRAUN 8% (8GM/100ML)	N018676	001	Aug 03, 1982	Jan DISC
	<u>AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE</u>				
	INJECTABLE;INJECTION PROCALAMINE				
@	B BRAUN 3%;26MG/100ML;3GM/100ML;54MG/100ML N018582 001 May 08, 1982				Jan DISC
	;41MG/100ML;150MG/100ML;200MG/100M				
	L;120MG/100ML				
	<u>AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE</u>				
	INJECTABLE;INJECTION FREAMINE III 8.5% W/ ELECTROLYTES				
@	B BRAUN 8.5%;110MG/100ML;230MG/100ML;10MG/ N016822 007 Jul 01, 1988				Jan DISC
	100ML;440MG/100ML;690MG/100ML				
	<u>AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE</u>				
	INJECTABLE;INJECTION FREAMINE III 3% W/ ELECTROLYTES				
@	B BRAUN 3%;54MG/100ML;40MG/100ML;150MG/100 N016822 003				Jan DISC
	ML;200MG/100ML;120MG/100ML				
	<u>AMINOCAPROIC ACID</u>				
	SOLUTION;ORAL AMINOCAPROIC ACID				
AA	TARO 0.25GM/ML	A214458	001	Mar 24, 2023	May CAHN
AA	TARO PHARMS 0.25GM/ML	A214458	001	Mar 24, 2023	Mar NEWA
	@ VISTAPHARM 0.25GM/ML	A212814	001	Feb 26, 2020	Mar DISC
	<u>AMINOPHYLLINE</u>				
	TABLET;ORAL AMINOPHYLLINE				
@	CHARTWELL MOLECULAR 100MG	A084588	001		Jul CAHN
@	200MG	A084588	002		Jul CAHN
	<u>AMIODARONE HYDROCHLORIDE</u>				
	TABLET;ORAL AMIODARONE HYDROCHLORIDE				
AB	CHARTWELL RX 100MG	A077069	003	Oct 04, 2016	Jun CAHN
AB	200MG	A077069	001	Apr 08, 2005	Jun CAHN
AB	400MG	A077069	002	Apr 08, 2005	Jun CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

>D>	AB	GRAVITI PHARMS	10MG	A217411	001	May 19, 2023	Aug CAHN
	AB		10MG	A217411	001	May 19, 2023	May NEWA
>D>	AB		25MG	A217411	002	May 19, 2023	Aug CAHN
	AB		25MG	A217411	002	May 19, 2023	May NEWA
>D>	AB		50MG	A217411	003	May 19, 2023	Aug CAHN
	AB		50MG	A217411	003	May 19, 2023	May NEWA
>D>	AB		75MG	A217411	004	May 19, 2023	Aug CAHN
	AB		75MG	A217411	004	May 19, 2023	May NEWA
>D>	AB		100MG	A217411	005	May 19, 2023	Aug CAHN
	AB		100MG	A217411	005	May 19, 2023	May NEWA
>D>	AB		150MG	A217411	006	May 19, 2023	Aug CAHN
	AB		150MG	A217411	006	May 19, 2023	May NEWA
>A>	AB	RISING	10MG	A217411	001	May 19, 2023	Aug CAHN
>A>	AB		25MG	A217411	002	May 19, 2023	Aug CAHN
>A>	AB		50MG	A217411	003	May 19, 2023	Aug CAHN
>A>	AB		75MG	A217411	004	May 19, 2023	Aug CAHN
>A>	AB		100MG	A217411	005	May 19, 2023	Aug CAHN
>A>	AB		150MG	A217411	006	May 19, 2023	Aug CAHN
AB	RUBICON		10MG	A215376	001	May 01, 2023	Apr NEWA
AB			25MG	A215376	002	May 01, 2023	Apr NEWA
AB			50MG	A215376	003	May 01, 2023	Apr NEWA
AB			75MG	A215376	004	May 01, 2023	Apr NEWA
AB			100MG	A215376	005	May 01, 2023	Apr NEWA
AB			150MG	A215376	006	May 01, 2023	Apr NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

LIMBITROL

+ @	CHARTWELL RX	EQ 12.5MG BASE;5MG	N016949	001		Mar CAHN
+ @	CHARTWELL RX	EQ 25MG BASE;10MG	N016949	002		Mar CAHN

AMLODIPINE BENZOATE

SUSPENSION;ORAL

AMLODIPINE BENZOATE

AB	@ AMNEAL	EQ 1MG BASE/ML	A215035	001	Jun 13, 2023	Jun DISC
	KATERZIA	EQ 1MG BASE/ML	A215035	001	Jun 13, 2023	Jun NFTG
AB	+! AZURITY	EQ 1MG BASE/ML	N211340	001	Jul 08, 2019	Jun CTEC
AB	+!	EQ 1MG BASE/ML	N211340	001	Jul 08, 2019	Jun CFTG

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB	COREPHARMA	EQ 2.5MG BASE	A076719	001	May 23, 2007	Feb CAHN
AB		EQ 5MG BASE	A076719	002	May 23, 2007	Feb CAHN
AB		EQ 10MG BASE	A076719	003	May 23, 2007	Feb CAHN

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

@ SOFIE		18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667	001	Apr 22, 2015	May DISC
---------	--	--------------------------------------	---------	-----	--------------	----------

AMOXICILLIN

FOR SUSPENSION;ORAL

AMOXICILLIN

@ CHARTWELL RX		125MG/5ML	A062059	001		Jan CAHN
@		250MG/5ML	A062059	002		Jan CAHN

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

ADZENYS XR-ODT

AB	+	NEOS THERAPS	EQ 3.1MG BASE	N204326	001	Jan 27, 2016	Jun CFTG
AB	+		EQ 6.3MG BASE	N204326	002	Jan 27, 2016	Jun CFTG
AB	+		EQ 9.4MG BASE	N204326	003	Jan 27, 2016	Jun CFTG
AB	+		EQ 12.5MG BASE	N204326	004	Jan 27, 2016	Jun CFTG
AB	+		EQ 15.7MG BASE	N204326	005	Jan 27, 2016	Jun CFTG
AB	+		EQ 18.8MG BASE	N204326	006	Jan 27, 2016	Jun CFTG

**TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL
AMPHETAMINE**

AB	ACTAVIS LABS FL INC	EQ 3.1MG BASE	A209253	001	Jun 22, 2023	Jun NFTG
AB		EQ 6.3MG BASE	A209253	002	Jun 22, 2023	Jun NFTG
AB		EQ 9.4MG BASE	A209253	003	Jun 22, 2023	Jun NFTG
AB		EQ 12.5MG BASE	A209253	004	Jun 22, 2023	Jun NFTG
AB		EQ 15.7MG BASE	A209253	005	Jun 22, 2023	Jun NFTG
AB		EQ 18.8MG BASE	A209253	006	Jun 22, 2023	Jun NFTG

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ANI PHARMS	2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Feb CMFD
AB	ASCENT PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A214959	001	Sep 29, 2021	Feb CTNA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A214959	002	Sep 29, 2021	Feb CTNA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A214959	003	Sep 29, 2021	Feb CTNA
AB		5MG;5MG;5MG;5MG	A214959	004	Sep 29, 2021	Feb CTNA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A214959	005	Sep 29, 2021	Feb CTNA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A214959	006	Sep 29, 2021	Feb CTNA
AB	GRANULES	1.25MG;1.25MG;1.25MG;1.25MG	A217027	001	Jan 23, 2023	Feb CTNA
AB		1.25MG;1.25MG;1.25MG;1.25MG	A217027	001	Jan 23, 2023	Jan NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A217027	002	Jan 23, 2023	Feb CTNA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A217027	002	Jan 23, 2023	Jan NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A217027	003	Jan 23, 2023	Feb CTNA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A217027	003	Jan 23, 2023	Jan NEWA
AB		5MG;5MG;5MG;5MG	A217027	004	Jan 23, 2023	Feb CTNA
AB		5MG;5MG;5MG;5MG	A217027	004	Jan 23, 2023	Jan NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A217027	005	Jan 23, 2023	Feb CTNA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A217027	005	Jan 23, 2023	Jan NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A217027	006	Jan 23, 2023	Jan NEWA
AB	LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A214403	001	Nov 26, 2021	Feb CMFD
AB	@	1.25MG;1.25MG;1.25MG;1.25MG	A214403	001	Nov 26, 2021	Feb CTNA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A214403	002	Nov 26, 2021	Feb CMFD
AB	@	2.5MG;2.5MG;2.5MG;2.5MG	A214403	002	Nov 26, 2021	Feb CTNA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A214403	003	Nov 26, 2021	Feb CMFD
AB	@	3.75MG;3.75MG;3.75MG;3.75MG	A214403	003	Nov 26, 2021	Feb CTNA
AB		5MG;5MG;5MG;5MG	A214403	004	Nov 26, 2021	Feb CMFD
AB	@	5MG;5MG;5MG;5MG	A214403	004	Nov 26, 2021	Feb CTNA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A214403	005	Nov 26, 2021	Feb CMFD
AB	@	6.25MG;6.25MG;6.25MG;6.25MG	A214403	005	Nov 26, 2021	Feb CTNA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A214403	006	Nov 26, 2021	Feb CMFD
AB	@	7.5MG;7.5MG;7.5MG;7.5MG	A214403	006	Nov 26, 2021	Feb CTNA
>A> AB	SPECGX LLC	3.125MG;3.125MG;3.125MG;3.125MG	A211546	001	Aug 31, 2023	Aug NEWA
>A> AB		6.25MG;6.25MG;6.25MG;6.25MG	A211546	002	Aug 31, 2023	Aug NEWA
>A> AB		9.375MG;9.375MG;9.375MG;9.375MG	A211546	003	Aug 31, 2023	Aug NEWA
>A> AB		12.5MG;12.5MG;12.5MG;12.5MG	A211546	004	Aug 31, 2023	Aug NEWA

MYDAYIS

>D>	+	TAKEDA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	N022063	001	Jun 20, 2017	Aug CTEC
>A> AB	+		3.125MG;3.125MG;3.125MG;3.125MG	N022063	001	Jun 20, 2017	Aug CTEC
>D>	+		6.25MG;6.25MG;6.25MG;6.25MG	N022063	002	Jun 20, 2017	Aug CTEC
>A> AB	+		6.25MG;6.25MG;6.25MG;6.25MG	N022063	002	Jun 20, 2017	Aug CTEC
>D>	+		9.375MG;9.375MG;9.375MG;9.375MG	N022063	003	Jun 20, 2017	Aug CTEC
>A> AB	+		9.375MG;9.375MG;9.375MG;9.375MG	N022063	003	Jun 20, 2017	Aug CTEC
>D>	+		9.375MG;9.375MG;9.375MG;9.375MG	N022063	004	Jun 20, 2017	Aug CTEC
>A> AB	+		12.5MG;12.5MG;12.5MG;12.5MG	N022063	004	Jun 20, 2017	Aug CTEC
>A> AB	+		12.5MG;12.5MG;12.5MG;12.5MG	N022063	004	Jun 20, 2017	Aug CTEC

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A215565	001	Jul 08, 2022	Feb CMFD
AB		1.875MG;1.875MG;1.875MG;1.875MG	A215565	002	Jul 08, 2022	Feb CMFD
AB		2.5MG;2.5MG;2.5MG;2.5MG	A215565	003	Jul 08, 2022	Feb CMFD
AB		3.125MG;3.125MG;3.125MG;3.125MG	A215565	004	Jul 08, 2022	Feb CMFD
AB		3.75MG;3.75MG;3.75MG;3.75MG	A215565	005	Jul 08, 2022	Feb CMFD
AB		5MG;5MG;5MG;5MG	A215565	006	Jul 08, 2022	Feb CMFD
AB		7.5MG;7.5MG;7.5MG;7.5MG	A215565	007	Jul 08, 2022	Feb CMFD

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

AP	STERISCIENCE	EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Jan CAHN
AP		EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Jan CAHN
AP		EQ 1GM BASE/VIAL	A201025	003	Apr 09, 2014	Jan CAHN
AP		EQ 2GM BASE/VIAL	A201025	004	Apr 09, 2014	Jan CAHN
AP		EQ 10GM BASE/VIAL	A202198	001	Apr 07, 2014	Jan CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP	STERISCIENCE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A201024	001	Apr 07, 2014	Jan CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A201024	002	Apr 07, 2014	Jan CAHN
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A202197	001	Apr 07, 2014	Jan CAHN

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

PRINCIPEN '250'

+ @ APOTHECON	EQ 250MG BASE	N050056	001	Jul CRLD
+ @ APOTHECON	EQ 500MG BASE	N050056	002	Jul CRLD

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

ANAGRELIDE HYDROCHLORIDE

>D>	@ MYLAN	EQ 0.5MG BASE	A076811	001	Apr 18, 2005	Aug CAHN
>D>	@	EQ 1MG BASE	A076811	002	Apr 18, 2005	Aug CAHN
>A>	@ NATCO PHARMA USA	EQ 0.5MG BASE	A076811	001	Apr 18, 2005	Aug CAHN
>A>	@	EQ 1MG BASE	A076811	002	Apr 18, 2005	Aug CAHN

APALUTAMIDE

TABLET; ORAL

ERLEADA

+ JANSSEN BIOTECH	60MG	N210951	001	Feb 14, 2018	Feb CHRS
+ !	240MG	N210951	002	Feb 17, 2023	Feb NEWA

APIXABAN

TABLET; ORAL

APIXABAN

AB	@ AUROBINDO PHARMA LTD	2.5MG	A210026	001	May 26, 2023	Jun DISC
AB	@	5MG	A210026	001	May 26, 2023	May NEWA
AB	@ ZYDUS PHARMS	5MG	A210026	002	May 26, 2023	Jun DISC
AB	@ ZYDUS PHARMS	2.5MG	A210185	001	Feb 27, 2023	May NEWA
AB	@	2.5MG	A210185	001	Feb 27, 2023	Jul DISC
AB	@	5MG	A210185	002	Feb 27, 2023	Feb NEWA
AB		5MG	A210185	002	Feb 27, 2023	Jul DISC

APOMORPHINE HYDROCHLORIDE

FILM; SUBLINGUAL

KYNMOBI

+ @ SUMITOMO PHARMA AM	10MG	N210875	001	May 21, 2020	Jul CAHN
+ @	15MG	N210875	002	May 21, 2020	Jul CAHN
+ @	20MG	N210875	003	May 21, 2020	Jul CAHN
+ @	25MG	N210875	004	May 21, 2020	Jul CAHN
+ @	30MG	N210875	005	May 21, 2020	Jul CAHN
+ @ SUNOVION PHARMS INC	10MG	N210875	001	May 21, 2020	Jul DISC
+ @	15MG	N210875	002	May 21, 2020	Jul DISC
+ @	20MG	N210875	003	May 21, 2020	Jul DISC
+ @	25MG	N210875	004	May 21, 2020	Jul DISC
+ @	30MG	N210875	005	May 21, 2020	Jul DISC

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

IOPIDINE

AT	+! HARROW EYE	EQ 0.5% BASE	N020258	001	Jul 30, 1993	May CAHN
	+!	EQ 1% BASE	N019779	001	Dec 31, 1987	May CAHN

APREMILAST

TABLET; ORAL

APREMILAST

AB	ANNORA	10MG	A211878	001	Jul 26, 2023	Jul NEWA
AB		20MG	A211878	002	Jul 26, 2023	Jul NEWA
AB		30MG	A211878	003	Jul 26, 2023	Jul NEWA
>D> AB	AUROBINDO PHARMA LTD	10MG	A211716	001	Jul 19, 2023	Aug DISC
>A>	@	10MG	A211716	001	Jul 19, 2023	Aug DISC
AB		10MG	A211716	001	Jul 19, 2023	Jul NEWA
>D> AB		20MG	A211716	002	Jul 19, 2023	Aug DISC
>A>	@	20MG	A211716	002	Jul 19, 2023	Aug DISC

TABLET;ORAL
APREMILAST

AB		20MG	A211716	002	Jul 19, 2023	Jul NEWA
>D> AB		30MG	A211716	003	Jul 19, 2023	Aug DISC
>A>	@	30MG	A211716	003	Jul 19, 2023	Aug DISC
AB		30MG	A211716	003	Jul 19, 2023	Jul NEWA
AB	DR REDDYS	10MG	A211756	001	Jul 14, 2023	Jul NEWA
AB		20MG	A211756	002	Jul 14, 2023	Jul NEWA
AB		30MG	A211756	003	Jul 14, 2023	Jul NEWA
AB	SHILPA	10MG	A211774	001	Apr 07, 2023	Mar NEWA
AB		20MG	A211774	002	Apr 07, 2023	Mar NEWA
AB		30MG	A211774	003	Apr 07, 2023	Mar NEWA
	@ TEVA PHARMS USA INC	10MG	A211897	001	Aug 18, 2022	Feb DISC
	@	20MG	A211897	002	Aug 18, 2022	Feb DISC
	@	30MG	A211897	003	Aug 18, 2022	Feb DISC

ARFORMOTEROL TARTRATE

SOLUTION;INHALATION
 ARFORMOTEROL TARTRATE

AN	RITEDOSE CORP	EQ 0.015MG BASE/2ML	A214736	001	Mar 02, 2022	Feb CMFD
----	---------------	---------------------	---------	-----	--------------	----------

ARGATROBAN

INJECTABLE;INJECTION
 ARGATROBAN

AP	GLAND PHARMA LTD	50MG/50ML (1MG/ML)	A217848	001	Jul 31, 2023	Jul NEWA
----	------------------	--------------------	---------	-----	--------------	----------

ARIPIPRAZOLE

SOLUTION;ORAL
 ARIPIPRAZOLE

AA	CHARTWELL RX	1MG/ML	A215595	001	Oct 25, 2022	May CAHN
	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR					
	ABILIFY ASIMTUFI					
+	OTSUKA	720MG/2.4ML (300MG/ML)	N217006	001	Apr 27, 2023	Apr NEWA
+!		960MG/3.2ML (300MG/ML)	N217006	002	Apr 27, 2023	Apr NEWA

ARMODAFINIL

TABLET;ORAL
 ARMODAFINIL
 @ COREPHARMA

50MG
 150MG
 250MG

A201514	001	Mar 25, 2019	Feb CAHN
A201514	002	Mar 25, 2019	Feb CAHN
A201514	003	Mar 25, 2019	Feb CAHN

ARSENIC TRIOXIDE

INJECTABLE;INJECTION
 ARSENIC TRIOXIDE

AP	ORBICULAR	1IMG/ML	A217413	001	Apr 20, 2023	Apr NEWA
AP		2MG/ML	A217413	002	Apr 20, 2023	Apr NEWA
AP	PENN LIFE	1IMG/ML	A209873	001	May 06, 2019	May CAHN

ASPIRIN

CAPSULE, EXTENDED RELEASE;ORAL
 DURLAZA

>D>	+! ESPERO	162.5MG	N200671	001	Sep 04, 2015	Aug DISC
>A>	+ @	162.5MG	N200671	001	Sep 04, 2015	Aug DISC

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL
 BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
 @ DR REDDYS LABS SA 325MG;50MG;40MG;30MG

A203335	001	Oct 30, 2015	Apr CAHN
---------	-----	--------------	----------

ASPIRIN; CARISOPRODOL

TABLET;ORAL
 CARISOPRODOL AND ASPIRIN
 @ CHARTWELL RX

325MG;200MG

A089594	001	Mar 31, 1989	Mar CAHN
---------	-----	--------------	----------

ASPIRIN; METHOCARBAMOL

TABLET;ORAL
 ROBAXISAL
 + @ ROBINS AH

325MG;400MG

N012281	001		Mar CRLD
---------	-----	--	----------

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRIN

@ DR REDDYS LABS SA

325MG; 4.8355MG

A091670 001 Mar 16, 2011 Apr CAHN

ATAZANAVIR SULFATE

CAPSULE; ORAL

ATAZANAVIR SULFATE

>D>	AB	CIPILA	EQ 100MG BASE	A200626 001 Aug 09, 2018	Aug DISC
>A>	@		EQ 100MG BASE	A200626 001 Aug 09, 2018	Aug DISC
>D>	AB		EQ 150MG BASE	A200626 002 Aug 09, 2018	Aug DISC
>A>	@		EQ 150MG BASE	A200626 002 Aug 09, 2018	Aug DISC
>D>	AB		EQ 200MG BASE	A200626 003 Aug 09, 2018	Aug DISC
>A>	@		EQ 200MG BASE	A200626 003 Aug 09, 2018	Aug DISC
>D>	AB		EQ 300MG BASE	A200626 004 Aug 09, 2018	Aug DISC
>A>	@		EQ 300MG BASE	A200626 004 Aug 09, 2018	Aug DISC

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

@ AUROBINDO PHARMA USA 50MG; 25MG
@ 100MG; 25MGA074203 001 Oct 31, 1993 Apr CAHN
A074203 002 Oct 31, 1993 Apr CAHNATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

AB ZYDUS PHARMS USA INC 10MG

A079017 007 Apr 05, 2023 Mar NEWA

ATORVASTATIN CALCIUM

SUSPENSION; ORAL

ATORVALIQ

+! CMP DEV LLC 20MG/5ML

N213260 001 Feb 01, 2023 Feb NEWA

TABLET; ORAL

ATORVASTATIN CALCIUM

@ LEPU PHARM EQ 10MG BASE
@ EQ 20MG BASE
@ EQ 40MG BASE
@ EQ 80MG BASEA216848 001 Nov 03, 2022 Apr DISC
A216848 002 Nov 03, 2022 Apr DISC
A216848 003 Nov 03, 2022 Apr DISC
A216848 004 Nov 03, 2022 Apr DISCATROPINE

SOLUTION; INTRAMUSCULAR

ATROOPEN

+ @ MMT

EQ 0.25MG SULFATE/0.3ML

N017106 004 Sep 17, 2004 May DISC

+ @

EQ 0.5MG SULFATE/0.7ML

N017106 003 Jun 19, 2003 May DISC

+ @

EQ 1MG SULFATE/0.7ML

N017106 002 Jun 19, 2003 May DISC

+ @

EQ 2MG SULFATE/0.7ML

N017106 001 May DISC

ATROPINE SULFATE

SOLUTION/DROPS; OPHTHALMIC

ATROPINE SULFATE

AT + AKORN 1%
AT ! AMNEAL 1%N206289 001 Jul 18, 2014 Jul CHRS
A214752 001 Jul 14, 2022 Jul CHRSATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

@ UPSHER SMITH LABS 0.025MG; 2.5MG

A210571 001 Aug 31, 2018 Jun DISC

>A> AVACINCAPTAD PEGOL SODIUM

>A> SOLUTION; INTRAVITREAL

>A> IZERVAY

>A> +! IVERIC BIO EQ 2MG BASE/0.1ML (EQ 2MG
BASE/0.1ML)

N217225 001 Aug 04, 2023 Aug NEWA

AZACITIDINE

POWDER; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

AP JIANGSU HANSOH PHARM 100MG/VIAL

A215905 001 Jun 28, 2023 Jun NEWA

AZELAIC ACID

AEROSOL, FOAM;TOPICAL

FINACEA

+! LEO PHARMA AS

15%

N207071 001 Jul 29, 2015 Feb CTEC

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

AB BIONPHARMA

0.137MG/SPRAY

A090176 001 Jul 28, 2015 Jun CAHN

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB HAINAN POLY

EQ 100MG BASE/5ML

A217036 001 Jul 27, 2023 Jul NEWA

AB

EQ 200MG BASE/5ML

A217036 002 Jul 27, 2023 Jul NEWA

TABLET;ORAL

AZITHROMYCIN

@ ACI

EQ 250MG BASE

A215772 001 Jul 15, 2022 Jan DISC

@

EQ 500MG BASE

A215773 001 Jul 12, 2022 Jan DISC

@ AUROBINDO PHARMA USA

EQ 600MG BASE

A065360 001 Jan 08, 2007 May CAHN

ZYDUS PHARMS

EQ 250MG BASE

A213275 001 Apr 11, 2023 Aug DISC

>A@

EQ 250MG BASE

A213275 001 Apr 11, 2023 Aug DISC

AB

EQ 250MG BASE

A213275 001 Apr 11, 2023 Mar NEWA

>D>

AB

EQ 500MG BASE

A213056 001 Apr 07, 2023 Aug DISC

>A>

EQ 500MG BASE

A213056 001 Apr 07, 2023 Aug DISC

AB

EQ 500MG BASE

A213056 001 Apr 07, 2023 Mar NEWA

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

@ AKORN

400 UNITS/GM;1%;EQ 3.5MG

A065213 001 Jul 25, 2012 Jan DISC

BASE/GM;10,000 UNITS/GM

! BAUSCH AND LOMB

400 UNITS/GM;1%;EQ 3.5MG

A064068 001 Oct 30, 1995 Jan CTEC

BASE/GM;10,000 UNITS/GM

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

@ AKORN

400 UNITS/GM;EQ 3.5MG

A065088 001 Feb 06, 2004 Jan DISC

BASE/GM;10,000 UNITS/GM

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

>A> AP ACIC PHARMS

0.5MG/ML

A216309 001 Aug 10, 2023 Aug NEWA

>A> AP

2MG/ML

A216309 002 Aug 10, 2023 Aug NEWA

AP RUBICON

0.5MG/ML

A217324 001 Feb 22, 2023 Feb NEWA

AP

1MG/ML

A217324 002 Feb 22, 2023 Feb NEWA

AP

2MG/ML

A217324 003 Feb 22, 2023 Feb NEWA

SUSPENSION;ORAL

BACLOFEN

>A> AB ANI PHARMS

25MG/5ML

A217252 001 Jun 08, 2023 Aug CAHN

>D> AB

25MG/5ML

A217252 001 Jun 08, 2023 Aug CAHN

AB

25MG/5ML

A217252 001 Jun 08, 2023 Jun NFTG

FLEQSUVY

AB +! AZURITY

25MG/5ML

N215602 001 Feb 04, 2022 Jun CFTG

TABLET;ORAL

BACLOFEN

AB UNICHEM

5MG

A212067 003 Mar 09, 2023 Mar NEWA

BALOXAVIR MARBOXIL

TABLET;ORAL

XOFLUZA

+ @ GENENTECH INC

20MG

N210854 001 Oct 24, 2018 Jun DISC

+

40MG

N210854 002 Oct 24, 2018 Jun CHRS

+!

80MG

N210854 003 Mar 18, 2021 Jun CHRS

BALSALAZIDE DISODIUM

CAPSULE;ORAL
BALSALAZIDE DISODIUM
@ DASH PHARMS NATCO 750MG A077807 001 Dec 28, 2007 Feb CAHN
AB ZYDUS 750MG A217592 001 Jun 08, 2023 Jun NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL
BENAZEPRIL HYDROCHLORIDE
AB COREPHARMA 5MG A077128 001 Mar 08, 2006 Mar CAHN
AB 10MG A077128 002 Mar 08, 2006 Mar CAHN
AB 20MG A077128 003 Mar 08, 2006 Mar CAHN
AB 40MG A077128 004 Mar 08, 2006 Mar CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
AB APOTEX 5MG;6.25MG A078794 001 Aug 21, 2014 May CMFD
AB 10MG;12.5MG A078794 002 Aug 21, 2014 May CMFD
AB 20MG;12.5MG A078794 003 Aug 21, 2014 May CMFD
AB 20MG;25MG A078794 004 Aug 21, 2014 May CMFD

BENDAMUSTINE HYDROCHLORIDE

POWDER;IV (INFUSION)
BENDAMUSTINE HYDROCHLORIDE
AP APOTEX 25MG/VIAL A204230 001 Jun 05, 2023 May NEWA
AP 100MG/VIAL A204230 002 Jun 05, 2023 May NEWA
AP BRECKENRIDGE 25MG/VIAL A205447 001 Feb 14, 2023 Feb NEWA
AP 100MG/VIAL A205447 002 Feb 14, 2023 Feb NEWA
AP EUGIA PHARMA 25MG/VIAL A214739 001 Jun 05, 2023 May NEWA
AP 100MG/VIAL A214739 002 Jun 05, 2023 May NEWA
AP KINDOS 25MG/VIAL A211001 001 Jun 05, 2023 May NEWA
AP 100MG/VIAL A211001 002 Jun 05, 2023 May NEWA
AP @ MYLAN LABS LTD 25MG/VIAL A204104 001 Apr 28, 2023 May DISC
AP 25MG/VIAL A204104 001 Apr 28, 2023 Apr NEWA
AP @ 100MG/VIAL A204104 002 Apr 28, 2023 May DISC
AP 100MG/VIAL A204104 002 Apr 28, 2023 Apr NEWA
AP NANG KUANG PHARM CO 25MG/VIAL A206554 001 Jun 07, 2023 May NEWA
AP 100MG/VIAL A206554 002 Jun 07, 2023 May NEWA
>A> SOLUTION;INTRAVENOUS N205580 001 May 15, 2018 Aug CDFR
>A> BELRAPZO
>A> AP +! EAGLE PHARMS 100MG/4ML (25MG/ML) N205580 001 May 15, 2018 Aug CDFR
BENDAMUSTINE HYDROCHLORIDE
>D> +! APOTEX 100MG/4ML (25MG/ML) N215033 001 Dec 07, 2022 Aug CTEC
>A> AP +! 100MG/4ML (25MG/ML) N215033 001 Dec 07, 2022 Aug CTEC
+ @ HOSPIRA 25MG/ML (25MG/ML) N211530 001 Dec 15, 2022 Jan DISC
+ @ 100MG/4ML (25MG/ML) N211530 002 Dec 15, 2022 Jan DISC
+ @ 200MG/8ML (25MG/ML) N211530 003 Dec 15, 2022 Jan DISC
>D> SOLUTION;IV (INFUSION) N205580 001 May 15, 2018 Aug CDFR
>D> BELRAPZO
>D> +! EAGLE PHARMS 100MG/4ML (25MG/ML) N205580 001 May 15, 2018 Aug CDFR

BENZONATATE

CAPSULE;ORAL
BENZONATATE
>D> AA CHARTWELL RX 100MG A040682 001 Jul 30, 2007 Aug CAHN
AA 100MG A040682 001 Jul 30, 2007 Feb CAHN
>D> AA 200MG A040682 002 Jul 30, 2007 Aug CAHN
AA 200MG A040682 002 Jul 30, 2007 Feb CAHN
>A> AA HERITAGE PHARMS LABS 100MG A040682 001 Jul 30, 2007 Aug CAHN
>A> AA 200MG A040682 002 Jul 30, 2007 Aug CAHN
>D> AA PURACAP PHARM LLC 100MG A206948 001 Dec 19, 2018 Aug CHRS
>A> AA ! 100MG A206948 001 Dec 19, 2018 Aug CHRS
>D> AA 200MG A206948 002 Dec 19, 2018 Aug CHRS
>A> AA ! 200MG A206948 002 Dec 19, 2018 Aug CHRS
>D> AA ! THEPHARMANETWORK LLC 100MG A040627 001 Mar 30, 2007 Aug DISC
>A> @ 100MG A040627 001 Mar 30, 2007 Aug DISC
>D> AA ! 150MG A040627 003 Sep 24, 2014 Aug DISC
>A> @ 150MG A040627 003 Sep 24, 2014 Aug DISC
>D> AA ! 200MG A040627 002 Jul 25, 2007 Aug DISC
>A> @ 200MG A040627 002 Jul 25, 2007 Aug DISC

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

BENZACLIN

+ @ BAUSCH 5%;EQ 1% BASE

N050756 001 Dec 21, 2000 Feb DISC

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB ! GLENMARK PHARMS 5%;EQ 1% BASE

A209252 001 Mar 14, 2019 Feb CHRS

>D> @ TARO 3.75%;EQ 1.2% BASE

A208683 001 Jun 05, 2018 Aug CMFD

>A> AB 3.75%;EQ 1.2% BASE

A208683 001 Jun 05, 2018 Aug CMFD

ONEXTON

>D> +! BAUSCH 3.75%;EQ 1.2% BASE

N050819 002 Nov 24, 2014 Aug CTEC

>A> AB +! 3.75%;EQ 1.2% BASE

N050819 002 Nov 24, 2014 Aug CTEC

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC

BEPOTASTINE BESILATE

AT ALEMBIC 1.5%

A214588 001 Apr 05, 2023 Mar NEWA

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

AB HIKMA 3MG/ML;EQ 3MG BASE/ML

A077838 001 Jan 17, 2023 Jan NEWA

BETAMETHASONE DIPROPIONATE

LOTION, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

@ PAI HOLDINGS PHARM EQ 0.05% BASE

A206389 001 Feb 13, 2018 May DISC

OINTMENT, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

@ PAI HOLDINGS PHARM EQ 0.05% BASE

A206118 001 Nov 09, 2017 May DISC

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

AEROSOL, FOAM;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB GLENMARK PHARMS LTD 0.064%;0.005%

A214688 001 Mar 21, 2023 Mar NFTG

ENSTILAR

AB +! LEO PHARMA AS 0.064%;0.005%

N207589 001 Oct 16, 2015 Mar CFTG

OINTMENT;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

@ TOLMAR 0.064%;0.005%

A201615 001 Jan 14, 2013 Feb DISC

SUSPENSION;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB COSETTE 0.064%;0.005%

A210765 001 May 11, 2020 Feb CAHN

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB ! TARO EQ 0.05% BASE;1%

A075673 001 May 29, 2001 May CHRS

LOTRISONE

+ @ ORGANON EQ 0.05% BASE;1%

N018827 001 Jul 10, 1984 May DISC

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

BETAMETHASONE VALERATE

>D> AB TARO 0.12%

A208204 001 May 24, 2017 Aug CHRS

>A> AB ! 0.12%

A208204 001 May 24, 2017 Aug CHRS

AB XIROMED 0.12%

A210639 001 Apr 18, 2023 Apr NEWA

>D> LUXIQ

>D> AB +! MYLAN 0.12%

N020934 001 Feb 28, 1999 Aug DISC

>A> + @ 0.12%

N020934 001 Feb 28, 1999 Aug DISC

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

@ AKORN EQ 0.5% BASE

A075386 001 Jun 30, 2000 Feb DISC

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

AA	CHARTWELL RX	5MG	A040728	002	Oct 26, 2007	May CAHN
AA		10MG	A040728	003	Oct 26, 2007	May CAHN
AA		25MG	A040728	004	Oct 26, 2007	May CAHN
AA		50MG	A040728	001	Oct 26, 2007	May CAHN

BEXAGLIFLOZIN

TABLET;ORAL

BRENZAVVY

+! THERACOSBIO

20MG

N214373 001 Jan 20, 2023 Jan NEWA

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

AB	PINNACLE LIFE SCI	50MG	A079089	001	Jul 06, 2009	Jan CAHN
----	-------------------	------	---------	-----	--------------	----------

BIMATOPROST

IMPLANT;OPHTHALMIC

DURYSTA

+! ABBVIE

10MCG

N211911 001 Mar 04, 2020 Jan CAHN

SOLUTION/DROPS;OPHTHALMIC

LUMIGAN

+! ABBVIE

0.01%

N022184 001 Aug 31, 2010 Jul CAHN

+ @

0.03%

N021275 001 Mar 16, 2001 Jul CAHN

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

AB	PAR PHARM	140MG;125MG;125MG	A205770	001	Mar 06, 2023	Feb NFTG
AB	RICONPHARMA LLC	140MG;125MG;125MG	A217511	001	Jul 03, 2023	Jun NEWA
	PYLERA					
AB	+! ABBVIE	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Mar CAHN
AB	+! ALLERGAN	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Feb CFTG

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL

BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

>D>	! AILEX PHARMS LLC	262.4MG, N/A, N/A;N/A, 250MG, N/A;N/A, N/A, 500MG	A202584	001	Nov 30, 2018	Aug CAHN
>A>	! NOSTRUM LABS INC	262.4MG, N/A, N/A;N/A, 250MG, N/A;N/A, N/A, 500MG	A202584	001	Nov 30, 2018	Aug CAHN

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

AB	ALEMBIC	5MG	A204891	001	Jan 11, 2017	Feb CAHN
AB		10MG	A204891	002	Jan 11, 2017	Feb CAHN
	@ DASH PHARMS NATCO	5MG	A075831	001	Dec 14, 2005	Feb CAHN
	@	10MG	A075831	002	Dec 14, 2005	Feb CAHN
AB	PRINSTON INC	5MG	A217368	001	Jul 14, 2023	Jul NEWA
AB		10MG	A217368	002	Jul 14, 2023	Jul NEWA

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

@ ACCORD HLTHCARE

3.5MG/VIAL

A204405 001 Jul 26, 2022 Feb DISC

POWDER;INTRAVENOUS

BORTEZOMIB

@ DR REDDYS

3.5MG/VIAL

N206927 001 Oct 04, 2019 May DISC

@ FRESENIUS KABI USA

3.5MG/VIAL

N205004 001 Nov 06, 2017 May DISC

BOSENTAN

TABLET;ORAL

BOSENTAN

@ PAR PHARM INC

62.5MG

A205699 001 Apr 26, 2019 Apr DISC

@

125MG

A205699 002 Apr 26, 2019 Apr DISC

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

@ BRECKENRIDGE

50MG/ML

A204386 001 Dec 21, 2018 Feb DISC

BREXIPRAZOLE

TABLET; ORAL

BREXIPRAZOLE

>D>	AB	AJANTA PHARMA LTD	0.25MG	A213718	001	Feb 03, 2023	Aug DISC
>A>		@	0.25MG	A213718	001	Feb 03, 2023	Aug DISC
	AB		0.25MG	A213718	001	Feb 03, 2023	Jan NEWA
>D>	AB		0.5MG	A213718	002	Feb 03, 2023	Aug DISC
>A>		@	0.5MG	A213718	002	Feb 03, 2023	Aug DISC
	AB		0.5MG	A213718	002	Feb 03, 2023	Jan NEWA
>D>	AB		1MG	A213718	003	Feb 03, 2023	Aug DISC
>A>		@	1MG	A213718	003	Feb 03, 2023	Aug DISC
	AB		1MG	A213718	003	Feb 03, 2023	Jan NEWA
>D>	AB		2MG	A213718	004	Feb 03, 2023	Aug DISC
>A>		@	2MG	A213718	004	Feb 03, 2023	Aug DISC
	AB		2MG	A213718	004	Feb 03, 2023	Jan NEWA
>D>	AB		3MG	A213718	005	Feb 03, 2023	Aug DISC
>A>		@	3MG	A213718	005	Feb 03, 2023	Aug DISC
	AB		3MG	A213718	005	Feb 03, 2023	Jan NEWA
>D>	AB		4MG	A213718	006	Feb 03, 2023	Aug DISC
>A>		@	4MG	A213718	006	Feb 03, 2023	Aug DISC
	AB		4MG	A213718	006	Feb 03, 2023	Jan NEWA
		@ AMNEAL	0.25MG	A213562	001	Jan 31, 2023	Mar DISC
	AB		0.25MG	A213562	001	Jan 31, 2023	Jan NEWA
		@	0.5MG	A213562	002	Jan 31, 2023	Mar DISC
	AB		0.5MG	A213562	002	Jan 31, 2023	Jan NEWA
		@	1MG	A213562	003	Jan 31, 2023	Mar DISC
	AB		1MG	A213562	003	Jan 31, 2023	Jan NEWA
		@	2MG	A213562	004	Jan 31, 2023	Mar DISC
	AB		2MG	A213562	004	Jan 31, 2023	Jan NEWA
		@	3MG	A213562	005	Jan 31, 2023	Mar DISC
	AB		3MG	A213562	005	Jan 31, 2023	Jan NEWA
		@	4MG	A213562	006	Jan 31, 2023	Mar DISC
	AB		4MG	A213562	006	Jan 31, 2023	Jan NEWA
		@ LUPIN LTD	0.25MG	A213512	001	Mar 17, 2023	May DISC
	AB		0.25MG	A213512	001	Mar 17, 2023	Mar NEWA
		@	0.5MG	A213512	002	Mar 17, 2023	May DISC
	AB		0.5MG	A213512	002	Mar 17, 2023	Mar NEWA
		@	1MG	A213512	003	Mar 17, 2023	May DISC
	AB		1MG	A213512	003	Mar 17, 2023	Mar NEWA
		@	2MG	A213512	004	Mar 17, 2023	May DISC
	AB		2MG	A213512	004	Mar 17, 2023	Mar NEWA
		@	3MG	A213512	005	Mar 17, 2023	May DISC
	AB		3MG	A213512	005	Mar 17, 2023	Mar NEWA
		@	4MG	A213512	006	Mar 17, 2023	May DISC
	AB		4MG	A213512	006	Mar 17, 2023	Mar NEWA
		@ TEVA PHARMS USA INC	0.25MG	A213692	001	Aug 11, 2022	Feb DISC
		@	0.5MG	A213692	002	Aug 11, 2022	Feb DISC
		@	1MG	A213692	003	Aug 11, 2022	Feb DISC
		@	2MG	A213692	004	Aug 11, 2022	Feb DISC
		@	3MG	A213692	005	Aug 11, 2022	Feb DISC
		@	4MG	A213692	006	Aug 11, 2022	Feb DISC
		@ ZYDUS PHARMS	0.25MG	A213660	001	Jan 10, 2023	Jun DISC
		@	0.5MG	A213660	002	Jan 10, 2023	Jun DISC
		@	1MG	A213660	003	Jan 10, 2023	Jun DISC
		@	2MG	A213660	004	Jan 10, 2023	Jun DISC
		@	3MG	A213660	005	Jan 10, 2023	Jun DISC
		@	4MG	A213660	006	Jan 10, 2023	Jun DISC
		REXULTI					
>D>	AB	+	OTSUKA	N205422	001	Jul 10, 2015	Aug CTEC
>A>		+		N205422	001	Jul 10, 2015	Aug CTEC
>D>	AB	+		N205422	002	Jul 10, 2015	Aug CTEC
>A>		+		N205422	002	Jul 10, 2015	Aug CTEC
>D>	AB	+		N205422	003	Jul 10, 2015	Aug CTEC
>A>		+		N205422	003	Jul 10, 2015	Aug CTEC
>D>	AB	+	!	N205422	004	Jul 10, 2015	Aug CTEC
>A>		+	!	N205422	004	Jul 10, 2015	Aug CTEC
>D>	AB	+		N205422	005	Jul 10, 2015	Aug CTEC
>A>		+		N205422	005	Jul 10, 2015	Aug CTEC

TABLET;ORAL
REXULTI

>D> AB	+	4MG	N 205422	006	Jul 10, 2015	Aug CTEC
>A>	+	4MG	N 205422	006	Jul 10, 2015	Aug CTEC

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC
BRIMONIDINE TARTRATE

AB	ALEMBIC	0.1%	A 216909	001	Aug 01, 2023	Jul NEWA
AT		0.15%	A 215225	001	Mar 29, 2023	Mar NEWA

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

>A> AB	ALEMBIC	0.2%;EQ 0.5% BASE	A 215230	001	Aug 25, 2023	Aug NEWA
AB	SENTISS	0.2%;EQ 0.5% BASE	A 091086	001	Oct 31, 2022	Jul CAHN

BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC
BRINZOLAMIDE

AB	PADAGIS US	1%	A 211914	001	Jul 28, 2023	Jul NEWA
----	------------	----	----------	-----	--------------	----------

BRIVARACETAM

TABLET;ORAL
BRIVARACETAM

@ AUROBINDO PHARMA LTD	50MG	A 214848	001	Jan 06, 2023	Mar DISC
@	100MG	A 214848	002	Jan 06, 2023	Mar DISC
@ LUPIN LTD	10MG	A 214918	001	Dec 20, 2022	Mar DISC
@	25MG	A 214918	002	Dec 20, 2022	Mar DISC
@	50MG	A 214918	003	Dec 20, 2022	Mar DISC
@	75MG	A 214918	004	Dec 20, 2022	Mar DISC
@	100MG	A 214918	005	Dec 20, 2022	Mar DISC
BRIVIACT					
+ UCB INC	10MG	N 205836	001	May 12, 2016	Mar CTEC
+	25MG	N 205836	002	May 12, 2016	Mar CTEC
+	50MG	N 205836	003	May 12, 2016	Mar CTEC
+	75MG	N 205836	004	May 12, 2016	Mar CTEC
+!	100MG	N 205836	005	May 12, 2016	Mar CTEC

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC
BROMFENAC SODIUM

AT2	AKORN	EQ 0.09% ACID	A 203395	001	Jan 22, 2014	Jun CHRS
AT2	! ALEMBIC	EQ 0.09% ACID	A 210560	001	Jun 21, 2019	Jun CHRS
>A> AT2	LUPIN LTD	EQ 0.09% ACID	A 202903	001	Aug 15, 2023	Aug NEWA
AT2	SENTISS	EQ 0.09% ACID	A 203395	001	Jan 22, 2014	Jul CAHN

BROMOCRIPTINE MESYLATE

TABLET;ORAL
BROMOCRIPTINE MESYLATE

@ AUROBINDO PHARMA USA	EQ 2.5MG BASE	A 076962	001	Sep 24, 2004	Apr CAHN
------------------------	---------------	----------	-----	--------------	----------

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL
BROMFED-DM

AA	+ WOCKHARDT BIO AG	2MG/5ML;10MG/5ML;30MG/5ML	A 088811	001	Jun 07, 1985	Jun CHRS
AA	+!	2MG/5ML;10MG/5ML;30MG/5ML	A 088811	001	Jun 07, 1985	Jun CRLD
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE						
@ BIONPHARMA		2MG/5ML;10MG/5ML;30MG/5ML	A 203997	001	Sep 30, 2020	Jun CAHN
@ BRECKENRIDGE		2MG/5ML;10MG/5ML;30MG/5ML	A 203997	001	Sep 30, 2020	Jan DISC
AA	! PADAGIS US	2MG/5ML;10MG/5ML;30MG/5ML	A 205292	001	Jul 15, 2014	Jun CHRS

BUDESONIDE

AEROSOL, FOAM;RECTAL
BUDESONIDE

AB	PADAGIS ISRAEL	2MG/ACTUATION	A 215328	001	Apr 12, 2023	Mar NFTG
AB	UCERIS					
AB	+! SALIX	2MG/ACTUATION	N 205613	001	Oct 07, 2014	Mar CFTG

BUDESONIDE; FORMOTEROL FUMARATE

AEROSOL, METERED; INHALATION
SYMBICORT AEROSPHERE
+! ASTRAZENECA 0.16MG/INH;0.0048MG/INH

N216579 001 Apr 28, 2023 Apr NEWA

BUMETANIDE

INJECTABLE; INJECTION
BUMETANIDE

>D> AP	ATHENEX INC	0.25MG/ML	A074441	001	Jan 27, 1995	Aug CAHN
>A> AP	SAGENT	0.25MG/ML	A074441	001	Jan 27, 1995	Aug CAHN
	TABLET; ORAL BUMETANIDE					
AB	TARO	0.5MG	A213458	001	Jul 24, 2023	Jul NEWA
AB		1MG	A213458	002	Jul 24, 2023	Jul NEWA
AB		2MG	A213458	003	Jul 24, 2023	Jul NEWA

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
BUPIVACAINE HYDROCHLORIDE

AP	KINDOS	0.25%	A216039	001	Jun 23, 2023	Jun NEWA
AP		0.5%	A216039	002	Jun 23, 2023	Jun NEWA
AP	STERISCIENCE	0.25%	A091503	001	Oct 18, 2011	Jun CMFD
AP		0.5%	A091503	002	Oct 18, 2011	Jun CMFD
	BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE					
AP	STERISCIENCE	0.25%	A091487	002	Oct 18, 2011	Jun CMFD
AP		0.5%	A091487	001	Oct 18, 2011	Jun CMFD
AP		0.75%	A091487	003	Oct 18, 2011	Jun CMFD
	INJECTABLE; SPINAL BUPIVACAINE HYDROCHLORIDE					
>D> AP	BAXTER HLTHCARE CORP	0.75%	A207266	001	Jul 25, 2016	Aug DISC
>A>	@	0.75%	A207266	001	Jul 25, 2016	Aug DISC

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL
BUPRENORPHINE

AB	ALVOGEN	7.5MCG/HR	A207490	005	Mar 21, 2023	Mar NEWA
	SOLUTION, EXTENDED RELEASE; SUBCUTANEOUS BRIXADI					
+!	BRAEBURN	8MG/0.16ML (50MG/ML)	N210136	001	May 23, 2023	May NEWA
+		16MG/0.32ML (50MG/ML)	N210136	002	May 23, 2023	May NEWA
+		24MG/0.48ML (50MG/ML)	N210136	003	May 23, 2023	May NEWA
+		32MG/0.64ML (50MG/ML)	N210136	004	May 23, 2023	May NEWA
+		64MG/0.18ML (356MG/ML)	N210136	005	May 23, 2023	May NEWA
+		96MG/0.27ML (356MG/ML)	N210136	006	May 23, 2023	May NEWA
+		128MG/0.36ML (356MG/ML)	N210136	007	May 23, 2023	May NEWA

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
BUPRENEK

+ @ INDIVIOR	EQ 0.3MG BASE/ML	N018401	001		Jul DISC
AP ! PAR STERILE PRODUCTS	EQ 0.3MG BASE/ML	A206586	001	Jul 28, 2015	Jul CHRS

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE
@ DR REDDYS LABS SA EQ 2MG BASE;EQ 0.5MG BASE
@ EQ 8MG BASE;EQ 2MG BASE

A206953 001 Jul 17, 2020 Apr CAHN
A206953 002 Jul 17, 2020 Apr CAHNBUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
BUPROPION HYDROCHLORIDE

AB1	ANNORA PHARMA	100MG	A216800	001	May 31, 2023	May NEWA
AB1		150MG	A216800	002	May 31, 2023	May NEWA
AB1		200MG	A216800	003	May 31, 2023	May NEWA

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

>D>	@ GRAVITI PHARMS	5MG	A075413	001	Mar 19, 2002	Aug CAHN
	@	5MG	A075413	001	Mar 19, 2002	Feb CAHN
>D>	@	10MG	A075413	002	Mar 19, 2002	Aug CAHN
	@	10MG	A075413	002	Mar 19, 2002	Feb CAHN
>D>	@	15MG	A075413	003	Mar 19, 2002	Aug CAHN
	@	15MG	A075413	003	Mar 19, 2002	Feb CAHN
>A>	@ RISING	5MG	A075413	001	Mar 19, 2002	Aug CAHN
>A>	@	10MG	A075413	002	Mar 19, 2002	Aug CAHN
>A>	@	15MG	A075413	003	Mar 19, 2002	Aug CAHN
AB	ZYDUS PHARMS	7.5MG	A078888	005	Mar 21, 2023	Mar NEWA

BUSULFAN

INJECTABLE;INJECTION

BUSULFAN

@ AM REGENT	6MG/ML	A202259	001	Dec 22, 2015	Jan DISC
@ ARTHUR GRP	6MG/ML	A205106	001	Sep 21, 2018	Mar DISC

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL

MENTAX

+ @ MYLAN

1%

N020524 001 Oct 18, 1996 Jul DISC

CABAZITAXEL

SOLUTION;INTRAVENOUS

CABAZITAXEL

+! ACCORD HLTHCARE

60MG/3ML (20MG/ML)

N207949 001 Dec 29, 2021 Feb CMFD

AP APOTEX

60MG/1.5ML (40MG/ML)

A207736 001 Feb 10, 2023 Aug DISC

>A> @

60MG/1.5ML (40MG/ML)

A207736 001 Feb 10, 2023 Aug DISC

AP

60MG/1.5ML (40MG/ML)

A207736 001 Feb 10, 2023 Feb NEWA

AP

DR REDDYS

60MG/1.5ML (40MG/ML)

A207718 001 Feb 10, 2023 Feb NEWA

@ MYLAN LABS LTD

60MG/1.5ML (40MG/ML)

A207381 001 Jul 05, 2023 Jul DISC

AP

+! SANDOZ

60MG/1.5ML (40MG/ML)

A207381 001 Jul 05, 2023 Jun NEWA

+!

45MG/4.5ML (10MG/ML)

N208715 001 Jan 05, 2023 Jan NEWA

+!

60MG/6ML (10MG/ML)

N208715 002 Jan 05, 2023 Jan NEWA

CABOZANTINIB S-MALATE

CAPSULE;ORAL

COMETRIQ

+ EXELIXIS

EQ 20MG BASE

N203756 001 Nov 29, 2012 Jun CHRS

+!

EQ 80MG BASE

N203756 002 Nov 29, 2012 Jun CHRS

CALCIPOTRIENE

CREAM;TOPICAL

CALCIPOTRIENE

@ TOLMAR

0.005%

A200935 001 May 30, 2012 Feb DISC

SOLUTION;TOPICAL

CALCIPOTRIENE

@ CHARTWELL RX

0.005%

A077029 001 Nov 20, 2009 Jul CAHN

AT

0.005%

A207163 001 Dec 26, 2017 Jul CAHN

AT

! COSETTE

0.005%

A078468 001 Mar 24, 2011 Feb CHRS

@ TOLMAR

0.005%

A077029 001 Nov 20, 2009 Feb DISC

CALCITRICAL

CAPSULE;ORAL

CALCITRIOL

AB

! STRIDES PHARMA

0.5MCG

A091356 002 Dec 12, 2014 May CHRS

ROCALTROL

AB

+ VALIDUS PHARMS

0.5MCG

N018044 002 May CHRS

INJECTABLE;INJECTION

CALCITRIOL

>D> AP

! AKORN

0.001MG/ML

A078066 001 Jan 29, 2008 Aug CAHN

@

0.002MG/ML

A078066 002 Jan 29, 2008 Aug CAHN

>A> AP

! LONG GROVE PHARMS

0.001MG/ML

A078066 001 Jan 29, 2008 Aug CAHN

>A>

@

0.002MG/ML

A078066 002 Jan 29, 2008 Aug CAHN

SOLUTION;ORAL

CALCITRIOL

AA

PATRIN

1MCG/ML

A203973 001 Jul 28, 2023 Jul NEWA

AA

RISING

1MCG/ML

A209798 001 Nov 21, 2018 Jul CAHN

CALCIUM ACETATE

CAPSULE;ORAL	CALCIUM ACETATE					
AB	SQUARE PHARMS	667MG	A217205	001	Mar 13, 2023	Mar NEWA
	SOLUTION;ORAL					
	PHOSLYRA					
+ @	FRESENIUS MEDCL	667MG/5ML	N022581	001	Apr 18, 2011	Jun DISC

CALCIUM GLUCONATE

SOLUTION;INTRAVENOUS	CALCIUM GLUCONATE					
>A> AP	B BRAUN MEDICAL INC	10GM/100ML (100MG/ML)	A216541	001	Aug 21, 2023	Aug NFTG
>D>	+! FRESENIUS KABI USA	10GM/100ML (100MG/ML)	N208418	003	Jun 15, 2017	Aug CFTG
>A> AP	+!	10GM/100ML (100MG/ML)	N208418	003	Jun 15, 2017	Aug CFTG
	CALCIUM GLUCONATE IN SODIUM CHLORIDE					
>A> AP	AMNEAL	1GM/50ML (20MG/ML)	A217174	001	Sep 05, 2023	Aug NFTG
>A> AP		2GM/100ML (20MG/ML)	A217174	002	Sep 05, 2023	Aug NFTG
>D>	+! FRESENIUS KABI USA	1GM/50ML (20MG/ML)	N208418	004	Jun 17, 2021	Aug CFTG
>A> AP	+!	1GM/50ML (20MG/ML)	N208418	004	Jun 17, 2021	Aug CFTG
>D>	+!	2GM/100ML (20MG/ML)	N208418	005	Jun 17, 2021	Aug CFTG
>A> AP	+!	2GM/100ML (20MG/ML)	N208418	005	Jun 17, 2021	Aug CFTG

CANDESARTAN CILEXETIL

TABLET;ORAL	CANDESARTAN CILEXETIL					
>A> AB	PRINSTON INC	8MG	A206233	001	Aug 21, 2023	Aug NEWA
>A> AB		16MG	A206233	002	Aug 21, 2023	Aug NEWA
>A> AB		32MG	A206233	003	Aug 21, 2023	Aug NEWA
AB	ZYDUS LIFESCIENCES	4MG	A091390	001	Aug 23, 2017	May CAHN
AB		8MG	A091390	002	Aug 23, 2017	May CAHN
AB		16MG	A091390	003	Aug 23, 2017	May CAHN
AB		32MG	A091390	004	Aug 23, 2017	May CAHN

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL	CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE					
AB	ZYDUS LIFESCIENCES	16MG;12.5MG	A203466	001	Nov 27, 2017	May CAHN
AB		32MG;12.5MG	A203466	002	Nov 27, 2017	May CAHN
AB		32MG;25MG	A203466	003	Nov 27, 2017	May CAHN

CANTHARIDIN

SOLUTION;TOPICAL						
YCANTH						
+!	VERRICA PHARMS	0.7%	N212905	001	Jul 21, 2023	Jul NEWA

CAPECITABINE

TABLET;ORAL						
	XELODA					
AB	+ CHEPLAPHARM	150MG	N020896	001	Apr 30, 1998	Apr CAHN
AB	+!	500MG	N020896	002	Apr 30, 1998	Apr CAHN

CAPTOPRIL

TABLET;ORAL	CAPTOPRIL					
	@ AUROBINDO PHARMA USA	12.5MG	A074434	001	Feb 13, 1996	May CAHN
	@	25MG	A074434	002	Feb 13, 1996	May CAHN
	@	50MG	A074434	003	Feb 13, 1996	May CAHN
	@	100MG	A074434	004	Feb 13, 1996	May CAHN
AB	CHANGZHOU PHARM	12.5MG	A214442	001	Jan 27, 2023	Jan NEWA
AB		25MG	A214442	002	Jan 27, 2023	Jan NEWA
AB		50MG	A214442	003	Jan 27, 2023	Jan NEWA
AB		100MG	A214442	004	Jan 27, 2023	Jan NEWA
AB	COREPHARMA	12.5MG	A074737	001	Oct 28, 1998	Mar CAHN
AB		25MG	A074737	002	Oct 28, 1998	Mar CAHN
AB		50MG	A074737	003	Oct 28, 1998	Mar CAHN
AB		100MG	A074737	004	Oct 28, 1998	Mar CAHN

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

Captopril And Hydrochlorothiazide

RISING	25MG;15MG	A074896	001	Dec 29, 1997	May CMFD
!	25MG;25MG	A074896	002	Dec 29, 1997	May CMFD
!	50MG;15MG	A074896	004	Dec 29, 1997	May CMFD
	50MG;25MG	A074896	003	Dec 29, 1997	May CMFD

CARBAMAZEPINE

SUSPENSION; ORAL

Carbamazepine

AB	CHARTWELL RX	100MG/5ML	A075714	001	Jun 05, 2002	Jan CAHN
	TABLET; ORAL					
	CARBAMAZEPINE					
	@ RK PHARMA	200MG	A214328	001	Aug 16, 2021	Jun CAHN
	TABLET, EXTENDED RELEASE; ORAL					
	CARBAMAZEPINE					
AB	AJANTA PHARMA LTD	100MG	A216193	001	Mar 24, 2023	Mar NEWA
AB		200MG	A216193	002	Mar 24, 2023	Mar NEWA
AB		400MG	A216193	003	Mar 24, 2023	Mar NEWA
AB	RICONPHARMA LLC	100MG	A216404	001	Dec 02, 2022	Jun CMFD
AB		200MG	A216404	002	Dec 02, 2022	Jun CMFD
AB		400MG	A216404	003	Dec 02, 2022	Jun CMFD
AB	SCIECURE PHARMA INC	100MG	A216235	001	Mar 02, 2023	Feb NEWA
AB		200MG	A216235	002	Mar 02, 2023	Feb NEWA
AB		400MG	A216235	003	Mar 02, 2023	Feb NEWA

CARBIDOPA; LEVODOPA

TABLET; ORAL

Carbidopa And Levodopa

>D> AB	ZYDUS PHARMS	10MG;100MG	A215999	001	Apr 04, 2023	Aug DISC
>A>	@	10MG;100MG	A215999	001	Apr 04, 2023	Aug DISC
	AB	10MG;100MG	A215999	001	Apr 04, 2023	Mar NEWA
>D> AB		25MG;100MG	A215999	002	Apr 04, 2023	Aug DISC
>A>	@	25MG;100MG	A215999	002	Apr 04, 2023	Aug DISC
	AB	25MG;100MG	A215999	002	Apr 04, 2023	Mar NEWA
>D> AB		25MG;250MG	A215999	003	Apr 04, 2023	Aug DISC
>A>	@	25MG;250MG	A215999	003	Apr 04, 2023	Aug DISC
	AB	25MG;250MG	A215999	003	Apr 04, 2023	Mar NEWA
	TABLET, EXTENDED RELEASE; ORAL					
	CARBIDOPA AND LEVODOPA					
AB	! SCIEGEN PHARMS INC	50MG;200MG	A214091	002	Oct 05, 2021	May CHRS
AB	SUN PHARM INDNS	50MG;200MG	A077828	002	Aug 23, 2007	May CHRS
	TABLET, ORALLY DISINTEGRATING; ORAL					
	CARBIDOPA AND LEVODOPA					
	SUN PHARM	10MG;100MG	A078690	001	Jul 31, 2009	Apr CTEC
		25MG;100MG	A078690	002	Jul 31, 2009	Apr CTEC

CARBOPLATIN

INJECTABLE; INTRAVENOUS

Carboplatin

AP	NOVAST LABS	450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	May CMFD
AP		600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	May CMFD

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

Carboprost Tromethamine

AP	ALEMBIC	EQ 0.25MG BASE/ML	A217198	001	Jun 15, 2023	Jun NEWA
AP	CAPLIN	EQ 0.25MG BASE/ML	A216882	001	Feb 13, 2023	Feb NEWA
AP	EUGIA PHARMA	EQ 0.25MG BASE/ML	A216939	001	May 25, 2023	May NEWA
AP	GLAND PHARMA LTD	EQ 0.25MG BASE/ML	A217657	001	Aug 07, 2023	Jul NEWA
AP	SOLA PHARMS	EQ 0.25MG BASE/ML	A216824	001	May 19, 2023	Jun CAHN
AP	STERISCIENCE	EQ 0.25MG BASE/ML	A216897	001	Jul 25, 2023	Jul NEWA
AP	WELDING	EQ 0.25MG BASE/ML	A216824	001	May 19, 2023	May NEWA

CARFILZOMIB

POWDER; INTRAVENOUS

Kyprolis

+	ONYX PHARMS AMGEN	10MG/VIAL	N202714	003	Jun 07, 2018	Jun CAHN
+		30MG/VIAL	N202714	002	Jun 03, 2016	Jun CAHN
AP	+!	60MG/VIAL	N202714	001	Jul 20, 2012	Jun CAHN

CARIPRAZINE HYDROCHLORIDE

CAPSULE;ORAL

CARIPRAZINE HYDROCHLORIDE

@ ZYDUS	EQ 1.5MG BASE	A213984	001	Sep 09, 2022	May CAHN
@	EQ 3MG BASE	A213984	002	Sep 09, 2022	May CAHN
@	EQ 4.5MG BASE	A213984	003	Sep 09, 2022	May CAHN
@	EQ 6MG BASE	A213984	004	Sep 09, 2022	May CAHN
VRAYLAR					
+! ABBVIE	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Jan CAHN
+	EQ 3MG BASE	N204370	002	Sep 17, 2015	Jan CAHN
+	EQ 4.5MG BASE	N204370	003	Sep 17, 2015	Jan CAHN
+	EQ 6MG BASE	N204370	004	Sep 17, 2015	Jan CAHN

CARMUSTINE

INJECTABLE;INJECTION

CARMUSTINE

AP @ ACCORD HLTHCARE	100MG/VIAL	A214117	001	Dec 27, 2022	Jul DISC
AP AP MSN	100MG/VIAL	A214117	001	Dec 27, 2022	Mar CTNA
AP @ MYLAN LABS LTD	100MG/VIAL	A214814	001	May 11, 2023	May NEWA
AP AP PENN LIFE	100MG/VIAL	A215368	001	Mar 03, 2023	Mar DISC
	100MG/VIAL	A215368	001	Mar 03, 2023	Feb NEWA
	100MG/VIAL	A209278	001	Apr 02, 2019	May CAHN

CEFAZOLIN SODIUM

POWDER; INTRAVENOUS

CEFAZOLIN SODIUM

+! HQ SPCLT PHARMA	EQ 2GM BASE/VIAL	N211413	001	May 08, 2023	May NEWA
--------------------	------------------	---------	-----	--------------	----------

CEFOTAXIME SODIUM

INJECTABLE;INJECTION

CEFOTAXIME

@ HIKMA	EQ 500MG BASE/VIAL	A065072	001	Nov 20, 2002	Mar DISC
@	EQ 1GM BASE/VIAL	A065072	002	Nov 20, 2002	Mar DISC
@	EQ 2GM BASE/VIAL	A065072	003	Nov 20, 2002	Mar DISC
@	EQ 10GM BASE/VIAL	A065071	001	Nov 20, 2002	Mar DISC

CEFOTETAN DISODIUM

INJECTABLE;INJECTION

CEFOTAN

+ @ PAI HOLDINGS PHARM	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	May DISC
+ @	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	May DISC
CEFOTETAN					
! FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A065374	001	Aug 09, 2007	May CTEC
!	EQ 2GM BASE/VIAL	A065374	002	Aug 09, 2007	May CTEC

CEFTAROLINE FOSAMIL

POWDER; INTRAVENOUS

TEFLARO

+! ABBVIE	400MG/VIAL	N200327	001	Oct 29, 2010	May CAHN
+	600MG/VIAL	N200327	002	Oct 29, 2010	May CAHN

CEFTAZIDIME

INJECTABLE;INJECTION

CEFTAZIDIME

AP ! ACS DOBFAR	1GM/VIAL	A062640	002	Nov 20, 1985	May CHRS
AP !	2GM/VIAL	A062640	003	Nov 20, 1985	May CHRS
AP !	6GM/VIAL	A062640	004	Feb 03, 1992	May CHRS
FORTAZ					
+ @ PAI HOLDINGS PHARM	500MG/VIAL	N050578	001	Jul 19, 1985	May DISC
+ @	1GM/VIAL	N050578	002	Jul 19, 1985	May DISC
+ @	2GM/VIAL	N050578	003	Jul 19, 1985	May DISC
+ @	6GM/VIAL	N050578	004	Jul 19, 1985	May DISC
TAZICEF					
@ HOSPIRA	500MG/VIAL	A062662	001	Mar 06, 1986	May DISC
	500MG/VIAL	A062662	001	Mar 06, 1986	May CTEC

CEFURXIME SODIUM

INJECTABLE; INJECTION

CEFURXIME AND DEXTROSE IN DUPLEX CONTAINER

+ @ B BRAUN	EQ 750MG BASE/VIAL	N050780	001	Feb 21, 2001	Jun DISC
+ !	EQ 750MG BASE/VIAL	N050780	001	Feb 21, 2001	May CTEC
+ @	EQ 1.5GM BASE/VIAL	N050780	002	Feb 21, 2001	Jun DISC
CEFURXIME SODIUM					
@ ACS DOBFAR SPA	EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997	Jun DISC
AP ! HIKMA	EQ 1.5GM BASE/VIAL	A065048	002	Jan 09, 2004	Jun CHRS
@	EQ 7.5GM BASE/VIAL	A065046	001	Jan 09, 2004	Jun DISC
ZINACEF					
+ @ PAI HOLDINGS PHARM	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jun DISC
+ @	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jun DISC
INJECTABLE; INTRAMUSCULAR, INTRAVENOUS					
CEFURXIME SODIUM					
AB ! HIKMA	EQ 750MG BASE/VIAL	A065048	001	Jan 09, 2004	Jun CHRS
ZINACEF					
+ @ PAI HOLDINGS PHARM	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jun DISC

CELECOXIB

CAPSULE; ORAL

CELECOXIB

@ MYLAN	50MG	A078857	001	May 30, 2014	Jun DISC
@	100MG	A078857	002	Feb 11, 2015	Mar DISC
@	200MG	A078857	003	Feb 11, 2015	Jun DISC
@	400MG	A078857	004	Feb 11, 2015	Jun DISC
AB YABAO PHARM	100MG	A212564	001	Apr 10, 2023	Mar NEWA
AB	200MG	A212564	002	Apr 10, 2023	Mar NEWA
AB	400MG	A212564	003	Apr 10, 2023	Mar NEWA
SOLUTION; ORAL					
ELYXYB					
+ @ SCILEX HLDG	25MG/ML	N212157	001	May 05, 2020	Feb CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

AA BIONPHARMA	5MG/5ML	A078488	001	Oct 06, 2008	Jun CAHN
---------------	---------	---------	-----	--------------	----------

CETRORELIx ACETATE

POWDER; SUBCUTANEOUS

CETRORELIx ACETATE

AP TEVA PHARMS INC	EQ 0.25MG BASE/VIAL	A215737	001	Aug 12, 2022	Jul CAHN
--------------------	---------------------	---------	-----	--------------	----------

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

CEVIMELINE HYDROCHLORIDE

AB AUROBINDO PHARMA	30MG	A215056	001	Apr 18, 2023	Apr NEWA
AB RUBICON	30MG	A216682	001	Apr 06, 2023	Mar NEWA

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

AT CHARTWELL RX	0.12%	A075006	001	Mar 03, 2004	Jan CAHN
-----------------	-------	---------	-----	--------------	----------

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB ALEMBIC	10MG	A217350	001	Jul 18, 2023	Jul NEWA
	25MG	A217350	002	Jul 18, 2023	Jul NEWA
AB	50MG	A217350	003	Jul 18, 2023	Jul NEWA
AB	100MG	A217350	004	Jul 18, 2023	Jul NEWA
AB	200MG	A217350	005	Jul 18, 2023	Jul NEWA
AB AMNEAL PHARMS CO	10MG	A209755	001	Sep 10, 2018	Apr CTEC
AB	25MG	A209755	002	Sep 10, 2018	Apr CTEC
AB	50MG	A209755	003	Sep 10, 2018	Apr CTEC
AB	100MG	A209755	004	Sep 10, 2018	Apr CTEC
AB	200MG	A209755	005	Sep 10, 2018	Apr CTEC
AB APPCO	10MG	A213590	001	Aug 31, 2020	Jul CMFD
AB	25MG	A213590	002	Aug 31, 2020	Jul CMFD
AB	50MG	A213590	003	Aug 31, 2020	Jul CMFD
AB	100MG	A213590	004	Aug 31, 2020	Jul CMFD

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB		200MG	A213590	005	Aug 31, 2020	Jul CMFD
AB	LUPIN	10MG	A213327	001	Jul 13, 2023	Jul NEWA
AB		25MG	A213327	002	Jul 13, 2023	Jul NEWA
AB		50MG	A213327	003	Jul 13, 2023	Jul NEWA
AB		100MG	A213327	004	Jul 13, 2023	Jul NEWA
AB		200MG	A213327	005	Jul 13, 2023	Jul NEWA

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

AA	ACME LABS	500MG	A214365	001	Apr 27, 2023	Apr NEWA	
AB	APPCO	375MG	A212047	001	Jan 27, 2023	Jan NEWA	
AB		750MG	A212047	002	Jan 27, 2023	Jan NEWA	
>A>	AB	AUROBINDO PHARMA LTD	375MG	A089853	002	Aug 17, 2023	Aug NEWA
>A>	AB		750MG	A089853	003	Aug 17, 2023	Aug NEWA
AA	BELCHER	250MG	A215540	001	Jan 24, 2023	Jan NEWA	
AA	COREPHARMA	250MG	A214702	001	Apr 10, 2023	Mar NEWA	
AA	GRAVITI PHARMS	250MG	A216925	001	Aug 09, 2023	Jul NEWA	

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE

>D>	AB	ANI PHARMS	EQ 4GM RESIN/PACKET	A074554	001	Oct 02, 1996	Aug DISC
>A>		@	EQ 4GM RESIN/PACKET	A074554	001	Oct 02, 1996	Aug DISC
>D>	AB		EQ 4GM RESIN/SCOOPFUL	A074554	002	Oct 02, 1996	Aug DISC
>A>		@	EQ 4GM RESIN/SCOOPFUL	A074554	002	Oct 02, 1996	Aug DISC

CHOLINE C-11

INJECTABLE;INTRAVENOUS

CHOLINE C-11

@ WA UNIV SCH MED

4-33.1mCi/ML

A208413 001 Jan 10, 2017 Jul DISC

CICLOPIROX

SHAMPOO;TOPICAL

CICLOPIROX

@ PAI HOLDINGS PHARM

1%

A209975 001 Apr 05, 2018 May DISC

SOLUTION;TOPICAL

CICLOPIROX

AT ! PADAGIS US
PENLAC

8%

A077623 001 Sep 18, 2007

Jan CHRS

+ @ VALEANT BERMUDA

8%

N021022 001 Dec 17, 1999

Jan DISC

CILOSTAZOL

TABLET;ORAL

CILOSTAZOL

@ AUROBINDO PHARMA USA

50MG

A077019 001 Nov 23, 2004

Apr CAHN

@

100MG

A077019 002 Nov 23, 2004

Apr CAHN

AB EPIC PHARMA LLC

50MG

A077022 002 Mar 11, 2005

Jun CMFD

AB

100MG

A077022 001 Nov 23, 2004

Jun CMFD

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

@ XTRRIUM LABS INC

EQ 300MG BASE/5ML

A074757 001 Oct 17, 1997

Jul DISC

AA

EQ 300MG BASE/5ML

A074757 001 Oct 17, 1997

Mar CAHN

CINACALCET HYDROCHLORIDE

TABLET;ORAL

CINACALCET HYDROCHLORIDE

AB CHARTWELL RX

EQ 30MG BASE

A213325 001 May 18, 2020

Jun CAHN

AB

EQ 60MG BASE

A213325 002 May 18, 2020

Jun CAHN

AB

EQ 90MG BASE

A213325 003 May 18, 2020

Jun CAHN

CIPROFLOXACIN

FOR SUSPENSION;ORAL

CIPRO

AB + BAYER HLTHCARE

250MG/5ML

N020780 001 Sep 26, 1997

May CTEC

AB +!

500MG/5ML

N020780 002 Sep 26, 1997

May CTEC

FOR SUSPENSION;ORAL

CIPROFLOXACIN

AB	CHARTWELL	250MG/5ML	A200563	001	Mar 05, 2014	May CMFD
AB		500MG/5ML	A200563	002	Mar 05, 2014	May CMFD
	INJECTABLE, SUSPENSION;OTIC					
	OTIPRIO					

+ @ ALK ABELLO 6% (60MG/ML)

N207986 001 Dec 10, 2015 Jan DISC

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

>D> AT	@ AKORN	EQ 0.3% BASE	A076555	001	Dec 11, 2008	Feb DISC
>A>	PAI HOLDINGS PHARM	EQ 0.3% BASE	A076754	001	Jun 09, 2004	Aug DISC
>D>	@	EQ 0.3% BASE	A076754	001	Jun 09, 2004	Aug DISC
>A> AT	RUBICON	EQ 0.3% BASE	A075928	001	Jun 09, 2004	Aug CMFD
		EQ 0.3% BASE	A075928	001	Jun 09, 2004	Aug CMFD

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB	AMNEAL	EQ 100MG BASE	A075939	001	Mar 03, 2005	Jun CMFD
AB		EQ 250MG BASE	A075939	002	Jun 09, 2004	Jun CMFD
AB		EQ 500MG BASE	A075939	003	Jun 09, 2004	Jun CMFD
AB		EQ 750MG BASE	A075939	004	Jun 09, 2004	Jun CMFD
>D> AB	TARO	EQ 100MG BASE	A076912	001	Feb 18, 2005	Aug DISC
>A>	@	EQ 100MG BASE	A076912	001	Feb 18, 2005	Aug DISC
>D> AB		EQ 250MG BASE	A076912	002	Oct 06, 2004	Aug DISC
>A>	@	EQ 250MG BASE	A076912	002	Oct 06, 2004	Aug DISC
>D> AB		EQ 500MG BASE	A076912	003	Oct 06, 2004	Aug DISC
>A>	@	EQ 500MG BASE	A076912	003	Oct 06, 2004	Aug DISC
>D> AB		EQ 750MG BASE	A076912	004	Oct 06, 2004	Aug DISC
>A>	@	EQ 750MG BASE	A076912	004	Oct 06, 2004	Aug DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

@ RISING	212.6MG;EQ 287.5MG BASE	A078183	001	Mar 22, 2007	Jun CAHN
@	425.2MG;EQ 574.9MG BASE	A078183	002	Mar 22, 2007	Jun CAHN

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS;OTIC

CIPROFLOXACIN AND DEXAMETHASONE

>D> AB	AKORN	0.3%;0.1%	A215768	001	Jun 09, 2023	Aug CAHN
AB		0.3%;0.1%	A215768	001	Jun 09, 2023	Jun NEWA
>A> AB	SENTISSL	0.3%;0.1%	A215768	001	Jun 09, 2023	Aug CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP	CAPLIN	EQ 2MG BASE/ML	A217725	001	Jun 09, 2023	Jun NEWA
AP		EQ 10MG BASE/ML	A217725	002	Jun 09, 2023	Jun NEWA
AP	HIKMA	EQ 2MG BASE/ML	A203079	001	Apr 19, 2023	Apr NEWA

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CELEXA

AB	+ ABBVIE	EQ 10MG BASE	N020822	001	Apr 27, 2000	Feb CAHN
AB	+	EQ 20MG BASE	N020822	002	Jul 17, 1998	Feb CAHN
AB	+!	EQ 40MG BASE	N020822	003	Jul 17, 1998	Feb CAHN
	@	EQ 60MG BASE	N020822	004	Jul 17, 1998	Feb CAHN

CLARITHROMYCIN

FOR SUSPENSION;ORAL

CLARITHROMYCIN

SANDOZ	125MG/5ML	A065283	002	Sep 04, 2007	May CTEC
!	250MG/5ML	A065283	003	Sep 04, 2007	May CTEC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

AB	GLENMARK PHARMS LTD	EQ 75MG BASE	A216957	001	Mar 10, 2023	Mar NEWA
AB		EQ 150MG BASE	A216957	002	Mar 10, 2023	Mar NEWA
AB		EQ 300MG BASE	A216957	003	Mar 10, 2023	Mar NEWA

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA CHARTWELL RX EQ 75MG BASE/5ML A206958 001 May 05, 2017 Feb CAHN

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL

CLINDAMYCIN PHOSPHATE

AT ! PADAGIS ISRAEL 1% A090785 001 Mar 31, 2010 Jun CHRS

EVOCLIN

+ @ MYLAN 1% N050801 001 Oct 22, 2004 Jun DISC

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

AP HIKMA EQ 6MG BASE/ML A214401 001 Apr 05, 2023 Mar NEWA

AP EQ 12MG BASE/ML A214401 002 Apr 05, 2023 Mar NEWA

AP EQ 18MG BASE/ML A214401 003 Apr 05, 2023 Mar NEWA

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

AT CHARTWELL RX EQ 1% BASE A209846 001 Feb 08, 2018 May CAHN

>D> AT PAI HOLDINGS PHARM EQ 1% BASE A206945 001 Dec 30, 2016 Aug DISC

>A> @ EQ 1% BASE A206945 001 Dec 30, 2016 Aug DISC

@ XTTRIUM LABS INC EQ 1% BASE A063304 001 Jul 15, 1997 Jan CAHN

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

>A> AB2 ENCUBE 1.2%;0.025% A216943 001 Sep 01, 2023 Aug NEWA

CLOBAZAM

SUSPENSION;ORAL

CLOBAZAM

@ ACCORD HLTHCARE 2.5MG/ML A216008 001 Sep 06, 2022 Mar DISC

@ UPSHER SMITH LABS 2.5MG/ML A210569 001 Oct 22, 2018 Mar DISC

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE

@ CHARTWELL RX 0.05% A211207 001 Mar 26, 2021 May CAHN

AB1 ! ENCUBE 0.05% A212982 001 Aug 28, 2020 Jun CHRS

>D> AB1 PAI HOLDINGS PHARM 0.05% A209974 001 Apr 17, 2018 Aug DISC

>A> @ 0.05% A209974 001 Apr 17, 2018 Aug DISC

@ TORRENT 0.05% A211836 001 Dec 30, 2019 Feb DISC

CLOBETASOL PROPIONATE (EMOLLIENT)

@ ANI PHARMS 0.05% A075733 001 Aug 22, 2001 Apr DISC

>D> AB2 PAI HOLDINGS PHARM 0.05% A209411 001 Aug 21, 2017 Aug DISC

>A> @ 0.05% A209411 001 Aug 21, 2017 Aug DISC

CORMAX

AB1 AKORN 0.05% A074220 001 May 16, 1997 Jun CHRS

GEL;TOPICAL

CLOBETASOL PROPIONATE

>D> AB PAI HOLDINGS PHARM 0.05% A208881 001 Mar 06, 2017 Aug DISC

>A> @ 0.05% A208881 001 Mar 06, 2017 Aug DISC

LOTION;TOPICAL

CLOBETASOL PROPIONATE

>D> AB PAI HOLDINGS PHARM 0.05% A208667 001 Nov 29, 2016 Aug DISC

>A> @ 0.05% A208667 001 Nov 29, 2016 Aug DISC

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

>D> AB PAI HOLDINGS PHARM 0.05% A208589 001 Jan 23, 2019 Aug DISC

>A> @ 0.05% A208589 001 Jan 23, 2019 Aug DISC

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

>D> AT TARO 0.05% A075224 001 Nov 16, 1998 Aug CHRS

>A> AT ! 0.05% A075224 001 Nov 16, 1998 Aug CHRS

EMBELINE

>D> AT ! AKORN 0.05% A074222 001 Dec 06, 1995 Aug CHRS

>A> AT 0.05% A074222 001 Dec 06, 1995 Aug CHRS

CLOFARABINE

SOLUTION; INTRAVENOUS
 CLOFARABINE
 @ EUGIA PHARMA 20MG/20ML (1MG/ML) A212457 001 Oct 03, 2022 Mar DISC

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
 CLOMIPRAMINE HYDROCHLORIDE

AB AUROBINDO PHARMA	25MG	A216440	001	Mar 20, 2023	Mar NEWA
AB	50MG	A216440	002	Mar 20, 2023	Mar NEWA
AB	75MG	A216440	003	Mar 20, 2023	Mar NEWA
AB RK PHARMA	25MG	A213221	001	Jun 22, 2020	Jun CAHN
AB	50MG	A213221	002	Jun 22, 2020	Jun CAHN
AB	75MG	A213221	003	Jun 22, 2020	Jun CAHN

CLONAZEPAM

TABLET; ORAL
 CLONAZEPAM

AB AUROBINDO PHARMA USA	0.5MG	A075150	001	Oct 05, 1998	Jan CMFD
AB	1MG	A075150	002	Oct 05, 1998	Jan CMFD
AB	2MG	A075150	003	Oct 05, 1998	Jan CMFD

CLOPIDOGREL BISULFATE

TABLET; ORAL
 CLOPIDOGREL BISULFATE

@ CHARTWELL RX	EQ 75MG BASE	A202266	001	Aug 14, 2012	Jun CAHN
@	EQ 300MG BASE	A202266	002	Nov 20, 2012	Jun CAHN
>D> AB GRAVITI PHARMS	EQ 75MG BASE	A204359	001	Feb 02, 2017	Aug CAHN
>A> AB HETERO LABS LTD V	EQ 75MG BASE	A205345	001	Aug 04, 2023	Aug NEWA
>A> AB	EQ 300MG BASE	A205345	002	Aug 04, 2023	Aug NEWA
>A> AB RISING	EQ 75MG BASE	A204359	001	Feb 02, 2017	Aug CAHN

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
 CLORAZEPATE DIPOTASSIUM

@ DASH PHARMS	3.75MG	A071509	001	Oct 19, 1987	Feb CAHN
@	7.5MG	A071510	001	Oct 19, 1987	Feb CAHN
@	15MG	A071511	001	Oct 19, 1987	Feb CAHN

CLOZAPINE

TABLET; ORAL
 CLOZAPINE

@ DR REDDYS LABS SA	25MG	A203807	001	Sep 17, 2015	Apr CAHN
@	50MG	A203807	003	Aug 22, 2017	Apr CAHN
@	100MG	A203807	002	Sep 17, 2015	Apr CAHN
@	200MG	A203807	004	Aug 22, 2017	Apr CAHN
@ MAYNE PHARMA	25MG	A203807	001	Sep 17, 2015	Apr DISC
@	50MG	A203807	003	Aug 22, 2017	Apr DISC
@	100MG	A203807	002	Sep 17, 2015	Apr DISC
@	200MG	A203807	004	Aug 22, 2017	Apr DISC

TABLET, ORALLY DISINTEGRATING; ORAL
 CLOZAPINE

AB MYLAN	150MG	A201824	004	Aug 07, 2023	Jul NEWA
AB	200MG	A201824	005	Aug 07, 2023	Jul NEWA
AB TEVA PHARMS USA	150MG	A203039	001	Nov 25, 2015	Jul CTEC
AB	200MG	A203039	002	Nov 25, 2015	Jul CTEC

COCAINE HYDROCHLORIDE

SOLUTION; NASAL
 NUMBRINO

>D> +! CODY LABS INC	4%	N209575	001	Jan 10, 2020	Aug CAHN
>A> +! OMNIVIUM PHARMS	4%	N209575	001	Jan 10, 2020	Aug CAHN

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
 TRIACIN-C

! ANIMA	10MG/5ML; 30MG/5ML; 1.25MG/5ML	A088704	001	Mar 22, 1985	Mar CAHN
---------	--------------------------------	---------	-----	--------------	----------

COLCHICINE

CAPSULE;ORAL	COLCHICINE				
AB PAR PHARM INC	0.6MG	A208678	001	Nov 29, 2018	Jun CMFD
MITIGARE					
AB +! HIKMA INTL PHARMS	0.6MG	N204820	001	Sep 26, 2014	Jun CTEC
TABLET;ORAL					
LODOC					
+! AGEPHA PHARMA FZ	0.5MG	N215727	001	Jun 16, 2023	Jun NEWA

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION;ORAL	COLESEVELAM HYDROCHLORIDE				
AB IMPAX	3.75GM/PACKET	A212886	001	Jan 18, 2023	Jan NEWA
TABLET;ORAL					
COLESEVELAM HYDROCHLORIDE					
@ CHARTWELL RX	625MG	A201354	001	Dec 17, 2020	May CAHN

COlestipol Hydrochloride

TABLET;ORAL	COlestipol Hydrochloride				
AB ANI PHARMS	1GM	A216517	001	Mar 10, 2023	Apr CAHN
AB PRAXGEN	1GM	A216517	001	Mar 10, 2023	Mar NEWA

CORTISONE ACETATE

TABLET;ORAL	CORTISONE ACETATE				
@ HIKMA INTL PHARMS	25MG	A080776	002		Jul DISC

CROMOLYN SODIUM

SOLUTION;INHALATION	CROMOLYN SODIUM				
AN @ EUGIA PHARMA	10MG/ML	A074209	001	Apr 26, 1994	May CAHN
VIRTUS	10MG/ML	A075437	001	Apr 21, 2000	Apr CAHN
SOLUTION/DROPS;OPHTHALMIC	CROMOLYN SODIUM				
@ AKORN	4%	A074706	001	Apr 29, 1998	Feb DISC
! SANDOZ	4%	A075282	001	Jun 16, 1999	Feb CTEC
AT ! SANDOZ INC	4%	A075282	001	Jun 16, 1999	Feb CHRS

CYANOCOBALAMIN

SPRAY, METERED;NASAL	CYANOCOBALAMIN				
AB LUPIN	0.5MG/SPRAY	A210629	001	Jun 30, 2023	Jun NEWA
NASCOBAL					
AB +! ENDO PHARMS INC	0.5MG/SPRAY	N021642	001	Jan 31, 2005	Jun CTEC

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL	CYCLOBENZAPRINE HYDROCHLORIDE				
@ APOTEX	15MG	A206703	001	Jul 24, 2018	Mar DISC
@	30MG	A206703	002	Jul 24, 2018	Mar DISC
TABLET;ORAL	CYCLOBENZAPRINE HYDROCHLORIDE				
AB CHARTWELL RX	5MG	A078218	002	Jun 19, 2015	Feb CAHN
AB	7.5MG	A078218	003	Nov 03, 2020	Feb CAHN
AB	10MG	A078218	001	Apr 18, 2008	Feb CAHN

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC	CYCLOGYL				
+! ALCON LABS INC	0.5%	A084109	001		Feb CTEC
CYCLOPENTOLATE HYDROCHLORIDE					
@ AKORN	0.5%	A205937	001	Dec 09, 2015	Feb DISC

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

AP	SAGENT PHARMS INC	500MG/VIAL	A214529	001	Jul 17, 2023	Jul NEWA
AP		1GM/VIAL	A214529	002	Jul 17, 2023	Jul NEWA
AP		2GM/VIAL	A214529	003	Jul 17, 2023	Jul NEWA
AP	XGEN PHARMS	500MG/VIAL	A211757	001	Oct 18, 2022	May CAHN
AP		1GM/VIAL	A211757	002	Oct 18, 2022	May CAHN
AP		2GM/VIAL	A211757	003	Oct 18, 2022	May CAHN
	SOLUTION; INTRAVENOUS					
	CYCLOPHOSPHAMIDE					
+!	DR REDDYS	500MG/ML (500MG/ML)	N210852	001	Jun 07, 2023	Jun NEWA
+!		1GM/2ML (500MG/ML)	N210852	002	Jun 07, 2023	Jun NEWA
+!		2GM/4ML (500MG/ML)	N210852	003	Jun 07, 2023	Jun NEWA
>D>	+! NEVAKAR INJECTABLES	500MG/2.5ML (200MG/ML)	N217651	001	Jun 28, 2023	Aug DISC
>A>	+ @	500MG/2.5ML (200MG/ML)	N217651	001	Jun 28, 2023	Aug DISC
+!		500MG/2.5ML (200MG/ML)	N217651	001	Jun 28, 2023	Jun NEWA
>D>	+!	1GM/5ML (200MG/ML)	N217651	002	Jun 28, 2023	Aug DISC
>A>	+ @	1GM/5ML (200MG/ML)	N217651	002	Jun 28, 2023	Aug DISC
+!		1GM/5ML (200MG/ML)	N217651	002	Jun 28, 2023	Jun NEWA

CYCLOSPORINEEMULSION; OPHTHALMIC
CYCLOSPORINE

AB	APOTEX	0.05%	A207606	001	Jan 12, 2023	Jan NEWA
	SOLUTION; OPHTHALMIC VEVYE					
+!	NOVALIQ GMBH	0.1%	N217469	001	May 30, 2023	May NEWA
	SOLUTION; ORAL CYCLOSPORINE					
	@ XTTRIUM LABS INC	100MG/ML	A065133	001	Sep 17, 2004	Jul DISC
		100MG/ML	A065133	001	Sep 17, 2004	Jan CAHN
AB2	SANDIMMUNE					
+!	NOVARTIS	100MG/ML	N050574	001	Nov 14, 1983	Jul CTEC

CYPROHEPTADINE HYDROCHLORIDETABLET; ORAL
CYPROHEPTADINE HYDROCHLORIDE

AA	CHARTWELL RX	4MG	A088212	001	May 26, 1983	Mar CMFD
>D> AA	ELYSIUM	4MG	A207555	001	Jan 31, 2017	Aug CAHN
>A> AA	RISING	4MG	A207555	001	Jan 31, 2017	Aug CAHN
	@	4MG	A207783	001	Dec 29, 2016	May DISC

CYSTEINE HYDROCHLORIDEINJECTABLE; INJECTION
CYSTEINE HYDROCHLORIDE

@ HIKMA		7.25%	A213073	001	Jan 26, 2023	Apr CAHN
@ NIVAGEN PHARMS INC		7.25%	A213073	001	Jan 26, 2023	Apr DISC
		7.25%	A213073	001	Jan 26, 2023	Jan NFTG

DABRAFENIB MESYLATETABLET, FOR SUSPENSION; ORAL
TAFINLAR

+!	NOVARTIS	EQ 10MG BASE	N217514	001	Mar 16, 2023	Mar NEWA
----	----------	--------------	---------	-----	--------------	----------

DALBAVANCIN HYDROCHLORIDEPOWDER; INTRAVENOUS
DALVANCE

+!	ABBVIE	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	Jun CAHN
----	--------	--------------------	---------	-----	--------------	----------

DAPRODUSTATTABLET; ORAL
JESDUVROQ

+!	GLAXOSMITHKLINE	1MG	N216951	001	Feb 01, 2023	Feb NEWA
+!		2MG	N216951	002	Feb 01, 2023	Feb NEWA
+!		4MG	N216951	003	Feb 01, 2023	Feb NEWA
+!		6MG	N216951	004	Feb 01, 2023	Feb NEWA
+!		8MG	N216951	005	Feb 01, 2023	Feb NEWA

DAPSONE

	GEL;TOPICAL ACZONE						
AB	+! ABBVIE	5%		N 021794	001	Jul 07, 2005	Jun CAHN
	DAPSONE						
AB	ACRUX DDS	5%		A 213907	001	Jun 06, 2023	May NEWA
AB	AMNEAL	7.5%		A 212701	001	May 31, 2023	May NEWA
	TABLET;ORAL DAPSONE						
AB	+ EVEREST LIFE SCI	100MG		A 086842	001		Jun CHRS
AB	! NOVITIUM PHARMA	100MG		A 206505	002	Dec 01, 2016	Jun CHRS
AB	RISING	25MG		A 207165	002	Jul 20, 2023	Jul NEWA

DAPTOMYCIN

	POWDER;INTRAVENOUS DAPTOMYCIN						
AP	@ HAINAN POLY PHARM	500MG/VIAL		A 215890	001	Aug 18, 2022	Feb DISC
	MYLAN	500MG/VIAL		A 213966	001	Aug 07, 2023	Jul NEWA
AP	! QILU PHARM HAINAN	500MG/VIAL		A 215316	001	Aug 24, 2021	May CHRS
	+! XELLIA PHARMS APS	350MG/VIAL		N 217415	001	Jan 30, 2023	Jan NEWA
	+!	500MG/VIAL		N 217415	002	Jan 30, 2023	Jan NEWA
	SOLUTION;INTRAVENOUS DAPTOMYCIN IN 0.9% SODIUM CHLORIDE						
	+! BAXTER HLTHCARE CORP	350MG/50ML (7MG/ML)		N 213645	002	Feb 27, 2023	Mar NEWA
	+!	500MG/50ML (10MG/ML)		N 213645	003	Feb 27, 2023	Mar NEWA
	+!	700MG/100ML (7MG/ML)		N 213645	004	Feb 27, 2023	Mar NEWA
	+!	1GM/100ML (10MG/ML)		N 213645	005	Feb 27, 2023	Mar NEWA

DARIFENACIN HYDROBROMIDE

	TABLET, EXTENDED RELEASE;ORAL ENABLEX						
	+ @ ABBVIE	EQ 7.5MG BASE		N 021513	001	Dec 22, 2004	Apr CAHN
	+ @	EQ 15MG BASE		N 021513	002	Dec 22, 2004	Apr CAHN

DEFERASIROX

	GRANULE;ORAL DEFERASIROX						
AB	ANNORA PHARMA	90MG		A 216229	003	Mar 16, 2023	Mar NEWA
	TABLET;ORAL DEFERASIROX						
AB	CHARTWELL RX	90MG		A 212669	001	May 27, 2021	Mar CAHN
AB		180MG		A 212669	002	May 27, 2021	Mar CAHN
AB		360MG		A 212669	003	May 27, 2021	Mar CAHN
	@ CIPLA	90MG		A 211852	001	Feb 11, 2020	Mar DISC
	@	180MG		A 211852	003	Jun 15, 2020	Mar DISC
	@	360MG		A 211852	002	Feb 11, 2020	Mar DISC
	TABLET, FOR SUSPENSION;ORAL DEFERASIROX						
	@ TEVA PHARMS USA	125MG		A 207124	001	Sep 23, 2022	Mar DISC
	@	250MG		A 207124	002	Sep 23, 2022	Mar DISC
	@	500MG		A 207124	003	Sep 23, 2022	Mar DISC

DEFERIPRONE

	TABLET;ORAL DEFERIPRONE						
AB	! HIKMA FERRIPROX	1GM		A 213239	002	Feb 08, 2022	May CHRS
AB	+ CHIESI	1GM		N 021825	002	Jul 25, 2019	May CHRS

DESLORATADINE

	TABLET;ORAL DESLORATADINE						
	@ DASH PHARMS	5MG		A 078351	001	Feb 10, 2012	Feb CAHN

DESMOPRESSIN ACETATE

	INJECTABLE;INJECTION DESMOPRESSIN ACETATE						
AP	GLAND	0.004MG/ML		A 216904	001	Mar 20, 2023	Mar NEWA

**SPRAY, METERED;NASAL
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)**

>A> AB	! APOTEX	0.01MG/SPRAY	A076703	001	Jan 27, 2005	Aug CHRS
>D> AB	APOTEX INC	0.01MG/SPRAY	A076703	001	Jan 27, 2005	Aug CHRS
>D> AB	! SUN PHARM	0.01MG/SPRAY	A078271	001	Dec 23, 2013	Aug DISC
>A>	@	0.01MG/SPRAY	A078271	001	Dec 23, 2013	Aug DISC

DESONIDE

LOTION;TOPICAL DESONIDE			A207855	001	Sep 28, 2017	May DISC
@ PAI HOLDINGS PHARM 0.05%			A212002	001	Mar 12, 2019	Aug DISC
OINTMENT;TOPICAL DESONIDE			A212002	001	Mar 12, 2019	Aug DISC
>D> AB	PAI HOLDINGS PHARM	0.05%				
>A>	@	0.05%				

DESOXIMETASONE

OINTMENT;TOPICAL DESOXIMETASONE			A208101	001	Feb 25, 2016	Aug DISC
>D> AB	PAI HOLDINGS PHARM	0.25%	A208101	001	Feb 25, 2016	Aug DISC
>A>	@	0.25%				

DEUTETRABENAZINE

TABLET, EXTENDED RELEASE;ORAL AUSTEDO XR			N216354	001	Feb 17, 2023	Feb NEWA
+ TEVA	6MG	N216354	002	Feb 17, 2023	Feb NEWA	
+!	12MG	N216354	003	Feb 17, 2023	Feb NEWA	
	24MG					

DEXAMETHASONE

ELIXIR;ORAL DEXAMETHASONE			A088254	001	Jul 27, 1983	Jan CAHN
+ @ XTTRIUM LABS INC	0.5MG/5ML					
SUSPENSION/DROPS;OPHTHALMIC MAXIDEX			N013422	001		May CAHN
+! HARROW EYE	0.1%					
TABLET;ORAL DEXAMETHASONE						
AB ALVOGEN	4MG	A088481	004	Apr 28, 1983	Apr CTEC	
AB	6MG	A088481	001	Nov 28, 1983	Apr CTEC	
>A> BP APOTEX	0.5MG	A217695	001	Aug 23, 2023	Aug NEWA	
>A> BP	0.75MG	A217695	002	Aug 23, 2023	Aug NEWA	
>A> BP	1MG	A217695	003	Aug 23, 2023	Aug NEWA	
>A> AB	1.5MG	A217695	004	Aug 23, 2023	Aug NEWA	
>A> AB	2MG	A217695	005	Aug 23, 2023	Aug NEWA	
>A> AB	4MG	A217695	006	Aug 23, 2023	Aug NEWA	
>A> AB	6MG	A217695	007	Aug 23, 2023	Aug NEWA	
AB BIONPHARMA	2MG	A217538	001	Apr 26, 2023	Apr NEWA	
AB	4MG	A217001	001	Apr 19, 2023	Apr NEWA	
AB	6MG	A217001	002	Apr 19, 2023	Apr NEWA	
AB NOVITIUM PHARMA	2MG	A217696	001	May 09, 2023	Apr NEWA	
AB PRASCO	4MG	A080399	002	Apr 20, 2022	Apr CMFD	
@	4MG	A080399	002	Apr 20, 2022	Feb DISC	

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION DEXAMETHASONE SODIUM PHOSPHATE						
AP GENEYORK PHARMS	EQ 10MG PHOSPHATE/ML	A214890	001	Jul 07, 2023	Jun NEWA	
AP HIKMA	EQ 4MG PHOSPHATE/ML	A211451	001	Aug 01, 2023	Jul NEWA	

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS;OPHTHALMIC MAXITROL						
AT +! HARROW EYE	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050023	002			

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC TOBRAMYCIN AND DEXAMETHASONE						
@ AMNEAL	0.1%;0.3%	A212991	001	Jul 15, 2021	Jun DISC	

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP	AMNEAL	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A216604	001	May 15, 2023	May NEWA
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A216604	002	May 15, 2023	May NEWA
AP	MILLA PHARMS	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A217308	001	Jun 07, 2023	May NEWA
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A217308	002	Jun 07, 2023	May NEWA

DEXTROAMPHETAMINE SULFATE

SOLUTION; ORAL

DEXTROAMPHETAMINE SULFATE

AA	! PRASCO	5MG/5ML	A040776	001	Jan 29, 2008	Mar CAHN
	TABLET; ORAL					
		DEXTROAMPHETAMINE SULFATE				
AA	ARBOR PHARMS LLC	2.5MG	A090533	001	Oct 25, 2011	Jan CTEC
AA		7.5MG	A090533	003	Oct 25, 2011	Jan CTEC
AA		15MG	A090533	005	Oct 25, 2011	Jan CTEC
AA		20MG	A090533	006	Oct 25, 2011	Jan CTEC
AA		30MG	A090533	007	Oct 25, 2011	Jan CTEC
AA	WINDER LABS LLC	2.5MG	A212160	001	Jun 07, 2021	Jan CMFD
AA		5MG	A212160	002	Jun 07, 2021	Jan CMFD
AA		7.5MG	A212160	003	Jun 07, 2021	Jan CMFD
AA		10MG	A212160	004	Jun 07, 2021	Jan CMFD
AA		15MG	A212160	005	Jun 07, 2021	Jan CMFD
AA		20MG	A212160	006	Jun 07, 2021	Jan CMFD
AA		30MG	A212160	007	Jun 07, 2021	Jan CMFD

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	5GM/100ML;149MG/100ML;225MG/100ML	A212348	001	Jul 30, 2021	Mar CMFD
AP	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
AP	FRESENIUS KABI USA	5GM/100ML;74.5MG/100ML;450MG/100ML	A213523	001	Mar 09, 2021	Mar CMFD
AP	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
AP	FRESENIUS KABI USA	5GM/100ML;149MG/100ML;225MG/100ML	A212348	002	Jul 30, 2021	Mar CMFD
AP	+! ICU MEDICAL INC	5GM/100ML;149MG/100ML;225MG/100ML	N018365	001		Mar CHRS
AP	+	5GM/100ML;149MG/100ML;225MG/100ML	N018365	001		Mar CTEC
AP	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
AP	FRESENIUS KABI USA	5GM/100ML;149MG/100ML;450MG/100ML	A213523	002	Mar 09, 2021	Mar CMFD
AP	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%					
AP	FRESENIUS KABI USA	5GM/100ML;149MG/100ML;900MG/100ML	A213445	001	Mar 09, 2021	Mar CMFD
AP	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
AP	FRESENIUS KABI USA	5GM/100ML;224MG/100ML;450MG/100ML	A213523	003	Mar 09, 2021	Mar CMFD
AP	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
AP	FRESENIUS KABI USA	5GM/100ML;298MG/100ML;450MG/100ML	A213523	004	Mar 09, 2021	Mar CMFD
AP	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%					
AP	FRESENIUS KABI USA	5GM/100ML;298MG/100ML;900MG/100ML	A213445	002	Mar 09, 2021	Mar CMFD

DIAZEPAM

GEL; RECTAL

DIASTAT ACUDIAL

AB	+! BAUSCH	10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005	May CFTG
AB	+!	20MG/4ML (5MG/ML)	N020648	006	Sep 15, 2005	May CFTG
	DIAZEPAM					
AB	NOVEL LABS INC	10MG/2ML (5MG/ML)	A091076	001	May 30, 2023	May NFTG
AB		20MG/4ML (5MG/ML)	A091076	002	May 30, 2023	May NFTG

DICLOFENAC EPOLAMINE

SYSTEM; TOPICAL

FLECTOR

>A>	+! IBSA	1.3%	N021234	001	Jan 31, 2007	Aug CAHN
>D>	+! INST BIOCHEM	1.3%	N021234	001	Jan 31, 2007	Aug CAHN

DICLOFENAC POTASSIUM

TABLET;ORAL

DICLOFENAC POTASSIUM

AB	@ CHARTWELL RX	50MG	A075582	001	Feb 23, 2001	May CAHN
	SENORES PHARMS	50MG	A215787	001	Mar 15, 2023	Mar NEWA

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

AB	AMNEAL	3%	A200936	001	Oct 28, 2013	Feb CAHN
----	--------	----	---------	-----	--------------	----------

SOLUTION;TOPICAL

DICLOFENAC SODIUM

AB	AUROLIFE PHARMA LLC	2%	A213040	001	Feb 03, 2023	Jan NEWA
>D> AT	PAI HOLDINGS PHARM	1.5%	A202769	001	Jul 08, 2015	Aug DISC
>A>	@	1.5%	A202769	001	Jul 08, 2015	Aug DISC

SOLUTION/DROPS;OPHTHALMIC

DICLOFENAC SODIUM

>D>	@ RUBICON	0.1%	A077600	001	Nov 13, 2008	Aug CMFD
>A> AT		0.1%	A077600	001	Nov 13, 2008	Aug CMFD

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM

AB	RUBICON	25MG	A216548	001	May 11, 2023	May NEWA
AB		50MG	A216548	002	May 11, 2023	May NEWA
AB		75MG	A216548	003	May 11, 2023	May NEWA

TABLET, EXTENDED RELEASE;ORAL

DICLOFENAC SODIUM

@ AUROBINDO PHARMA USA 100MG

A076152 001 Dec 13, 2001 Apr CAHN

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

AB	ZYDUS PHARMS	50MG;0.2MG	A206771	001	Jun 12, 2023	Jun NEWA
AB		75MG;0.2MG	A206771	002	Jun 12, 2023	Jun NEWA

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

DICYCLOMINE HYDROCHLORIDE

AB	COREPHARMA	10MG	A216639	001	Mar 24, 2023	Mar NEWA
>A> AB	PRINSTON INC	10MG	A217531	001	Aug 30, 2023	Aug NEWA

INJECTABLE;INJECTION

BENTYL

AP	+! ABBVIE	10MG/ML	N008370	001	Oct 15, 1984	Feb CAHN
AP	BENTYL PRESERVATIVE FREE		N008370	002	Oct 15, 1984	Feb CAHN

AP	+! ABBVIE	10MG/ML	N008370	002	Oct 15, 1984	Feb CAHN
	DICYCLOMINE HYDROCHLORIDE					

>D> AP	AKORN	10MG/ML	A207084	001	May 04, 2018	Aug CAHN
>A> AP	@ PRAZGEN PHARMS	10MG/ML	A212058	001	Apr 26, 2019	Jul CAHN
>A> AP	RENEW PHARMS	10MG/ML	A207084	001	May 04, 2018	Aug CAHN

TABLET;ORAL

DICYCLOMINE HYDROCHLORIDE

AB	AUROBINDO PHARMA USA	20MG	A040317	001	Sep 07, 1999	Feb CMFD
AB	BIONPHARMA	20MG	A217916	001	Aug 04, 2023	Jul NEWA
AB	TWI PHARMS	20MG	A216782	001	Jun 01, 2023	May NEWA

DIETHYLPROMION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

DIETHYLPROMION HYDROCHLORIDE

!	LANNETT CO INC	75MG	A091680	001	Oct 24, 2011	Feb CTEC
---	----------------	------	---------	-----	--------------	----------

DIFLORASONE DIACETATE

CREAM;TOPICAL

DIFLORASONE DIACETATE

AB	@ AVONDALE PHARMS	0.05%	A075187	001	Mar 30, 1998	May CAHN
----	-------------------	-------	---------	-----	--------------	----------

OINTMENT;TOPICAL

DIFLORASONE DIACETATE

AB	AVONDALE PHARMS	0.05%	A075374	001	Apr 27, 1999	May CAHN
----	-----------------	-------	---------	-----	--------------	----------

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

DIHYDROERGOTAMINE MESYLATE

>A>	AP	GLAND PHARMA LTD	1MG/ML	A215623	001	Aug 18, 2023	Aug NEWA
		SPRAY, METERED; NASAL					
		DIHYDROERGOTAMINE MESYLATE					

AB	AMNEAL	0.5MG/SPRAY	A214105	001	Jan 04, 2022	Apr CMFD
AB	RUBICON	0.5MG/SPRAY	A216881	001	Jun 22, 2023	Jun NEWA

DILTIAZEM HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HYDROCHLORIDE

AB1	TWI PHARMS	60MG	A217377	001	Mar 01, 2023	Feb NEWA
AB1		90MG	A217377	002	Mar 01, 2023	Feb NEWA
AB1		120MG	A217377	003	Mar 01, 2023	Feb NEWA

INJECTABLE; INJECTION
DILTIAZEM HYDROCHLORIDE

>D>	AP	! ATHENEX INC	5MG/ML	A074617	001	Feb 28, 1996	Aug CAHN
	AP	EUGIA PHARMA	5MG/ML	A216552	001	Mar 29, 2023	Mar NEWA
>A>	AP	! SAGENT	5MG/ML	A074617	001	Feb 28, 1996	Aug CAHN

TABLET; ORAL
DILTIAZEM HYDROCHLORIDE

>D>	AB	EDENBRIDGE PHARMS	30MG	A211596	001	Nov 18, 2019	Aug DISC
>A>		@	30MG	A211596	001	Nov 18, 2019	Aug DISC
>D>	AB		60MG	A211596	002	Nov 18, 2019	Aug DISC
>A>		@	60MG	A211596	002	Nov 18, 2019	Aug DISC
>D>	AB		90MG	A211596	003	Nov 18, 2019	Aug DISC
>A>		@	90MG	A211596	003	Nov 18, 2019	Aug DISC
>D>	AB		120MG	A211596	004	Nov 18, 2019	Aug DISC
>A>		@	120MG	A211596	004	Nov 18, 2019	Aug DISC

TABLET, EXTENDED RELEASE; ORAL
DILTIAZEM HYDROCHLORIDE

AB	AMTA	120MG	A216439	001	Mar 07, 2023	Feb NEWA
AB		180MG	A216439	002	Mar 07, 2023	Feb NEWA
AB		240MG	A216439	003	Mar 07, 2023	Feb NEWA
AB		300MG	A216439	004	Mar 07, 2023	Feb NEWA
AB		360MG	A216439	005	Mar 07, 2023	Feb NEWA
AB		420MG	A216439	006	Mar 07, 2023	Feb NEWA
AB	SCIEGEN PHARMS INC	120MG	A216327	001	Apr 06, 2023	Mar NEWA
AB		180MG	A216327	002	Apr 06, 2023	Mar NEWA
AB		240MG	A216327	003	Apr 06, 2023	Mar NEWA
AB		300MG	A216327	004	Apr 06, 2023	Mar NEWA
AB		360MG	A216327	005	Apr 06, 2023	Mar NEWA
AB		420MG	A216327	006	Apr 06, 2023	Mar NEWA

DIMERCAVROLINJECTABLE; INJECTION
BAL

>D>		+! AKORN	10%	N005939	001		Aug CAHN
>A>		+! PROVEPHARM SAS	10%	N005939	001		Aug CAHN

DIMETHYL FUMARATECAPSULE, DELAYED RELEASE; ORAL
DIMETHYL FUMARATE

AB	SOLA PHARMS	120MG	A210436	001	Mar 26, 2021	Feb CMFD
AB		240MG	A210436	002	Mar 26, 2021	Feb CMFD

DIPHENHYDRAMINE HYDROCHLORIDEELIXIR; ORAL
DIPHENHYDRAMINE HYDROCHLORIDE
+! PHARM ASSOC 12.5MG/5ML

A087513 001 Feb 10, 1982 Apr CRLD

DIPYRIDAMOLEINJECTABLE; INJECTION
DIPYRIDAMOLE
@ FRESENIUS KABI USA 5MG/ML

A074956 001 Sep 30, 1998 Jun DISC

TABLET; ORAL	DIPYRIDAMOLE						
@ ANI PHARMS	25MG		A086944	002	Apr 16, 1991	Apr DISC	
@	50MG		A086944	001	Feb 25, 1992	Apr DISC	
@	75MG		A086944	003	Feb 25, 1992	Apr DISC	

DISULFIRAM

TABLET;ORAL

DISULFIRAM

>D>	AB	CHARTWELL MOLECULES	500MG	A091563	002	Dec 31, 2012	Aug CHRS
>A>	AB	!	500MG	A091563	002	Dec 31, 2012	Aug CHRS
	@	DASH PHARMS	250MG	A203916	001	Mar 04, 2015	Feb CAHN
	@		500MG	A203916	002	Mar 04, 2015	Feb CAHN
>D>	AB	! HIKMA	500MG	A202652	002	Feb 05, 2014	Aug CHRS
>A>	AB		500MG	A202652	002	Feb 05, 2014	Aug CHRS

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM

AB	CHARTWELL RX	EQ 125MG VALPROIC ACID	A077296	001	Jul 31, 2008	Jun CAHN	
AB		EQ 250MG VALPROIC ACID	A077296	002	Jul 31, 2008	Jun CAHN	
AB		EQ 500MG VALPROIC ACID	A077296	003	Jul 31, 2008	Jun CAHN	
	TABLET, EXTENDED RELEASE;ORAL						
	DEPAKOTE ER						
>D>	AB	+! ABBVIE	EQ 500MG VALPROIC ACID	N021168	001	Aug 04, 2000	Aug CHRS
>A>	AB	+	EQ 500MG VALPROIC ACID	N021168	001	Aug 04, 2000	Aug CHRS
	DIVALPROEX SODIUM						
>D>	AB	AMNEAL PHARMS	EQ 500MG VALPROIC ACID	A203730	002	May 29, 2015	Aug CHRS
>A>	AB	!	EQ 500MG VALPROIC ACID	A203730	002	May 29, 2015	Aug CHRS

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

AP	ALEMBIC	20MG/2ML (10MG/ML)	A215744	001	Feb 28, 2023	Feb NEWA
AP		80MG/8ML (10MG/ML)	A215744	002	Feb 28, 2023	Feb NEWA
AP		160MG/16ML (10MG/ML)	A215744	003	Feb 28, 2023	Feb NEWA
AP	MYLAN LABS LTD	20MG/ML (20MG/ML)	A203892	001	May 11, 2023	Apr NEWA
AP		80MG/4ML (20MG/ML)	A203892	002	May 11, 2023	Apr NEWA
	SOLUTION;INTRAVENOUS					
	DOCETAXEL					
+ @	INGENUS PHARMS LLC	20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	Jul CAHN
+ @		80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	Jul CAHN
+ @		160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	Jul CAHN
+ @	MERIDIAN LABS	20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	May DISC
+ @		80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	May DISC
+ @		160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	May DISC

DOFETILIDE

CAPSULE;ORAL

DOFETILIDE

@ RK PHARMA

@

@

0.125MG

A215323

001

Apr 14, 2022

Jun CAHN

A215323

002

Apr 14, 2022

Jun CAHN

A215323

003

Apr 14, 2022

Jun CAHN

DONEPEZIL HYDROCHLORIDE

SOLUTION;ORAL

ARICEPT

+ @ EISAI INC

5MG/5ML

N021719

001

Oct 18, 2004

Jun CRLD

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%

+ @ B BRAUN

80MG/100ML

N019099

002

Oct 15, 1986

Apr DISC

N019099

004

Oct 15, 1986

Apr DISC

N019099

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

+ @ B BRAUN

40MG/100ML

N019099

001

Oct 15, 1986

Apr DISC

N019099

+ @

160MG/100ML

N019099

003

Oct 15, 1986

Apr DISC

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

>D>		@ RUBICON	EQ 2% BASE	A078395	001	Oct 28, 2008	Aug CMFD
>A>	AT		EQ 2% BASE	A078395	001	Oct 28, 2008	Aug CMFD

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

COSOPT

AT1	+! THEA PHARMA	EQ 2% BASE;EQ 0.5% BASE	N020869	001	Apr 07, 1998	May CTEC
	COSOPT PF					
AT2	+! THEA PHARMA	EQ 2% BASE;EQ 0.5% BASE	N202667	001	Feb 01, 2012	May CTEC
	DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE					
AT1	AKORN	EQ 2% BASE;EQ 0.5% BASE	A077847	001	Oct 28, 2008	May CTEC
AT1		EQ 2% BASE;EQ 0.5% BASE	A203058	001	Sep 22, 2014	May CTEC
AT1	ALEMBIC	EQ 2% BASE;EQ 0.5% BASE	A213099	001	May 04, 2021	May CTEC
AT1	BAUSCH AND LOMB	EQ 2% BASE;EQ 0.5% BASE	A090037	001	Jul 14, 2009	May CTEC
AT1	EUGIA PHARMA	EQ 2% BASE;EQ 0.5% BASE	A207629	001	May 14, 2021	May CTEC
AT2		EQ 2% BASE;EQ 0.5% BASE	A207630	001	Jul 24, 2018	May CTEC
AT1	FDC LTD	EQ 2% BASE;EQ 0.5% BASE	A205295	001	Jun 13, 2019	May CTEC
AT1	GLAND PHARMA LTD	EQ 2% BASE;EQ 0.5% BASE	A215520	001	Sep 19, 2022	May CTEC
AT1	INDOCO	EQ 2% BASE;EQ 0.5% BASE	A202054	001	Sep 03, 2014	May CTEC
AT2	INGENUS PHARMS LLC	EQ 2% BASE;EQ 0.5% BASE	A217260	001	May 01, 2023	May CTEC
AT		EQ 2% BASE;EQ 0.5% BASE	A217260	001	May 01, 2023	Apr NEWA
AT1	MICRO LABS	EQ 2% BASE;EQ 0.5% BASE	A204777	001	May 28, 2020	May CTEC
AT2		EQ 2% BASE;EQ 0.5% BASE	A215936	001	Jan 25, 2022	May CTEC
AT1	SANDOZ	EQ 2% BASE;EQ 0.5% BASE	A078749	001	Nov 06, 2008	May CTEC
AT1		EQ 2% BASE;EQ 0.5% BASE	A090604	001	Nov 18, 2009	May CTEC
AT1	SOMERSET	EQ 2% BASE;EQ 0.5% BASE	A207523	001	Jun 25, 2019	May CTEC
AT1	TEVA PHARMS	EQ 2% BASE;EQ 0.5% BASE	A078704	001	Sep 28, 2009	May CTEC

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

>A> AB	MLV	EQ 1MG BASE	A212727	001	Mar 15, 2022	Aug CAHN
>A> AB		EQ 2MG BASE	A212727	002	Mar 15, 2022	Aug CAHN
>A> AB		EQ 4MG BASE	A212727	003	Mar 15, 2022	Aug CAHN
>A> AB		EQ 8MG BASE	A212727	004	Mar 15, 2022	Aug CAHN
>D> AB	PHARMGEN	EQ 1MG BASE	A212727	001	Mar 15, 2022	Aug CAHN
>D> AB		EQ 2MG BASE	A212727	002	Mar 15, 2022	Aug CAHN
>D> AB		EQ 4MG BASE	A212727	003	Mar 15, 2022	Aug CAHN
>D> AB		EQ 8MG BASE	A212727	004	Mar 15, 2022	Aug CAHN

DOXEPIPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIPIN HYDROCHLORIDE

AB	MICRO LABS	EQ 10MG BASE	A217688	001	Jun 27, 2023	Jun NEWA
AB		EQ 25MG BASE	A217688	002	Jun 27, 2023	Jun NEWA
AB		EQ 50MG BASE	A217688	003	Jun 27, 2023	Jun NEWA
AB		EQ 75MG BASE	A217688	004	Jun 27, 2023	Jun NEWA
AB		EQ 100MG BASE	A217688	005	Jun 27, 2023	Jun NEWA
>A> AB	UNIQUE PHARM	EQ 10MG BASE	A217975	001	Aug 21, 2023	Aug NEWA
>A> AB		EQ 25MG BASE	A217975	002	Aug 21, 2023	Aug NEWA
>A> AB		EQ 50MG BASE	A217975	003	Aug 21, 2023	Aug NEWA
>A> AB		EQ 75MG BASE	A217975	004	Aug 21, 2023	Aug NEWA
>A> AB		EQ 100MG BASE	A217975	005	Aug 21, 2023	Aug NEWA
AB	ZYDUS LIFESCIENCES	EQ 10MG BASE	A210700	001	Mar 23, 2023	Mar CAHN
AB		EQ 25MG BASE	A210700	002	Mar 23, 2023	Mar CAHN
AB		EQ 50MG BASE	A210700	003	Mar 23, 2023	Mar CAHN
AB		EQ 75MG BASE	A210700	004	Mar 23, 2023	Mar CAHN
AB		EQ 100MG BASE	A210700	005	Mar 23, 2023	Mar CAHN
AB		EQ 150MG BASE	A210140	001	Mar 21, 2023	Mar CAHN
AB	ZYDUS PHARMS	EQ 10MG BASE	A210700	001	Mar 23, 2023	Mar NEWA
AB		EQ 25MG BASE	A210700	002	Mar 23, 2023	Mar NEWA
AB		EQ 50MG BASE	A210700	003	Mar 23, 2023	Mar NEWA
AB		EQ 75MG BASE	A210700	004	Mar 23, 2023	Mar NEWA
AB		EQ 100MG BASE	A210700	005	Mar 23, 2023	Mar NEWA
AB		EQ 150MG BASE	A210140	001	Mar 21, 2023	Mar NEWA

CONCENTRATE;ORAL

DOXEPIPIN HYDROCHLORIDE

!	LANNETT CO INC	EQ 10MG BASE/ML	A074721	001	Dec 29, 1998	Jul CTEC
@	XTTRIUM LABS INC	EQ 10MG BASE/ML	A071918	001	Jul 20, 1988	Jul DISC

CREAM;TOPICAL

DOXEPIPIN HYDROCHLORIDE

>A> AB	AMNEAL	5%	A212357	001	Aug 16, 2023	Aug NEWA
AB	TEVA PHARMS	5%	A215408	001	Feb 17, 2023	Feb NFTG

	CREAM;TOPICAL ZONALON						
AB	+! MYLAN	5%		N 020126	001	Apr 01, 1994	Feb CFTG
	TABLET;ORAL DOXEPEPIN HYDROCHLORIDE						
AB	MSN	EQ 3MG BASE		A 214823	001	Apr 03, 2023	Mar NEWA
AB		EQ 6MG BASE		A 214823	002	Apr 03, 2023	Mar NEWA
>A> AB	ZYDUS PHARMS	EQ 3MG BASE		A 202761	001	Aug 16, 2023	Aug NEWA
>A> AB		EQ 6MG BASE		A 202761	002	Aug 16, 2023	Aug NEWA
	<u>DOXERCALCIFEROL</u>						
	INJECTABLE; INJECTION DOXERCALCIFEROL						
AP	ALEMBIC	4MCG/2ML (2MCG/ML)		A 215810	001	Jun 15, 2023	Jun NEWA
	<u>DOXYCYCLINE HYCLATE</u>						
	INJECTABLE; INJECTION DOXYCYCLINE						
>D> AP	! HIKMA	EQ 100MG BASE/VIAL		A 062569	001	Mar 09, 1988	Aug DISC
>A>	@	EQ 100MG BASE/VIAL		A 062569	001	Mar 09, 1988	Aug DISC
>D> AP	ZYDUS PHARMS	EQ 100MG BASE/VIAL		A 207757	001	Sep 28, 2017	Aug CHRS
>A> AP	!	EQ 100MG BASE/VIAL		A 207757	001	Sep 28, 2017	Aug CHRS
	DOXYCYCLINE HYCLATE						
AP	GLAND PHARMA LTD	EQ 100MG BASE/VIAL		A 215583	001	Apr 12, 2023	Mar NEWA
	@ PAR STERILE PRODUCTS	EQ 100MG BASE/VIAL		A 216690	001	Dec 07, 2022	Jun DISC
	TABLET;ORAL DOXYCYCLINE HYCLATE						
>D>	@ ORYZA PHARMS SHENZHN	EQ 100MG BASE		A 213475	001	Mar 10, 2021	Aug CAHN
	@	EQ 100MG BASE		A 213475	001	Mar 10, 2021	Feb CAHN
>A>	@ PHARMOBEDIENT	EQ 100MG BASE		A 213475	001	Mar 10, 2021	Aug CAHN
	TABLET, DELAYED RELEASE;ORAL DORYX						
	+ @ MAYNE PHARMA	EQ 50MG BASE		N 050795	006	Dec 19, 2014	Jun DISC
>D>	+	EQ 80MG BASE		N 050795	004	Apr 11, 2013	Aug CTEC
>A>	+	EQ 80MG BASE		N 050795	004	Apr 11, 2013	Aug CTEC
	+ @	EQ 100MG BASE		N 050795	002	May 06, 2005	Jun DISC
AB	+	EQ 200MG BASE		N 050795	005	Apr 11, 2013	Jul CHRS
	DORYX MPC						
>D>	+ MAYNE PHARMA	EQ 60MG BASE		N 050795	007	May 20, 2016	Aug CTEC
>A>	+	EQ 60MG BASE		N 050795	007	May 20, 2016	Aug CTEC
	+ @	EQ 120MG BASE		N 050795	008	May 20, 2016	Jun DISC
	DOXYCYCLINE HYCLATE						
	@ AUROBINDO PHARMA USA	EQ 150MG BASE		A 091052	001	Feb 08, 2012	May CAHN
AB	! HERITAGE PHARMS	EQ 200MG BASE		A 200856	004	Nov 13, 2018	Jul CHRS
>A>	@ LUPIN	EQ 50MG BASE		A 208741	001	Aug 11, 2023	Aug DISC
>A>	@	EQ 60MG BASE		A 208741	002	Aug 11, 2023	Aug DISC
>A>	@	EQ 75MG BASE		A 208741	003	Aug 11, 2023	Aug DISC
>A>	@	EQ 80MG BASE		A 208741	004	Aug 11, 2023	Aug DISC
>A>	@	EQ 100MG BASE		A 208741	005	Aug 11, 2023	Aug DISC
>A>	@	EQ 120MG BASE		A 208741	006	Aug 11, 2023	Aug DISC
>A>	@	EQ 150MG BASE		A 208741	007	Aug 11, 2023	Aug DISC
>A>	@	EQ 200MG BASE		A 208741	008	Aug 11, 2023	Aug DISC
	<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE</u>						
	TABLET, DELAYED RELEASE;ORAL DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE						
AB	BIONPHARMA	10MG;10MG		A 217000	001	Aug 04, 2023	Jul NEWA
	<u>DROPERIDOL</u>						
	INJECTABLE; INJECTION DROPERIDOL						
AP	! AM REGENT	2.5MG/ML		A 072123	001	Oct 24, 1988	Jul CTEC
	!	2.5MG/ML		A 072123	001	Oct 24, 1988	Jul CHRS
AP	@ HIKMA	2.5MG/ML		A 208197	001	Dec 14, 2017	Jul DISC
		2.5MG/ML		A 208197	001	Dec 14, 2017	May CAHN
AP	@ HOSPIRA INAPSINE	2.5MG/ML		A 071981	001	Feb 29, 1988	Jul DISC
	+ @ AKORN	2.5MG/ML		N 016796	001		Jul DISC

DROSPIRENONONE

TABLET, CHEWABLE;ORAL
DROSPIRENONE
+ @ EXELTIS USA INC 3.5MG N216285 001 Jun 29, 2022 Jun DISC

DROXIDOPA

CAPSULE;ORAL
DROXIDOPA
@ CHARTWELL RX 100MG A214217 001 May 05, 2022 May CAHN
@ 200MG A214217 002 May 05, 2022 May CAHN
@ 300MG A214217 003 May 05, 2022 May CAHN

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL
DRIZALMA SPRINKLE
+ @ SUN PHARM EQ 30MG BASE N212516 002 Jul 19, 2019 Mar DISC
+ @ EQ 40MG BASE N212516 003 Jul 19, 2019 Jan DISC
+ @ EQ 60MG BASE N212516 004 Jul 19, 2019 Mar DISC
DULOXETINE HYDROCHLORIDE
AB ZYDUS HLTHCARE EQ 40MG BASE A090739 004 Apr 18, 2023 Apr NEWA

DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM

POWDER;INTRAVENOUS
XACDURO (COPACKAGED)
+! ENTASIS THERAP EQ 500MG BASE/VIAL; EQ 500MG N216974 001 May 23, 2023 Jun CMS1
BASE/VIAL;EQ 1GM BASE/VIAL
+! EQ 500MG BASE/VIAL; EQ 500MG N216974 001 May 24, 2023 May NEWA
BASE/VIAL;EQ 1GM BASE/VIAL

DYCLONINE HYDROCHLORIDE

SOLUTION;TOPICAL
DYCLOPRO
! SEPTODONT 0.5% A200480 001 Nov 20, 2018 May CAHN
! 1% A200480 002 Nov 20, 2018 May CAHN

ECONAZOLE NITRATE

CREAM;TOPICAL
ECONAZOLE NITRATE
@ AUROBINDO PHARMA USA 1% A210364 001 Apr 18, 2018 Apr CAHN
@ PAI HOLDINGS PHARM 1% A076574 001 Dec 17, 2004 May DISC

EDETA TE CALCIUM DISODIUM

INJECTABLE;INJECTION
CALCIUM DISODIUM VERSENATE
+ @ BAUSCH 200MG/ML N008922 001 Mar DISC
EDETA TE CALCIUM DISODIUM
! CASPER PHARMA LLC 200MG/ML A216435 001 May 03, 2023 Apr NFTG
200MG/ML A216435 001 May 03, 2023 Apr NFTG

EFAVIRENZ

CAPSULE;ORAL
EFAVIRENZ
AUROBINDO PHARMA 50MG A078064 001 Dec 15, 2017 Mar CTEC
!
200MG A078064 003 Dec 15, 2017 Mar CHRS
200MG A078064 003 Dec 15, 2017 Mar CTEC
SUSTIVA
+ @ BRISTOL MYERS SQUIBB 50MG N020972 001 Sep 17, 1998 Mar DISC
+ @ 200MG N020972 003 Sep 17, 1998 Mar DISC

ELACESTRANT DIHYDROCHLORIDE

TABLET;ORAL
ORSERDU
+ STEMLINE THERAP EQ 86MG BASE N217639 001 Jan 27, 2023 Jan NEWA
+! EQ 345MG BASE N217639 002 Jan 27, 2023 Jan NEWA

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

GRANULES;ORAL
TRIKAFTA (COPACKAGED)
+ VERTEX PHARMS INC 80MG, 60MG, 40MG;59.5MG N217660 001 Apr 26, 2023 Apr NEWA
+! 100MG, 75MG, 50MG;75MG N217660 002 Apr 26, 2023 Apr NEWA

ELIGLUSTAT TARTRATE

CAPSULE;ORAL

ELIGLUSTAT TARTRATE

AB ZENARA EQ 84MG BASE A212420 001 May 02, 2023 Apr NEWA

EMPAGLIFLOZIN

TABLET;ORAL

EMPAGLIFLOZIN

@ ZYDUS PHARMS	10MG	A212138	001	Aug 03, 2022	Jan DISC
@	25MG	A212138	002	Aug 03, 2022	Jan DISC
JARDIANCE					
+ BOEHRINGER INGELHEIM	10MG	N204629	001	Aug 01, 2014	Jan CTEC
+!	25MG	N204629	002	Aug 01, 2014	Jan CTEC

EMTRICITABINE

CAPSULE;ORAL

EMTRICITABINE

AB AUROBINDO PHARMA LTD 200MG A079188 001 Mar 15, 2023 Mar NEWA

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

@ APOTEX	200MG;300MG	A208740	001	Jun 16, 2021	Apr DISC
AB AUROBINDO PHARMA LTD	100MG;150MG	A211640	001	Mar 09, 2023	Mar NEWA
AB	133MG;200MG	A211640	002	Mar 09, 2023	Mar NEWA
AB	167MG;250MG	A211640	003	Mar 09, 2023	Mar NEWA

ENALAPRIL MALEATE

TABLET;ORAL

ENALAPRIL MALEATE

@ CHARTWELL RX	2.5MG	A075048	001	Aug 22, 2000	May CAHN
@	5MG	A075048	002	Aug 22, 2000	May CAHN
@	10MG	A075048	003	Aug 22, 2000	May CAHN
@	20MG	A075048	004	Aug 22, 2000	May CAHN

ENALAPRILAT

INJECTABLE;INJECTION

ENALAPRILAT

AP DR REDDYS 1.25MG/ML A075578 001 Aug 22, 2000 Apr CMFD

ENOXAPARIN SODIUM

INJECTABLE;SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

AP BE PHARMS	30MG/0.3ML (100MG/ML)	A214646	001	Jun 06, 2023	May NEWA
AP	40MG/0.4ML (100MG/ML)	A214646	002	Jun 06, 2023	May NEWA
AP	60MG/0.6ML (100MG/ML)	A214646	003	Jun 06, 2023	May NEWA
AP	80MG/0.8ML (100MG/ML)	A214646	004	Jun 06, 2023	May NEWA
AP	100MG/ML (100MG/ML)	A214646	005	Jun 06, 2023	May NEWA
AP	120MG/0.8ML (150MG/ML)	A214646	006	Jun 06, 2023	May NEWA
AP	150MG/ML (150MG/ML)	A214646	007	Jun 06, 2023	May NEWA
AP GLAND	30MG/0.3ML (100MG/ML)	A078990	001	Sep 28, 2018	Jun CAHN
AP	40MG/0.4ML (100MG/ML)	A078990	002	Sep 28, 2018	Jun CAHN
AP	60MG/0.6ML (100MG/ML)	A078990	003	Sep 28, 2018	Jun CAHN
AP	80MG/0.8ML (100MG/ML)	A078990	004	Sep 28, 2018	Jun CAHN
AP	100MG/ML (100MG/ML)	A078990	005	Sep 28, 2018	Jun CAHN
AP	120MG/0.8ML (150MG/ML)	A078990	006	Sep 28, 2018	Jun CAHN
AP	150MG/ML (150MG/ML)	A078990	007	Sep 28, 2018	Jun CAHN
AP SHENZHEN TECHDOW	30MG/0.3ML (100MG/ML)	A205660	001	Mar 15, 2023	Mar NEWA
AP	40MG/0.4ML (100MG/ML)	A205660	002	Mar 15, 2023	Mar NEWA
AP	60MG/0.6ML (100MG/ML)	A205660	003	Mar 15, 2023	Mar NEWA
AP	80MG/0.8ML (100MG/ML)	A205660	004	Mar 15, 2023	Mar NEWA
AP	100MG/ML (100MG/ML)	A205660	005	Mar 15, 2023	Mar NEWA
AP	120MG/0.8ML (150MG/ML)	A205660	006	Mar 15, 2023	Mar NEWA
AP	150MG/ML (150MG/ML)	A205660	007	Mar 15, 2023	Mar NEWA

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

EPHEDRINE SULFATE

>D> AP AKORN	50MG/ML (50MG/ML)	N208609	001	Mar 01, 2017	Aug CAHN
+! OPERAND PHARMS	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Jun CAHN
+!	50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Jun CAHN

SOLUTION; INTRAVENOUS EPHEDRINE SULFATE				
>A>	AP	RENEW PHARMS	50MG/ML (50MG/ML)	N 208609 001 Mar 01, 2017 Aug CAHN
AP		SAGENT PHARMS INC	50MG/ML (50MG/ML)	A 214528 001 Mar 09, 2023 Feb NEWA
<u>EPINEPHRINE</u>				
SOLUTION; INTRAVENOUS EPINEPHRINE				
+!	BPI LABS	1MG/ML (1MG/ML)	N 205029 003 May 12, 2023 Jun NEWA	
EPINEPHRINE IN 0.9% SODIUM CHLORIDE				
+!	PAR STERILE PRODUCTS	2MG/250ML (8MCG/ML)	N 215875 001 Apr 21, 2023 Apr NEWA	
+!		4MG/250ML (16MCG/ML)	N 215875 002 Apr 21, 2023 Apr NEWA	
+!		5MG/250ML (20MCG/ML)	N 215875 003 Apr 21, 2023 Apr NEWA	
+!		8MG/250ML (32MCG/ML)	N 215875 004 Apr 21, 2023 Apr NEWA	
+!		10MG/250ML (40MCG/ML)	N 215875 005 Apr 21, 2023 Apr NEWA	
<u>EPINEPHRINE; LIDOCAINE HYDROCHLORIDE</u>				
INJECTABLE; INJECTION LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE				
!	HOSPIRA	0.01MG/ML; 2%	A 089646 001 Jun 21, 1988 Apr CTEC	
XYLOCAINE W/ EPINEPHRINE				
+!	FRESENIUS KABI USA	0.02MG/ML; 2%	N 006488 005 May CTEC	
<u>EPLERENONE</u>				
TABLET; ORAL EPLERENONE				
AB		ANNORA PHARMA	25MG	A 213812 001 Jun 02, 2023 May NEWA
AB			50MG	A 213812 002 Jun 02, 2023 May NEWA
<u>EPOPROSTENOL SODIUM</u>				
INJECTABLE; INJECTION EPOPROSTENOL SODIUM				
AP2	!	SUN PHARM VELETRI	EQ 0.5MG BASE/VIAL	A 210473 001 Jan 15, 2021 Feb CHRS
AP2	+	ACTELION	EQ 0.5MG BASE/VIAL	N 022260 002 Jun 28, 2012 Feb CHRS
<u>ERGOCALCIFEROL</u>				
CAPSULE; ORAL DRISDOL				
AA	+	VALIDUS PHARMS ERGOCALCIFEROL	50,000 IU	N 003444 001 Feb CHRS
AA		CHARTWELL RX	50,000 IU	A 040833 001 May 20, 2009 Feb CAHN
AA	!	STRIDES PHARMA	50,000 IU	A 090455 001 Aug 03, 2010 Feb CHRS
<u>ERLOTINIB HYDROCHLORIDE</u>				
TABLET; ORAL ERLOTINIB HYDROCHLORIDE				
AB	!	ZYDUS PHARMS TARCEVA	EQ 150MG BASE	A 213065 003 Apr 16, 2020 Apr CHRS
	+	OSI PHARMS	EQ 25MG BASE	N 021743 001 Nov 18, 2004 Apr DISC
	+	@	EQ 100MG BASE	N 021743 002 Nov 18, 2004 Apr DISC
	+	@	EQ 150MG BASE	N 021743 003 Nov 18, 2004 Apr DISC
<u>ERTAPENEM SODIUM</u>				
INJECTABLE; INTRAMUSCULAR, INTRAVENOUS ERTAPENEM SODIUM				
AP		SUN PHARM	EQ 1GM BASE/VIAL	A 209145 001 May 02, 2023 Apr NEWA
<u>ERTUGLIFLOZIN</u>				
TABLET; ORAL ERTUGLIFLOZIN				
AB	@	AUROBINDO PHARMA LTD	5MG	A 216947 001 Jul 13, 2023 Jul DISC
			5MG	A 216947 001 Jul 13, 2023 Jul NFTG
AB	@		15MG	A 216947 002 Jul 13, 2023 Jul DISC
			15MG	A 216947 002 Jul 13, 2023 Jul NFTG
STEGLATRO				
AB	+	MSD SUB MERCK	5MG	N 209803 001 Dec 19, 2017 Jul CTEC
AB	+		5MG	N 209803 001 Dec 19, 2017 Jul CFTG
	+	!	15MG	N 209803 002 Dec 19, 2017 Jul CTEC
AB	+	!	15MG	N 209803 002 Dec 19, 2017 Jul CFTG

ERYTHROMYCIN

GEL;TOPICAL

ERYTHROMYCIN

@ PAI HOLDINGS PHARM 2%

A208154 001 Jul 19, 2017 May DISC

OINTMENT;OPHTHALMIC

ERYTHROMYCIN

>D> AT

AKORN 0.5%

A064030 001 Jul 18, 1996 Aug CAHN

>A> AT

SENTISS 0.5%

A064030 001 Jul 18, 1996 Aug CAHN

SOLUTION;TOPICAL

ERYTHROMYCIN

>D> AT

PAI HOLDINGS PHARM 2%

A208100 001 Nov 20, 2017 Aug DISC

>A>

@ 2%

A208100 001 Nov 20, 2017 Aug DISC

@ XTTRIUM LABS INC 2%

A062825 001 Oct 23, 1987 Jul DISC

TABLET;ORAL

ERYTHROMYCIN

>A> AB

ALEMBIC 250MG

A215661 001 Aug 24, 2023 Aug NEWA

>A> AB

500MG

A215661 002 Aug 24, 2023 Aug NEWA

AB

ARBOR PHARMS LLC 500MG

A061621 002 Jan CHRS

AB

! CADILA PHARMS LTD 500MG

A213628 002 Jun 28, 2021 Jan CHRS

AB

ZYDUS 250MG

A212693 001 Mar 07, 2023 Feb NEWA

AB

500MG

A212693 002 Mar 07, 2023 Feb NEWA

>A> AB

ZYDUS PHARMS 250MG

A215440 001 Aug 31, 2023 Aug NEWA

>A> AB

500MG

A215440 002 Aug 31, 2023 Aug NEWA

ERYTHROMYCIN ETHYLSUCCINATE

TABLET;ORAL

ERYTHROMYCIN ETHYLSUCCINATE

@ AUROBINDO PHARMA USA EQ 400MG BASE

A062847 001 Sep 14, 1988 Apr CAHN

ERYTHROMYCIN LACTOBIONATE

INJECTABLE;INJECTION

ERYTHROMYCIN LACTOBIONATE

@ EXELA PHARMA EQ 500MG BASE/VIAL

A211086 001 Sep 17, 2020 May DISC

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATE

AA

CHARTWELL MOLECULAR EQ 5MG BASE/5ML
LEXAPRO

A090477 001 Jun 12, 2013 Jul CAHN

+ @ ABBVIE

EQ 5MG BASE/5ML

N021365 001 Nov 27, 2002 Jan CAHN

TABLET;ORAL

ESCITALOPRAM OXALATE

@ DASH PHARMS EQ 5MG BASE

A077550 001 May 14, 2015 Feb CAHN

@ EQ 10MG BASE

A077550 002 May 14, 2015 Feb CAHN

@ EQ 20MG BASE

A077550 003 May 14, 2015 Feb CAHN

AB

JUBILANT CADISTA EQ 5MG BASE

A202280 001 Sep 12, 2012 May CAHN

AB

EQ 10MG BASE

A202280 002 Sep 12, 2012 May CAHN

AB

EQ 20MG BASE

A202280 003 Sep 12, 2012 May CAHN

LEXAPRO

AB

+ ABBVIE EQ 5MG BASE

N021323 001 Aug 14, 2002 Jan CAHN

AB

EQ 10MG BASE

N021323 002 Aug 14, 2002 Jan CAHN

AB

+! EQ 20MG BASE

N021323 003 Aug 14, 2002 Jan CAHN

ESLICARBAZEPINE ACETATE

TABLET;ORAL

APTIOM

AB

+ SUMITOMO PHARMA AM 200MG

N022416 001 Nov 08, 2013 Jul CAHN

AB

+ 400MG

N022416 002 Nov 08, 2013 Jul CAHN

AB

+ 600MG

N022416 003 Nov 08, 2013 Jul CAHN

AB

+! 800MG

N022416 004 Nov 08, 2013 Jul CAHN

ESLICARBAZEPINE ACETATE

AB

HETERO LABS LTD V 200MG

A211186 001 Aug 03, 2023 Jul NEWA

AB

400MG

A211186 002 Aug 03, 2023 Jul NEWA

AB

600MG

A211186 003 Aug 03, 2023 Jul NEWA

AB

800MG

A211186 004 Aug 03, 2023 Jul NEWA

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

AP	+!	BAXTER HLTHCARE	2GM/100ML	N019386	005	Jan 27, 2003	Jan CTEC
		BREVIBLOC IN PLASTIC CONTAINER					
AP	+!	BAXTER HLTHCARE	1GM/100ML	N019386	004	Feb 16, 2001	Jan CTEC
		ESMOLOL HYDROCHLORIDE					
AP		AMNEAL	1GM/100ML	A216603	001	Dec 13, 2022	Jan CPOT
AP			2GM/100ML	A216603	002	Dec 13, 2022	Jan CPOT
AP		EUGIA PHARMA	1GM/100ML	A216244	001	Mar 21, 2022	Jan CPOT
AP			2GM/100ML	A216244	002	Mar 21, 2022	Jan CPOT
>A>		FRESENIUS KABI USA	20MG/ML	A076573	002	Aug 23, 2023	Aug NEWA
AP		HQ SPCLT PHARMA	1GM/100ML	A214172	001	Dec 02, 2022	Jan CPOT
AP			2GM/100ML	A214172	002	Dec 02, 2022	Jan CPOT
AP		MYLAN LABS LTD	1GM/100ML	A206608	001	Jun 08, 2018	Jan CPOT
AP			2GM/100ML	A206608	002	Jun 08, 2018	Jan CPOT
AP		SAGENT PHARMS INC	1GM/100ML	A207107	001	Jun 08, 2018	Jan CPOT
AP			2GM/100ML	A207107	002	Jun 08, 2018	Jan CPOT

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

ESOMEPRAZOLE MAGNESIUM

>D>	@	GUANGZHOU NOVAKEN	EQ 20MG BASE	A213859	001	Nov 18, 2020	Aug CMFD
>A> AB			EQ 20MG BASE	A213859	001	Nov 18, 2020	Aug CMFD
>D>	@		EQ 40MG BASE	A213859	002	Nov 18, 2020	Aug CMFD
>A> AB			EQ 40MG BASE	A213859	002	Nov 18, 2020	Aug CMFD
>D> AB		HETERO LABS LTD III	EQ 20MG BASE	A202784	001	Sep 21, 2015	Aug DISC
>A>	@		EQ 20MG BASE	A202784	001	Sep 21, 2015	Aug DISC
>D> AB			EQ 40MG BASE	A202784	002	Sep 21, 2015	Aug DISC
>A>	@		EQ 40MG BASE	A202784	002	Sep 21, 2015	Aug DISC
AB		PRINSTON INC	EQ 20MG BASE	A214920	001	Mar 28, 2023	Mar NEWA
AB			EQ 40MG BASE	A214920	002	Mar 28, 2023	Mar NEWA
>D> AB		TORRENT	EQ 20MG BASE	A203636	001	Oct 19, 2015	Aug DISC
>A>	@		EQ 20MG BASE	A203636	001	Oct 19, 2015	Aug DISC
>D> AB			EQ 40MG BASE	A203636	002	Oct 19, 2015	Aug DISC
>A>	@		EQ 40MG BASE	A203636	002	Oct 19, 2015	Aug DISC
		FOR SUSPENSION, DELAYED RELEASE; ORAL					
		ESOMEPRAZOLE MAGNESIUM					
AB		ZYDUS PHARMS	EQ 20MG BASE/PACKET	A206055	001	Jun 07, 2023	May NEWA
AB			EQ 40MG BASE/PACKET	A206055	002	Jun 07, 2023	May NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE; ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

>D> AB	@	ACTAVIS LABS FL INC	EQ 20MG BASE;375MG	A204470	001	Aug 24, 2022	Feb DISC
	@		EQ 20MG BASE;500MG	A204470	002	Aug 24, 2022	Feb DISC
>A> AB	!	DR REDDYS	EQ 20MG BASE;500MG	A204206	002	Feb 18, 2020	Aug CHRS
>A> AB	!		EQ 20MG BASE;500MG	A204206	002	Feb 18, 2020	Aug CHRS
>D>	VIMOVO						
>D> AB	+	HORIZON	EQ 20MG BASE;375MG	N022511	002	Apr 30, 2010	Aug DISC
>A>	+	@	EQ 20MG BASE;375MG	N022511	002	Apr 30, 2010	Aug DISC
>D> AB	+	!	EQ 20MG BASE;500MG	N022511	001	Apr 30, 2010	Aug DISC
>A>	+	@	EQ 20MG BASE;500MG	N022511	001	Apr 30, 2010	Aug DISC

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

ESOMEPRAZOLE SODIUM

AP		EUGIA PHARMA	EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Jan CHRS
		GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A203349	001	Apr 01, 2020	Apr CTEC

ESTRADIOOL

CREAM; VAGINAL

ESTRADIOL

AB		PRASCO	0.01%	A212313	001	Jul 15, 2021	Jun CAHN
		FILM, EXTENDED RELEASE; TRANSDERMAL					
		ESTRADIOL					
AB2		ZYDUS NOVELTECH INC	0.025MG/24HR	A202985	001	Mar 29, 2023	Mar NEWA
AB2			0.0375MG/24HR	A202985	002	Mar 29, 2023	Mar NEWA
AB2			0.05MG/24HR	A202985	003	Mar 29, 2023	Mar NEWA
AB			0.06MG/24HR	A202985	004	Mar 29, 2023	Mar NEWA
AB2			0.075MG/24HR	A202985	005	Mar 29, 2023	Mar NEWA

FILM, EXTENDED RELEASE;TRANSDERMAL
ESTRADIOL

AB2	@ ZYDUS PHARMS	0.1MG/24HR 0.025MG/24HR	A202985 006 Mar 29, 2023	Mar NEWA
AB2	@	0.025MG/24HR	A202985 001 Mar 29, 2023	Jul DISC
AB2	@	0.0375MG/24HR	A202985 001 Mar 29, 2023	Apr CAHN
AB2	@	0.0375MG/24HR	A202985 002 Mar 29, 2023	Jul DISC
AB2	@	0.05MG/24HR	A202985 002 Mar 29, 2023	Apr CAHN
AB2	@	0.05MG/24HR	A202985 003 Mar 29, 2023	Jul DISC
AB2	@	0.06MG/24HR	A202985 003 Mar 29, 2023	Apr CAHN
AB2	@	0.06MG/24HR	A202985 004 Mar 29, 2023	Jul DISC
AB2	@	0.075MG/24HR	A202985 004 Mar 29, 2023	Apr CAHN
AB2	@	0.075MG/24HR	A202985 005 Mar 29, 2023	Jul DISC
AB2	@	0.1MG/24HR	A202985 005 Mar 29, 2023	Apr CAHN
AB2		0.1MG/24HR	A202985 006 Mar 29, 2023	Jul DISC
			A202985 006 Mar 29, 2023	Apr CAHN

GEL;TRANSDERMAL
ESTRADIOL

>A> AB	NOVITIUM PHARMA	0.1%	A217610 001 Aug 24, 2023	Aug NEWA
	INSERT;VAGINAL			
	IMVEXXY			

+ MAYNE PHARMA 0.004MG

+! 0.01MG

SYSTEM;TRANSDERMAL
ESTRADIOL

AB	ZYDUS NOVELTECH INC	0.014MG/24HR	A204379 001 Apr 17, 2023	Apr NFTG
AB	ZYDUS PHARMS	0.014MG/24HR	A204379 001 Apr 17, 2023	May CAHN
AB1		0.025MG/24HR	A206241 001 Dec 01, 2022	May CAHN
AB1		0.0375MG/24HR	A206241 002 Dec 01, 2022	May CAHN
AB1		0.05MG/24HR	A206241 003 Dec 01, 2022	May CAHN
AB1		0.075MG/24HR	A206241 004 Dec 01, 2022	May CAHN
AB1		0.1MG/24HR	A206241 005 Dec 01, 2022	May CAHN

MENOSTAR

AB	+! BAYER HLTHCARE	0.014MG/24HR	N021674 001 Jun 08, 2004	Apr CFTG
	VIVELLE			
	@ SANDOZ	0.025MG/24HR	N020323 005 Aug 16, 2000	May CAHN
	@	0.0375MG/24HR	N020323 001 Oct 28, 1994	May CAHN
	@	0.05MG/24HR	N020323 002 Oct 28, 1994	May CAHN
	@	0.075MG/24HR	N020323 003 Oct 28, 1994	May CAHN
	@	0.1MG/24HR	N020323 004 Oct 28, 1994	May CAHN

VIVELLE-DOT

AB1	+ SANDOZ	0.025MG/24HR	N020538 009 May 03, 2002	May CAHN
AB1	+	0.0375MG/24HR	N020538 005 Jan 08, 1999	May CAHN
AB1	+	0.05MG/24HR	N020538 006 Jan 08, 1999	May CAHN
AB1	+	0.075MG/24HR	N020538 007 Jan 08, 1999	May CAHN
AB1	+!	0.1MG/24HR	N020538 008 Jan 08, 1999	May CAHN

TABLET;ORAL
ESTRADIOL

>A> AB	NOVITIUM PHARMA	0.5MG	A217334 001 Sep 06, 2023	Aug NEWA
>A> AB		1MG	A217334 002 Sep 06, 2023	Aug NEWA
>A> AB		2MG	A217334 003 Sep 06, 2023	Aug NEWA

ESTRADIOL VALERATE

INJECTABLE;INJECTION
ESTRADIOL VALERATE

AO	XIROMED	10MG/ML	A216656 001 Apr 28, 2023	Apr NEWA
AO		20MG/ML	A216656 002 Apr 28, 2023	Apr NEWA
AO		40MG/ML	A216656 003 Apr 28, 2023	Apr NEWA

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL
ESTRADIOL AND NORETHINDRONE ACETATE

AB	AUROBINDO PHARMA LTD	0.5MG;0.1MG	A214729 001 Jun 30, 2023	Jun NEWA
AB		1MG;0.5MG	A214729 002 Jun 30, 2023	Jun NEWA

ETHINYL ESTRADIOL; ETONOGESTREL

RING;VAGINAL
ENILLORING

AB	XIROMED	0.015MG/24HR;0.12MG/24HR	A211157 001 Jun 29, 2023	Jun NEWA
----	---------	--------------------------	--------------------------	----------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

BALCOLTRA

>D>	+!	AVION PHARMS	0.02MG;0.1MG	N208612	001	Jan 09, 2018	Aug CFTG
>A>	+!		0.02MG;0.1MG	N208612	001	Jan 09, 2018	Aug CFTG
>A>		LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
>A>	AB3	XIROMED	0.02MG;0.1MG	A214640	001	Aug 16, 2023	Aug NFTG
		TABLET;ORAL-28					
		LEVONORGESTREL AND ETHINYL ESTRADIOL					
	@	AMNEAL PHARMS	0.02MG;0.1MG	A201108	001	Feb 05, 2014	Jan DISC
	@		0.03MG;0.15MG	A201095	001	Dec 08, 2014	Jan DISC
AB1		HETERO LABS	0.02MG;0.1MG	A212298	001	Feb 13, 2023	Feb NEWA
AB		LUPIN LTD	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A200248	001	Nov 19, 2015	Jan CTEC

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

RHUZDAH

@ AUROBINDO PHARMA 0.035MG;0.4MG

A207585 001 Oct 11, 2022 Apr DISC

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

HAILEY 24 FE

AB	!	GLENMARK PHARMS LTD	0.02MG;1MG	A204847	001	Nov 17, 2017	Feb CTNA
	+	@ APIL	0.02MG;1MG	N203667	001	May 08, 2013	Apr DISC
			NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE				
AB	!	GLENMARK PHARMS LTD	0.02MG;1MG	A210369	001	Dec 26, 2017	Apr CHRS

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

@ AMNEAL PHARMS 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG

@ 0.035MG;0.25MG

A203865 001 Oct 27, 2015 Jun DISC

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-28

TURQOZ

AB LUPIN LTD 0.03MG;0.3MG A202980 001 Jul 31, 2023 Jul NEWA

ETHINYL ESTRADIOL; SEGESTERONE ACETATE

RING;VAGINAL

ANNOVERA

+! MAYNE PHARMA 0.013MG/24HR;0.15MG/24HR N209627 001 Aug 10, 2018 Jan CAHN

ETODOLAC

TABLET;ORAL

ETODOLAC

>D>	AB	EDENBRIDGE PHARMS	400MG	A209888	001	Nov 30, 2018	Aug DISC
>A>		@	400MG	A209888	001	Nov 30, 2018	Aug DISC
>D>	AB		500MG	A209888	002	Nov 30, 2018	Aug DISC
>A>		@	500MG	A209888	002	Nov 30, 2018	Aug DISC

ETOPOSIDE

INJECTABLE;INJECTION

ETOPOSIDE

@ DASH PHARMS 20MG/ML

@ DASH PHARMS NATCO 20MG/ML

A204927 001 Oct 31, 2017 Mar CAHN

A203507 001 Nov 20, 2017 Feb CAHN

EVEROLIMUS

TABLET;ORAL

EVEROLIMUS

AB TEVA PHARMS USA 10MG A210050 004 Dec 09, 2019 Apr CMFD

EXEMESTANE

TABLET;ORAL

EXEMESTANE

@ ALVOGEN 25MG

A200898 001 Jul 28, 2014 Feb DISC

EZETIMIBE

TABLET;ORAL
EZETIMIBE
@ ORIENT PHARMA 10MG A215693 001 Sep 13, 2022 Mar DISC

FAMOTIDINE

FOR SUSPENSION;ORAL
FAMOTIDINE

AB	ALKEM LABS LTD	40MG/5ML	A216400	001	May 15, 2023	May NEWA
>A> AB	ANNORA PHARMA	40MG/5ML	A217330	001	Aug 17, 2023	Aug NEWA
AB	APPCO	40MG/5ML	A217655	001	Jun 16, 2023	Jun NEWA
AB	CARNEGIE	40MG/5ML	A217137	001	Jul 07, 2023	Jun NEWA
AB	LUPIN LTD	40MG/5ML	A090440	001	Jun 29, 2010	Jun CHRS
AB	! NOVITIUM PHARMA	40MG/5ML	A215043	001	Apr 20, 2021	Jun CHRS

INJECTABLE;INJECTION
FAMOTIDINE

>D> AP	ATHENEX INC	10MG/ML	A075651	001	Apr 16, 2001	Aug CAHN
>A> AP	SAGENT	10MG/ML	A075651	001	Apr 16, 2001	Aug CAHN
	@ ZYDUS PHARMS	10MG/ML	A215828	001	Nov 22, 2022	Apr DISC
>D> AP	ATHENEX INC	10MG/ML	A075622	001	Apr 16, 2001	Aug CAHN
>D> AP		10MG/ML	A075825	001	Apr 17, 2001	Aug CAHN
>A> AP	SAGENT	10MG/ML	A075622	001	Apr 16, 2001	Aug CAHN
>A> AP		10MG/ML	A075825	001	Apr 17, 2001	Aug CAHN

TABLET;ORAL
FAMOTIDINE

AB	ALKEM LABS LTD	20MG	A217375	001	Apr 24, 2023	Apr NEWA
AB		40MG	A217375	002	Apr 24, 2023	Apr NEWA
>A> AB	CHARTWELL RX	20MG	A215630	001	Jan 07, 2022	Aug CAHN
>A> AB		40MG	A215630	002	Jan 07, 2022	Aug CAHN
>D> AB	VKT PHARMA	20MG	A215630	001	Jan 07, 2022	Aug CAHN
AB		20MG	A215630	001	Jan 07, 2022	Jan CAHN
>D> AB		40MG	A215630	002	Jan 07, 2022	Aug CAHN
AB		40MG	A215630	002	Jan 07, 2022	Jan CAHN

FAMOTIDINE; IBUPROFEN

TABLET;ORAL
IBUPROFEN AND FAMOTIDINE

AB	ASCENT PHARMS INC	26.6MG;800MG	A216814	001	Mar 15, 2023	Mar NEWA
----	-------------------	--------------	---------	-----	--------------	----------

FEBUXOSTAT

TABLET;ORAL
FEBUXOSTAT

AB	@ MYLAN	80MG	A205385	002	Jul 01, 2019	Jun DISC
AB	ZYDUS LIFESCIENCES	40MG	A205443	001	Jan 09, 2023	Jan CAHN
AB		80MG	A205443	002	Jan 09, 2023	Jan CAHN

FENFLURAMINE HYDROCHLORIDE

SOLUTION;ORAL
FINTEPLA

+! UCB INC		EQ 2.2MG BASE/ML	N212102	001	Jun 25, 2020	Jun CAHN
------------	--	------------------	---------	-----	--------------	----------

FENOFOBRATE

CAPSULE;ORAL
ANTARA (MICRONIZED)

+ @ LUPIN		90MG	N021695	005	Oct 18, 2013	Jun DISC
-----------	--	------	---------	-----	--------------	----------

TABLET;ORAL

FENOFOBRATE						
AB	CHARTWELL RX	54MG	A209660	001	Feb 11, 2019	Feb CAHN
AB		160MG	A209660	002	Feb 11, 2019	Feb CAHN

FENOPROFEN CALCIUM

CAPSULE;ORAL
FENOPROFEN CALCIUM

AB	MISEMER	EQ 200MG BASE	A215548	001	May 16, 2023	May NEWA
		EQ 300MG BASE	A215548	002	May 16, 2023	May NEWA
AB		EQ 400MG BASE	A215548	003	May 16, 2023	May NEWA
AB	NALFON					
AB	+ XSPIRE PHARMA	EQ 200MG BASE	N017604	003		May CTEC

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

AB	AVEVA	100MCG/HR	A077449	004	Oct 20,	2008	Jul CMFD
AB	ZYDUS NOVELTECH INC	100MCG/HR	A209655	008	Jan 24,	2023	Jan NEWA
@	ZYDUS PHARMS	100MCG/HR	A209655	008	Jan 24,	2023	Jun DISC
AB		100MCG/HR	A209655	008	Jan 24,	2023	May CAHN
	FENTANYL-12						
AB	AVEVA	12.5MCG/HR	A077449	005	Sep 11,	2015	Jul CMFD
AB	ZYDUS NOVELTECH INC	12.5MCG/HR	A209655	001	Jan 24,	2023	Jan NEWA
@	ZYDUS PHARMS	12.5MCG/HR	A209655	001	Jan 24,	2023	Jun DISC
AB		12.5MCG/HR	A209655	001	Jan 24,	2023	May CAHN
	FENTANYL-25						
AB	AVEVA	25MCG/HR	A077449	001	Oct 20,	2008	Jul CMFD
AB	ZYDUS NOVELTECH INC	25MCG/HR	A209655	002	Jan 24,	2023	Jan NEWA
@	ZYDUS PHARMS	25MCG/HR	A209655	002	Jan 24,	2023	Jun DISC
AB		25MCG/HR	A209655	002	Jan 24,	2023	May CAHN
	FENTANYL-37						
AB	AVEVA	37.5MCG/HR	A077449	006	Dec 06,	2017	Jul CMFD
AB	ZYDUS NOVELTECH INC	37.5MCG/HR	A209655	003	Jan 24,	2023	Jan NEWA
@	ZYDUS PHARMS	37.5MCG/HR	A209655	003	Jan 24,	2023	Jun DISC
AB		37.5MCG/HR	A209655	003	Jan 24,	2023	May CAHN
	FENTANYL-50						
AB	AVEVA	50MCG/HR	A077449	002	Oct 20,	2008	Jul CMFD
AB	ZYDUS NOVELTECH INC	50MCG/HR	A209655	004	Jan 24,	2023	Jan NEWA
@	ZYDUS PHARMS	50MCG/HR	A209655	004	Jan 24,	2023	Jun DISC
AB		50MCG/HR	A209655	004	Jan 24,	2023	May CAHN
	FENTANYL-62						
AB	AVEVA	62.5MCG/HR	A077449	007	Dec 06,	2017	Jul CMFD
AB	ZYDUS NOVELTECH INC	62.5MCG/HR	A209655	005	Jan 24,	2023	Jan NEWA
@	ZYDUS PHARMS	62.5MCG/HR	A209655	005	Jan 24,	2023	Jun DISC
AB		62.5MCG/HR	A209655	005	Jan 24,	2023	May CAHN
	FENTANYL-75						
AB	AVEVA	75MCG/HR	A077449	003	Oct 20,	2008	Jul CMFD
AB	ZYDUS NOVELTECH INC	75MCG/HR	A209655	006	Jan 24,	2023	Jan NEWA
@	ZYDUS PHARMS	75MCG/HR	A209655	006	Jan 24,	2023	Jun DISC
AB		75MCG/HR	A209655	006	Jan 24,	2023	May CAHN
	FENTANYL-87						
AB	AVEVA	87.5MCG/HR	A077449	008	Dec 06,	2017	Jul CMFD
AB	MYLAN TECHNOLOGIES	87.5MCG/HR	A076258	008	Dec 29,	2014	Jul CTEC
		87.5MCG/HR	A076258	008	Dec 29,	2014	Jun CTEC
AB		87.5MCG/HR	A076258	008	Dec 29,	2014	Jan CTEC
AB	ZYDUS NOVELTECH INC	87.5MCG/HR	A209655	007	Jan 24,	2023	Jan NEWA
@	ZYDUS PHARMS	87.5MCG/HR	A209655	007	Jan 24,	2023	Jun DISC
AB		87.5MCG/HR	A209655	007	Jan 24,	2023	May CAHN

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

AP	+! HIKMA	EQ 0.025MG BASE/0.5ML	N019101	002	Jan 20, 2023	Jan NEWA
	+!	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Jan CTNA
	SOLUTION; INTRAVENOUS FENTANYL CITRATE					
	+ @ EXELA PHARMA	EQ 2.5MG BASE/50ML (EQ 0.05MG BASE/ML)	N215870	001	Feb 08, 2023	May DISC
	+!	EQ 2.5MG BASE/50ML (EQ 0.05MG BASE/ML)	N215870	001	Feb 08, 2023	Feb NEWA
	+ @	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N215870	002	Feb 08, 2023	May DISC
	+!	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N215870	002	Feb 08, 2023	Feb NEWA

TABLET: BUCCAL, SUBLINGUAL

FENTANYL CITRATE

@	DR REDDYS LABS SA	EQ	0.1MG	BASE	A206329	001	Aug 22, 2022	Apr CAHN
@		EQ	0.2MG	BASE	A206329	002	Aug 22, 2022	Apr CAHN
@		EQ	0.3MG	BASE	A206329	003	Aug 22, 2022	Apr CAHN
@		EQ	0.4MG	BASE	A206329	004	Aug 22, 2022	Apr CAHN
@		EQ	0.6MG	BASE	A206329	005	Aug 22, 2022	Apr CAHN
@		EQ	0.8MG	BASE	A206329	006	Aug 22, 2022	Apr CAHN

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

FESOTERODINE FUMARATE

@ ACCORD HLTHCARE	4MG	A205012	001	Jan 04, 2023	Jul DISC
@	8MG	A205012	002	Jan 04, 2023	Jul DISC
@ ACTAVIS LABS FL INC	4MG	A204868	001	Jan 04, 2023	Jul DISC
@	8MG	A204868	002	Jan 04, 2023	Jul DISC
@ LUPIN LTD	4MG	A204983	001	Jan 05, 2023	Feb DISC
@	8MG	A204983	002	Jan 05, 2023	Feb DISC

FEZOLINETANT

TABLET;ORAL

VEOZAH

+! ASTELLAS

45MG

N216578 001 May 12, 2023 May NEWA

FINAFLOXACIN

SUSPENSION/DROPS;OTIC

XTORO

+ @ FONSECA BIOSCIENCES

0.3%

N206307 001 Dec 17, 2014 Jan CAHN

FINASTERIDE; TADALAFIL

CAPSULE;ORAL

ENTADFI

+! BLUE WATER BIOTECH

5MG;5MG

N215423 001 Dec 09, 2021 Jul CAHN

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL

FINGOLIMOD HYDROCHLORIDE

AB

BIONPHARMA

EQ 0.5MG BASE

A210252 001 May 24, 2023 May NEWA

FINGOLIMOD LAURYL SULFATE

TABLET, ORALLY DISINTEGRATING;ORAL

TASCENO ODT

+! CYCLE

EQ 0.25MG BASE

N214962 001 Dec 23, 2021 Jan CAHN

+!

EQ 0.5MG BASE

N214962 002 Dec 09, 2022 Jan CAHN

FLOTUFOLASTAT F-18 GALLIUM

SOLUTION;INTRAVENOUS

POSLUMA

>A>

+! BLUE EARTH

25ML (8-158mCi/ML)

N216023 001 May 25, 2023 Aug CPOT

>D>

+!

50ML (8-158mCi/ML)

N216023 001 May 25, 2023 Aug CPOT

+!

50ML (8-158mCi/ML)

N216023 001 May 25, 2023 May NEWA

FLUCONAZOLE

INJECTABLE;INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

>D> AP

BAXTER HLTHCARE CORP

200MG/100ML (2MG/ML)

A077947 001 May 26, 2010 Aug DISC

>A>

@

200MG/100ML (2MG/ML)

A077947 001 May 26, 2010 Aug DISC

>D> AP

+!

400MG/200ML (2MG/ML)

A077947 002 May 26, 2010 Aug DISC

>A>

@

400MG/200ML (2MG/ML)

A077947 002 May 26, 2010 Aug DISC

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

@ ACTAVIS LLC

50MG/2ML (25MG/ML)

A203738 001 Feb 28, 2017 Jun DISC

AP2

50MG/2ML (25MG/ML)

A203738 001 Feb 28, 2017 Jan CTEC

AP1

AREVA PHARMS

50MG/2ML (25MG/ML)

A090724 001 Sep 27, 2010 Jan CTEC

AP1

FRESENIUS KABI USA

50MG/2ML (25MG/ML)

A078393 001 Oct 15, 2007 Jan CTEC

AP

SAGENT PHARMS INC

50MG/2ML (25MG/ML)

A078393 001 Oct 15, 2007 Jan CHRS

AP1

+ @ SANDOZ

50MG/2ML (25MG/ML)

A076661 001 Apr 28, 2004 Jan CTEC

AP2

+!

50MG/2ML (25MG/ML)

N022137 001 Sep 21, 2007 Jun DISC

FLUDROCORTISONE ACETATE

TABLET;ORAL

FLUDROCORTISONE ACETATE

@ HIKMA

0.1MG

A216013 001 Oct 27, 2022 Apr DISC

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL

FLUOCINOLONE ACETONIDE

@ INVATECH

0.025%

A088045 001 Dec 16, 1982 Mar CAHN

IMPLANT;INTRAVITREAL

YUTIQ

+! ALIMERA SCIENCES INC

0.18MG

N210331 001 Oct 12, 2018 Jun CAHN

OIL;TOPICAL

FLUOCINOLONE ACETONIDE

AT NOVEL LABS INC

0.01%

A207345 001 Jul 31, 2023 Jul NEWA

AT NOVEL LABS INC

0.01%

A207347 001 Aug 07, 2023 Jul NEWA

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

AT CHARTWELL RX

0.01%

A209596 001 Dec 26, 2017 May CAHN

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

AB1 ! AMNEAL

0.05%

A210554 001 Aug 21, 2018 Feb CHRS

PAI HOLDINGS PHARM

0.1%

A211758 001 Apr 03, 2019 Aug DISC

>A>

@

0.1%

A211758 001 Apr 03, 2019 Aug DISC

+ @ TARO

0.05%

N019117 001 Jun 26, 1984 Feb DISC

GEL;TOPICAL

FLUOCINONIDE

@ PAI HOLDINGS PHARM

0.05%

A209030 001 Jun 19, 2018 May DISC

OINTMENT;TOPICAL

FLUOCINONIDE

AB CHARTWELL RX

0.05%

A207538 001 Jul 31, 2017 Apr CAHN

PAI HOLDINGS PHARM

0.05%

A207680 001 Sep 28, 2018 Aug DISC

>A>

@

0.05%

A207680 001 Sep 28, 2018 Aug DISC

SOLUTION;TOPICAL

FLUOCINONIDE

AT CHARTWELL RX

0.05%

A209118 001 Apr 23, 2018 May CAHN

@ PAI HOLDINGS PHARM

0.05%

A207554 001 Mar 18, 2019 May DISC

FLUORESCIN SODIUM

INJECTABLE;INTRAVENOUS

AK-FLUOR 10%

>D> AP + AKORN

EQ 500MG BASE/5ML (EQ 100MG
BASE/ML)

N022186 001 Aug 08, 2008 Aug CAHN

>A> AP + LONG GROVE PHARMS

EQ 500MG BASE/5ML (EQ 100MG
BASE/ML)

N022186 001 Aug 08, 2008 Aug CAHN

AK-FLUOR 25%

>D> +! AKORN

EQ 500MG BASE/2ML (EQ 250MG
BASE/ML)

N022186 002 Aug 08, 2008 Aug CAHN

>A> +! LONG GROVE PHARMS

EQ 500MG BASE/2ML (EQ 250MG
BASE/ML)

N022186 002 Aug 08, 2008 Aug CAHN

FLUOROESTRADIOL F-18

SOLUTION;INTRAVENOUS

CERIANNA

>A> +! GE HEALTHCARE

50ML (4-100mCi/ML)

N212155 001 May 20, 2020 Aug CAHN

>D> +! ZIONEXA

50ML (4-100mCi/ML)

N212155 001 May 20, 2020 Aug CAHN

FLUOROMETHOLONE

SUSPENSION/DROPS;OPHTHALMIC

FML

+! ABBVIE

0.1%

N016851 002 Jul 28, 1982 Jan CAHN

FML FORTE

+! ABBVIE

0.25%

N019216 001 Apr 23, 1986 Jan CAHN

FLUOROURACIL

INJECTABLE;INJECTION

FLUOROURACIL

AP ALEMBIC

2.5GM/50ML (50MG/ML)

A217295 001 Mar 03, 2023 Feb NEWA

FLUOXETINE HYDROCHLORIDE

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

AA	@ CHARTWELL MOLECULAR	EQ 20MG BASE/5ML	A076458	001	May 14, 2004	Jul CAHN
	NOSTRUM LABS INC	EQ 20MG BASE/5ML	A075292	001	Feb 07, 2002	Mar CMFD
	@ XTRIUM LABS INC	EQ 20MG BASE/5ML	A075514	001	Aug 29, 2002	Jul DISC
AA		EQ 20MG BASE/5ML	A075514	001	Aug 29, 2002	Jan CAHN
	TABLET;ORAL					
	FLUOXETINE HYDROCHLORIDE					
	@ PIRAMAL HLTHCARE UK	EQ 10MG BASE	A211444	001	Sep 13, 2022	Mar DISC
	@	EQ 20MG BASE	A211444	002	Sep 13, 2022	Mar DISC

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

AO	GLAND PHARMA LTD	25MG/ML	A215509	001	Mar 30, 2023	Mar NEWA
----	------------------	---------	---------	-----	--------------	----------

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

@ AJANTA PHARMA LTD	1MG	A217410	001	Jan 05, 2023	Jun DISC	
@	2.5MG	A217410	002	Jan 05, 2023	Jun DISC	
@	5MG	A217410	003	Jan 05, 2023	Jun DISC	
@	10MG	A217410	004	Jan 05, 2023	Jun DISC	
>A> AB	AUROBINDO PHARMA LTD	1MG	A218055	001	Aug 18, 2023	Aug NEWA
>A> AB		2.5MG	A218055	002	Aug 18, 2023	Aug NEWA
>A> AB		5MG	A218055	003	Aug 18, 2023	Aug NEWA
>A> AB		10MG	A218055	004	Aug 18, 2023	Aug NEWA
	@ PRASCO	1MG	A089804	002	Aug 12, 1988	Apr DISC
	@	2.5MG	A089804	003	Aug 12, 1988	Apr DISC
	@	5MG	A089804	004	Aug 12, 1988	Apr DISC
	@	10MG	A089804	001	Aug 12, 1988	Apr DISC

FLURANDRENOLIDE

CREAM;TOPICAL

FLURANDRENOLIDE

>A>	@ CHARTWELL RX	0.05%	A205342	001	Apr 13, 2016	Aug CAHN
>D>	@ CINTEX SVCS	0.05%	A205342	001	Apr 13, 2016	Aug CAHN

LOTION;TOPICAL

CORDRAN

+ @ ALMIRALL FLURANDRENOLIDE

>A>	@ CHARTWELL RX	0.05%	A205343	001	Dec 22, 2016	Aug CAHN
>D>	@ CINTEX SVCS	0.05%	A205343	001	Dec 22, 2016	Aug CAHN

! PADAGIS ISRAEL

AT	!	0.05%	A207133	001	Aug 30, 2016	May CTEC
	OINTMENT;TOPICAL					

CORDRAN

+ @ ALMIRALL FLURANDRENOLIDE

! TELIGENT

AT	!	0.05%	A207851	001	Dec 30, 2016	May CTEC
	OINTMENT;TOPICAL					

CORDRAN

+ @ ALMIRALL FLURANDRENOLIDE

! TELIGENT

AT	!	0.05%	A207851	001	Dec 30, 2016	May CHRS
----	---	-------	---------	-----	--------------	----------

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER;INHALATION

BREO ELLIPTA

+ GLAXO GRP LTD	0.05MG/INH;EQ 0.025MG BASE/INH	N204275	003	May 12, 2023	May NEWA
-----------------	--------------------------------	---------	-----	--------------	----------

FLUTICASONE PROPIONATE

OINTMENT;TOPICAL

FLUTICASONE PROPIONATE

>A> AB	BRIGHT	0.005%	A215343	001	Sep 01, 2023	Aug NEWA
--------	--------	--------	---------	-----	--------------	----------

FLUVOXAMINE MALEATE

TABLET;ORAL

LUVOX

AB	+ ANI PHARMS	25MG	N021519	001	Dec 20, 2007	Jan CRLD
AB	+	50MG	N021519	002	Dec 20, 2007	Jan CRLD
AB	+	100MG	N021519	003	Dec 20, 2007	Jan CRLD

FOMEPIZOLE

INJECTABLE; INJECTION
FOMEPIZOLE
AP GLAND PHARMA LTD 1.5GM/1.5ML (1GM/ML) A216791 001 Jul 06, 2023 Jun NEWA

FORMOTEROL FUMARATE

SOLUTION; INHALATION
FORMOTEROL FUMARATE
AN MANKIND PHARMA 0.02MG/2ML A215883 001 Mar 22, 2023 Mar NEWA

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS
FOSAPREPITANT DIMEGLUMINE
AP PIRAMAL CRITICAL EQ 150MG BASE/VIAL A214683 001 May 16, 2023 May NEWA
SOLUTION; INTRAVENOUS
FOCINVEZ
>A> +! SPES PHARMS EQ 150MG BASE/50ML (EQ 3MG BASE/ML) N216686 001 Aug 22, 2023 Aug NEWA

FOSCARNET SODIUM

INJECTABLE; INJECTION
FOSCARNET SODIUM
AP AVET LIFESCIENCES 2.4GM/100ML A213807 001 Jun 05, 2023 May NEWA

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION
FOSPHENYTOIN SODIUM
@ MYLAN LABS LTD EQ 50MG PHENYTOIN NA/ML A078736 001 Jun 08, 2010 Apr DISC

FROVATRIPTAN SUCCINATE

TABLET; ORAL
FROVATRIPTAN SUCCINATE
@ MYLAN EQ 2.5MG BASE A202931 001 Aug 28, 2014 Apr DISC

FULVESTRANT

SOLUTION; INTRAMUSCULAR
FULVESTRANT
AO EUGIA PHARMA 250MG/5ML (50MG/ML) A215169 001 Jun 30, 2023 Jun NEWA

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE
>D> @ AMNEAL PHARMS CO 10MG/ML A207552 001 Jul 20, 2016 Aug CMFD
>A> AP 10MG/ML A207552 001 Jul 20, 2016 Aug CMFD
>D> AP ATHENEX INC 10MG/ML A214766 001 Jan 27, 2021 Aug CAHN
>A> AP SAGENT 10MG/ML A214766 001 Jan 27, 2021 Aug CAHN
SOLUTION; ORAL
FUROSEMIDE
@ XTTRIUM LABS INC 10MG/ML A070655 001 Oct 02, 1987 Jan CAHN
TABLET; ORAL
FUROSEMIDE
@ CHARTWELL RX 20MG N018413 001 Nov 30, 1983 Mar CAHN
@ 40MG N018413 002 Nov 30, 1983 Mar CAHN

GABAPENTIN

CAPSULE; ORAL
GABAPENTIN
AB LAURUS 100MG A217546 001 May 12, 2023 May NEWA
AB 300MG A217546 002 May 12, 2023 May NEWA
AB 400MG A217546 003 May 12, 2023 May NEWA
SOLUTION; ORAL
GABAPENTIN
>D> AA AKORN 250MG/5ML A078974 001 Feb 18, 2011 Aug CAHN
>A> AA MISSION PHARMACAL 250MG/5ML A078974 001 Feb 18, 2011 Aug CAHN
AA RUBICON 250MG/5ML A216492 001 Jan 18, 2023 Jan NEWA
TABLET; ORAL
GABAPENTIN
@ CHARTWELL RX 600MG A076120 001 Jan 27, 2006 May CAHN
@ 800MG A076120 002 Jan 27, 2006 May CAHN
AB GRANULES 600MG A217116 001 Mar 28, 2023 Mar NEWA

TABLET;ORAL
GABAPENTIN

AB		800MG	A217116	002	Mar 28, 2023	Mar NEWA
>D>	AB	GRAVITI PHARMS	A217995	001	Jul 19, 2023	Aug CAHN
AB		600MG	A217995	001	Jul 19, 2023	Jul NEWA
>D>	AB	800MG	A217995	002	Jul 19, 2023	Aug CAHN
AB		800MG	A217995	002	Jul 19, 2023	Jul NEWA
>A>	AB	RISING	A217995	001	Jul 19, 2023	Aug CAHN
>A>	AB	800MG	A217995	002	Jul 19, 2023	Aug CAHN
		GRALISE				
>A>	+	ALMATICHA	N022544	003	Apr 18, 2023	Aug NEWA
>A>	+	750MG	N022544	004	Apr 18, 2023	Aug NEWA
>A>	+	900MG	N022544	005	Apr 18, 2023	Aug NEWA

GADOBUTROL

SOLUTION;INTRAVENOUS
GADOBUTROL

AP	HAINAN POLY PHARM	4.5354GM/7.5ML (604.72MG/ML)	A217480	001	Mar 15, 2023	Mar NEWA
AP		9.0708GM/15ML (604.72MG/ML)	A217480	002	Mar 15, 2023	Mar NEWA

GADOTERATE MEGLUMINE

SOLUTION;INTRAVENOUS
GADOTERATE MEGLUMINE

AP	HENGRIU PHARMA	37.69GM/100ML (376.9MG/ML)	A215304	005	Apr 15, 2022	Feb CMS1
----	----------------	----------------------------	---------	-----	--------------	----------

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL
GALANTAMINE HYDROBROMIDE

AB	! AUROBINDO PHARMA	EQ 8MG BASE	A204895	001	Aug 05, 2016	Jul CHRS
	RAZADYNE ER					
+ @	JANSSEN PHARMS	EQ 8MG BASE	N021615	001	Apr 01, 2005	Jul DISC
+ @		EQ 16MG BASE	N021615	002	Apr 01, 2005	Jul DISC
+ @		EQ 24MG BASE	N021615	003	Apr 01, 2005	Jul DISC

GALLIUM GA-68 DOTATOC

SOLUTION;INTRAVENOUS
GALLIUM GA 68 DOTATOC

>D>	UIHC PET IMAGING	0.5-4mCi/ML	N210828	001	Aug 21, 2019	Aug CAIN
-----	------------------	-------------	---------	-----	--------------	----------

GALLIUM GA-68 EDOTREOTIDE

SOLUTION;INTRAVENOUS
GALLIUM GA 68 EDOTREOTIDE

>A>	UIHC PET IMAGING	0.5-4mCi/ML	N210828	001	Aug 21, 2019	Aug CAIN
-----	------------------	-------------	---------	-----	--------------	----------

GANIRELIX ACETATE

INJECTABLE;INJECTION
GANIRELIX ACETATE

AP	GLAND PHARMA LTD	250MCG/0.5ML	A215658	001	Feb 28, 2023	Feb NEWA
AP	+! ORGANON USA ORGANON	250MCG/0.5ML	N021057	001	Jul 29, 1999	May CAHN

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC
ZYMAR

+ @ ALLERGAN
ZYMAXID

AT	ABBVIE	0.5%	N022548	001	May 18, 2010	Jan CAHN
----	--------	------	---------	-----	--------------	----------

GEFITINIB

TABLET;ORAL
GEFITINIB

AB	ACTAVIS LABS FL INC	250MG	A208913	001	Apr 26, 2023	Apr NEWA
AB	NATCO	250MG	A212827	001	May 31, 2023	May NEWA
AB	QILU PHARM HAINAN	250MG	A211591	001	Feb 13, 2023	Feb NEWA

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION
GEMCITABINE HYDROCHLORIDE

AP	HIKMA	200MG/5.26ML (38MG/ML)	A213175	001	Mar 07, 2023	Feb NEWA
AP		1GM/26.3ML (38MG/ML)	A213175	002	Mar 07, 2023	Feb NEWA
AP		2GM/52.6ML (38MG/ML)	A213175	003	Mar 07, 2023	Feb NEWA
AP	NOVAST LABS	200MG/5.26ML (38MG/ML)	A210383	001	Feb 14, 2019	Jun CMFD
AP		1GM/26.3ML (38MG/ML)	A210383	002	Feb 14, 2019	Jun CMFD

	<u>INJECTABLE; INJECTION</u>					
	GEMCITABINE HYDROCHLORIDE					
AP	SOLUTION; INTRAVENOUS INFUGEM	2GM/52.6ML (38MG/ML)		A210383	003	Feb 14, 2019 Jun CMFD
	+ @ SUN PHARM	EQ 1200MG BASE/120ML (EQ 10MG BASE/ML)	N208313	001	Jul 16, 2018 Jul DISC	
	+ @	EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)	N208313	002	Jul 16, 2018 Jul DISC	
	+ @	EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)	N208313	003	Jul 16, 2018 Jul DISC	
	+ @	EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)	N208313	004	Jul 16, 2018 Jul DISC	
	+ @	EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)	N208313	005	Jul 16, 2018 Jul DISC	
	+ @	EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)	N208313	006	Jul 16, 2018 Jul DISC	
	+ @	EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)	N208313	007	Jul 16, 2018 Jul DISC	
	+ @	EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)	N208313	008	Jul 16, 2018 Jul DISC	
	+ @	EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)	N208313	009	Jul 16, 2018 Jul DISC	
	+ @	EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)	N208313	010	Jul 16, 2018 Jul DISC	
	<u>GENTAMICIN SULFATE</u>					
	OINTMENT; OPHTHALMIC GENTAMICIN SULFATE					
	@ AKORN	EQ 0.3% BASE	A064093	001	Aug 31, 1995 Feb DISC	
	! FERA PHARMS LLC	EQ 0.3% BASE	A065024	001	Jul 30, 2004 Feb CTEC	
AT	!	EQ 0.3% BASE	A065024	001	Jul 30, 2004 Feb CHRS	
	OINTMENT; TOPICAL GENTAMICIN SULFATE					
	@ PAI HOLDINGS PHARM	EQ 0.1% BASE	A209233	001	Dec 31, 2018 May DISC	
	SOLUTION/DROPS; OPHTHALMIC GENOPTIC					
	@ ALLERGAN	EQ 0.3% BASE	A062452	001	Oct 10, 1984 Feb DISC	
	GENTAK					
	@ AKORN	EQ 0.3% BASE	A064163	001	Oct 12, 2001 Feb DISC	
	GENTAMICIN SULFATE					
AT	! SANDOZ	EQ 0.3% BASE	A062196	001		Feb CHRS
	<u>GENTAMICIN SULFATE; PREDNISOLONE ACETATE</u>					
	OINTMENT; OPHTHALMIC PRED-G					
	+ @ ALLERGAN	EQ 0.3% BASE; 0.6%	N050612	001	Dec 01, 1989 Jan DISC	
	<u>GLATIRAMER ACETATE</u>					
	FOR SOLUTION; SUBCUTANEOUS COPAXONE					
	+ @ TEVA PHARMS USA	20MG/VIAL	N020622	001	Dec 20, 1996 Jun CRLD	
	<u>GLIPIZIDE; METFORMIN HYDROCHLORIDE</u>					
	TABLET; ORAL GLIPIZIDE AND METFORMIN HYDROCHLORIDE					
	@ DASH PHARMS	2.5MG; 250MG	A078083	001	Apr 12, 2007 Feb CAHN	
	@	2.5MG; 500MG	A078083	002	Apr 12, 2007 Feb CAHN	
	@	5MG; 500MG	A078083	003	Apr 12, 2007 Feb CAHN	
	<u>GLUCAGON</u>					
	SOLUTION; SUBCUTANEOUS GVOKE KIT					
	+! XERIS	1MG/0.2ML (1MG/0.2ML)	N212097	005	Aug 20, 2021 May NEWA	
	GVOKE PFS					
	+ @ XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097	001	Sep 10, 2019 Jan DISC	
	<u>GLYCEROL PHENYLBUTYRATE</u>					
	LIQUID; ORAL RAVICTI					
	+! HORIZON THERAP US	1.1GM/ML	N203284	001	Feb 01, 2013 Jan CAHN	

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

>D>	AP	ATHENEX INC	0.2MG/ML	A210083	001	Feb 21, 2020	Aug CAHN
	AP	@ LUPIN LTD	0.2MG/ML	A213655	001	Feb 07, 2023	Apr DISC
	AP		0.2MG/ML	A213655	001	Feb 07, 2023	Jan NEWA
>D>	AP	MANKIND PHARMA	0.2MG/ML	A217354	001	Feb 27, 2023	Aug DISC
>A>	AP	@	0.2MG/ML	A217354	001	Feb 27, 2023	Aug DISC
	AP		0.2MG/ML	A217354	001	Feb 27, 2023	Feb NEWA
>A>	AP	SAGENT	0.2MG/ML	A210083	001	Feb 21, 2020	Aug CAHN
		SOLUTION; INHALATION					
		LONHALA MAGNAIR KIT					
	+ @	SUMITOMO PHARMA AM	25MCG/ML	N208437	001	Dec 05, 2017	Jul CAHN
	+ @	SUNOVION RESP	25MCG/ML	N208437	001	Dec 05, 2017	Jul DISC
		TABLET; ORAL					
		GLYCOPYRROLATE					
AA		ALEMBIC	1MG	A203657	001	Nov 30, 2018	Feb CAHN
AA			2MG	A203657	002	Nov 30, 2018	Feb CAHN
AA		AUROBINDO PHARMA	1MG	A202675	001	Apr 15, 2013	Jan CAHN
AA			2MG	A202675	002	Oct 30, 2018	Jan CAHN
		TABLET, ORALLY DISINTEGRATING; ORAL					
		DARTISLA ODT					
	+ @	EDENBRIDGE PHARMS	1.7MG	N215019	001	Dec 16, 2021	Jun DISC

GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

PREVDUO

+!	SLAYBACK PHARMA LLC	0.6MG/3ML (0.2MG/ML); 3MG/3ML (1MG/ML)	N216903	001	Feb 23, 2023	Feb NEWA
----	---------------------	---	---------	-----	--------------	----------

GRANISETRON HYDROCHLORIDE

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

@ AUROBINDO PHARMA USA EQ 1MG BASE

A078725 001 Jan 30, 2008 May CAHN

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

AB	AJANTA PHARMA LTD	EQ 1MG BASE
AB		EQ 2MG BASE
AB	AUROBINDO PHARMA USA	EQ 1MG BASE
AB		EQ 2MG BASE

A217293 001 Apr 27, 2023 Apr NEWA
A217293 002 Apr 27, 2023 Apr NEWA
A074796 001 Jan 27, 1997 Jul CMFD
A074796 002 Jan 27, 1997 Jul CMFD

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

AB	ALEMBIC	EQ 1MG BASE
AB		EQ 2MG BASE
AB		EQ 3MG BASE
AB		EQ 4MG BASE

A217269 001 Aug 07, 2023 Jul NEWA
A217269 002 Aug 07, 2023 Jul NEWA
A217269 003 Aug 07, 2023 Jul NEWA
A217269 004 Aug 07, 2023 Jul NEWAHALCINONIDE

CREAM; TOPICAL

HALCINONIDE

AB	CHARTWELL RX	0.1%
----	--------------	------

A214723 001 Sep 08, 2021 May CAHN

HALOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

HALOBETASOL PROPIONATE

>A>		
>A>	AB	

A215266 001 Aug 11, 2023 Aug NFTG

PADAGIS ISRAEL

LEXETTE

+! MAYNE PHARMA 0.05%

+! 0.05%

N210566 001 May 24, 2018 Aug CFTG

N210566 001 May 24, 2018 Aug CFTG

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

@ PAI HOLDINGS PHARM 0.05%

A209978 001 Mar 20, 2018 May DISC

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

	@ ACTAVIS GROUP	0.5MG	A200854	001	Jul 01, 2022	Jan DISC
	@	1MG	A200854	002	Jul 01, 2022	Jan DISC
	@	2MG	A200854	003	Jul 01, 2022	Jan DISC
	@	5MG	A200854	004	Jul 01, 2022	Jan DISC
	@	10MG	A200854	005	Jul 01, 2022	Jan DISC
	@	20MG	A200854	006	Jul 01, 2022	Jan DISC
>A>	@ AIPING PHARM INC	0.5MG	A071128	001	Feb 17, 1987	Aug CAHN
>A>	@	1MG	A071129	001	Feb 17, 1987	Aug CAHN
>A> AB		2MG	A071130	001	Feb 17, 1987	Aug CAHN
>A> AB		5MG	A071131	001	Feb 17, 1987	Aug CAHN
>A> AB		10MG	A071132	001	May 12, 1987	Aug CAHN
>A>	@	20MG	A071133	001	May 12, 1987	Aug CAHN
>D>	@ CYCLE	0.5MG	A071128	001	Feb 17, 1987	Aug CAHN
>D>	@	1MG	A071129	001	Feb 17, 1987	Aug CAHN
>D> AB		2MG	A071130	001	Feb 17, 1987	Aug CAHN
>D> AB		5MG	A071131	001	Feb 17, 1987	Aug CAHN
>D> AB		10MG	A071132	001	May 12, 1987	Aug CAHN
>D>	@	20MG	A071133	001	May 12, 1987	Aug CAHN
AB	ZYDUS PHARMS USA	0.5MG	A077580	001	Jan 17, 2023	Jan NEWA
AB		1MG	A077580	002	Jan 17, 2023	Jan NEWA
AB		2MG	A077580	006	Jan 17, 2023	Jan NEWA

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

AO	MANKIND PHARMA	EQ 50MG BASE/ML	A216730	001	May 23, 2023	May NEWA
AO		EQ 100MG BASE/ML	A216730	002	May 23, 2023	May NEWA

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

AP	NANJING KING-FRIEND	5,000 UNITS/ML	A212061	001	Jul 15, 2020	Feb CMFD
AP		HEPARIN SODIUM PRESERVATIVE FREE				
AP	NANJING KING-FRIEND	10,000 UNITS/ML	A212060	001	Apr 02, 2020	Feb CMFD

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

AP	EUGIA PHARMA	20MG/ML	A215147	001	Feb 13, 2023	Feb NEWA
	@ MYLAN INSTITUTIONAL	20MG/ML	A204680	001	Apr 28, 2016	May DISC
	TABLET;ORAL					
	HYDRALAZINE HYDROCHLORIDE					
AA	HERITAGE PHARMS INC	10MG	A040858	001	Feb 26, 2010	May CMFD
AA		25MG	A040858	002	Feb 26, 2010	May CMFD
AA		50MG	A040858	003	Feb 26, 2010	May CMFD
AA		100MG	A040858	004	Feb 26, 2010	May CMFD

HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDROCHLOROTHIAZIDE

AB	HERITAGE PHARMS	12.5MG	A085182	003	May 02, 2023	Apr NEWA
----	-----------------	--------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB	! INVAGEN PHARMS	12.5MG;20MG	A204058	002	May 23, 2017	Jun CHRS
AB	!	25MG;20MG	A204058	003	May 23, 2017	Jun CHRS
	ZESTORETIC					
AB	+ ALMATICA	12.5MG;20MG	N019888	001	Sep 20, 1990	Jun CHRS
AB	+	25MG;20MG	N019888	002	Jul 20, 1989	Jun CHRS

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB	MACLEODS PHARMS LTD	12.5MG;20MG	A204801	001	Jun 01, 2023	May NEWA
AB		12.5MG;40MG	A204801	002	Jun 01, 2023	May NEWA
AB		25MG;40MG	A204801	003	Jun 01, 2023	May NEWA
>D> AB	TORRENT	12.5MG;20MG	A206515	001	May 03, 2017	Aug DISC

TABLET;ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

>A>	@	12.5MG;20MG	A206515	001	May 03, 2017	Aug DISC
>D> AB		12.5MG;40MG	A206515	002	May 03, 2017	Aug DISC
>A>	@	12.5MG;40MG	A206515	002	May 03, 2017	Aug DISC
>D> AB		25MG;40MG	A206515	003	May 03, 2017	Aug DISC
>A>	@	25MG;40MG	A206515	003	May 03, 2017	Aug DISC
	@ ZYDUS PHARMS	12.5MG;20MG	A206377	001	Feb 24, 2023	Jul DISC
AB		12.5MG;20MG	A206377	001	Feb 24, 2023	Feb NEWA
	@	12.5MG;40MG	A206377	002	Feb 24, 2023	Jul DISC
AB		12.5MG;40MG	A206377	002	Feb 24, 2023	Feb NEWA
	@	25MG;40MG	A206377	003	Feb 24, 2023	Jul DISC
AB		25MG;40MG	A206377	003	Feb 24, 2023	Feb NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDETABLET;ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	APOTEX	12.5MG;EQ 10MG BASE	A091524	001	Mar 12, 2013	Jan CAHN
AB		12.5MG;EQ 20MG BASE	A091524	002	Mar 12, 2013	Jan CAHN
AB		25MG;EQ 20MG BASE	A091524	003	Mar 12, 2013	Jan CAHN
	@ CHARTWELL RX	12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	Apr CAHN
	@	12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	Apr CAHN
	@	25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	Apr CAHN

HYDROCHLOROTHIAZIDE; VALSARTANTABLET;ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

>A> AB	AMNEAL PHARMS	12.5MG;80MG	A204382	001	Aug 11, 2023	Aug NEWA
>A> AB		12.5MG;160MG	A204382	002	Aug 11, 2023	Aug NEWA
>A> AB		12.5MG;320MG	A204382	004	Aug 11, 2023	Aug NEWA
>A> AB		25MG;160MG	A204382	003	Aug 11, 2023	Aug NEWA
>A> AB		25MG;320MG	A204382	005	Aug 11, 2023	Aug NEWA

HYDROCORTISONETABLET;ORAL

HYDROCORTISONE

AB	AUROBINDO PHARMA LTD	5MG	A214649	001	Jul 17, 2023	Jul NEWA
AB		10MG	A214649	002	Jul 17, 2023	Jul NEWA
AB		20MG	A214649	003	Jul 17, 2023	Jul NEWA

HYDROMORPHONE HYDROCHLORIDEINJECTABLE;INJECTION

HYDROMORPHONE HYDROCHLORIDE

AP	HIKMA	2MG/ML	A202159	001	Apr 27, 2018	May CAHN
	HOSPIRA INC	0.25MG/0.5ML	N200403	005	Mar 03, 2023	Mar NEWA
		4MG/ML	N200403	003	Dec 01, 2011	Apr CTEC

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDESOLUTION/DROPS;OPHTHALMIC

PAREMYD

+ @ AKORN 1%;0.25%

N019261 001 Jan 30, 1992 Feb DISC

HYDROXYCHLOROQUINE SULFATETABLET;ORAL

HYDROXYCHLOROQUINE SULFATE

AB	CHARTWELL RX	200MG	A210543	001	Jul 06, 2018	May CAHN
----	--------------	-------	---------	-----	--------------	----------

HYDROXYPROGESTERONE CAPROATESOLUTION;INTRAMUSCULAR

HYDROXYPROGESTERONE CAPROATE

@ ASPEN GLOBAL INC 1250MG/5ML (250MG/ML)

A200271 001 Aug 24, 2015 Jul DISC

HYDROXYPROPYL CELLULOSEINSERT;OPHTHALMIC

LACRISERT

+! BAUSCH 5MG

N018771 001 Jan CAHN

+! BAUSCH AND LOMB INC 5MG

N018771 001 Jan CAHN

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HYDROCHLORIDE

+!	AM REGENT	25MG/ML	A087408	001	Feb	CRLD
+!		50MG/ML	A087408	002	Feb	CRLD

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

>A>	AA	+!	CHARTWELL RX	10MG/5ML	A087294	001	Apr 12, 1982	Aug CAHN
>D>	AA	+!	WOCKHARDT BIO AG	10MG/5ML	A087294	001	Apr 12, 1982	Aug CAHN

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

AB		CHARTWELL RX	10MG	A040804	001	Jun 30, 2008	Jan CAHN
AB			25MG	A040804	002	Jun 30, 2008	Jan CAHN
AB			50MG	A040804	003	Jun 30, 2008	Jan CAHN
>A>	AB	GRAVITI PHARMS	10MG	A217652	001	Aug 17, 2023	Aug NEWA
>A>	AB		25MG	A217652	002	Aug 17, 2023	Aug NEWA
>A>	AB		50MG	A217652	003	Aug 17, 2023	Aug NEWA

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

AB		HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Mar CTEC
AB			EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Mar CTEC

IBRUTINIB

CAPSULE; ORAL

IMBRUVICA

+!	PHARMACYCLICS LLC	70MG	N205552	002	Dec 20, 2017	Jun CAHN
+!		140MG	N205552	001	Nov 13, 2013	Jun CAHN

SUSPENSION; ORAL

IMBRUVICA

+!	PHARMACYCLICS LLC	70MG/ML	N217003	001	Aug 24, 2022	Jun CAHN
----	-------------------	---------	---------	-----	--------------	----------

TABLET; ORAL

IMBRUVICA

+!	PHARMACYCLICS LLC	140MG	N210563	001	Feb 16, 2018	Jun CAHN
+		280MG	N210563	002	Feb 16, 2018	Jun CAHN
+		420MG	N210563	003	Feb 16, 2018	Jun CAHN
+ @		560MG	N210563	004	Feb 16, 2018	Jul DISC
+ !		560MG	N210563	004	Feb 16, 2018	Jun CAHN

IBUPROFEN

SUSPENSION; ORAL

IBUPROFEN

>D>		@ STRIDES PHARMA	100MG/5ML	A215311	001	May 27, 2022	Aug CMFD
>A>	AB		100MG/5ML	A215311	001	May 27, 2022	Aug CMFD

ICATIBANT ACETATE

INJECTABLE; SUBCUTANEOUS

ICATIBANT ACETATE

>A>	AP	EUGIA PHARMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A213521	001	Aug 14, 2023	Aug NEWA
-----	----	--------------	------------------------------------	---------	-----	--------------	----------

ICOSAPENT ETHYL

CAPSULE; ORAL

ICOSAPENT ETHYL

AB		DR REDDYS	500MG	A209499	002	Mar 08, 2023	Feb NEWA
AB		HIKMA	500MG	A209457	002	Mar 08, 2023	Feb NEWA
AB		ZYDUS	500MG	A217656	001	Apr 20, 2023	Apr NEWA
AB			1GM	A217656	002	Apr 20, 2023	Apr NEWA

IMATINIB MESYLATE

TABLET; ORAL

IMATINIB MESYLATE

@	BRECKENRIDGE	EQ 100MG BASE	A205990	001	Feb 08, 2019	Mar DISC
@		EQ 400MG BASE	A205990	002	Feb 08, 2019	Jun DISC
AB	CHARTWELL RX	EQ 100MG BASE	A208429	001	Jan 17, 2019	Jan CAHN
AB		EQ 400MG BASE	A208429	002	Jan 17, 2019	Jan CAHN

IMIQUIMOD

CREAM;TOPICAL					
ALDARA					
+ @ BAUSCH	5%		N 020723	001	Feb 27, 1997
IMIQUIMOD					Feb DISC
AB ! GLENMARK GENERICS	5%		A 201994	001	Mar 06, 2012
					Feb CHRS

INDAPAMIDE

TABLET;ORAL					
INDAPAMIDE					
@ AUROBINDO PHARMA USA	1.25MG		A 075105	001	Jul 23, 1998
@	2.5MG		A 075105	002	Jul 23, 1998
AB RISING	1.25MG		A 074461	002	Mar 26, 1997
AB	2.5MG		A 074461	001	Mar 27, 1996
					Jul CMFD
					Jul CMFD

INDOCYANINE GREEN

INJECTABLE;INJECTION					
IC-GREEN					
>D> @ AKORN	10MG/VIAL		N 011525	003	Aug CAHN
>D> AP +!	25MG/VIAL		N 011525	001	Aug CAHN
>D> @	40MG/VIAL		N 011525	004	Aug CAHN
>D> @	50MG/VIAL		N 011525	002	Aug CAHN
>A> @ RENEW PHARMS	10MG/VIAL		N 011525	003	Aug CAHN
>A> AP +!	25MG/VIAL		N 011525	001	Aug CAHN
>A> @	40MG/VIAL		N 011525	004	Aug CAHN
>A> @	50MG/VIAL		N 011525	002	Aug CAHN

INDOMETHACIN

CAPSULE;ORAL					
INDOMETHACIN					
AB CHARTWELL MOLECULES	25MG		N 018829	002	Aug 06, 1984
AB	50MG		N 018829	001	Aug 06, 1984
SUPPOSITORY;RECTAL					
INDOCIN					
+ @ ZYLA LIFE SCIENCES	50MG		N 017814	001	Aug 13, 1984
INDOMETHACIN					Jul CAHN
AB ! COSETTE	50MG		A 073314	001	Aug 31, 1992
AB ZYDUS	50MG		A 216184	001	Aug 02, 2023
SUSPENSION;ORAL					
INDOCIN					
+! ZYLA	25MG/5ML		N 018332	001	Oct 10, 1985
					Jun CAHN

INFIGRATINIB PHOSPHATE

CAPSULE;ORAL					
TRUSELTIQ					
+ @ HELSINN HLTHCARE	25MG		N 214622	001	May 28, 2021
+ @	100MG		N 214622	002	May 28, 2021
					Apr DISC

IOPAMIDOL

INJECTABLE;INJECTION					
IOPAMIDOL					
AP HAINAN POLY	41%		A 215382	001	Feb 27, 2023
AP	61%		A 215382	002	Feb 27, 2023
ISOVUE-250					
+ @ BRACCO	51%		N 020327	002	Oct 12, 1994
ISOVUE-M 200					Jun DISC
AP +! BRACCO	41%		N 018735	001	Dec 31, 1985
ISOVUE-M 300					Feb CTEC
AP +! BRACCO	61%		N 018735	004	Dec 31, 1985
					Feb CTEC

IPRATROPIUM BROMIDE

SPRAY, METERED;NASAL					
IPRATROPIUM BROMIDE					
@ AUROBINDO PHARMA USA	0.021MG/SPRAY		A 075552	001	Mar 31, 2003
@	0.042MG/SPRAY		A 075553	001	Mar 31, 2003
					Apr CAHN
					Apr CAHN

IRBESARTAN

TABLET;ORAL
IRBESARTAN

AB	UNICHEM	75MG	A203020	001	Dec 07, 2015	Jun CMFD
AB		150MG	A203020	002	Dec 07, 2015	Jun CMFD
AB		300MG	A203020	003	Dec 07, 2015	Jun CMFD

ISONIAZID

TABLET;ORAL
LANIAZID
© CHARTWELL MOLECULAR 50MG
© 100MG

A080140	001	Feb CAHN
A080140	002	Feb CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE;INJECTION
ISOPROTERENOL HYDROCHLORIDE

AP	© AM REGENT	0.2MG/ML	A214775	001	Oct 19, 2022	Apr DISC
AP	HIKMA	0.2MG/ML	A211703	001	Apr 26, 2023	Apr NEWA
AP	© MYLAN LABS LTD	0.2MG/ML	A212573	001	Sep 06, 2022	Jul DISC
>D> AP	PENN LIFE	0.2MG/ML	A215542	001	Sep 20, 2022	May CAHN
>A>	ZYDUS PHARMS	0.2MG/ML	A215557	001	Apr 14, 2023	Aug DISC
AP	©	0.2MG/ML	A215557	001	Apr 14, 2023	Aug DISC
AP	ISUPREL	0.2MG/ML	A215557	001	Apr 14, 2023	Apr NEWA
	+ © BAUSCH	0.2MG/ML	N010515	001		Jun DISC

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE;ORAL
ISOSORBIDE MONONITRATE
© SHANDONG 120MG

A214115	001	Apr 29, 2022	May DISC
---------	-----	--------------	----------

ISOSULFAN BLUE

INJECTABLE;INJECTION
ISOSULFAN BLUE

AP	AM REGENT	1%	A210294	001	May 17, 2023	May NEWA
----	-----------	----	---------	-----	--------------	----------

ISOTRETINOIN

CAPSULE;ORAL
ISOTRETINOIN

>A> AB1	ZYDUS PHARMS	10MG	A211568	001	Aug 29, 2023	Aug NEWA
>A> AB1		20MG	A211568	002	Aug 29, 2023	Aug NEWA
>A> AB1		30MG	A211568	003	Aug 29, 2023	Aug NEWA
>A> AB1		40MG	A211568	004	Aug 29, 2023	Aug NEWA

IVACAFTOR

GRANULE;ORAL
KALYDECO
+ VERTEX PHARMS INC 5.8MG/PACKET
+ 13.4MG/PACKET

N207925	004	May 03, 2023	May NEWA
N207925	005	May 03, 2023	May NEWA

IVERMECTIN

CREAM;TOPICAL
IVERMECTIN

AB	ZYDUS	1%	A215210	001	Aug 02, 2022	Jul CMFD
	©	1%	A215210	001	Aug 02, 2022	Jan DISC

KETAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
KETAMINE HYDROCHLORIDE
© FRESENIUS KABI USA EQ 10MG BASE/ML
EQ 10MG BASE/ML
© EQ 50MG BASE/ML
EQ 50MG BASE/ML
AP GLAND PHARMA LTD EQ 50MG BASE/ML
EQ 100MG BASE/ML

A215808	001	Jan 13, 2023	Jul DISC
A215808	001	Jan 13, 2023	Jan NEWA
A215808	002	Jan 13, 2023	Jul DISC
A215808	002	Jan 13, 2023	Jan NEWA
A216809	002	Jan 24, 2023	Jan NEWA
A216809	003	Jan 24, 2023	Jan NEWA

KETOCONAZOLE

TABLET;ORAL

KETOCONAZOLE

@ AUROBINDO PHARMA USA 200MG

A075597 001 Dec 23, 1999 May CAHN

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

AP	ASPIRO	15MG/ML	A217166	001	Jun 20, 2023	Jun NEWA
AP		30MG/ML	A217166	002	Jun 20, 2023	Jun NEWA
AP	CAPLIN	15MG/ML	A217789	001	May 10, 2023	Apr NEWA
AP		30MG/ML	A217789	002	May 10, 2023	Apr NEWA
	SOLUTION/DROPS;OPHTHALMIC					
	ACULAR					
AT	+! ABBVIE	0.5%	N019700	001	Nov 09, 1992	Jan CAHN
	KETOROLAC TROMETHAMINE					
	@ AKORN	0.5%	A078434	001	Nov 05, 2009	Jan DISC
	TABLET;ORAL					
	KETOROLAC TROMETHAMINE					
>A>	@ AIPING PHARM INC	10MG	A074790	001	Jun 26, 1997	Aug CAHN
>A> AB		10MG	A210616	001	Aug 16, 2018	Aug CAHN
AB	BIONPHARMA	10MG	A216759	001	Feb 23, 2023	Feb NEWA
>D>	@ CYCLE	10MG	A074790	001	Jun 26, 1997	Aug CAHN
>D> AB		10MG	A210616	001	Aug 16, 2018	Aug CAHN
AB	LEADING	10MG	A215745	001	Feb 23, 2023	Feb NEWA

KETOTIFEN FUMARATE

DRUG-ELUTING CONTACT LENS;OPHTHALMIC

ACUVUE THERAVISION WITH KETOTIFEN

+ @ JOHNSON JOHNSON VISN EQ 19MCG BASE

N022388 001 Feb 25, 2022 May DISC

LACOSAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

MOTPOLY XR

+	AUCTA	100MG	N216185	001	May 04, 2023	May NEWA
+		150MG	N216185	002	May 04, 2023	May NEWA
+!		200MG	N216185	003	May 04, 2023	May NEWA

SOLUTION;INTRAVENOUS

LACOSAMIDE

AP	MSN	200MG/20ML (10MG/ML)	A215979	001	Feb 09, 2023	Feb NEWA
	SOLUTION;ORAL					
	LACOSAMIDE					
>A> AA	LEADING PHARMA	10MG/ML	A216461	001	Feb 06, 2023	Aug CAHN
>D> AA	MEDLEY PHARMS	10MG/ML	A216461	001	Feb 06, 2023	Aug CAHN
AA		10MG/ML	A216461	001	Feb 06, 2023	Jan NEWA
	TABLET;ORAL					
	LACOSAMIDE					
	@ ACCORD HLTHCARE	50MG	A205011	001	Jul 12, 2022	Jan DISC
	@	100MG	A205011	002	Jul 12, 2022	Jan DISC
	@	150MG	A205011	003	Jul 12, 2022	Jan DISC
	@	200MG	A205011	004	Jul 12, 2022	Jan DISC
	@ ACTAVIS LABS FL INC	50MG	A204855	001	Jan 05, 2023	Jul DISC
	@	100MG	A204855	002	Jan 05, 2023	Jul DISC
	@	150MG	A204855	003	Jan 05, 2023	Jul DISC
	@	200MG	A204855	004	Jan 05, 2023	Jul DISC
	@ APOTEX	50MG	A214567	001	Sep 23, 2022	Mar DISC
	@	100MG	A214567	002	Sep 23, 2022	Mar DISC
	@	150MG	A214567	003	Sep 23, 2022	Mar DISC
	@	200MG	A214567	004	Sep 23, 2022	Mar DISC

LACTULOSE

SOLUTION;ORAL

LACTULOSE

AA	XTTRIUM LABS INC	10GM/15ML	A075911	001	Feb 21, 2002	Mar CMFD
	SOLUTION;ORAL, RECTAL					
	LACTULOSE					
AA	BAJAJ	10GM/15ML	A076645	001	Jul 28, 2003	Feb CMFD

LAMIVUDINE

SOLUTION;ORAL

LAMIVUDINE

AA	CHARTWELL MOLECULAR	10MG/ML	A203564	001	Oct 31, 2014	Jul CAHN
	TABLET;ORAL					

LAMIVUDINE

@ AUROBINDO PHARMA USA 100MG

A204002 001 Dec 31, 2014 May CAHN

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

TEMIXYS

+ @ CHARTWELL RX

300MG;300MG

N211284 001 Nov 16, 2018 Mar CAHN

LAMOTRIGINE

TABLET;ORAL

LAMOTRIGINE

@ CHARTWELL MOLECULAR	25MG	A077783	001	Nov 01, 2010	Jan CAHN
@	100MG	A077783	002	Nov 01, 2010	Jan CAHN
@	150MG	A077783	003	Nov 01, 2010	Jan CAHN
@	200MG	A077783	004	Nov 01, 2010	Jan CAHN

LANSOPRAZOLETABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
LANSOPRAZOLE

AB	AUROBINDO PHARMA LTD	15MG	A207167	001	Mar 28, 2023	Mar NEWA
AB		30MG	A207167	002	Mar 28, 2023	Mar NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

@ AKORN 0.005%

A090887 001 Jul 19, 2011 Jan DISC

LATANOPROST; NETARSUDIL DIMESYLATE

SOLUTION/DROPS;OPHTHALMIC

ROCKLATAN

+! ALCON LABS INC 0.005%;EQ 0.02% BASE

N208259 001 Mar 12, 2019 May CAHN

LENALIDOMIDE

CAPSULE;ORAL

LENALIDOMIDE

AB	APOTEX	2.5MG	A211022	005	Mar 07, 2023	Feb NEWA
AB		20MG	A211022	006	Mar 07, 2023	Feb NEWA
AB	ARROW INTL	2.5MG	A201452	005	Mar 06, 2023	Feb NEWA
AB		20MG	A201452	006	Mar 06, 2023	Feb NEWA
AB	CIPLA	2.5MG	A214618	001	Mar 06, 2023	Feb NEWA
AB		20MG	A210435	005	Mar 06, 2023	Feb NEWA
AB	EUGIA PHARMA	2.5MG	A213885	001	Mar 06, 2023	Feb NEWA
AB		5MG	A213885	002	Mar 06, 2023	Feb NEWA
AB		10MG	A213885	003	Mar 06, 2023	Feb NEWA
AB		15MG	A213885	004	Mar 06, 2023	Feb NEWA
AB		20MG	A213885	005	Mar 06, 2023	Feb NEWA
AB		25MG	A213885	006	Mar 06, 2023	Feb NEWA
AB	HETERO LABS LTD V	2.5MG	A212414	001	May 11, 2023	May NEWA
AB		5MG	A212414	002	May 11, 2023	May NEWA
AB		10MG	A212414	003	May 11, 2023	May NEWA
AB		15MG	A212414	004	May 11, 2023	May NEWA
AB		20MG	A212414	005	May 11, 2023	May NEWA
AB		25MG	A212414	006	May 11, 2023	May NEWA
AB	LOTUS PHARM CO LTD	2.5MG	A210480	005	Mar 06, 2023	Feb NEWA
AB		20MG	A210480	006	Mar 06, 2023	Feb NEWA
AB	MYLAN	2.5MG	A213912	005	Mar 06, 2023	Feb NEWA
AB		20MG	A213912	006	Mar 06, 2023	Feb NEWA
AB	SUN PHARM	2.5MG	A211846	005	Mar 06, 2023	Feb NEWA
AB		5MG	A211846	001	Feb 08, 2023	Jan NEWA
AB		10MG	A211846	002	Feb 08, 2023	Jan NEWA
AB		15MG	A211846	003	Feb 08, 2023	Jan NEWA
AB		20MG	A211846	006	Feb 08, 2023	Feb NEWA
AB		25MG	A211846	004	Feb 08, 2023	Jan NEWA
>D> AB	TORRENT	10MG	A213405	001	Feb 17, 2023	Aug DISC
>A>	@	10MG	A213405	001	Feb 17, 2023	Aug DISC
AB		10MG	A213405	001	Feb 17, 2023	Feb NEWA

CAPSULE;ORAL LENALIDOMIDE							
>D>	AB	20MG	A213405	003	Aug 03, 2023	Aug DISC	
>A>	@	20MG	A213405	003	Aug 03, 2023	Aug DISC	
	AB	20MG	A213405	003	Aug 03, 2023	Jul NEWA	
>D>	AB	25MG	A213405	002	Feb 17, 2023	Aug DISC	
>A>	@	25MG	A213405	002	Feb 17, 2023	Aug DISC	
	AB	25MG	A213405	002	Feb 17, 2023	Feb NEWA	
AB	ZYDUS PHARMS	2.5MG	A210154	005	Mar 06, 2023	Feb NEWA	
AB		20MG	A210154	006	Mar 06, 2023	Feb NEWA	
<u>LENIOLISIB PHOSPHATE</u>							
TABLET;ORAL JOENJA							
+!	PHARMING	EQ 70MG BASE	N217759	001	Mar 24, 2023	Mar NEWA	
<u>LETROZOLE</u>							
TABLET;ORAL LETROZOLE							
	@ CHARTWELL RX	2.5MG	A202716	001	May 16, 2013	Feb CAHN	
<u>LEUCOVORIN CALCIUM</u>							
INJECTABLE;INJECTION LEUCOVORIN CALCIUM							
!	FRESENIUS KABI USA	EQ 10MG BASE/ML	A207226	001	Jul 27, 2018	Apr CHRS	
		EQ 10MG BASE/ML	A207226	001	Jul 27, 2018	Apr CTEC	
!		EQ 10MG BASE/ML	A207241	001	Mar 14, 2018	Apr CHRS	
AP	HAINAN POLY	EQ 50MG BASE/VIAL	A217021	001	Jul 10, 2023	Jun NEWA	
AP		EQ 100MG BASE/VIAL	A217021	002	Jul 10, 2023	Jun NEWA	
AP		EQ 200MG BASE/VIAL	A217021	003	Jul 10, 2023	Jun NEWA	
AP		EQ 500MG BASE/VIAL	A217021	004	Jul 10, 2023	Jun NEWA	
AP	KINDOS	EQ 50MG BASE/VIAL	A216590	001	Jul 19, 2023	Jul NEWA	
AP		EQ 100MG BASE/VIAL	A216590	002	Jul 19, 2023	Jul NEWA	
AP		EQ 200MG BASE/VIAL	A216590	003	Jul 19, 2023	Jul NEWA	
AP		EQ 350MG BASE/VIAL	A216590	004	Jul 19, 2023	Jul NEWA	
AP		EQ 500MG BASE/VIAL	A216590	005	Jul 19, 2023	Jul NEWA	
LEUCOVORIN CALCIUM PRESERVATIVE FREE							
@	HIKMA	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000	Apr DISC	
<u>LEUPROLIDE ACETATE</u>							
INJECTABLE;INJECTION LEUPROLIDE ACETATE							
AP	RK PHARMA	1MG/0.2ML	A213829	001	Aug 13, 2021	Jun CAHN	
LUPRON DEPOT							
+!	ABBVIE ENDOCRINE INC	7.5MG	N019732	001	Jan 26, 1989	Jul CPOT	
+!		11.25MG	N020708	001	Mar 07, 1997	Jul CPOT	
+		22.5MG	N020517	001	Dec 22, 1995	Jul CPOT	
+!		30MG	N020517	002	May 30, 1997	Jul CPOT	
+!		45MG	N020517	003	Jun 17, 2011	Jul CPOT	
POWDER;INTRAMUSCULAR LUPRON DEPOT-PED KIT							
+!	ABBVIE ENDOCRINE INC	45MG	N020263	009	Apr 14, 2023	Apr NEWA	
POWDER;SUBCUTANEOUS ELIGARD KIT							
+!	TOLMAR	7.5MG	N021343	001	Jan 23, 2002	Feb CAHN	
+!		22.5MG	N021379	001	Jul 24, 2002	Feb CAHN	
+!		30MG	N021488	001	Feb 13, 2003	Feb CAHN	
+!		45MG	N021731	001	Dec 14, 2004	Feb CAHN	
<u>LEVETIRACETAM</u>							
INJECTABLE;INTRAVENOUS LEVETIRACETAM IN SODIUM CHLORIDE							
AP	FRESENIUS KABI USA	500MG/100ML (5MG/ML)	A208619	001	Jan 31, 2023	Jan NEWA	
AP		1.5GM/100ML (15MG/ML)	A208619	003	Jan 31, 2023	Jan NEWA	
SOLUTION;ORAL LEVETIRACETAM							
AA	ALEMBIC	100MG/ML	A203067	001	May 09, 2013	Feb CAHN	
AA	BIONPHARMA	100MG/ML	A079120	001	Jan 16, 2009	Jun CAHN	
AA	QUAGEN	100MG/ML	A090079	001	Apr 11, 2012	Feb CAHN	
@	XTTRIUM LABS INC	100MG/ML	A090028	001	Mar 03, 2010	Mar CAHN	

TABLET;ORAL
LEVETIRACETAM

AB	GRANULES	250MG	A217878	001	Jun 13, 2023	Jun NEWA
AB		500MG	A217878	002	Jun 13, 2023	Jun NEWA
AB		750MG	A217878	003	Jun 13, 2023	Jun NEWA
AB		1GM	A217878	004	Jun 13, 2023	Jun NEWA
	@ MYLAN	250MG	A076919	001	Nov 04, 2008	Apr DISC
	<u>TABLET, EXTENDED RELEASE;ORAL</u>					
	LEVETIRACETAM					
	@ AUROBINDO PHARMA USA	500MG	A200475	001	Dec 19, 2011	Apr CAHN
	@	750MG	A200475	002	Dec 19, 2011	Apr CAHN
	@	1GM	A200475	003	Dec 07, 2015	Apr CAHN
AB	OVERSEAS	500MG	A212688	002	May 05, 2023	Apr NEWA
>D> AB	SUN PHARM	500MG	A203059	001	Sep 09, 2013	Aug DISC
>A>	@	500MG	A203059	001	Sep 09, 2013	Aug DISC
>D> AB		750MG	A203059	002	Sep 09, 2013	Aug DISC
>A>	@	750MG	A203059	002	Sep 09, 2013	Aug DISC

LEVOFLOXACIN

	SOLUTION;ORAL					
	LEVOFLOXACIN					
>D> AA	! AKORN	250MG/10ML	A091678	001	Jun 20, 2011	Aug CAHN
>A> AA	! NOVITIUM PHARMA	250MG/10ML	A091678	001	Jun 20, 2011	Aug CAHN
	SOLUTION/DROPS;OPHTHALMIC					
	LEVOFLOXACIN					
	@ AKORN	0.5%	A090268	001	Dec 20, 2010	Jan DISC
	! RISING	0.5%	A077700	001	Dec 20, 2010	Jan CTEC

LEVOLEUCOVORIN

	POWDER; INTRAVENOUS					
	KHAPZORY					
>D>	+! ACROTECH BIOPHARMA	300MG/VIAL	N211226	002	Oct 19, 2018	Aug DISC
>A>	+ @	300MG/VIAL	N211226	002	Oct 19, 2018	Aug DISC

LEVOLEUCOVORIN CALCIUM

	SOLUTION; INTRAVENOUS					
	LEVOLEUCOVORIN CALCIUM					
AP	! GLAND PHARMA LTD	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210892	002	Sep 14, 2018	May CTEC
AP	HAINAN POLY PHARM	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A217314	001	May 22, 2023	May NEWA
AP		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A217314	002	May 22, 2023	May NEWA

LEVOMILNACIPRAN HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE;ORAL					
	FETZIMA					
	+ ABBVIE	EQ 20MG BASE	N204168	001	Jul 25, 2013	Mar CTEC
AB	+	EQ 20MG BASE	N204168	001	Jul 25, 2013	Jan CAHN
	+	EQ 40MG BASE	N204168	002	Jul 25, 2013	Mar CTEC
AB	+	EQ 40MG BASE	N204168	002	Jul 25, 2013	Jan CAHN
	+	EQ 80MG BASE	N204168	003	Jul 25, 2013	Mar CTEC
AB	+	EQ 80MG BASE	N204168	003	Jul 25, 2013	Jan CAHN
	!+	EQ 120MG BASE	N204168	004	Jul 25, 2013	Mar CTEC
AB	!+	EQ 120MG BASE	N204168	004	Jul 25, 2013	Jan CAHN
	LEVOMILNACIPRAN HYDROCHLORIDE					
	@ AUROBINDO PHARMA LTD	EQ 20MG BASE	A210826	001	Jan 06, 2023	Mar DISC
	@	EQ 40MG BASE	A210826	002	Jan 06, 2023	Mar DISC
	@	EQ 80MG BASE	A210826	003	Jan 06, 2023	Mar DISC
	@	EQ 120MG BASE	A210826	004	Jan 06, 2023	Mar DISC
AB	PRINSTON INC	EQ 20MG BASE	A210771	001	Mar 20, 2023	Mar NEWA
AB		EQ 40MG BASE	A210771	002	Mar 20, 2023	Mar NEWA
AB		EQ 80MG BASE	A210771	003	Mar 20, 2023	Mar NEWA
AB		EQ 120MG BASE	A210771	004	Mar 20, 2023	Mar NEWA

LEVORPHANOL TARTRATE

	TABLET;ORAL					
	LEVORPHANOL TARTRATE					
AB	HIKMA	2MG	A074278	001	Mar 31, 2000	Jan CMFD
AB	! NOVITIUM PHARMA	3MG	A213479	002	Jan 12, 2021	Apr CTEC
AB	SUN PHARM INDs INC	3MG	A213906	002	Apr 25, 2023	Apr NEWA

LEVOTHYROXINE SODIUM

CAPSULE;ORAL

LEVOTHYROXINE SODIUM

AB	@ TEVA PHARMS USA INC	0.137MG	A211369	005	May 02, 2023	May DISC
		0.137MG	A211369	005	May 02, 2023	Apr NFTG
AB	@	0.175MG	A211369	006	May 02, 2023	May DISC
		0.175MG	A211369	006	May 02, 2023	Apr NFTG
	@	0.2MG	A211369	004	Nov 09, 2022	May DISC

TIROSINT

>A>	+	IBSA	0.013MG	N021924	013	Aug 01, 2007	Aug CAHN
>A>	+		0.025MG	N021924	002	Oct 13, 2006	Aug CAHN
>A>	+		0.0375MG	N021924	014	Jun 22, 2022	Aug CAHN
>A>	+		0.044MG	N021924	015	Jun 22, 2022	Aug CAHN
>A>	+		0.05MG	N021924	003	Oct 13, 2006	Aug CAHN
>A>	+		0.0625MG	N021924	016	Jun 22, 2022	Aug CAHN
>A>	+		0.075MG	N021924	004	Oct 13, 2006	Aug CAHN
>A>	+		0.088MG	N021924	010	Oct 02, 2009	Aug CAHN
>A>	+		0.1MG	N021924	005	Oct 13, 2006	Aug CAHN
>A>	+		0.112MG	N021924	008	Oct 02, 2009	Aug CAHN
>A>	+		0.125MG	N021924	006	Oct 13, 2006	Aug CAHN
>A>	+		0.137MG	N021924	009	Oct 02, 2009	Aug CAHN
>A>	+		0.15MG	N021924	007	Oct 13, 2006	Aug CAHN
>A>	+		0.175MG	N021924	011	Apr 25, 2017	Aug CAHN
>A>	+!		0.2MG	N021924	012	Apr 25, 2017	Aug CAHN
>D>	+	INSTITUT BIOCHIMIQUE	0.013MG	N021924	013	Aug 01, 2007	Aug CAHN
>D>	+		0.025MG	N021924	002	Oct 13, 2006	Aug CAHN
>D>	+		0.0375MG	N021924	014	Jun 22, 2022	Aug CAHN
>D>	+		0.044MG	N021924	015	Jun 22, 2022	Aug CAHN
>D>	+		0.05MG	N021924	003	Oct 13, 2006	Aug CAHN
>D>	+		0.0625MG	N021924	016	Jun 22, 2022	Aug CAHN
>D>	+		0.075MG	N021924	004	Oct 13, 2006	Aug CAHN
>D>	+		0.088MG	N021924	010	Oct 02, 2009	Aug CAHN
>D>	+		0.1MG	N021924	005	Oct 13, 2006	Aug CAHN
>D>	+		0.112MG	N021924	008	Oct 02, 2009	Aug CAHN
>D>	+		0.125MG	N021924	006	Oct 13, 2006	Aug CAHN
>D>	+		0.137MG	N021924	009	Oct 02, 2009	Aug CAHN
>D>	+		0.15MG	N021924	007	Oct 13, 2006	Aug CAHN
>D>	+		0.175MG	N021924	011	Apr 25, 2017	Aug CAHN
>D>	+!		0.2MG	N021924	012	Apr 25, 2017	Aug CAHN
AB	+		0.137MG	N021924	009	Oct 02, 2009	May CTEC
>D>	+		0.137MG	N021924	009	Oct 02, 2009	Apr CFTG
>D>	+		0.15MG	N021924	007	Oct 13, 2006	Aug CAHN
AB	+		0.175MG	N021924	011	Apr 25, 2017	Aug CAHN
>D>	+!		0.175MG	N021924	011	Apr 25, 2017	May CTEC
>D>	+!		0.2MG	N021924	011	Apr 25, 2017	Apr CFTG
>D>	+!		0.2MG	N021924	012	Apr 25, 2017	Aug CAHN

POWDER;INTRAVENOUS

LEVOTHYROXINE SODIUM

AP	ZYDUS PHARMS	100MCG/VIAL	A217066	001	Mar 24, 2023	Mar NEWA
AP		200MCG/VIAL	A217066	002	Mar 24, 2023	Mar NEWA
AP		500MCG/VIAL	A217066	003	Mar 24, 2023	Mar NEWA

SOLUTION;ORAL

TIROSINT-SOL

>A>	+	IBSA	13MCG/ML	N206977	001	Dec 15, 2016	Aug CAHN
>A>	+		25MCG/ML	N206977	002	Dec 15, 2016	Aug CAHN
>A>	+		37.5MCG/ML	N206977	013	Jan 13, 2021	Aug CAHN
>A>	+		44MCG/ML	N206977	014	Jan 13, 2021	Aug CAHN
>A>	+		50MCG/ML	N206977	003	Dec 15, 2016	Aug CAHN
>A>	+		62.5MCG/ML	N206977	015	Jan 13, 2021	Aug CAHN
>A>	+		75MCG/ML	N206977	004	Dec 15, 2016	Aug CAHN
>A>	+		88MCG/ML	N206977	005	Dec 15, 2016	Aug CAHN
>A>	+		100MCG/ML	N206977	006	Dec 15, 2016	Aug CAHN
>A>	+		112MCG/ML	N206977	007	Dec 15, 2016	Aug CAHN
>A>	+		125MCG/ML	N206977	008	Dec 15, 2016	Aug CAHN
>A>	+		137MCG/ML	N206977	009	Dec 15, 2016	Aug CAHN
>A>	+		150MCG/ML	N206977	010	Dec 15, 2016	Aug CAHN
>A>	+		175MCG/ML	N206977	011	Dec 15, 2016	Aug CAHN
>A>	+!		200MCG/ML	N206977	012	Dec 15, 2016	Aug CAHN
>D>	+	INSTITUT BIOCHIMIQUE	13MCG/ML	N206977	001	Dec 15, 2016	Aug CAHN
>D>	+		25MCG/ML	N206977	002	Dec 15, 2016	Aug CAHN
>D>	+		37.5MCG/ML	N206977	013	Jan 13, 2021	Aug CAHN
>D>	+		44MCG/ML	N206977	014	Jan 13, 2021	Aug CAHN
>D>	+		50MCG/ML	N206977	003	Dec 15, 2016	Aug CAHN
>D>	+		62.5MCG/ML	N206977	015	Jan 13, 2021	Aug CAHN

SOLUTION;ORAL
TIROSINT-SOL

>D>	+	75MCG/ML	N206977	004	Dec 15, 2016	Aug CAHN
>D>	+	88MCG/ML	N206977	005	Dec 15, 2016	Aug CAHN
>D>	+	100MCG/ML	N206977	006	Dec 15, 2016	Aug CAHN
>D>	+	112MCG/ML	N206977	007	Dec 15, 2016	Aug CAHN
>D>	+	125MCG/ML	N206977	008	Dec 15, 2016	Aug CAHN
>D>	+	137MCG/ML	N206977	009	Dec 15, 2016	Aug CAHN
>D>	+	150MCG/ML	N206977	010	Dec 15, 2016	Aug CAHN
>D>	+	175MCG/ML	N206977	011	Dec 15, 2016	Aug CAHN
>D>	+!	200MCG/ML	N206977	012	Dec 15, 2016	Aug CAHN

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL

LEVOTHYROXINE SODIUM

AB4	ASCENT PHARMS INC	0.025MG	A215259	001	Jan 18, 2023	Jan NEWA
AB4		0.05MG	A215259	002	Jan 18, 2023	Jan NEWA
AB4		0.075MG	A215259	003	Jan 18, 2023	Jan NEWA
AB4		0.088MG	A215259	004	Jan 18, 2023	Jan NEWA
AB4		0.1MG	A215259	005	Jan 18, 2023	Jan NEWA
AB4		0.112MG	A215259	006	Jan 18, 2023	Jan NEWA
AB4		0.125MG	A215259	007	Jan 18, 2023	Jan NEWA
AB4		0.137MG	A215259	008	Jan 18, 2023	Jan NEWA
AB4		0.15MG	A215259	009	Jan 18, 2023	Jan NEWA
AB4		0.175MG	A215259	010	Jan 18, 2023	Jan NEWA
AB4		0.2MG	A215259	011	Jan 18, 2023	Jan NEWA
AB4		0.3MG	A215259	012	Jan 18, 2023	Jan NEWA
AB2	MACLEODS PHARMS LTD	0.025MG	A211417	001	Dec 21, 2022	Jan CTEC
AB2		0.05MG	A211417	002	Dec 21, 2022	Jan CTEC
AB2		0.075MG	A211417	003	Dec 21, 2022	Jan CTEC
AB2		0.088MG	A211417	004	Dec 21, 2022	Jan CTEC
AB2		0.1MG	A211417	005	Dec 21, 2022	Jan CTEC
AB2		0.112MG	A211417	006	Dec 21, 2022	Jan CTEC
AB2		0.125MG	A211417	007	Dec 21, 2022	Jan CTEC
AB2		0.137MG	A211417	008	Dec 21, 2022	Jan CTEC
AB2		0.15MG	A211417	009	Dec 21, 2022	Jan CTEC
AB2		0.175MG	A211417	010	Dec 21, 2022	Jan CTEC
AB2		0.2MG	A211417	011	Dec 21, 2022	Jan CTEC
AB2		0.3MG	A211417	012	Dec 21, 2022	Jan CTEC

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

@ PAI HOLDINGS PHARM 5%

A205318 001 Feb 01, 2016 May DISC

PATCH;TOPICAL

LIDOCAINE

>A> AB	IBSA	5%
>D> AB	INST BIOCHIMIQUE SA	5%
AB		5%

A209190 001 Apr 30, 2020 Aug CAHN
 A209190 001 Apr 30, 2020 Aug CAHN
 A209190 001 Apr 30, 2020 Apr CAHN

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

>D> AP	! HOSPIRA	1%	A083158	001	Aug CRLD
>A> AP	+!	1%	A083158	001	Aug CRLD
>D> AP	!	2%	A083158	002	Aug CRLD
>A> AP	+!	2%	A083158	002	Aug CRLD
AP	HUONS	2%	A212821	002	Jun 15, 2023 Jun NEWA
AP	MANKIND PHARMA	1%	A217692	001	Jun 16, 2023 Jun NEWA
AP		1%	A217693	001	Jul 11, 2023 Jun NEWA
AP		2%	A217692	002	Jun 16, 2023 Jun NEWA
AP		2%	A217693	002	Jul 11, 2023 Jun NEWA

A083158 002 Aug CRLD
 A212821 002 Jun 15, 2023 Jun NEWA
 A217692 001 Jun 16, 2023 Jun NEWA
 A217693 001 Jul 11, 2023 Jun NEWA
 A217692 002 Jun 16, 2023 Jun NEWA
 A217693 002 Jul 11, 2023 Jun NEWA

JELLY;TOPICAL

GLYDO

AT ! SAGENT PHARMS INC 2%
LIDOCAINE HYDROCHLORIDE

A201094 001 Apr 28, 2014 Apr CHRS

>D> AT	AKORN	2%	A040433	001	Feb 12, 2003 Aug CAHN
AT		2%	A040433	001	Feb 12, 2003 Apr CHRS
>A> AT	SENTISSL	2%	A040433	001	Feb 12, 2003 Aug CAHN

	SOLUTION;ORAL LIDOCAINE HYDROCHLORIDE					
AT	RUBICON 2%	A216780	001	Mar 28, 2023	Mar NEWA	
	LIDOCAINE HYDROCHLORIDE VISCOSUS					
AT	CHARTWELL MOLECULAR 2%	A040708	001	Feb 27, 2007	Jul CAHN	
	<u>LIDOCAINE; PRILOCAINE</u>					
	CREAM;TOPICAL LIDOCAINE AND PRILOCAINE					
	@ PAI HOLDINGS PHARM 2.5%;2.5%	A205887	001	Jun 29, 2018	May DISC	
>D>	<u>LIDOCAINE; TETRACAIN</u>					
>D>	CREAM;TOPICAL					
>D>	PLIAGLIS					
>D>	+! TARO PHARMS 7%;7%	N021717	001	Jun 29, 2006	Aug DISC	
>A>	+ @ 7%;7%	N021717	001	Jun 29, 2006	Aug DISC	
	<u>LINACLOTIDE</u>					
	CAPSULE;ORAL LINACLOTIDE					
AB	@ AUROBINDO PHARMA 145MCG	A209611	001	Feb 07, 2023	Mar DISC	
	145MCG	A209611	001	Feb 07, 2023	Jan NEWA	
AB	@ 290MCG	A209611	002	Feb 07, 2023	Mar DISC	
	290MCG	A209611	002	Feb 07, 2023	Jan NEWA	
	LINZESS					
	+! ABBVIE 145MCG	N202811	001	Aug 30, 2012	Mar CTEC	
	+	N202811	002	Aug 30, 2012	Mar CTEC	
AB	+! ALLERGAN 145MCG	N202811	001	Aug 30, 2012	Jan CTEC	
AB	+	N202811	002	Aug 30, 2012	Jan CTEC	
	<u>LINAGLIPTIN</u>					
	TABLET;ORAL LINAGLIPTIN					
AB	@ ZYDUS PHARMS 5MG	A208448	001	Mar 30, 2023	Jul DISC	
	5MG	A208448	001	Mar 30, 2023	Mar NEWA	
	<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE</u>					
	TABLET;ORAL LINAGLIPTIN AND METFORMIN HYDROCHLORIDE					
AB	@ ZYDUS PHARMS 2.5MG;500MG	A208449	001	Mar 30, 2023	Jul DISC	
	2.5MG;500MG	A208449	001	Mar 30, 2023	Mar NEWA	
AB	@ 2.5MG;850MG	A208449	002	Mar 30, 2023	Jul DISC	
	2.5MG;850MG	A208449	002	Mar 30, 2023	Mar NEWA	
AB	@ 2.5MG;1GM	A208449	003	Mar 30, 2023	Jul DISC	
	2.5MG;1GM	A208449	003	Mar 30, 2023	Mar NEWA	
	<u>LINCOMYCIN HYDROCHLORIDE</u>					
	INJECTABLE;INJECTION LINCOMYCIN HYDROCHLORIDE					
	@ HAINAN POLY EQ 300MG BASE/ML	A216662	001	Dec 21, 2022	Jun DISC	
	@ PRAXGEN PHARMS EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	Jul CAHN	
	<u>LINEZOLID</u>					
	TABLET;ORAL LINEZOLID					
AB	CHARTWELL RX 600MG	A210702	001	Apr 25, 2019	Mar CAHN	
	<u>LIOTHYRONINE SODIUM</u>					
	INJECTABLE;INJECTION LIOTHYRONINE SODIUM					
!	XGEN PHARMS EQ 0.01MG BASE/ML	A076923	001	Aug 17, 2005	Jun CHRS	
	EQ 0.01MG BASE/ML	A076923	001	Aug 17, 2005	Jun CTEC	
	TRIOSTAT					
+	@ PAR STERILE PRODUCTS EQ 0.01MG BASE/ML	N020105	001	Dec 31, 1991	Jun DISC	
	<u>LISDEXAMFETAMINE DIMESYLATE</u>					
	CAPSULE;ORAL LISDEXAMFETAMINE DIMESYLATE					
>A>	ACTAVIS ELIZABETH 10MG	A202802	001	Aug 25, 2023	Aug NFTG	
>A> AB	20MG	A202802	002	Aug 25, 2023	Aug NFTG	
>A> AB	30MG	A202802	003	Aug 25, 2023	Aug NFTG	
>A> AB	40MG	A202802	004	Aug 25, 2023	Aug NFTG	

CAPSULE;ORAL

>A>	LISDEXAMFETAMINE DIMESYLYATE							
>A> AB		50MG	A202802	005	Aug 25, 2023	Aug NFTG		
>A> AB		60MG	A202802	006	Aug 25, 2023	Aug NFTG		
>A> AB		70MG	A202802	007	Aug 25, 2023	Aug NFTG		
>A> AB	ALKEM LABS LTD	10MG	A217194	001	Aug 25, 2023	Aug NFTG		
>A> AB		20MG	A217194	002	Aug 25, 2023	Aug NFTG		
>A> AB		30MG	A217194	003	Aug 25, 2023	Aug NFTG		
>A> AB		40MG	A217194	004	Aug 25, 2023	Aug NFTG		
>A> AB		50MG	A217194	005	Aug 25, 2023	Aug NFTG		
>A> AB		60MG	A217194	006	Aug 25, 2023	Aug NFTG		
>A> AB		70MG	A217194	007	Aug 25, 2023	Aug NFTG		
>A> AB	AMNEAL	20MG	A202830	001	Aug 25, 2023	Aug NFTG		
>A> AB		30MG	A202830	002	Aug 25, 2023	Aug NFTG		
>A> AB		40MG	A202830	003	Aug 25, 2023	Aug NFTG		
>A> AB		50MG	A202830	004	Aug 25, 2023	Aug NFTG		
>A> AB		60MG	A202830	005	Aug 25, 2023	Aug NFTG		
>A> AB		70MG	A202830	006	Aug 25, 2023	Aug NFTG		
>A> AB	APOTEX	10MG	A216944	001	Aug 25, 2023	Aug NFTG		
>A> AB		20MG	A216944	002	Aug 25, 2023	Aug NFTG		
>A> AB		30MG	A216944	003	Aug 25, 2023	Aug NFTG		
>A> AB		40MG	A216944	004	Aug 25, 2023	Aug NFTG		
>A> AB		50MG	A216944	005	Aug 25, 2023	Aug NFTG		
>A> AB		60MG	A216944	006	Aug 25, 2023	Aug NFTG		
>A> AB		70MG	A216944	007	Aug 25, 2023	Aug NFTG		
>A> AB	ASCENT PHARMS INC	10MG	A217442	001	Aug 25, 2023	Aug NFTG		
>A> AB		20MG	A217442	002	Aug 25, 2023	Aug NFTG		
>A> AB		30MG	A217442	003	Aug 25, 2023	Aug NFTG		
>A> AB		40MG	A217442	004	Aug 25, 2023	Aug NFTG		
>A> AB		50MG	A217442	005	Aug 25, 2023	Aug NFTG		
>A> AB		60MG	A217442	006	Aug 25, 2023	Aug NFTG		
>A> AB		70MG	A217442	007	Aug 25, 2023	Aug NFTG		
>A> AB	HIKMA	20MG	A202827	001	Aug 25, 2023	Aug NFTG		
>A> AB		30MG	A202827	002	Aug 25, 2023	Aug NFTG		
>A> AB		40MG	A202827	003	Aug 25, 2023	Aug NFTG		
>A> AB		50MG	A202827	004	Aug 25, 2023	Aug NFTG		
>A> AB		60MG	A202827	005	Aug 25, 2023	Aug NFTG		
>A> AB		70MG	A202827	006	Aug 25, 2023	Aug NFTG		
>A> AB	LANNETT CO INC	10MG	A215802	001	Aug 25, 2023	Aug NFTG		
>A> AB		20MG	A215802	002	Aug 25, 2023	Aug NFTG		
>A> AB		30MG	A215802	003	Aug 25, 2023	Aug NFTG		
>A> AB		40MG	A215802	004	Aug 25, 2023	Aug NFTG		
>A> AB		50MG	A215802	005	Aug 25, 2023	Aug NFTG		
>A> AB		60MG	A215802	006	Aug 25, 2023	Aug NFTG		
>A> AB		70MG	A215802	007	Aug 25, 2023	Aug NFTG		
>A> AB	MYLAN	10MG	A202835	001	Aug 25, 2023	Aug NFTG		
>A> AB		20MG	A202835	002	Aug 25, 2023	Aug NFTG		
>A> AB		30MG	A202835	003	Aug 25, 2023	Aug NFTG		
>A> AB		40MG	A202835	004	Aug 25, 2023	Aug NFTG		
>A> AB		50MG	A202835	005	Aug 25, 2023	Aug NFTG		
>A> AB		60MG	A202835	006	Aug 25, 2023	Aug NFTG		
>A> AB		70MG	A202835	007	Aug 25, 2023	Aug NFTG		
>A> AB	NORWICH	10MG	A214547	001	Aug 25, 2023	Aug NFTG		
>A> AB		20MG	A214547	002	Aug 25, 2023	Aug NFTG		
>A> AB		30MG	A214547	003	Aug 25, 2023	Aug NFTG		
>A> AB		40MG	A214547	004	Aug 25, 2023	Aug NFTG		
>A> AB		50MG	A214547	005	Aug 25, 2023	Aug NFTG		
>A> AB		60MG	A214547	006	Aug 25, 2023	Aug NFTG		
>A> AB		70MG	A214547	007	Aug 25, 2023	Aug NFTG		
>A> AB	PRINSTON INC	10MG	A216266	001	Aug 25, 2023	Aug NFTG		
>A> AB		20MG	A216266	002	Aug 25, 2023	Aug NFTG		
>A> AB		30MG	A216266	003	Aug 25, 2023	Aug NFTG		
>A> AB		40MG	A216266	004	Aug 25, 2023	Aug NFTG		
>A> AB		50MG	A216266	005	Aug 25, 2023	Aug NFTG		
>A> AB		60MG	A216266	006	Aug 25, 2023	Aug NFTG		
>A> AB		70MG	A216266	007	Aug 25, 2023	Aug NFTG		
>A> AB	RHODES PHARMS	10MG	A215330	001	Aug 25, 2023	Aug NFTG		
>A> AB		20MG	A215330	002	Aug 25, 2023	Aug NFTG		
>A> AB		30MG	A215330	003	Aug 25, 2023	Aug NFTG		
>A> AB		40MG	A215330	004	Aug 25, 2023	Aug NFTG		
>A> AB		50MG	A215330	005	Aug 25, 2023	Aug NFTG		
>A> AB		60MG	A215330	006	Aug 25, 2023	Aug NFTG		
>A> AB		70MG	A215330	007	Aug 25, 2023	Aug NFTG		
>A> AB	SPECGX LLC	10MG	A211840	001	Aug 25, 2023	Aug NFTG		

CAPSULE;ORAL

>A>	LISDEXAMFETAMINE DIMESYLYATE						
>A> AB		20MG	A211840	002	Aug 25,	2023	Aug NFTG
>A> AB		30MG	A211840	003	Aug 25,	2023	Aug NFTG
>A> AB		40MG	A211840	004	Aug 25,	2023	Aug NFTG
>A> AB		50MG	A211840	005	Aug 25,	2023	Aug NFTG
>A> AB		60MG	A211840	006	Aug 25,	2023	Aug NFTG
>A> AB		70MG	A211840	007	Aug 25,	2023	Aug NFTG
>A> AB	SUN PHARM INDNS INC	10MG	A214484	001	Aug 25,	2023	Aug NFTG
>A> AB		20MG	A214484	002	Aug 25,	2023	Aug NFTG
>A> AB		30MG	A214484	003	Aug 25,	2023	Aug NFTG
>A> AB		40MG	A214484	004	Aug 25,	2023	Aug NFTG
>A> AB		50MG	A214484	005	Aug 25,	2023	Aug NFTG
>A> AB		60MG	A214484	006	Aug 25,	2023	Aug NFTG
>A> AB		70MG	A214484	007	Aug 25,	2023	Aug NFTG

VYVANSE

>D>	+	TAKEDA PHARMS USA	10MG	N021977	007	Oct 30,	2014	Aug CFTG
>A> AB	+		10MG	N021977	007	Oct 30,	2014	Aug CFTG
>D>	+		20MG	N021977	004	Dec 10,	2007	Aug CFTG
>A> AB	+		20MG	N021977	004	Dec 10,	2007	Aug CFTG
>D>	+		30MG	N021977	001	Feb 23,	2007	Aug CFTG
>A> AB	+		30MG	N021977	001	Feb 23,	2007	Aug CFTG
>D>	+		40MG	N021977	005	Dec 10,	2007	Aug CFTG
>A> AB	+		40MG	N021977	005	Dec 10,	2007	Aug CFTG
>D>	+		50MG	N021977	002	Feb 23,	2007	Aug CFTG
>A> AB	+		50MG	N021977	002	Feb 23,	2007	Aug CFTG
>D>	+		60MG	N021977	006	Dec 10,	2007	Aug CFTG
>A> AB	+		60MG	N021977	006	Dec 10,	2007	Aug CFTG
>D>	+!		70MG	N021977	003	Feb 23,	2007	Aug CFTG
>A> AB	+!		70MG	N021977	003	Feb 23,	2007	Aug CFTG

TABLET, CHEWABLE;ORAL

>A>	LISDEXAMFETAMINE DIMESYLYATE						
>A> AB	ASCENT PHARMS INC	10MG	A217068	001	Aug 25,	2023	Aug NFTG
>A> AB		20MG	A217068	002	Aug 25,	2023	Aug NFTG
>A> AB		30MG	A217068	003	Aug 25,	2023	Aug NFTG
>A> AB		40MG	A217068	004	Aug 25,	2023	Aug NFTG
>A> AB		50MG	A217068	005	Aug 25,	2023	Aug NFTG
>A> AB		60MG	A217068	006	Aug 25,	2023	Aug NFTG
>A> AB	SUN PHARM INDNS INC	10MG	A214134	001	Aug 25,	2023	Aug NFTG
>A> AB		20MG	A214134	002	Aug 25,	2023	Aug NFTG
>A> AB		30MG	A214134	003	Aug 25,	2023	Aug NFTG
>A> AB		40MG	A214134	004	Aug 25,	2023	Aug NFTG
>A> AB		50MG	A214134	005	Aug 25,	2023	Aug NFTG
>A> AB		60MG	A214134	006	Aug 25,	2023	Aug NFTG
>A> AB	TEVA PHARMS	10MG	A215415	001	Aug 25,	2023	Aug NFTG
>A> AB		20MG	A215415	002	Aug 25,	2023	Aug NFTG
>A> AB		30MG	A215415	003	Aug 25,	2023	Aug NFTG
>A> AB		40MG	A215415	004	Aug 25,	2023	Aug NFTG
>A> AB		50MG	A215415	005	Aug 25,	2023	Aug NFTG
>A> AB		60MG	A215415	006	Aug 25,	2023	Aug NFTG

VYVANSE

>D>	+	TAKEDA PHARMS USA	10MG	N208510	001	Jan 28,	2017	Aug CFTG
>A> AB	+		10MG	N208510	001	Jan 28,	2017	Aug CFTG
>D>	+		20MG	N208510	002	Jan 28,	2017	Aug CFTG
>A> AB	+		20MG	N208510	002	Jan 28,	2017	Aug CFTG
>D>	+		30MG	N208510	003	Jan 28,	2017	Aug CFTG
>A> AB	+		30MG	N208510	003	Jan 28,	2017	Aug CFTG
>D>	+		40MG	N208510	004	Jan 28,	2017	Aug CFTG
>A> AB	+		40MG	N208510	004	Jan 28,	2017	Aug CFTG
>D>	+		50MG	N208510	005	Jan 28,	2017	Aug CFTG
>A> AB	+		50MG	N208510	005	Jan 28,	2017	Aug CFTG
>D>	+!		60MG	N208510	006	Jan 28,	2017	Aug CFTG
>A> AB	+!		60MG	N208510	006	Jan 28,	2017	Aug CFTG

LISINOPRIL

TABLET;ORAL								
LISINOPRIL								
>D>	@	GRAVITI PHARMS	2.5MG	A075999	001	Jul 01,	2002	Aug CAHN
>D>	@		5MG	A075999	002	Jul 01,	2002	Aug CAHN
>D>	@		10MG	A075999	003	Jul 01,	2002	Aug CAHN
>D>	@		20MG	A075999	004	Jul 01,	2002	Aug CAHN
>D>	@		30MG	A075999	005	Jul 01,	2002	Aug CAHN
>D>	@		40MG	A075999	006	Jul 01,	2002	Aug CAHN

TABLET;ORAL
LISINOPRIL

>D>	AB	HERITAGE PHARMA	2.5MG	A075752	001	Jul 01, 2002	Aug DISC
>A>	@		2.5MG	A075752	001	Jul 01, 2002	Aug DISC
	AB		2.5MG	A075752	001	Jul 01, 2002	Mar CMFD
>D>	AB		5MG	A075752	002	Jul 01, 2002	Aug DISC
>A>	@		5MG	A075752	002	Jul 01, 2002	Aug DISC
	AB		5MG	A075752	002	Jul 01, 2002	Mar CMFD
>D>	AB		10MG	A075752	003	Jul 01, 2002	Aug DISC
>A>	@		10MG	A075752	003	Jul 01, 2002	Aug DISC
	AB		10MG	A075752	003	Jul 01, 2002	Mar CMFD
>D>	AB		20MG	A075752	004	Jul 01, 2002	Aug DISC
>A>	@		20MG	A075752	004	Jul 01, 2002	Aug DISC
	AB		20MG	A075752	004	Jul 01, 2002	Mar CMFD
>D>	AB		30MG	A075752	005	Jul 01, 2002	Aug DISC
>A>	@		30MG	A075752	005	Jul 01, 2002	Aug DISC
	AB		30MG	A075752	005	Jul 01, 2002	Mar CMFD
>D>	AB		40MG	A075752	006	Jul 01, 2002	Aug DISC
>A>	@		40MG	A075752	006	Jul 01, 2002	Aug DISC
	AB		40MG	A075752	006	Jul 01, 2002	Mar CMFD
>A>	@ RISING		2.5MG	A075999	001	Jul 01, 2002	Aug CAHN
>A>	@		5MG	A075999	002	Jul 01, 2002	Aug CAHN
>A>	@		10MG	A075999	003	Jul 01, 2002	Aug CAHN
>A>	@		20MG	A075999	004	Jul 01, 2002	Aug CAHN
>A>	@		30MG	A075999	005	Jul 01, 2002	Aug CAHN
>A>	@		40MG	A075999	006	Jul 01, 2002	Aug CAHN

LITHIUM CITRATE

SYRUP;ORAL
LITHIUM CITRATE

>D>	!	PAI HOLDINGS PHARM	EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Aug CTEC
>A>	AA	!	EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Aug CTEC
>A>	AA	RUBICON	EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Aug NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL
LOPERAMIDE HYDROCHLORIDE

>A>	AB	AUROBINDO PHARMA LTD	2MG	A218122	001	Sep 05, 2023	Aug NEWA
	AB	JUBILANT CADISTA	2MG	A217840	001	Jul 05, 2023	Jun NEWA
	AB	RUBICON	2MG	A216876	001	Jan 26, 2023	Jan NEWA
	AB	ZYDUS LIFESCIENCES	2MG	A217471	001	Mar 23, 2023	Apr CAHN
	AB	ZYDUS PHARMS	2MG	A217471	001	Mar 23, 2023	Mar NEWA

LORAZEPAM

TABLET;ORAL
LORAZEPAM

@ AMNEAL PHARMS	0.5MG	A078826	001	Jun 23, 2010	May DISC
@	1MG	A078826	002	Jun 23, 2010	May DISC
@	2MG	A078826	003	Jun 23, 2010	May DISC

LOSARTAN POTASSIUM

TABLET;ORAL
LOSARTAN POTASSIUM

AB	GRANULES	25MG	A215959	001	Feb 23, 2023	Feb NEWA	
		50MG	A215959	002	Feb 23, 2023	Feb NEWA	
		100MG	A215959	003	Feb 23, 2023	Feb NEWA	
>A>	AB	MSN	25MG	A217396	001	Aug 14, 2023	Aug NEWA
>A>	AB		50MG	A217396	002	Aug 14, 2023	Aug NEWA
>A>	AB		100MG	A217396	003	Aug 14, 2023	Aug NEWA

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC
LOTEPREDNOL ETABONATE

>D>	AB	AKORN	0.5%	A212080	001	Feb 10, 2021	Aug CAHN
>A>	AB	SENTISSL	0.5%	A212080	001	Feb 10, 2021	Aug CAHN
	AB	SUN PHARM	0.5%	A215384	001	Aug 09, 2023	Jul NEWA

SUSPENSION/DROPS;OPHTHALMIC
ALREX

AB	+! BAUSCH AND LOMB	0.2%	N020803	001	Mar 09, 1998	Mar CFTG	
>D>	AB	AKORN	0.2%	A215933	001	Apr 12, 2023	Aug CAHN
	AB		0.2%	A215933	001	Apr 12, 2023	Mar NFTG
>A>	AB	SENTISSL	0.2%	A215933	001	Apr 12, 2023	Aug CAHN

SUSPENSION/DROPS;OPHTHALMIC
LOTEPREDNOL ETABONATE

AB		0.5%	A207609	001	Apr 17, 2019	Jul CAHN
----	--	------	---------	-----	--------------	----------

LOTILANER

SOLUTION/DROPS;OPHTHALMIC
XDEMVY
+! TARSUS

0.25%

N217603 001 Jul 24, 2023 Jul NEWA

LOVASTATIN

TABLET;ORAL

LOVASTATIN

@ AUROBINDO PHARMA USA	10MG
@	10MG
@	20MG
@	20MG
@	40MG
@	40MG

A075451	001	Dec 17, 2001	May CAHN
A075935	001	Dec 17, 2001	Apr CAHN
A075451	002	Dec 17, 2001	May CAHN
A075935	002	Dec 17, 2001	Apr CAHN
A075451	003	Dec 17, 2001	May CAHN
A075935	003	Dec 17, 2001	Apr CAHN

LUBIPROSTONE

CAPSULE;ORAL

LUBIPROSTONE

AB	AMNEAL	8MCG	A209450	001	Nov 30, 2021	Jan CMFD
AB		24MCG	A209450	002	Nov 30, 2021	Jan CMFD
AB	ZYDUS PHARMS	8MCG	A214131	001	Mar 23, 2023	Mar NEWA
AB		24MCG	A214131	002	Mar 23, 2023	Mar NEWA

LUMASIRAN SODIUM

SOLUTION;SUBCUTANEOUS
OXLUMO

>D>	+! ALNYLAM PHARMS INC	EQ 94.5MG/0.5ML BASE (EQ 94.5MG/0.5ML BASE)	N214103	001	Nov 23, 2020	Aug CPOT
>A>	+!	EQ 94.5MG BASE/0.5ML (EQ 94.5MG BASE/0.5ML)	N214103	001	Nov 23, 2020	Aug CPOT

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	20MG	A208002	001	Jan 03, 2019	Feb CMFD
AB		40MG	A208002	002	Jan 03, 2019	Feb CMFD
AB		60MG	A208002	003	Jan 03, 2019	Feb CMFD
AB		80MG	A208002	004	Jan 03, 2019	Feb CMFD
AB		120MG	A208002	005	Jan 03, 2019	Feb CMFD
AB	AUROBINDO PHARMA LTD	20MG	A208045	001	Mar 10, 2023	Mar NEWA
AB		40MG	A208045	002	Mar 10, 2023	Mar NEWA
AB		60MG	A208045	003	Mar 10, 2023	Mar NEWA
AB		80MG	A208045	004	Mar 10, 2023	Mar NEWA
AB		120MG	A208045	005	Mar 10, 2023	Mar NEWA
	© AVET LIFESCIENCES	120MG	A208058	005	Feb 28, 2023	Mar DISC
AB		120MG	A208058	005	Feb 28, 2023	Feb NEWA
AB	LUPIN LTD	20MG	A208031	001	Jan 03, 2019	Feb CMFD
AB		40MG	A208031	002	Jan 03, 2019	Feb CMFD
AB		60MG	A208031	003	Jan 03, 2019	Feb CMFD
AB		80MG	A208031	004	Jan 03, 2019	Feb CMFD
AB		120MG	A208031	005	Jan 03, 2019	Feb CMFD
AB	MACLEODS PHARMS LTD	20MG	A212124	001	Jun 09, 2023	Jun NEWA
AB		40MG	A212124	002	Jun 09, 2023	Jun NEWA
AB		60MG	A212124	003	Jun 09, 2023	Jun NEWA
AB		80MG	A212124	004	Jun 09, 2023	Jun NEWA
AB		120MG	A212124	005	Jun 09, 2023	Jun NEWA
AB	PIRAMAL HLTHCARE UK	20MG	A212091	001	Dec 28, 2020	Feb CMFD
AB		40MG	A212091	002	Dec 28, 2020	Feb CMFD
AB		60MG	A212091	003	Dec 28, 2020	Feb CMFD
AB		80MG	A212091	004	Dec 28, 2020	Feb CMFD
AB		120MG	A212091	005	Dec 28, 2020	Feb CMFD
AB	TORRENT	20MG	A208055	001	Jan 03, 2019	Feb CMFD
AB		40MG	A208055	002	Jan 03, 2019	Feb CMFD
AB		80MG	A208055	003	Jan 03, 2019	Feb CMFD
AB		120MG	A208055	004	Jan 03, 2019	Feb CMFD

MACIMORELIN ACETATE

FOR SOLUTION;ORAL
MACRILEN
+ @ NOVO

EQ 60MG BASE/POUCH

N205598 001 Dec 20, 2017 May DISC

MACITENTAN

TABLET;ORAL
MACITENTAN

AB	@ AUROBINDO PHARMA LTD	10MG 10MG	A211198 001 Apr 18, 2023	Apr DISC
	OPSUMIT		A211198 001 Apr 18, 2023	Apr NEWA
AB	+! ACTELION	10MG	N204410 001 Oct 18, 2013	Apr CTEC
	+!	10MG	N204410 001 Oct 18, 2013	Apr CFTG

MAFENIDE ACETATE

FOR SOLUTION;TOPICAL
MAFENIDE ACETATE

@ NOVAST LABS 5%

A206716 001 Jul 31, 2017 May DISC

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5

AP	FRESENIUS KABI USA	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	A215370 001 Jun 29, 2022	Mar CMFD
AP	FRESENIUS KABI USA	MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4 30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	A215371 001 Jun 08, 2022	Mar CMFD
AP	+! BAXTER HLTHCARE	PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER 30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N017378 001	Mar CTEC
AP	+! BAXTER HLTHCARE	PLASMA-LYTE A IN PLASTIC CONTAINER 30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N017378 002 Nov 22, 1982	Mar CTEC

MAGNESIUM SULFATE

INJECTABLE;INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

AP	AMNEAL	2GM/50ML (40MG/ML)	A216597 001 Feb 15, 2023	Feb NEWA
AP		4GM/100ML (40MG/ML)	A216597 002 Feb 15, 2023	Feb NEWA

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

SUFLAVE

+! BRAINTREE LABS 0.9GM/BOT;178.7GM/BOT;1.12GM/BOT;0 .5GM/BOT;7.3GM/BOT N215344 001 Jun 15, 2023 Jun NEWA

MARAVIROC

TABLET;ORAL
MARAVIROC

>A> AB	I 3 PHARMS	150MG	A217114 001 Aug 17, 2023	Aug NEWA
>A> AB		300MG	A217114 002 Aug 17, 2023	Aug NEWA

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

>D> AA	ANI PHARMS	12.5MG	A084657 002	Aug DISC
>A>	@	12.5MG	A084657 002	Aug DISC
>D> AA		25MG	A084657 001	Aug DISC
>A>	@	25MG	A084657 001	Aug DISC
AA	WILSHIRE PHARMS INC	12.5MG	A205136 001 Feb 22, 2019	May CAHN
AA		25MG	A205136 002 Feb 22, 2019	May CAHN
AA		50MG	A205136 003 Feb 22, 2019	May CAHN

MECLOFENAMATE SODIUM

CAPSULE;ORAL

MECLOFENAMATE SODIUM

@ CHARTWELL RX EQ 50MG BASE

A072262 001 Nov 29, 1988 Jan CAHN

@ EQ 100MG BASE

A072263 001 Nov 29, 1988 Jan CAHN

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

AB	AMNEAL @ HIKMA	150MG/ML 150MG/ML	A215397 001 Jun 07, 2023 May NEWA A214309 001 Jan 05, 2023 Jul DISC
----	-------------------	----------------------	--

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

@ BIONPHARMA	125MG/ML	A204688 001 Dec 01, 2017 Jun CAHN
@ BRECKENRIDGE	125MG/ML	A204688 001 Dec 01, 2017 Jan DISC
@ XTTRIUM LABS INC	40MG/ML	A076721 001 Nov 01, 2004 Jul DISC
	40MG/ML	A076721 001 Nov 01, 2004 Jan CAHN

AB			
----	--	--	--

MELOXICAM

TABLET; ORAL

MELOXICAM

AB	ASCENT PHARMS INC	7.5MG	A217579 001 Jun 07, 2023 May NEWA
AB		15MG	A217579 002 Jun 07, 2023 May NEWA
AB	COREPHARMA	7.5MG	A077882 001 Jul 20, 2006 Feb CAHN
AB		15MG	A077882 002 Jul 20, 2006 Feb CAHN

MELPHALAN HYDROCHLORIDE

POWDER; INTRA-ARTERIAL

HEPZATO

>A>	+! DELCATH SYSTEMS INC	EQ 50MG BASE/VIAL	N201848 001 Aug 14, 2023 Aug NEWA
>A>	SOLUTION; INTRAVENOUS		
	MELPHALAN HYDROCHLORIDE		

>A>	+! APOTEX	EQ 90MG BASE/ML (EQ 90MG BASE/ML)	N217110 001 Aug 18, 2023 Aug NEWA
-----	-----------	-----------------------------------	-----------------------------------

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE

@ ANI PHARMS	28MG	A205365 004 Feb 28, 2020 Feb DISC
@ XIAMEN LP PHARM CO	7MG	A213985 001 Oct 11, 2022 Apr DISC
@	14MG	A213985 002 Oct 11, 2022 Apr DISC
@	28MG	A213985 003 Oct 11, 2022 Apr DISC

NAMENDA XR

>D> AB	+ ABBVIE	7MG	N022525 001 Jun 21, 2010 Aug DISC
>A>	+ @	7MG	N022525 001 Jun 21, 2010 Aug DISC
AB	+	7MG	N022525 001 Jun 21, 2010 Feb CAHN
AB	+	14MG	N022525 002 Jun 21, 2010 Feb CAHN
AB	+	21MG	N022525 003 Jun 21, 2010 Feb CAHN
AB	+!	28MG	N022525 004 Jun 21, 2010 Feb CAHN

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

>D> AB	RENATA	5MG	A209527 001 May 07, 2018 Aug CAHN
>D> AB		10MG	A209527 002 May 07, 2018 Aug CAHN
>A> AB	WESTMINSTER PHARMS	5MG	A209527 001 May 07, 2018 Aug CAHN
>A> AB		10MG	A209527 002 May 07, 2018 Aug CAHN
	@ YILING	5MG	A212947 001 Apr 03, 2020 Mar CAHN
	@	10MG	A212947 002 Apr 03, 2020 Mar CAHN

NAMENDA

AB	+ ABBVIE	5MG	N021487 001 Oct 16, 2003 Feb CAHN
AB	+!	10MG	N021487 002 Oct 16, 2003 Feb CAHN

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

SCANDONEST PLAIN

! DEPROCO 3%

A088387 001 Oct 10, 1984 May CTEC

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

AP	BROOKS STERISCIENCE	500MG/VIAL	A216154 001 Aug 18, 2022 Jul CMFD
	@	500MG/VIAL	A216154 001 Aug 18, 2022 Mar DISC
AP		1GM/VIAL	A216154 002 Aug 18, 2022 Jul CMFD
	@	1GM/VIAL	A216154 002 Aug 18, 2022 Mar DISC

POWDER; INTRAVENOUS

MEROPEHENM

+! HQ SPCLT PHARMA

2GM/VIAL

N215212 001 Jul 26, 2023 Jul NEWA

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL

DELZICOL

AB +! ABBVIE 400MG

N204412 001 Feb 01, 2013 Feb CAHN

CAPSULE, EXTENDED RELEASE; ORAL
MESALAMINE

AB AMTA 375MG

A217533 001 Jun 06, 2023 May NEWA

AB AUROBINDO PHARMA LTD 375MG

A214477 001 Mar 31, 2023 Mar NEWA

ENEMA; RECTAL

MESALAMINE

AB ENCUBE 4GM/60ML

A216941 001 May 30, 2023 May NEWA

SUPPOSITORY; RECTAL

CANASA

AB @ ABBVIE 500MG

N021252 001 Jan 05, 2001 Feb CAHN

AB +! 1GM

N021252 002 Nov 05, 2004 Feb CAHN

TABLET, DELAYED RELEASE; ORAL

MESALAMINE

AB SINOTHERAPEUTICS INC 1.2GM

A217337 001 May 12, 2023 May NEWA

METAXALONE

TABLET; ORAL

METAXALONE

AB ! AMNEAL PHARMS 800MG

A203399 001 Jun 21, 2013 Jul CHRS

AB + @ PRIMUS PHARMS 640MG

N022503 001 Jun 01, 2015 Jun DISC

AB +! 640MG

N022503 001 Jun 01, 2015 Feb CMFD

SKELAXIN

AB + @ KING PHARMS 800MG

N013217 003 Aug 30, 2002 Jul DISC

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

AB3 RK PHARMA 500MG

A215629 001 Jun 20, 2023 Jun CAHN

AB3 1GM

A215629 002 Jun 20, 2023 Jun CAHN

AB3 VGYAAN 500MG

A215629 001 Jun 20, 2023 Jun NEWA

AB3 1GM

A215629 002 Jun 20, 2023 Jun NEWA

METFORMIN HYDROCHLORIDE; SAXagliptin HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

AB + ASTRAZENECA AB 500MG; EQ 5MG BASE

N200678 001 Nov 05, 2010 Jul CFTG

AB + 1GM; EQ 2.5MG BASE

N200678 003 Nov 05, 2010 Jul CFTG

AB +! 1GM; EQ 5MG BASE

N200678 002 Nov 05, 2010 Jul CFTG

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

AB DR REDDYS LABS SA 500MG; EQ 5MG BASE

A207678 001 Aug 09, 2023 Jul NEWA

AB 1GM; EQ 2.5MG BASE

A207678 002 Aug 09, 2023 Jul NEWA

AB 1GM; EQ 5MG BASE

A207678 003 Aug 09, 2023 Jul NEWA

SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE

AB MYLAN 500MG; EQ 5MG BASE

A205981 001 Jul 31, 2023 Jul NFTG

AB 1GM; EQ 2.5MG BASE

A205981 002 Jul 31, 2023 Jul NFTG

AB 1GM; EQ 5MG BASE

A205981 003 Jul 31, 2023 Jul NFTG

AB SUN PHARM 500MG; EQ 5MG BASE

A206081 001 Jul 31, 2023 Jul NFTG

AB 1GM; EQ 2.5MG BASE

A206081 002 Jul 31, 2023 Jul NFTG

AB 1GM; EQ 5MG BASE

A206081 003 Jul 31, 2023 Jul NFTG

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUMET

+ MSD SUB MERCK 500MG; EQ 50MG BASE

N022044 001 Mar 30, 2007 Mar CAHN

+! 1GM; EQ 50MG BASE

N022044 002 Mar 30, 2007 Mar CAHN

METHADONE HYDROCHLORIDE

INJECTABLE; INJECTION

METHADONE HYDROCHLORIDE

>D> AP AKORN 10MG/ML

A208306 001 Oct 27, 2017 Aug CAHN

>A> AP LONG GROVE PHARMS 10MG/ML

A208306 001 Oct 27, 2017 Aug CAHN

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

AB	MACLEODS PHARMS LTD	5MG	A209827	001	May 24, 2023	May NEWA
AB		10MG	A209827	002	May 24, 2023	May NEWA

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

@ BAXTER HLTHCARE CORP 1GM/10ML (100MG/ML)

A215065 001 Jul 14, 2022 Feb DISC

TABLET;ORAL

METHOCARBAMOL

AA	AUROBINDO PHARMA LTD	500MG	A213967	002	Feb 09, 2023	Feb NEWA
AA		750MG	A213967	001	Aug 12, 2020	Feb CMFD
AB	! AUSTARPHARMA LLC	1GM	A200958	003	Dec 06, 2021	Jun CTEC
AA	DBL PHARMS	500MG	A203550	001	Feb 08, 2017	Feb CAHN
AA		750MG	A203550	002	Feb 08, 2017	Feb CAHN
AB	MIKART	1GM	A212707	001	Jun 12, 2023	Jun NEWA

METHOTREXATE

SOLUTION;ORAL

JYLAJMO

+ @ THERAKIND

2MG/ML

N212479 001 Nov 29, 2022 May DISC

SOLUTION;SUBCUTANEOUS

REDITREX

>D>	+! NORDIC GRP	15MG/0.6ML (15MG/0.6ML)	N210737	004	Nov 27, 2019	Aug DISC
>A>	+ @	15MG/0.6ML (15MG/0.6ML)	N210737	004	Nov 27, 2019	Aug DISC
>D>	+!	20MG/0.8ML (20MG/0.8ML)	N210737	006	Nov 27, 2019	Aug DISC
>A>	+ @	20MG/0.8ML (20MG/0.8ML)	N210737	006	Nov 27, 2019	Aug DISC
>D>	+!	25MG/1ML (25MG/1ML)	N210737	008	Nov 27, 2019	Aug DISC
>A>	+ @	25MG/1ML (25MG/1ML)	N210737	008	Nov 27, 2019	Aug DISC

METHOTREXATE SODIUM

TABLET;ORAL

METHOTREXATE SODIUM

AB	DAITO	EQ 2.5MG BASE	A213362	001	Aug 07, 2023	Jul NEWA
----	-------	---------------	---------	-----	--------------	----------

METHSUXIMIDE

CAPSULE;ORAL

CELONTIN

AB	+! PARKE DAVIS	300MG	N010596	008		Apr CFTG
AB	NOVITIUM PHARMA	300MG	A217213	001	May 01, 2023	Apr NFTG

METHYLDOPA

TABLET;ORAL

METHYLDOPA

@	CHARTWELL RX	250MG	N018934	001	Jun 29, 1984	Jun DISC
		250MG	N018934	001	Jun 29, 1984	May CMFD
@		500MG	N018934	002	Jun 29, 1984	Jun DISC
!		500MG	N018934	002	Jun 29, 1984	May CMFD

METHYLERGONOVINE MALEATE

TABLET;ORAL

METHYLERGONOVINE MALEATE

AB	! CHARTWELL RX	0.2MG	A091577	001	May 02, 2011	Jun CAHN
----	----------------	-------	---------	-----	--------------	----------

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	ALKEM LABS LTD	18MG	A214447	001	May 23, 2023	May NEWA
AB		27MG	A214447	002	May 23, 2023	May NEWA
AB		36MG	A214447	003	May 23, 2023	May NEWA
AB		54MG	A214447	004	May 23, 2023	May NEWA
AB	@ AMNEAL PHARMS	18MG	A207515	001	Feb 01, 2018	Jun DISC
AB	@	27MG	A207515	002	Feb 01, 2018	Jun DISC
AB	@	36MG	A207515	003	Feb 01, 2018	Jun DISC
AB	@	54MG	A207515	004	Feb 01, 2018	Jun DISC
>A> AB	SUN PHARM INDs INC	72MG	A217229	001	Aug 25, 2023	Aug NEWA

METHYLPREDNISOLONE

TABLET;ORAL

MEDROL

+ PFIZER	2MG	N 011153	002	Apr CTEC
METHYLPREDNISOLONE				
@ CHARTWELL RX	2MG	A 209097	001	Feb 22, 2019
@	4MG	A 209097	002	Feb 22, 2019
@	8MG	A 209097	003	Feb 22, 2019
@	16MG	A 209097	004	Feb 22, 2019
@	32MG	A 209097	005	Feb 22, 2019

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE ACETATE

AB	EUGIA PHARMA	40MG/ML	A 211930	001	Apr 13, 2023	Apr NEWA
AB		80MG/ML	A 211930	002	Apr 13, 2023	Apr NEWA
AB	PAR STERILE PRODUCTS	40MG/ML	A 214297	001	Jan 21, 2022	Jun CMFD
AB	SLAYBACK PHARMA LLC	40MG/ML	A 214870	002	May 10, 2023	Apr NEWA

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA	! PHARM ASSOC	EQ 5MG BASE/5ML	A 072744	001	May 28, 1991	Jul CHRS
	@ XTTRIUM LABS INC	EQ 5MG BASE/5ML	A 074703	001	Oct 31, 1997	Jul DISC
AA	!	EQ 5MG BASE/5ML	A 074703	001	Oct 31, 1997	Jan CAHN

METOLAZONE

TABLET;ORAL

METOLAZONE

>D>	@ AACE PHARMS	2.5MG	A 216216	001	Oct 25, 2022	Aug CMFD
>A> AB		2.5MG	A 216216	001	Oct 25, 2022	Aug CMFD
	@	2.5MG	A 216216	001	Oct 25, 2022	Apr DISC
>D>	@	5MG	A 216216	002	Oct 25, 2022	Aug CMFD
>A> AB		5MG	A 216216	002	Oct 25, 2022	Aug CMFD
	@	5MG	A 216216	002	Oct 25, 2022	Apr DISC
>D>	@	10MG	A 216216	003	Oct 25, 2022	Aug CMFD
>A> AB		10MG	A 216216	003	Oct 25, 2022	Aug CMFD
	@	10MG	A 216216	003	Oct 25, 2022	Apr DISC
	MYKROX					
	@ CHARTWELL MOLECULAR	0.5MG	N 019532	001	Oct 30, 1987	Jul CAHN

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

@ ACCORD HLTHCARE	EQ 25MG TARTRATE	A 215637	001	Oct 18, 2022	Apr DISC
@	EQ 50MG TARTRATE	A 215637	002	Oct 18, 2022	Apr DISC
@	EQ 100MG TARTRATE	A 215637	003	Oct 18, 2022	Apr DISC
@	EQ 200MG TARTRATE	A 215637	004	Oct 18, 2022	Apr DISC
AB	GRANULES	A 216509	001	Aug 07, 2023	Jul NEWA
AB		A 216916	001	Jun 12, 2023	Jun NEWA
AB		A 216509	002	Aug 07, 2023	Jul NEWA
AB		A 216916	002	Jun 12, 2023	Jun NEWA
AB		A 216509	003	Aug 07, 2023	Jul NEWA
AB		A 216916	003	Jun 12, 2023	Jun NEWA
AB		A 216509	004	Aug 07, 2023	Jul NEWA
AB		A 216916	004	Jun 12, 2023	Jun NEWA
>A>	@ LUPIN	A 209272	001	Aug 15, 2023	Aug DISC
>A>	@	A 209272	002	Aug 15, 2023	Aug DISC
>A>	@	A 209272	003	Aug 15, 2023	Aug DISC
>A>	@	A 209272	004	Aug 15, 2023	Aug DISC

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

@ HOSPIRA

1MG/ML

A 075160 001 Jul 06, 1998 Jun DISC

TABLET;ORAL

METOPROLOL TARTRATE

AB	ZYDUS PHARMS	25MG	A 212402	001	Apr 19, 2023	Apr NEWA
AB		50MG	A 212402	002	Apr 19, 2023	Apr NEWA
AB		100MG	A 212402	003	Apr 19, 2023	Apr NEWA

METRONIDAZOLE

CREAM;TOPICAL

METRONIDAZOLE

AB	ZYDUS LIFESCIENCES	0.75%	A217128	001	Apr 21, 2023	Apr NEWA
AB	GEL;TOPICAL					
	METRONIDAZOLE					
AB	COSETTE	1%	A216692	001	Jan 23, 2023	Jan NEWA
	@ TOLMAR	1%	A090903	001	Jul 22, 2011	Feb DISC
	GEL;VAGINAL					
	METRONIDAZOLE					
AB	COSETTE	0.75%	A216323	001	Jul 12, 2023	Jun NEWA
	@ ENCUBE	0.75%	A077264	001	Oct 31, 2006	Mar CAHN
AB		0.75%	A215610	001	Jun 16, 2023	Jun NEWA
	INJECTABLE;INJECTION					
	METRONIDAZOLE IN PLASTIC CONTAINER					
AP	AMNEAL	500MG/100ML	A217665	001	May 24, 2023	Jun CMS1
	TABLET;ORAL					
	METRONIDAZOLE					
AB	ALEMBIC	250MG	A208681	001	Jun 20, 2017	Feb CAHN
AB		500MG	A208681	002	Jun 20, 2017	Feb CAHN

METRONIDAZOLE IN PLASTIC CONTAINER

INJECTABLE;INJECTION

METRONIDAZOLE IN PLASTIC CONTAINER

AP	AMNEAL	500MG/100ML	A217665	001	May 24, 2023	May NEWA
----	--------	-------------	---------	-----	--------------	----------

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL

MEXILETINE HYDROCHLORIDE

AB	LEADING	150MG	A215876	001	Feb 27, 2023	Feb NEWA
AB		200MG	A215876	002	Feb 27, 2023	Feb NEWA
AB		250MG	A215876	003	Feb 27, 2023	Feb NEWA
AB	ZENARA	150MG	A215315	001	Aug 26, 2022	Feb CAHN
AB		200MG	A215315	002	Aug 26, 2022	Feb CAHN
AB		250MG	A215315	003	Aug 26, 2022	Feb CAHN

MICAFUNGIN SODIUM

INJECTABLE;INTRAVENOUS

MICAFUNGIN SODIUM

>D>	@ ZYDUS PHARMS	EQ 50MG BASE/VIAL	A215241	001	Oct 24, 2022	Aug CMFD
>A> AP		EQ 50MG BASE/VIAL	A215241	001	Oct 24, 2022	Aug CMFD
	@	EQ 50MG BASE/VIAL	A215241	001	Oct 24, 2022	Mar DISC
>D>	@	EQ 100MG BASE/VIAL	A215241	002	Oct 24, 2022	Aug CMFD
>A> AP		EQ 100MG BASE/VIAL	A215241	002	Oct 24, 2022	Aug CMFD
	@	EQ 100MG BASE/VIAL	A215241	002	Oct 24, 2022	Mar DISC

MIDAZOLAM

SOLUTION;INTRAVENOUS

MIDAZOLAM IN 0.9% SODIUM CHLORIDE

AP	HIKMA	50MG/50ML (1MG/ML)	A216159	001	Apr 17, 2023	Apr NFTG
AP		100MG/100ML (1MG/ML)	A216159	002	Apr 17, 2023	Apr NFTG
AP	+! INFORLIFE	50MG/50ML (1MG/ML)	N211844	001	Mar 22, 2021	Apr CFTG
AP	+!	100MG/100ML (1MG/ML)	N211844	002	Mar 22, 2021	Apr CFTG

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE

>A> AP	MICRO LABS	EQ 1MG BASE/ML	A217504	001	Aug 21, 2023	Aug NEWA
>A> AP		EQ 5MG BASE/ML	A217504	002	Aug 21, 2023	Aug NEWA

MIGLUSTAT

CAPSULE;ORAL

YARGESA

AB	EDENBRIDGE PHARMS	100MG	A209821	001	Aug 06, 2020	Jul CTNA
----	-------------------	-------	---------	-----	--------------	----------

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL

SAVELLA

+ ABBVIE	12.5MG
+	25MG
+!	50MG
+	100MG

N022256	001	Jan 14, 2009	Jan CAHN
N022256	002	Jan 14, 2009	Jan CAHN
N022256	003	Jan 14, 2009	Jan CAHN
N022256	004	Jan 14, 2009	Jan CAHN

MILRINONE LACTATEINJECTABLE; INJECTION
MILRINONE LACTATE

AP SHANDONG	EQ 1MG BASE/ML	A216373	001	Jan 23, 2023	Jan NEWA
-------------	----------------	---------	-----	--------------	----------

MINOCYCLINE HYDROCHLORIDEINJECTABLE; INJECTION
MINOCIN

+! REMPEX	EQ 100MG BASE/VIAL
-----------	--------------------

N050444	001	May CTEC
---------	-----	----------

TABLET, EXTENDED RELEASE;ORAL
MINOCYCLINE HYDROCHLORIDE

AB ZYDUS PHARMS	EQ 55MG BASE	A203553	002	Jun 16, 2023	Jun NEWA
AB	EQ 65MG BASE	A203553	003	Jun 16, 2023	Jun NEWA
AB	EQ 115MG BASE	A203553	007	Jun 16, 2023	Jun NEWA

MIRABEGRONTABLET, EXTENDED RELEASE;ORAL
MIRABEGRON

@ ZYDUS PHARMS	25MG	A209488	001	Sep 29, 2022	Mar DISC
@	50MG	A209488	002	Sep 29, 2022	Mar DISC

A209488	001	Sep 29, 2022	Mar DISC
---------	-----	--------------	----------

MIRTAZAPINETABLET;ORAL
MIRTAZAPINE

AB PRASCO	7.5MG	A216751	001	Jan 18, 2023	Jan NEWA
AB	15MG	A216751	002	Jan 18, 2023	Jan NEWA
AB	30MG	A216751	003	Jan 18, 2023	Jan NEWA
AB	45MG	A216751	004	Jan 18, 2023	Jan NEWA

REMERON

AB +! ORGANON	15MG	N020415	001	Jun 14, 1996	Apr CAHN
AB +	30MG	N020415	002	Jun 14, 1996	Apr CAHN
AB +	30MG	N020415	002	Jun 14, 1996	May CAHN
+ @	45MG	N020415	003	Mar 17, 1997	Apr CAHN
+ @	45MG	N020415	003	Mar 17, 1997	May CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
REMERON SOLTAB

AB +! ORGANON USA ORGANON	15MG	N021208	001	Jan 12, 2001	May CAHN
AB +	30MG	N021208	002	Jan 12, 2001	May CAHN
AB +	45MG	N021208	003	Jan 12, 2001	May CAHN

MISOPROSTOL

TABLET;ORAL

MISOPROSTOL

@ NOVEL LABS INC	0.1MG	A091667	001	Jul 25, 2012	Feb DISC
@	0.2MG	A091667	002	Jul 25, 2012	Feb DISC

A091667	001	Jul 25, 2012	Feb DISC
---------	-----	--------------	----------

MODAFINILTABLET;ORAL
PROVIGIL

AB + CEPHALON	100MG	N020717	001	Dec 24, 1998	Jul CAHN
AB +!	200MG	N020717	002	Dec 24, 1998	Jul CAHN

MOMETASONE FUROATELOTION;TOPICAL
ELOCON

+ @ ORGANON	0.1%	N019796	001	Mar 30, 1989	Mar DISC
-------------	------	---------	-----	--------------	----------

N019796	001	Mar 30, 1989	Mar DISC
---------	-----	--------------	----------

AB ! PADAGIS ISRAEL	0.1%	A077180	001	Apr 06, 2005	Mar CHRS
---------------------	------	---------	-----	--------------	----------

MONTELUKAST SODIUM

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

AB	CHARTWELL MOLECULAR	EQ 4MG BASE	A207464	001	Dec 06, 2018	Jan CAHN
AB		EQ 5MG BASE	A207464	002	Dec 06, 2018	Jan CAHN
>D> AB	GRAVITI PHARMS	EQ 4MG BASE	A209011	001	Apr 18, 2017	Aug CAHN
>D> AB		EQ 5MG BASE	A209011	002	Apr 18, 2017	Aug CAHN
>A> AB	RISING	EQ 4MG BASE	A209011	001	Apr 18, 2017	Aug CAHN
>A> AB		EQ 5MG BASE	A209011	002	Apr 18, 2017	Aug CAHN
>D> AB	UNICHEM	EQ 4MG BASE	A208621	001	Jul 02, 2018	Aug DISC
>A> @		EQ 4MG BASE	A208621	001	Jul 02, 2018	Aug DISC
>D> AB		EQ 5MG BASE	A208621	002	Jul 02, 2018	Aug DISC
>A> @		EQ 5MG BASE	A208621	002	Jul 02, 2018	Aug DISC

MORPHINE SULFATE

INJECTABLE;INJECTION

MORPHINE SULFATE

AP	HIKMA	2MG/ML	A211452	001	Jan 12, 2023	Jan NFTG
AP		4MG/ML	A211452	002	Jan 12, 2023	Jan NEWA
AP		8MG/ML	A211452	003	Jan 12, 2023	Jan NEWA
AP		10MG/ML	A211452	004	Jan 12, 2023	Jan NEWA
AP		15MG/ML	A211452	005	Jan 12, 2023	Jan NFTG
AP	+! HOSPIRA INC	2MG/ML	N202515	001	Nov 14, 2011	Jan CFTG
	TABLET;ORAL					
	MORPHINE SULFATE					
	@ DR REDDYS LABS SA	15MG	A207270	001	Jan 12, 2022	Apr CAHN
	@	30MG	A207270	002	Jan 12, 2022	Apr CAHN
	@ MAYNE PHARMA INC	15MG	A207270	001	Jan 12, 2022	Apr DISC
	@	30MG	A207270	002	Jan 12, 2022	Apr DISC
>A> AB	SPECGX LLC	15MG	A215194	001	Aug 21, 2023	Aug NEWA
>A> AB		30MG	A215194	002	Aug 21, 2023	Aug NEWA
	TABLET, EXTENDED RELEASE;ORAL					
	MORPHABOND ER					
	+ @ OHemo Life	15MG	N206544	001	Oct 02, 2015	Jun CAHN
	+ @	30MG	N206544	002	Oct 02, 2015	Jun CAHN
	+ @	60MG	N206544	003	Oct 02, 2015	Jun CAHN
	+ @	100MG	N206544	004	Oct 02, 2015	Jun CAHN
	MORPHINE SULFATE					
	@ DR REDDYS LABS SA	15MG	A205386	001	Oct 28, 2016	Apr CAHN
	@	30MG	A205386	002	Oct 28, 2016	Apr CAHN
	@	60MG	A205386	003	Oct 28, 2016	Apr CAHN
	@	100MG	A205386	004	Oct 28, 2016	Apr CAHN
	@ MAYNE PHARMA INC	15MG	A205386	001	Oct 28, 2016	Apr DISC
	@	30MG	A205386	002	Oct 28, 2016	Apr DISC
	@	60MG	A205386	003	Oct 28, 2016	Apr DISC
	@	100MG	A205386	004	Oct 28, 2016	Apr DISC

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

MOXEZA

AT2	+ @ HARROW EYE	EQ 0.5% BASE	N022428	001	Nov 19, 2010	Jun DISC
	+!	EQ 0.5% BASE	N022428	001	Nov 19, 2010	May CAHN
	MOXIFLOXACIN HYDROCHLORIDE					
	@ AKORN	EQ 0.5% BASE	A202916	001	Nov 09, 2017	Jan DISC
	! LUPIN LTD	EQ 0.5% BASE	A204079	001	May 28, 2015	Jun CHRS
		EQ 0.5% BASE	A204079	001	May 28, 2015	Jun CTEC
	TABLET;ORAL					
	MOXIFLOXACIN HYDROCHLORIDE					
AB	CHARTWELL RX	EQ 400MG BASE	A207285	001	Feb 13, 2017	Apr CAHN
AB	HETERO LABS LTD V	EQ 400MG BASE	A204836	001	Mar 02, 2023	Feb NEWA
	@ TORRENT	EQ 400MG BASE	A200160	001	Apr 03, 2014	Feb DISC

MYCOPHENOLATE MOFETIL

FOR SUSPENSION;ORAL

MYCOPHENOLATE MOFETIL

>A> AB	STRIDES PHARMA	200MG/ML	A212634	001	Aug 29, 2023	Aug NEWA
--------	----------------	----------	---------	-----	--------------	----------

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP BPI LABS 500MG/VIAL A214283 001 Jun 01, 2023 May NEWA

NABUMETONE

TABLET; ORAL

NABUMETONE

@ AUROBINDO PHARMA USA 500MG

@ 750MG

A090516 001 Jul 12, 2010 Apr CAHN
A090516 002 Jul 12, 2010 Apr CAHNNADOLOL

TABLET; ORAL

NADOLOL

AB ALEMBIC 20MG A211763 001 Jun 02, 2023 May NEWA
AB 40MG A211763 002 Jun 02, 2023 May NEWA
AB 80MG A211763 003 Jun 02, 2023 May NEWA
AB RK PHARMA 20MG A212856 001 Sep 13, 2019 Jun CAHN
AB 40MG A212856 002 Sep 13, 2019 Jun CAHN
AB 80MG A212856 003 Sep 13, 2019 Jun CAHNNAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

AP ! EUGIA PHARMA SPEC LTS EQ 1GM BASE/VIAL A091613 001 Dec 26, 2012 Jan CHRS
AP ! EQ 2GM BASE/VIAL A091613 002 Dec 26, 2012 Jan CHRS
AP ! EQ 10GM BASE/VIAL A091614 001 Dec 26, 2012 Jan CHRS
@ SANDOZ EQ 1GM BASE/VIAL A062527 002 Aug 02, 1984 Jan DISC
@ EQ 1GM BASE/VIAL A062732 001 Dec 23, 1986 Jan DISC
@ EQ 2GM BASE/VIAL A062527 003 Aug 02, 1984 Jan DISC
@ EQ 2GM BASE/VIAL A062732 002 Dec 23, 1986 Jan DISC
@ EQ 10GM BASE/VIAL A062527 004 Aug 02, 1984 Jan DISCNAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIFINE HYDROCHLORIDE

AB AMNEAL 2% A206960 001 Apr 10, 2017 Feb CAHN
GEL; TOPICAL
NAFTIFINE HYDROCHLORIDE
AB AMNEAL 1% A206165 001 Mar 20, 2019 Feb CAHN
AB TARO 2% A208201 001 Apr 10, 2019 Mar CMFD
NAFTIN
AB +! SEBELA IRELAND LTD 2% N204286 001 Jun 27, 2013 May CTEC
+! 2% N204286 001 Jun 27, 2013 Feb CTECNALMEFENE HYDROCHLORIDE

SPRAY; NASAL

OPVEE

+! INDIVIOR

EQ 2.7MG BASE/SPRAY

N217470 001 May 22, 2023 Jun CAHN

+! OPIANT PHARMS

EQ 2.7MG BASE/SPRAY

N217470 001 May 22, 2023 May NEWA

NALOXEGOL OXALATE

TABLET; ORAL

MOVANTIK

+! VALINOR

EQ 12.5MG BASE

N204760 001 Sep 16, 2014 Feb CAHN

+!

EQ 25MG BASE

N204760 002 Sep 16, 2014 Feb CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HYDROCHLORIDE

@ PAR STERILE PRODUCTS

1MG/ML

A215964 001 Jul 29, 2022 Jan DISC

SPRAY, METERED; NASAL

NALOXONE HYDROCHLORIDE

TEVA PHARMS USA

4MG/SPRAY

A209522 001 Apr 19, 2019 Jul CTEC

REXTOVY

+! AMPHASTAR PHARMS INC

4MG/SPRAY

N208969 001 Mar 07, 2023 Jun CTNA

+!

4MG/SPRAY

N208969 001 Mar 07, 2023 Mar NEWA

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
NALTREXONE

AP	TEVA PHARMS USA INC	380MG/VIAL	A213195	001	Jul 06, 2023	Jun NFTG
AP	+! ALKERMES	380MG/VIAL	N021897	001	Apr 13, 2006	Jun CFTG

NAPROXEN

TABLET, DELAYED RELEASE; ORAL
NAPROXEN

@	AUROBINDO PHARMA USA	375MG	A075390	001	Apr 19, 2001	Apr CAHN
@		500MG	A075390	002	Apr 19, 2001	Apr CAHN
AB	TULEX PHARMS INC	375MG	A216908	001	May 31, 2023	May NEWA
AB		500MG	A216908	002	May 31, 2023	May NEWA

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

@	AUROBINDO PHARMA USA	EQ 1MG BASE	A202431	001	May 31, 2012	Apr CAHN
@		EQ 2.5MG BASE	A202431	002	May 31, 2012	Apr CAHN

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

NEBIVOLOL HYDROCHLORIDE

AB	BEXIMCO PHARMS USA	EQ 2.5MG BASE	A216568	001	Mar 30, 2023	Mar NEWA
AB		EQ 5MG BASE	A216568	002	Mar 30, 2023	Mar NEWA
AB		EQ 10MG BASE	A216568	003	Mar 30, 2023	Mar NEWA
AB		EQ 20MG BASE	A216568	004	Mar 30, 2023	Mar NEWA

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

@	AUROBINDO PHARMA USA	100MG	A076129	002	Sep 16, 2003	Apr CAHN
@		150MG	A076129	003	Sep 16, 2003	Apr CAHN
@		200MG	A076129	004	Sep 16, 2003	Apr CAHN
@		250MG	A076129	005	Sep 16, 2003	Apr CAHN

NELARABINE

INJECTABLE; INTRAVENOUS

ARRANON

AP	+! SANDOZ	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005	May CAHN
AP	AMNEAL	250MG/50ML (5MG/ML)	A216346	001	Apr 04, 2023	Mar NEWA
AP	SHORLA	250MG/50ML (5MG/ML)	A214809	001	Mar 03, 2023	Feb NEWA

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

AP	HIKMA	5MG/10ML (0.5MG/ML)	A207042	001	Dec 28, 2015	May CAHN
AP		10MG/10ML (1MG/ML)	A207042	002	Dec 28, 2015	May CAHN
AP	SAGENT PHARMS INC	5MG/10ML (0.5MG/ML)	A216542	001	Feb 17, 2023	Feb NEWA
AP		10MG/10ML (1MG/ML)	A216542	002	Feb 17, 2023	Feb NEWA

NEPAFENAC

SUSPENSION/DROPS; OPHTHALMIC

ILEVRO

+!	HARROW EYE	0.3%
+!	NEVANAC	

+!	HARROW EYE	0.1%
----	------------	------

N203491	001	Oct 16, 2012	May CAHN
N021862	001	Aug 19, 2005	May CAHN

NETARSUDIL MESYLATE

SOLUTION/DROPS; OPHTHALMIC

RHOPRESSA

+!	ALCON LABS INC	EQ 0.02% BASE
----	----------------	---------------

N208254	001	Dec 18, 2017	May CAHN
---------	-----	--------------	----------

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

AB	AUROBINDO PHARMA USA	50MG	A074967	001	Jul 09, 1997	Apr CMFD
AB		100MG	A074967	002	Jul 09, 1997	Apr CMFD
AB		100MG	A077025	001	Aug 18, 2004	May CMFD
AB	MANKIND PHARMA	25MG	A217272	001	Mar 21, 2023	Mar NEWA
AB		50MG	A217272	002	Mar 21, 2023	Mar NEWA
AB		100MG	A217272	003	Mar 21, 2023	Mar NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

@	ALVOGEN	75MG;25MG	A215002	001	Jul 20, 2022	Jan DISC
AB	AUROBINDO PHARMA	75MG;25MG	A209225	001	Mar 30, 2023	Mar NEWA
AB	MANKIND PHARMA	75MG;25MG	A217357	001	Jul 11, 2023	Jun NEWA

NITROGLYCERIN

INJECTABLE;INJECTION

NITROGLYCERIN IN DEXTROSE 5%

+!	BAXTER HLTHCARE	10MG/100ML	N019970	001	Dec 29, 1989	May CTEC
+!		20MG/100ML	N019970	002	Dec 29, 1989	May CTEC
+!		40MG/100ML	N019970	003	Dec 29, 1989	May CTEC

OINTMENT;TRANSDERMAL

NITROGLYCERIN

+!	FOUGERA PHARMS INC	2%	A087355	001	Jul 08, 1988	May CRLD
----	--------------------	----	---------	-----	--------------	----------

NOREPINEPHRINE BITARTRATE

SOLUTION;INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

+ @	LONG GROVE PHARMS	EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	N214628	001	Oct 06, 2022	May CAHN
+ @		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214628	002	Oct 06, 2022	May CAHN
+ @		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214628	003	Oct 06, 2022	May CAHN
+ @	NEVAKAR INJECTABLES	EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	N214628	001	Oct 06, 2022	Apr DISC
+ @		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214628	002	Oct 06, 2022	Apr DISC
+ @		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214628	003	Oct 06, 2022	Apr DISC

NORTRIPTYLINE HYDROCHLORIDE

SOLUTION;ORAL

NORTRIPTYLINE HYDROCHLORIDE

>D>	! PHARM ASSOC	EQ 10MG BASE/5ML	A075606	001	Aug 23, 2000	Aug CTEC
>A> AA	!	EQ 10MG BASE/5ML	A075606	001	Aug 23, 2000	Aug CTEC
>A> AA	RUBICON	EQ 10MG BASE/5ML	A217731	001	Aug 15, 2023	Aug NEWA

NYSTATIN

OINTMENT;TOPICAL

NYSTATIN

@ TORRENT 100,000 UNITS/GM

A211838 001 Jan 28, 2019 Mar DISC

SUSPENSION;ORAL

NILSTAT

+ @	CHARTWELL MOLECULES	100,000 UNITS/ML
		N050299 001

Apr CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

>D> AT	TORRENT	100,000 UNITS/GM;0.1%	A213142	001	Jul 14, 2020	Aug DISC
>A>	@	100,000 UNITS/GM;0.1%	A213142	001	Jul 14, 2020	Aug DISC

OINTMENT;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

>D> AT	PAI HOLDINGS PHARM	100,000 UNITS/GM;0.1%	A208287	001	Dec 30, 2016	Aug DISC
>A>	@	100,000 UNITS/GM;0.1%	A208287	001	Dec 30, 2016	Aug DISC

OBETICHOOLIC ACID

TABLET;ORAL

OBETICHOOLIC ACID

AB	APOTEX	5MG	A214862	001	May 30, 2023	May NFTG
AB		10MG	A214862	002	May 30, 2023	May NFTG
AB	LUPIN LTD	5MG	A214980	001	May 30, 2023	May NFTG
AB		10MG	A214980	002	May 30, 2023	May NFTG
	@ MSN	5MG	A215017	001	May 30, 2023	Jun DISC
AB		5MG	A215017	001	May 30, 2023	May NFTG
	@	10MG	A215017	002	May 30, 2023	Jun DISC
AB		10MG	A215017	002	May 30, 2023	May NFTG
	OCALIVA					
AB	+ INTERCEPT PHARMS INC	5MG	N207999	001	May 27, 2016	May CFTG
AB	+!	10MG	N207999	002	May 27, 2016	May CFTG

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

AP	GLAND PHARMA LTD	EQ 0.1MG BASE/ML	A216839	002	Jun 22, 2023	Jun NEWA
AP		EQ 0.2MG BASE/ML	A216807	001	Jun 13, 2023	Jun NEWA
AP		EQ 0.5MG BASE/ML	A216839	001	Jun 22, 2023	Jun NEWA
AP		EQ 1MG BASE/ML	A216807	002	Jun 13, 2023	Jun NEWA

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

>D> AT	AKORN	0.3%	A076407	001	Apr 15, 2008	Aug CAHN
>A> AT	SENTISSL	0.3%	A076407	001	Apr 15, 2008	Aug CAHN

OLANZAPINE

INJECTABLE;INTRAMUSCULAR

OLANZAPINE

AP	ASPIRO	10MG/VIAL	A217466	001	Mar 22, 2023	Mar NEWA
	TABLET;ORAL					
	OLANZAPINE					
AB	CADILA PHARMS LTD	2.5MG	A210022	001	Feb 24, 2023	Feb NEWA
AB		5MG	A210022	002	Feb 24, 2023	Feb NEWA
AB		7.5MG	A210022	003	Feb 24, 2023	Feb NEWA
AB		10MG	A210022	004	Feb 24, 2023	Feb NEWA
AB		15MG	A210022	005	Feb 24, 2023	Feb NEWA
AB		20MG	A210022	006	Feb 24, 2023	Feb NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

AB	HISUN PHARM HANGZHOU	5MG	A206892	001	Dec 31, 2020	Apr CMFD
AB		10MG	A206892	002	Dec 31, 2020	Apr CMFD
AB		15MG	A206892	003	Dec 31, 2020	Apr CMFD
AB		20MG	A206892	004	Dec 31, 2020	Apr CMFD
	@ ZYDUS PHARMS	5MG	A202889	001	Mar 09, 2023	Jul DISC
AB		5MG	A202889	001	Mar 09, 2023	Mar NEWA
	@	10MG	A202889	002	Mar 09, 2023	Jul DISC
AB		10MG	A202889	002	Mar 09, 2023	Mar NEWA
	@	15MG	A202889	003	Mar 09, 2023	Jul DISC
AB		15MG	A202889	003	Mar 09, 2023	Mar NEWA
	@	20MG	A202889	004	Mar 09, 2023	Jul DISC
AB		20MG	A202889	004	Mar 09, 2023	Mar NEWA

OLANZAPINE PAMOATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ZYPREXA RELPREVV

>A>	+	CHEPLAPHARM	EQ 210MG BASE/VIAL	N022173	001	Dec 11, 2009	Aug CAHN
>A>	+		EQ 300MG BASE/VIAL	N022173	002	Dec 11, 2009	Aug CAHN
>A>	+!		EQ 405MG BASE/VIAL	N022173	003	Dec 11, 2009	Aug CAHN
>D>	+	ELI LILLY CO	EQ 210MG BASE/VIAL	N022173	001	Dec 11, 2009	Aug CAHN
>D>	+		EQ 300MG BASE/VIAL	N022173	002	Dec 11, 2009	Aug CAHN
>D>	+!		EQ 405MG BASE/VIAL	N022173	003	Dec 11, 2009	Aug CAHN

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

AB	AMNEAL	5MG	A207480	001	Jul 11, 2023	Jun NEWA
AB		20MG	A207480	002	Jul 11, 2023	Jun NEWA
AB		40MG	A207480	003	Jul 11, 2023	Jun NEWA
AB	MSN	5MG	A217399	001	Jan 18, 2023	Jan NEWA
AB		20MG	A217399	002	Jan 18, 2023	Jan NEWA
AB		40MG	A217399	003	Jan 18, 2023	Jan NEWA
>D> AB	TORRENT	5MG	A202375	001	Apr 24, 2017	Aug DISC
>A>	@	5MG	A202375	001	Apr 24, 2017	Aug DISC
>D> AB		20MG	A202375	002	Apr 24, 2017	Aug DISC
>A>	@	20MG	A202375	002	Apr 24, 2017	Aug DISC
>D> AB		40MG	A202375	003	Apr 24, 2017	Aug DISC
>A>	@	40MG	A202375	003	Apr 24, 2017	Aug DISC

OLOPATADINE HYDROCHLORIDE

SPRAY, METERED;NASAL

OLOPATADINE HYDROCHLORIDE

AB	! AMNEAL	0.665MG/SPRAY	A210901	001	Jan 28, 2020	May CHRS
	+ @ NOVARTIS	0.665MG/SPRAY	N021861	001	Apr 15, 2008	May DISC

OMAVELOXOLONE

CAPSULE;ORAL

SKYCLARYS

+! REATA PHARMS

50MG

N216718 001 Feb 28, 2023 Feb NEWA

OMIDENE PAG ISOPROPYL

SOLUTION;OPHTHALMIC

OMLONTI

+ @ SANTEN

0.002%

N215092 001 Sep 22, 2022 May DISC

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

! CHARTWELL MOLECULES

16MG

A077406 001 Dec 26, 2006 Mar CHRS

!

24MG

A077406 002 Dec 26, 2006 Mar CHRS

ZOFTRAN ODT

+ @ SANDOZ

4MG

N020781 001 Jan 27, 1999 May CAHN

+

8MG

N020781 002 Jan 27, 1999 May CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ZOFTRAN

+ @ SANDOZ

EQ 2MG BASE/ML

N020007 001 Jan 04, 1991 May CAHN

ZOFTRAN PRESERVATIVE FREE

+ @ SANDOZ

EQ 2MG BASE/ML

N020007 003 Dec 10, 1993 May CAHN

SOLUTION;ORAL

ONDANSETRON HYDROCHLORIDE

AA	CHARTWELL MOLECULAR	EQ 4MG BASE/5ML	A091342	001	Jan 27, 2011	Jul CAHN
	ZOFTRAN					
+ @ SANDOZ		EQ 4MG BASE/5ML	N020605	001	Jan 24, 1997	May CAHN
TABLET;ORAL						
	ONDANSETRON HYDROCHLORIDE					
!	CHARTWELL MOLECULES	EQ 24MG BASE	A077303	004	Jun 25, 2007	Feb CTEC
	ZOFTRAN					
+ @ SANDOZ		EQ 4MG BASE	N020103	001	Dec 31, 1992	May CAHN
+ @		EQ 8MG BASE	N020103	002	Dec 31, 1992	May CAHN
+ @		EQ 24MG BASE	N020103	003	Aug 27, 1999	May CAHN

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE;ORAL

ORPHENADRINE CITRATE

AB	RISING	100MG	A040249	001	Jan 29, 1999	Jan CAHN
----	--------	-------	---------	-----	--------------	----------

OSELTAMIVIR PHOSPHATE

	CAPSULE;ORAL						
	OSELTAMIVIR PHOSPHATE						
@	ACCORD HLTHCARE	EQ 30MG BASE		A214726	001	Jul 25, 2022	Feb DISC
@		EQ 45MG BASE		A214726	002	Jul 25, 2022	Feb DISC
@		EQ 75MG BASE		A214726	003	Jul 25, 2022	Feb DISC
AB	SUNSHINE	EQ 30MG BASE		A212739	001	Mar 04, 2020	Jun CMFD
AB		EQ 45MG BASE		A212739	002	Mar 04, 2020	Jun CMFD
AB		EQ 75MG BASE		A212739	003	Mar 04, 2020	Jun CMFD
	FOR SUSPENSION;ORAL						
	OSELTAMIVIR PHOSPHATE						
AB	EPIC PHARMA LLC	EQ 6MG BASE/ML		A215538	001	Feb 14, 2023	Feb NEWA

OSILODROSTAT PHOSPHATE

	TABLET;ORAL						
	ISTURISA						
+ @	RECORDATI RARE	EQ 10MG BASE		N212801	003	Mar 06, 2020	Jul DISC

OXCARBAZEPINE

	SUSPENSION;ORAL						
	OXCARBAZEPINE						
>D>	AB	AKORN	300MG/5ML	A211420	001	Jul 09, 2021	Aug CAHN
	AB	CHARTWELL RX	300MG/5ML	A212428	001	Jun 21, 2021	May CAHN
>A>	AB	RENEW PHARMS	300MG/5ML	A211420	001	Jul 09, 2021	Aug CAHN
	TABLET;ORAL						
	OXCARBAZEPINE						
AB	ZYDUS	150MG		A211747	001	Jul 03, 2023	Jun NEWA
AB		300MG		A211747	002	Jul 03, 2023	Jun NEWA
AB		600MG		A211747	003	Jul 03, 2023	Jun NEWA
	TABLET, EXTENDED RELEASE;ORAL						
	OXCARBAZEPINE						
AB	APOTEX	150MG		A213369	001	Jul 13, 2023	Jul NFTG
AB		300MG		A213369	002	Jul 13, 2023	Jul NFTG
AB		600MG		A213369	003	Jul 13, 2023	Jul NFTG
	OXTELLAR XR						
AB	+ SUPERNUS PHARMS	150MG		N202810	001	Oct 19, 2012	Jul CFTG
AB	+!	300MG		N202810	002	Oct 19, 2012	Jul CFTG
AB	+!	600MG		N202810	003	Oct 19, 2012	Jul CFTG

OXYBUTYNIN CHLORIDE

	GEL;TRANSDERMAL						
	GELNIQUE						
+!	ABBVIE	10% (100MG/PACKET)		N022204	001	Jan 27, 2009	Apr CAHN
	SYRUP;ORAL						
	OXYBUTYNIN CHLORIDE						
AA	CHARTWELL RX	5MG/5ML		A075039	001	Jan 29, 1999	Mar CMFD
	Ø XTRIUM LABS INC	5MG/5ML		A074868	001	Feb 12, 1997	Mar CAHN
	TABLET;ORAL						
	OXYBUTYNIN CHLORIDE						
!	APPCO	2.5MG		A209025	002	Feb 07, 2023	Jan NFTG
AB	AVET LIFESCIENCES	5MG		A211682	001	May 10, 2019	Jun CTEC

OXYCODONE HYDROCHLORIDE

	CAPSULE;ORAL						
	OXYCODONE HYDROCHLORIDE						
@	DR REDDYS LABS SA	5MG		A203107	001	Jul 26, 2012	Apr CAHN
@	MAYNE PHARMA INC	5MG		A203107	001	Jul 26, 2012	Apr DISC
	SOLUTION;ORAL						
	OXYCODONE HYDROCHLORIDE						
@	DR REDDYS LABS SA	100MG/5ML		A204092	001	Jun 05, 2014	Apr CAHN
@	MAYNE PHARMA INC	100MG/5ML		A204092	001	Jun 05, 2014	Apr DISC
	TABLET;ORAL						
	OXYCODONE HYDROCHLORIDE						
@	DR REDDYS LABS SA	5MG		A091313	001	Feb 18, 2011	Apr CAHN
@		10MG		A091313	004	Apr 29, 2016	Apr CAHN
@		15MG		A091313	002	Feb 18, 2011	Apr CAHN
@		20MG		A091313	005	Apr 29, 2016	Apr CAHN
@		30MG		A091313	003	Feb 18, 2011	Apr CAHN

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

@ DASH PHARMS

6MG/ML

A091540 001 Sep 29, 2011 Feb CAHN

POWDER; INTRAVENOUS

PACLITAXEL

+! AM REGENT

100MG/VIAL

N211875 001 Jul 27, 2022 Apr CAHN

PALBOCICLIB

TABLET; ORAL

IBRANCE

>D> + PFIZER

75MG

N212436 001 Nov 01, 2019 Aug CFTG

>A> AB +

75MG

N212436 001 Nov 01, 2019 Aug CFTG

>D> +

100MG

N212436 002 Nov 01, 2019 Aug CFTG

>A> AB +

100MG

N212436 002 Nov 01, 2019 Aug CFTG

>D> +!

125MG

N212436 003 Nov 01, 2019 Aug CFTG

>A> AB +!

125MG

N212436 003 Nov 01, 2019 Aug CFTG

>A> PALBOCICLIB

>A> AB SYNTHON PHARMS INC

75MG

A215570 001 Aug 28, 2023 Aug NFTG

>A> AB

100MG

A215570 002 Aug 28, 2023 Aug NFTG

>A> AB

125MG

A215570 003 Aug 28, 2023 Aug NFTG

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

PALIPERIDONE

>A> AB ASCENT PHARMS INC

1.5MG

A216174 001 Aug 23, 2023 Aug NEWA

>A> AB

3MG

A216174 002 Aug 23, 2023 Aug NEWA

>A> AB

6MG

A216174 003 Aug 23, 2023 Aug NEWA

>A> AB

9MG

A216174 004 Aug 23, 2023 Aug NEWA

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

@ CIPLA

EQ 0.25MG BASE/5ML (EQ 0.05MG
BASE/ML)

A206396 001 Sep 19, 2018 Feb DISC

@ INGENUS PHARMS LLC

EQ 0.25MG BASE/5ML (EQ 0.05MG
BASE/ML)

A208789 001 May 22, 2020 Feb DISC

>A> AP NANJING KING-FRIEND

EQ 0.25MG BASE/5ML (EQ 0.05MG
BASE/ML)

A215861 001 Aug 14, 2023 Aug NEWA

PALOVAROTENE

>A> CAPSULE; ORAL

>A> SOHONOS

>A> + IPSEN INC

1MG

N215559 001 Aug 16, 2023 Aug NEWA

>A> +

1.5MG

N215559 002 Aug 16, 2023 Aug NEWA

>A> +

2.5MG

N215559 003 Aug 16, 2023 Aug NEWA

>A> +

5MG

N215559 004 Aug 16, 2023 Aug NEWA

>A> +!

10MG

N215559 005 Aug 16, 2023 Aug NEWA

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP2 DR REDDYS

30MG/10ML (3MG/ML)

A078156 001 Aug 19, 2008 May CTEC

AP2

90MG/10ML (9MG/ML)

A078156 003 Aug 19, 2008 May CTEC

AP1 +! HIKMA

30MG/10ML (3MG/ML)

N021113 001 Mar 04, 2002 May CTEC

AP1 +!

90MG/10ML (9MG/ML)

N021113 002 Mar 04, 2002 May CTEC

AP2 HOSPIRA

30MG/10ML (3MG/ML)

A075841 001 Jun 27, 2002 May CTEC

AP

30MG/10ML (3MG/ML)

A075841 001 Jun 27, 2002 Apr CHRS

AP2

90MG/10ML (9MG/ML)

A075841 003 Jun 27, 2002 May CTEC

AP

90MG/10ML (9MG/ML)

A075841 003 Jun 27, 2002 Apr CHRS

AP2 MYLAN LABS LTD

30MG/10ML (3MG/ML)

A078520 001 Oct 31, 2008 May CTEC

AP2

90MG/10ML (9MG/ML)

A078520 002 Oct 31, 2008 May CTEC

AP1 SAGENT PHARMS INC

30MG/10ML (3MG/ML)

A078373 001 Dec 23, 2008 May CTEC

AP1

90MG/10ML (9MG/ML)

A078373 002 Dec 23, 2008 May CTEC

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB

AJANTA PHARMA LTD

EQ 40MG BASE

A217416 001 Feb 09, 2023 Feb NEWA

AB

DEXCEL

EQ 40MG BASE

A216247 001 Jun 16, 2023 Jun NEWA

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PAROXETINE HYDROCHLORIDE

@ EPIC PHARMA LLC	EQ 12.5MG BASE	A213612	001	Aug 11, 2021	Jan CAHN
@	EQ 25MG BASE	A213612	002	Aug 11, 2021	Jan CAHN
@	EQ 37.5MG BASE	A213612	003	May 26, 2022	Jan CAHN

PAROXETINE MESYLATE

TABLET;ORAL

PEXEVA

+ @ SEBELA IRELAND LTD	EQ 10MG BASE
+ @	EQ 20MG BASE
+ @	EQ 30MG BASE

N021299	001	Jul 03, 2003	May DISC
N021299	002	Jul 03, 2003	May DISC
N021299	003	Jul 03, 2003	May DISC

PEGCETACOPLAN

SOLUTION;INTRAVITREAL

SYFOVRE

+! APELLIS PHARMS	15MG/0.1ML (15MG/0.1ML)
-------------------	-------------------------

N217171	001	Feb 17, 2023	Feb NEWA
---------	-----	--------------	----------

PEMETREXED DISODIUM

POWDER; INTRAVENOUS

PEMETREXED DISODIUM

AP	@ AMNEAL	EQ 100MG BASE/VIAL	A210047	002	May 08, 2023	Jun DISC
	@	EQ 100MG BASE/VIAL	A210047	002	May 08, 2023	Apr NEWA
AP	MEITHEAL	EQ 500MG BASE/VIAL	A210047	001	Aug 04, 2022	Jun DISC
AP		EQ 100MG BASE/VIAL	A215479	001	Dec 13, 2022	Jan CAHN
AP		EQ 500MG BASE/VIAL	A215479	002	Dec 13, 2022	Jan CAHN
AP		EQ 750MG BASE/VIAL	A215479	003	Dec 13, 2022	Jan CAHN
AP	@ MYLAN LABS LTD	EQ 1GM BASE/VIAL	A215479	004	Dec 13, 2022	Jan CAHN
AP	SOLUTION; INTRAVENOUS	EQ 500MG BASE/VIAL	A203628	001	Mar 10, 2023	Mar DISC
	PEMETREXED	EQ 500MG BASE/VIAL	A203628	001	Mar 10, 2023	Mar NEWA
AP	+! SHILPA	EQ 100MG/10ML BASE (10MG/ML)	N215179	001	May 22, 2023	May NEWA
	+!	EQ 500MG/50ML BASE (10MG/ML)	N215179	002	May 22, 2023	May NEWA
	+!	EQ 1GM/100ML BASE (10MG/ML)	N215179	003	May 22, 2023	May NEWA
	PEMETREXED DISODIUM					
AP	+! SANDOZ	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214657	001	May 26, 2022	Jan CMS1

PENCICLOVIR

CREAM;TOPICAL

PENCICLOVIR

AB	TORRENT	1%	A216981	001	Aug 07, 2023	Jul NEWA
----	---------	----	---------	-----	--------------	----------

PENTAMIDINE ISETHIONATE

FOR SOLUTION;INHALATION

PENTAMIDINE ISETHIONATE

AN	X-GEN PHARMS INC	300MG/VIAL	A206983	001	Jan 20, 2023	Jan NEWA
----	------------------	------------	---------	-----	--------------	----------

PENTOBARBITAL SODIUM

INJECTABLE;INJECTION

PENTOBARBITAL SODIUM

AP	PRAXGEN PHARMS	50MG/ML	A206677	001	Nov 27, 2017	Jul CAHN
----	----------------	---------	---------	-----	--------------	----------

PERAMPANEL

SUSPENSION;ORAL

FYCOMPRA

+! CATALYST PHARMS	0.5MG/ML
--------------------	----------

N208277	001	Apr 29, 2016	Feb CAHN
---------	-----	--------------	----------

TABLET;ORAL

FYCOMPRA

+! CATALYST PHARMS	2MG
+	4MG
+	6MG
+	8MG
+	10MG
+	12MG

N202834	001	Oct 22, 2012	Feb CAHN
N202834	002	Oct 22, 2012	Feb CAHN
N202834	003	Oct 22, 2012	Feb CAHN
N202834	004	Oct 22, 2012	Feb CAHN
N202834	005	Oct 22, 2012	Feb CAHN
N202834	006	Oct 22, 2012	Feb CAHN

PERFLUOROHEXYLOCTANE

SOLUTION/DROPS;OPHTHALMIC

MIEBO

+! BAUSCH AND LOMB INC 1.338GM/ML

N216675 001 May 18, 2023 May NEWA

PERMETHRIN

CREAM;TOPICAL

PERMETHRIN

AB DR REDDYS LABS EU 5%

A209732 001 Aug 01, 2023 Jul NEWA

PEXIDARTINIB HYDROCHLORIDE

CAPSULE;ORAL

TURALIO

+ @ DAIICHI SANKYO INC EQ 200MG BASE

N211810 001 Aug 02, 2019 Jun DISC

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENOXYBENZAMINE HYDROCHLORIDE

AB AUROBINDO PHARMA 10MG

A215600 001 May 08, 2023 Apr NEWA

AB RISING 10MG

A204551 001 Jun 20, 2023 Jun NEWA

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE

@ LANNETT 15MG

A087022 002 Jan 20, 2012 Feb DISC

@ 30MG

A087022 001 Feb 03, 1983 Feb DISC

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

IMMPHENITIV

+! HIKMA 0.5MG/5ML (0.1MG/ML)

N203826 004 Mar 09, 2023 May CAHN

+! 0.5MG/5ML (0.1MG/ML)

N203826 004 Mar 09, 2023 Mar NEWA

+! 1MG/10ML (0.1MG/ML)

N203826 005 Mar 09, 2023 May CAHN

+! 1MG/10ML (0.1MG/ML)

N203826 005 Mar 09, 2023 Mar NEWA

PHENYLEPHRINE HYDROCHLORIDE

AP2 AVET LIFESCIENCES 10MG/ML (10MG/ML)

A209968 001 Feb 28, 2023 Feb NEWA

AP2 BE PHARMS 10MG/ML (10MG/ML)

A217521 001 Jun 26, 2023 Jun NEWA

AP2 50MG/5ML (10MG/ML)

A217521 002 Jun 26, 2023 Jun NEWA

AP2 100MG/10ML (10MG/ML)

A217521 003 Jun 26, 2023 Jun NEWA

AP2 +! HIKMA 10MG/ML (10MG/ML)

N203826 001 Dec 20, 2012 May CAHN

+! 50MG/5ML (10MG/ML)

N203826 002 Jun 19, 2019 Jun CTEC

AP2 +! 50MG/5ML (10MG/ML)

N203826 002 Jun 19, 2019 May CAHN

+! 100MG/10ML (10MG/ML)

N203826 003 Jun 19, 2019 Jun CTEC

AP2 +! 100MG/10ML (10MG/ML)

N203826 003 Jun 19, 2019 May CAHN

SOLUTION/DROPS;OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

AT + AKORN 2.5%

N207926 001 Jan 15, 2015 Jul CHRS

AT + 10%

N207926 002 Jan 15, 2015 Jul CHRS

AT + ALCON 2.5%

N207926 001 Jan 15, 2015 Jul CAHN

AT + 10%

N207926 002 Jan 15, 2015 Jul CAHN

AT ! MANKIND PHARMA 2.5%

A216859 001 Sep 29, 2022 Jul CHRS

AT ! 10%

A216496 001 Jan 11, 2023 Jul CHRS

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE VC PLAIN

@ XTTRIUM LABS INC 5MG/5ML;6.25MG/5ML

A088897 001 Jan 04, 1985 Jan CAHN

PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE

SPRAY, METERED;OPHTHALMIC

MYDCOMBI

+! EYENOVIA 2.5%;1%

N215352 001 May 05, 2023 May NEWA

PHENYTOIN SODIUM

CAPSULE;ORAL

DIPHENYLAN SODIUM

@ CHARTWELL MOLECULAR 30MG PROMPT

A080857 001

Jul CAHN

@ 100MG PROMPT

A080857 002

Jul CAHN

EXTENDED PHENYTOIN SODIUM

@ MYLAN 100MG EXTENDED

A040298 001 Dec 28, 1998 Mar DISC

@ UNICHEM 100MG EXTENDED

A213834 001 Oct 13, 2022 Apr DISC

PHYTONADIONE

	TABLET;ORAL MEPHYTON + @ BAUSCH PHYTONADIONE	5MG	N010104 003	Feb DISC
AB	SCIEGEN PHARMS INC	5MG	A213329 001	Jul 28, 2023
AB	! ZYDUS	5MG	A210189 001	Feb 20, 2019

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION
PIPERACILLIN AND TAZOBACTAM

AP	SHANDONG	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A204959 001	Aug 10, 2018	Apr CAHN
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A204959 002	Aug 10, 2018	Apr CAHN
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A204959 003	Aug 10, 2018	Apr CAHN
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A217243 001	Apr 14, 2023	Apr NEWA
	ZOSYN IN PLASTIC CONTAINER				
+!	BAXTER HLTHCARE CORP	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N050750 001	Feb 24, 1998	Mar CAHN
+!		EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N050750 002	Feb 24, 1998	Mar CAHN
+!		EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N050750 003	Feb 24, 1998	Mar CAHN

PIRFENIDONE

CAPSULE;ORAL
PIRFENIDONE

AB	APOTEX	267MG	A212687 001	Jun 09, 2023	Jun NEWA
>A> AB	LUPIN LTD	267MG	A212404 001	Aug 28, 2023	Aug NEWA
	TABLET;ORAL PIRFENIDONE				
AB	APOTEX	267MG	A212709 001	May 31, 2023	May NEWA
AB		801MG	A212709 002	May 31, 2023	May NEWA
>A> AB	LUPIN LTD	267MG	A212403 001	Aug 23, 2023	Aug NEWA
>A> AB		801MG	A212403 002	Aug 23, 2023	Aug NEWA

PIROXICAM

CAPSULE;ORAL
PIROXICAM

>D> BX	UNICHEM	10MG	A208340 001	Apr 13, 2017	Aug CTEC
>A> AB		10MG	A208340 001	Apr 13, 2017	Aug CTEC
>D> BX		20MG	A208340 002	Apr 13, 2017	Aug CTEC
>A> AB		20MG	A208340 002	Apr 13, 2017	Aug CTEC

PIRTOBRUTINIB

TABLET;ORAL
JAYPIRCA

+ ! LOXO ONCOL	50MG	N216059 001	Jan 27, 2023	Jan NEWA
+ !	100MG	N216059 002	Jan 27, 2023	Jan NEWA

PITAVASTATIN CALCIUM

TABLET;ORAL
PITAVASTATIN CALCIUM

AB	ZYDUS PHARMS	EQ 1MG BASE	A206047 001	Feb 22, 2023	Feb NEWA
AB		EQ 2MG BASE	A206047 002	Feb 22, 2023	Feb NEWA
AB		EQ 4MG BASE	A206047 003	Feb 22, 2023	Feb NEWA

PLERIXAFOR

SOLUTION;SUBCUTANEOUS
MOZOBIL

AP	+ ! GENZYME PLERIXAFOR	24MG/1.2ML (20MG/ML)	N022311 001	Dec 15, 2008	Jul CFTG
AP	AMNEAL	24MG/1.2ML (20MG/ML)	A215334 001	Jul 24, 2023	Jul NFTG
AP	DR REDDYS	24MG/1.2ML (20MG/ML)	A205182 001	Jul 24, 2023	Jul NFTG
AP	EUGIA PHARMA	24MG/1.2ML (20MG/ML)	A213672 001	Jul 24, 2023	Jul NFTG
AP	KINDOS	24MG/1.2ML (20MG/ML)	A215698 001	Jul 24, 2023	Jul NFTG
AP	MSN	24MG/1.2ML (20MG/ML)	A211901 001	Jul 24, 2023	Jul NFTG
AP	TEVA PHARMS USA INC	24MG/1.2ML (20MG/ML)	A205197 001	Jul 24, 2023	Jul NFTG
AP	ZYDUS PHARMS	24MG/1.2ML (20MG/ML)	A208980 001	Jul 26, 2023	Jul NEWA

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

POLYTRIM

+ @ ALLERGAN 10,000 UNITS/ML;EQ 1MG BASE/ML
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT ! SANDOZ 10,000 UNITS/ML;EQ 1MG BASE/ML

N050567 001 Oct 20, 1988 Feb DISC
A064211 001 Apr 13, 1998 Feb CHRSPOMALIDOMIDE

CAPSULE;ORAL

POMALYST

+ BRISTOL 1MG
+ 2MG
+ 3MG
+! 4MGN204026 001 Feb 08, 2013 Jan CAHN
N204026 002 Feb 08, 2013 Jan CAHN
N204026 003 Feb 08, 2013 Jan CAHN
N204026 004 Feb 08, 2013 Jan CAHNPONATINIB HYDROCHLORIDE

TABLET;ORAL

ICLUSIG

AB + TAKEDA PHARMS USA EQ 15MG BASE

N203469 001 Dec 14, 2012 Jul CFTG

AB +! EQ 45MG BASE

N203469 002 Dec 14, 2012 Jul CFTG

PONATINIB HYDROCHLORIDE

AB APOTEX EQ 15MG BASE

A215893 001 Jul 14, 2023 Jul NFTG

AB EQ 45MG BASE

A215893 002 Jul 14, 2023 Jul NFTG

POSACONAZOLE

TABLET, DELAYED RELEASE;ORAL

POSACONAZOLE

@ ACTAVIS LABS FL INC 100MG

A207355 001 Nov 30, 2022 May DISC

AB I 3 PHARMS 100MG

A216488 001 Aug 28, 2023 Aug NEWA

AB WELDING 100MG

A216326 001 Jun 20, 2023 Jun NEWA

AB WESTMINSTER PHARMS 100MG

A216326 001 Jun 20, 2023 Jul CAHN

POTASSIUM ACETATE

INJECTABLE;INJECTION

POTASSIUM ACETATE

AP EXELA PHARMA 2MEO/ML

A212692 001 Oct 20, 2021 Feb CMFD

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

@ CHARTWELL MOLECULAR 8MEO

A204210 001 Mar 28, 2016 Jul CAHN

@ 10MEO

A204210 002 Mar 28, 2016 Jul CAHN

FOR SOLUTION;ORAL

POTASSIUM CHLORIDE

AA GRANULES 20MEO

A213467 001 Jan 27, 2022 Jul CMFD

AA NOVITIUM PHARMA 20MEO

A212816 001 Jul 12, 2023 Jun NEWA

INJECTABLE;INJECTION

POTASSIUM CHLORIDE

>A> AP NEXUS PHARMS 2MEO/ML

A217704 001 Aug 14, 2023 Aug NEWA

SOLUTION;ORAL

POTASSIUM CHLORIDE

AA BELCHER 20MEO/15ML

A216156 001 Mar 07, 2023 Feb NEWA

AA 40MEO/15ML

A216156 002 Mar 07, 2023 Feb NEWA

@ STRIDES PHARMA 40MEO/15ML

A211665 001 Nov 17, 2022 May DISC

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AB1 RUBICON 10MEO

A216321 001 Jun 16, 2023 Jun NEWA

AB1 15MEO

A216321 002 Jun 16, 2023 Jun NEWA

AB1 20MEO

A216321 003 Jun 16, 2023 Jun NEWA

AB3 TWI PHARMS 10MEO

A209688 001 Jan 12, 2018 Apr CAHN

AB3 ! 20MEO

A209688 002 Jan 12, 2018 Apr CAHN

AB3 ! VITRUVIAS THERAP 20MEO

A209688 002 Jan 12, 2018 Feb CHRS

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

PRASUGREL

AB AMNEAL PHARMS EQ 5MG BASE

A205913 001 Jun 19, 2018 Mar CTEC

AB 10MG BASE

A205913 002 Jun 19, 2018 Mar CTEC

@ LUPIN LTD EQ 5MG BASE

A205930 001 Jan 09, 2023 Feb DISC

@ EQ 10MG BASE

A205930 002 Jan 09, 2023 Feb DISC

TABLET;ORAL PRASUGREL HYDROCHLORIDE						
>A> AB	UNICHEM	EQ 5MG BASE	A213315	001	Aug 28, 2023	Aug NEWA
>A> AB		EQ 10MG BASE	A213315	002	Aug 28, 2023	Aug NEWA
<u>PRAVASTATIN SODIUM</u>						
TABLET;ORAL PRAVASTATIN SODIUM						
AB	CHARTWELL RX	10MG	A077917	001	Jan 08, 2008	May CAHN
AB		20MG	A077917	002	Jan 08, 2008	May CAHN
AB		40MG	A077917	003	Jan 08, 2008	May CAHN
AB		80MG	A077917	004	Jan 08, 2008	May CAHN
<u>PRAZOSIN HYDROCHLORIDE</u>						
CAPSULE;ORAL PRAZOSIN HYDROCHLORIDE						
AB	ALEMBIC	EQ 1MG BASE	A217268	001	Mar 06, 2023	Feb NEWA
AB		EQ 2MG BASE	A217268	002	Mar 06, 2023	Feb NEWA
AB		EQ 5MG BASE	A217268	003	Mar 06, 2023	Feb NEWA
AB	AUROBINDO PHARMA LTD	EQ 1MG BASE	A213052	001	Mar 31, 2023	Mar NEWA
AB		EQ 2MG BASE	A213052	002	Mar 31, 2023	Mar NEWA
AB		EQ 5MG BASE	A213052	003	Mar 31, 2023	Mar NEWA
<u>PREDNISOLONE</u>						
SYRUP;ORAL PREDNISOLONE						
AA	AKORN	15MG/5ML	A040401	001	Feb 27, 2003	Jun CHRS
AA	! CHARTWELL RX	15MG/5ML	A040323	001	May 13, 1999	Jun CHRS
	@ XTTRIUM LABS INC	15MG/5ML	A040313	001	Sep 10, 2003	Jul DISC
AA		15MG/5ML	A040313	001	Sep 10, 2003	Jan CAHN
TABLET;ORAL PREDNISOLONE						
AB	AUROBINDO PHARMA LTD	5MG	A215673	001	Mar 17, 2023	Mar NEWA
BX	CHARTWELL MOLECULAR	5MG	A080531	002		May CMFD
AB	+! WATSON LABS	5MG	A080354	001		Mar CTEC
<u>PREDNISOLONE ACETATE</u>						
SUSPENSION/DROPS;OPHTHALMIC PRED FORTE						
AB	+! ABBVIE	1%	N017011	001		Jan CAHN
	PRED MILD					
	+! ABBVIE	0.12%	N017100	001		Feb CAHN
<u>PREDNISOLONE SODIUM PHOSPHATE</u>						
SOLUTION;ORAL PREDNISOLONE SODIUM PHOSPHATE						
AA	EDENBRIDGE PHARMS	EQ 15MG BASE/5ML	A203559	003	Feb 06, 2023	Jan NEWA
AA		EQ 15MG BASE/5ML	A203559	003	Feb 06, 2023	Jan NEWA
AA		EQ 25MG BASE/5ML	A203559	004	Feb 06, 2023	Jan NEWA
AA		EQ 25MG BASE/5ML	A203559	004	Feb 06, 2023	Jan NEWA
AA	! MISSION PHARMA	EQ 25MG BASE/5ML	A091396	001	Sep 13, 2010	Jan CTEC
AA	! PHARM ASSOC	EQ 15MG BASE/5ML	A076913	001	Apr 25, 2005	Jul CHRS
	@ XTTRIUM LABS INC	EQ 5MG BASE/5ML	A075099	001	Jun 28, 2002	Jul DISC
AA		EQ 5MG BASE/5ML	A075099	001	Jun 28, 2002	Jan CAHN
	@	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Jul DISC
AA	!	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Jan CAHN
<u>PREDNISONE</u>						
SOLUTION;ORAL PREDNISONE						
	@ XTTRIUM LABS INC	5MG/5ML	A089726	001	Aug 02, 1988	Jan CAHN
TABLET;ORAL PREDNISONE						
AB	+! HIKMA	2.5MG	A087801	001	Apr 22, 1982	Jan CRLD
AB	+!	5MG	A080352	001		Jan CRLD
AB	+!	50MG	A084283	001		Jan CRLD
AB	JUBILANT CADISTA	2.5MG	A040362	004	Apr 17, 2023	Apr NEWA
AB		50MG	A040362	005	Apr 17, 2023	Apr NEWA

PREGABALIN

CAPSULE;ORAL

PREGABALIN

AB	ACI	25MG	A215755	001	Apr 26, 2023	Apr NEWA
AB		50MG	A215755	002	Apr 26, 2023	Apr NEWA
AB		75MG	A215755	003	Apr 26, 2023	Apr NEWA
AB		100MG	A215755	004	Apr 26, 2023	Apr NEWA
AB		150MG	A215755	005	Apr 26, 2023	Apr NEWA
AB		200MG	A215755	006	Apr 26, 2023	Apr NEWA
AB		225MG	A215755	007	Apr 26, 2023	Apr NEWA
AB		300MG	A215755	008	Apr 26, 2023	Apr NEWA
AB	AUROBINDO PHARMA	25MG	A205321	001	Mar 29, 2023	Mar NEWA
AB		50MG	A205321	002	Mar 29, 2023	Mar NEWA
AB		75MG	A205321	003	Mar 29, 2023	Mar NEWA
AB		100MG	A205321	004	Mar 29, 2023	Mar NEWA
AB		150MG	A205321	005	Mar 29, 2023	Mar NEWA
AB		200MG	A205321	006	Mar 29, 2023	Mar NEWA
AB		225MG	A205321	007	Mar 29, 2023	Mar NEWA
AB		300MG	A205321	008	Mar 29, 2023	Mar NEWA
AB	CADILA PHARMS LTD	25MG	A206452	001	Jul 12, 2023	Jun NEWA
AB		50MG	A206452	002	Jul 12, 2023	Jun NEWA
AB		75MG	A206452	003	Jul 12, 2023	Jun NEWA
AB		100MG	A206452	004	Jul 12, 2023	Jun NEWA
AB		150MG	A206452	005	Jul 12, 2023	Jun NEWA
AB		200MG	A206452	006	Jul 12, 2023	Jun NEWA
AB		225MG	A206452	007	Jul 12, 2023	Jun NEWA
AB		300MG	A206452	008	Jul 12, 2023	Jun NEWA
AB	CHARTWELL RX	50MG	A212865	001	Mar 20, 2020	Mar CAHN
AB		75MG	A212865	002	Mar 20, 2020	Mar CAHN
AB		100MG	A212865	003	Mar 20, 2020	Mar CAHN
AB		150MG	A212865	004	Mar 20, 2020	Mar CAHN
>A> AB	CREEKWOOD PHARMS	25MG	A213423	001	Mar 23, 2020	Aug CAHN
>A> AB		50MG	A213423	002	Mar 23, 2020	Aug CAHN
>A> AB		75MG	A213423	003	Mar 23, 2020	Aug CAHN
>A> AB		100MG	A213423	004	Mar 23, 2020	Aug CAHN
>A> AB		150MG	A213423	005	Mar 23, 2020	Aug CAHN
>A> AB		200MG	A213423	006	Mar 23, 2020	Aug CAHN
>A> AB		225MG	A213423	007	Mar 23, 2020	Aug CAHN
>A> AB		300MG	A213423	008	Mar 23, 2020	Aug CAHN
>D> AB	HIKAL	25MG	A213423	001	Mar 23, 2020	Aug CAHN
>D> AB		50MG	A213423	002	Mar 23, 2020	Aug CAHN
>D> AB		75MG	A213423	003	Mar 23, 2020	Aug CAHN
>D> AB		100MG	A213423	004	Mar 23, 2020	Aug CAHN
>D> AB		150MG	A213423	005	Mar 23, 2020	Aug CAHN
>D> AB		200MG	A213423	006	Mar 23, 2020	Aug CAHN
>D> AB		225MG	A213423	007	Mar 23, 2020	Aug CAHN
>D> AB		300MG	A213423	008	Mar 23, 2020	Aug CAHN
AB	YILING	75MG	A210891	001	Sep 30, 2019	Mar CAHN
AB		300MG	A210891	002	Sep 30, 2019	Mar CAHN
AB	@ ZYDUS PHARMS	25MG	A206752	001	Dec 09, 2022	May DISC
AB	@	50MG	A206752	002	Dec 09, 2022	May DISC
AB	@	75MG	A206752	003	Dec 09, 2022	May DISC
AB	@	100MG	A206752	004	Dec 09, 2022	May DISC
AB	@	150MG	A206752	005	Dec 09, 2022	May DISC
AB	@	200MG	A206752	006	Dec 09, 2022	May DISC
AB	@	225MG	A206752	007	Dec 09, 2022	May DISC
AB	@	300MG	A206752	008	Dec 09, 2022	May DISC
SOLUTION;ORAL						
PREGABALIN						
AA	PATRIN	20MG/ML	A212604	001	Feb 18, 2022	Jan CAHN
TABLET, EXTENDED RELEASE;ORAL						
PREGABALIN						
>A> AB	EPIC PHARMA LLC	82.5MG	A214496	001	Jun 01, 2023	Aug CAHN
>A> AB		165MG	A214496	002	Jun 01, 2023	Aug CAHN
>A> AB		330MG	A214496	003	Jun 01, 2023	Aug CAHN
>A> AB	@ SCIEGEN PHARMS INC	82.5MG	A215675	001	Sep 14, 2022	May DISC
>A> AB	@	165MG	A215675	002	Sep 14, 2022	May DISC
>A> AB	@	330MG	A215675	003	Sep 14, 2022	May DISC
>D> AB	SINOATHERAPEUTICS INC	82.5MG	A214496	001	Jun 01, 2023	Aug CAHN
>D> AB		82.5MG	A214496	001	Jun 01, 2023	May NEWA
>D> AB		165MG	A214496	002	Jun 01, 2023	Aug CAHN
>D> AB		165MG	A214496	002	Jun 01, 2023	May NEWA

**TABLET, EXTENDED RELEASE;ORAL
PREGABALIN**

>D>	AB		330MG	A214496	003	Jun 01, 2023	Aug CAHN
	AB		330MG	A214496	003	Jun 01, 2023	May NEWA
	@	ZYDUS PHARMS	82.5MG	A215577	001	Aug 26, 2022	Jan DISC
	@		165MG	A215577	002	Aug 26, 2022	Jan DISC
	@		330MG	A215577	003	Aug 26, 2022	Jan DISC

PRIMIDONE

TABLET;ORAL
PRIMIDONE
RUBICON 125MG

A214896 003 Dec 28, 2022 May CTEC

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
PROCAINAMIDE HYDROCHLORIDE
AP ! HOSPIRA 500MG/ML

A089070 001 Feb 12, 1986 Feb CTEC

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE
AP SAGENT EQ 5MG BASE/ML

A040540 001 May 28, 2004 Jul CAHN

PROCHLORPERAZINE MALEATE

TABLET;ORAL
PROCHLORPERAZINE MALEATE

AB	AMNEAL	EQ 5MG BASE	A216598	001	Apr 17, 2023	Apr NEWA
AB		EQ 10MG BASE	A216598	002	Apr 17, 2023	Apr NEWA
AB	BIONPHARMA	EQ 5MG BASE	A217478	001	Apr 04, 2023	Mar NEWA
AB		EQ 10MG BASE	A217478	002	Apr 04, 2023	Mar NEWA
AB	GLENMARK PHARMS LTD	EQ 5MG BASE	A216595	001	Mar 17, 2023	Mar NEWA
AB		EQ 10MG BASE	A216595	002	Mar 17, 2023	Mar NEWA

PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL
PROMETHAZINE HYDROCHLORIDE
@ AMNEAL PHARMS 6.25MG/5ML

A040882 001 Dec 30, 2009 Jun DISC

TABLET;ORAL
PROMETHAZINE HYDROCHLORIDE
@ AUROBINDO PHARMA USA 12.5MG
@ 25MG
@ 50MG

A091054 001 Aug 30, 2011 Apr CAHN
A091054 002 Aug 30, 2011 Apr CAHN
A091054 003 Aug 30, 2011 Apr CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
PROPAFENONE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	225MG	A213096	001	Feb 21, 2023	Feb NEWA
AB		325MG	A213096	002	Feb 21, 2023	Feb NEWA
AB		425MG	A213096	003	Feb 21, 2023	Feb NEWA

PROPARACAINe HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
PROPARACAINe HYDROCHLORIDE

AT	AKORN	0.5%	A040277	001	Mar 16, 2000	Jul CHRS
AT	! BAUSCH AND LOMB	0.5%	A040074	001	Sep 29, 1995	Jul CHRS

PROPOFOL

INJECTABLE; INJECTION
PROPOFOL
AB AVET LIFESCIENCES 10MG/ML

A206408 001 Oct 12, 2021 Jan CAHN

PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL
PROPRANOLOL HYDROCHLORIDE
AB ! IMPAX LABS INC 80MG
AB WATSON LABS 80MG

A071976 001 Apr 06, 1988 Jun CHRS
A070178 001 May 13, 1986 Jun CHRS

PROPYLTHIOURACIL

TABLET;ORAL
PROPYLTHIOURACIL

AB	+!	DAVA PHARMS INC	50MG	N 006188	001	Apr	CTEC
AB		MACLEODS PHARMS LTD	50MG	A 208867	001	May 10,	2023 Apr NEWA

QUININE SULFATE

CAPSULE;ORAL
QUININE SULFATE

@	AUROBINDO PHARMA USA	324MG	A 202581	001	Dec 14,	2012 May CAHN
---	----------------------	-------	----------	-----	---------	---------------

QUIZARTINIB DIHYDROCHLORIDE

TABLET;ORAL
VANFLYTA

+	DAIICHI SANKYO INC	EQ 17.7MG BASE	N 216993	001	Jul 20,	2023 Jul NEWA
+!		EQ 26.5MG BASE	N 216993	002	Jul 20,	2023 Jul NEWA

RAMELTEON

TABLET;ORAL
RAMELTEON

AB		AUROBINDO PHARMA LTD	8MG	A 215972	001	Jul 10,	2023 Jun NEWA
AB		INNOGENIX	8MG	A 215435	001	Aug 24,	2022 May CMFD
	@		8MG	A 215435	001	Aug 24,	2022 Mar DISC
AB			8MG	A 215435	001	Aug 24,	2022 Jan CAHN
AB		MICRO LABS	8MG	A 215243	001	Feb 09,	2023 Feb NEWA

RAMIPRIL

CAPSULE;ORAL
RAMIPRIL

AB		COREPHARMA	1.25MG	A 079116	001	Jun 20,	2008 Feb CAHN
AB			2.5MG	A 079116	002	Jun 20,	2008 Feb CAHN
AB			5MG	A 079116	003	Jun 20,	2008 Feb CAHN
AB			10MG	A 079116	004	Jun 20,	2008 Feb CAHN

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION
RANITIDINE HYDROCHLORIDE

@	HIKMA	EQ 25MG BASE/ML	A 074777	001	Mar 02,	2005 May DISC
@		EQ 25MG BASE/ML	A 077458	001	Feb 16,	2006 May DISC
@	ZYDUS PHARMS USA INC	EQ 25MG BASE/ML	A 091534	001	Feb 22,	2013 May DISC
+ @	PAI HOLDINGS PHARM	EQ 25MG BASE/ML	N 019090	001	Oct 19,	1984 May DISC

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL
RANEXA

+ @	GILEAD	500MG	N 021526	002	Jan 27,	2006 Jan DISC
+ @		1GM	N 021526	001	Feb 12,	2007 Jan DISC

RANOLAZINE

>D>	AB	GRAVITI PHARMS	500MG	A 212889	001	Jan 28,	2021 Aug CAHN
>D>	AB		1GM	A 212889	002	Jan 28,	2021 Aug CAHN
	AB	PIRAMAL HLTHCARE UK	500MG	A 213085	001	Jul 25,	2023 Jul NEWA
	AB		1GM	A 213085	002	Jul 25,	2023 Jul NEWA
>A>	AB	RISING	500MG	A 212889	001	Jan 28,	2021 Aug CAHN
>A>	AB		1GM	A 212889	002	Jan 28,	2021 Aug CAHN
AB	!	SUN PHARM	1GM	A 211707	002	May 28,	2019 Jan CHRS
AB		UNICHEM	500MG	A 213083	001	Mar 16,	2023 Mar NEWA
AB			1GM	A 213083	002	Mar 16,	2023 Mar NEWA

REGADENOSON

SOLUTION;INTRAVENOUS
REGADENOSON

AP		BAXTER HLTHCARE CORP	0.4MG/5ML (0.08MG/ML)	A 217455	001	May 23,	2023 May NEWA
AP		HIKMA	0.4MG/5ML (0.08MG/ML)	A 215827	001	Feb 02,	2023 Jan NEWA
AP		IMS LTD	0.4MG/5ML (0.08MG/ML)	A 214252	001	May 23,	2022 Apr CMFD

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

AB	MACLEODS PHARMS LTD	0.5MG	A207209	001	Mar 22, 2023	Mar NEWA
AB		1MG	A207209	002	Mar 22, 2023	Mar NEWA
AB		2MG	A207209	003	Mar 22, 2023	Mar NEWA

REZAFUNGIN ACETATE

POWDER; INTRAVENOUS

REZZAYO

+! CIDARA THERAPS EQ 200MG BASE/VIAL

N217417 001 Mar 22, 2023 Mar NEWA

RIBOFLAVIN 5'-PHOSPHATE

SOLUTION/DROPS;OPHTHALMIC

PHOTREXA

+! GLAUkos 0.146%

N203324 001 Apr 15, 2016 Jun CAIN

PHOTREXA VISCOSUS IN DEXTRAN 20%

+! GLAUkos 0.146%

N203324 002 Apr 15, 2016 Jun CAIN

RIMEGEPANT SULFATE

TABLET, ORALLY DISINTEGRATING;ORAL

NURTEC ODT

+! PFIZER EQ 75MG BASE

N212728 001 Feb 27, 2020 Feb CAHN

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

RYKINDO

+! SHANDONG LUYE 12.5MG

N212849 001 Jan 13, 2023 Jan NEWA

+! 25MG

N212849 002 Jan 13, 2023 Jan NEWA

+! 37.5MG

N212849 003 Jan 13, 2023 Jan NEWA

+! 50MG

N212849 004 Jan 13, 2023 Jan NEWA

SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

UZEDY

+ TEVA 50MG/0.14ML (50MG/0.14ML)

N213586 001 Apr 28, 2023 Apr NEWA

+ 75MG/0.21ML (75MG/0.21ML)

N213586 002 Apr 28, 2023 Apr NEWA

+ 100MG/0.28ML (100MG/0.28ML)

N213586 003 Apr 28, 2023 Apr NEWA

+ 125MG/0.35ML (125MG/0.35ML)

N213586 004 Apr 28, 2023 Apr NEWA

+ 150MG/0.42ML (150MG/0.42ML)

N213586 005 Apr 28, 2023 Apr NEWA

+ 200MG/0.56ML (200MG/0.56ML)

N213586 006 Apr 28, 2023 Apr NEWA

+! 250MG/0.7ML (250MG/0.7ML)

N213586 007 Apr 28, 2023 Apr NEWA

TABLET;ORAL

RISPERIDONE

@ DASH PHARMS 0.25MG

A076288 001 Sep 15, 2008 Feb CAHN

@ 0.5MG

A076288 002 Sep 15, 2008 Feb CAHN

@ 1MG

A076288 003 Sep 15, 2008 Feb CAHN

@ 2MG

A076288 004 Sep 15, 2008 Feb CAHN

@ 3MG

A076288 005 Sep 15, 2008 Feb CAHN

@ 4MG

A076288 006 Sep 15, 2008 Feb CAHN

>D> AB RENATA 0.25MG

A078707 001 Dec 29, 2008 Aug CAHN

>D> AB 0.5MG

A078707 002 Dec 29, 2008 Aug CAHN

>D> AB 1MG

A078707 003 Dec 29, 2008 Aug CAHN

>D> AB 2MG

A078707 004 Dec 29, 2008 Aug CAHN

>D> AB 3MG

A078707 005 Dec 29, 2008 Aug CAHN

>D> AB 4MG

A078707 006 Dec 29, 2008 Aug CAHN

>A> AB WESTMINSTER PHARMS 0.25MG

A078707 001 Dec 29, 2008 Aug CAHN

>A> AB 0.5MG

A078707 002 Dec 29, 2008 Aug CAHN

>A> AB 1MG

A078707 003 Dec 29, 2008 Aug CAHN

>A> AB 2MG

A078707 004 Dec 29, 2008 Aug CAHN

>A> AB 3MG

A078707 005 Dec 29, 2008 Aug CAHN

>A> AB 4MG

A078707 006 Dec 29, 2008 Aug CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

@ DASH PHARMS 0.25MG

A091537 006 Feb 12, 2013 Feb CAHN

@ 0.5MG

A091537 001 Mar 30, 2011 Feb CAHN

@ 1MG

A091537 002 Mar 30, 2011 Feb CAHN

@ 2MG

A091537 003 Mar 30, 2011 Feb CAHN

@ 3MG

A091537 004 Mar 30, 2011 Feb CAHN

@ 4MG

A091537 005 Mar 30, 2011 Feb CAHN

RITLEGITINIB TOSYLATE

CAPSULE;ORAL

LITFULO

+! PFIZER

EQ 50MG BASE

N215830 001 Jun 23, 2023 Jun NEWA

RITONAVIR

SOLUTION;ORAL

NORVIR

+ @ ABBVIE

80MG/ML

N020659 001 Mar 01, 1996 Feb DISC

RIZATRIPTAN BENZOATE

FILM;ORAL

RIZAFILM

+! INTEGENX CORP

EQ 10MG BASE

N205394 001 Apr 14, 2023 Apr NEWA

TABLET;ORAL

RIZATRIPTAN BENZOATE

AB CHARTWELL RX

EQ 5MG BASE

A077526 001 Mar 26, 2013 May CAHN

AB

EQ 10MG BASE

A077526 002 Mar 26, 2013 May CAHN

>A> AB

CREEKWOOD PHARMS

EQ 5MG BASE

A202047 001 Dec 31, 2012 Aug CAHN

>A> AB

EQ 10MG BASE

A202047 002 Dec 31, 2012 Aug CAHN

>D> AB

PHARMGEN

EQ 5MG BASE

A202047 001 Dec 31, 2012 Aug CAHN

>D> AB

EQ 10MG BASE

A202047 002 Dec 31, 2012 Aug CAHN

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

AP CAPLIN

50MG/5ML (10MG/ML)

A216234 001 Mar 02, 2023 Feb NEWA

AP

100MG/10ML (10MG/ML)

A216234 002 Mar 02, 2023 Feb NEWA

AP HIKMA

50MG/5ML (10MG/ML)

A217034 001 May 24, 2023 May NEWA

>D> AP

HONG KONG

50MG/5ML (10MG/ML)

A213453 001 May 08, 2023 Aug CAHN

AP

50MG/5ML (10MG/ML)

A213453 001 May 08, 2023 Apr NEWA

>D> AP

100MG/10ML (10MG/ML)

A213453 002 May 08, 2023 Aug CAHN

AP

100MG/10ML (10MG/ML)

A213453 002 May 08, 2023 Apr NEWA

>A> AP

MEITHEAL

50MG/5ML (10MG/ML)

A213453 001 May 08, 2023 Aug CAHN

>A> AP

100MG/10ML (10MG/ML)

A213453 002 May 08, 2023 Aug CAHN

ROFLUMILAST

TABLET;ORAL

ROFLUMILAST

AB ALKEM LABS LTD

250MCG

A212490 001 Apr 18, 2023 Apr NEWA

AB

500MCG

A212490 002 Apr 18, 2023 Apr NEWA

AB

AUROBINDO PHARMA LTD

500MCG

A213298 001 Apr 17, 2023 Apr NEWA

AB

HETERO LABS LTD III

250MCG

A208213 002 Apr 18, 2023 Apr NEWA

AB

MICRO LABS

250MCG

A208180 002 Apr 18, 2023 Apr NEWA

AB

STRIDES PHARMA

250MCG

A208247 002 Jun 20, 2023 Jun NEWA

AB

ZYDUS PHARMS

250MCG

A208303 002 Apr 18, 2023 Apr NEWA

ROMIDEPSEN

POWDER;INTRAVENOUS

ISTODAX

AP +! BRISTOL-MYERS

10MG/VIAL

N022393 001 Nov 05, 2009 Jul CAHN

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB CHARTWELL RX

EQ 0.25MG BASE

A079050 001 May 29, 2008 Jun CAHN

AB

EQ 0.5MG BASE

A079050 002 May 29, 2008 Jun CAHN

AB

EQ 1MG BASE

A079050 003 May 29, 2008 Jun CAHN

AB

EQ 2MG BASE

A079050 004 May 29, 2008 Jun CAHN

AB

EQ 3MG BASE

A079050 005 May 29, 2008 Jun CAHN

AB

EQ 4MG BASE

A079050 006 May 29, 2008 Jun CAHN

AB

EQ 5MG BASE

A079050 007 May 29, 2008 Jun CAHN

@ MYLAN

EQ 0.25MG BASE

A078881 001 May 05, 2008 May DISC

@

EQ 0.5MG BASE

A078881 002 May 05, 2008 May DISC

@

EQ 1MG BASE

A078881 003 May 05, 2008 May DISC

@

EQ 2MG BASE

A078881 004 May 05, 2008 May DISC

@

EQ 3MG BASE

A078881 005 May 05, 2008 May DISC

@

EQ 4MG BASE

A078881 006 May 05, 2008 May DISC

@

EQ 5MG BASE

A078881 007 May 19, 2008 Mar DISC

TABLET, EXTENDED RELEASE;ORAL
ROPINIROLE HYDROCHLORIDE

AB	CHARTWELL RX	EQ 2MG BASE	A091395	001	Aug 27, 2012	Jun CAHN
AB		EQ 4MG BASE	A091395	002	Aug 27, 2012	Jun CAHN
AB		EQ 6MG BASE	A091395	003	Aug 27, 2012	Jun CAHN
AB		EQ 8MG BASE	A091395	004	Aug 27, 2012	Jun CAHN
AB		EQ 12MG BASE	A091395	005	Aug 27, 2012	Jun CAHN

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION
ROPIVACAINE HYDROCHLORIDE

AP	AMNEAL	200MG/100ML (2MG/ML)	A216605	001	Mar 08, 2023	Feb NEWA
AP		400MG/200ML (2MG/ML)	A216605	002	Mar 08, 2023	Feb NEWA
AP		500MG/100ML (5MG/ML)	A216605	003	Mar 07, 2023	Feb NEWA
AP		1GM/200ML (5MG/ML)	A216605	004	Mar 07, 2023	Feb NEWA

ROSIGLITAZONE MALEATE

	TABLET;ORAL					
	AVANDIA					
+ @	WOODWARD	EQ 2MG BASE	N021071	002	May 25, 1999	Jun DISC
+ @		EQ 4MG BASE	N021071	003	May 25, 1999	Jun DISC

ROSUVASTATIN CALCIUM

	TABLET;ORAL					
	ROSVASTATIN CALCIUM					
AB	UMEDICA LABS PVT LTD	EQ 5MG BASE	A207626	001	Apr 09, 2019	Jul CMFD
AB		EQ 10MG BASE	A207626	002	Apr 09, 2019	Jul CMFD
AB		EQ 20MG BASE	A207626	003	Apr 09, 2019	Jul CMFD
AB		EQ 40MG BASE	A207626	004	Apr 09, 2019	Jul CMFD

RUCAPARIB CAMSYLATE

	TABLET;ORAL					
	RUBRACA					
+ @	ZR PHARMA	EQ 200MG BASE	N209115	001	Dec 19, 2016	May CAHN
+		EQ 250MG BASE	N209115	003	May 01, 2017	May CAHN
+!		EQ 300MG BASE	N209115	002	Dec 19, 2016	May CAHN

RUFINAMIDE

	SUSPENSION;ORAL					
	RUFINAMIDE					
AB	CHARTWELL RX	40MG/ML	A214009	001	Nov 07, 2022	May CAHN
	TABLET;ORAL					
	RUFINAMIDE					
AB	AUROBINDO PHARMA	200MG	A217230	001	Jun 16, 2023	Jun NEWA
AB		400MG	A217230	002	Jun 16, 2023	Jun NEWA
AB	MICRO LABS	200MG	A216688	001	May 15, 2023	May NEWA
AB		400MG	A216688	002	May 15, 2023	May NEWA

SAFINAMIDE MESYLATE

	TABLET;ORAL					
	SAFINAMIDE MESYLATE					
AB	@ AUROBINDO PHARMA	EQ 50MG BASE	A215902	001	Jun 14, 2023	Jun DISC
	@	EQ 50MG BASE	A215902	001	Jun 14, 2023	Jun NFTG
AB	@	EQ 100MG BASE	A215902	002	Jun 14, 2023	Jun DISC
	XADAGO	EQ 100MG BASE	A215902	002	Jun 14, 2023	Jun NFTG
AB	+ MDD US	EQ 50MG BASE	N207145	001	Mar 21, 2017	Jun CTEC
AB	+	EQ 50MG BASE	N207145	001	Mar 21, 2017	Jun CFTG
	+!	EQ 100MG BASE	N207145	002	Mar 21, 2017	Jun CTEC
AB	+!	EQ 100MG BASE	N207145	002	Mar 21, 2017	Jun CFTG

SAXAGLIPTIN HYDROCHLORIDE

	TABLET;ORAL					
	ONGLYZA					
AB	+ ASTRazeneca AB	EQ 2.5MG BASE	N022350	001	Jul 31, 2009	Jul CFTG
AB	+!	EQ 5MG BASE	N022350	002	Jul 31, 2009	Jul CFTG
	SAXAGLIPTIN					
AB	AMNEAL	EQ 2.5MG BASE	A205941	001	Jul 31, 2023	Jul NFTG
AB		EQ 5MG BASE	A205941	002	Jul 31, 2023	Jul NFTG
AB	AUROBINDO PHARMA	EQ 2.5MG BASE	A205972	001	Jul 31, 2023	Jul NFTG
AB		EQ 5MG BASE	A205972	002	Jul 31, 2023	Jul NFTG
AB	GLENMARK PHARMS LTD	EQ 2.5MG BASE	A205994	001	Jul 31, 2023	Jul NFTG

TABLET;ORAL
SAXAGLIPTIN

AB		EQ 5MG BASE	A205994	002	Jul 31, 2023	Jul NFTG
AB	MYLAN	EQ 2.5MG BASE	A205980	001	Jul 31, 2023	Jul NFTG
AB		EQ 5MG BASE	A205980	002	Jul 31, 2023	Jul NFTG
AB	SUN PHARM	EQ 2.5MG BASE	A206078	001	Jul 31, 2023	Jul NFTG
AB		EQ 5MG BASE	A206078	002	Jul 31, 2023	Jul NFTG

SELEGILINE HYDROCHLORIDE

TABLET;ORAL
SELEGILINE HYDROCHLORIDE
@ DASH PHARMS NATCO 5MG

A074866 001 Nov 26, 1997 Mar CAHN

SELENIUM SULFIDE

LOTION/SHAMPOO;TOPICAL
SELENIUM SULFIDE
@ XTTRIUM LABS INC 2.5%

A088228 001 Sep 01, 1983 Mar CAHN

SELEXIPAG

TABLET;ORAL
SELEXIPAG
@ ZYDUS 0.2MG
@ 0.4MG
@ 0.6MG
@ 0.8MG
@ 1MG
@ 1.2MG
@ 1.4MG
@ 1.6MG
UPTRAVI
+ ACTELION 0.2MG
+! 0.4MG
+ 0.6MG
+ 0.8MG
+ 1MG
+ 1.2MG
+ 1.4MG
+ 1.6MG

A214302	001	Dec 21, 2022	May DISC
A214302	002	Dec 21, 2022	May DISC
A214302	003	Dec 21, 2022	May DISC
A214302	004	Dec 21, 2022	May DISC
A214302	005	Dec 21, 2022	May DISC
A214302	006	Dec 21, 2022	May DISC
A214302	007	Dec 21, 2022	May DISC
A214302	008	Dec 21, 2022	May DISC
N207947	001	Dec 21, 2015	May CTEC
N207947	002	Dec 21, 2015	May CTEC
N207947	003	Dec 21, 2015	May CTEC
N207947	004	Dec 21, 2015	May CTEC
N207947	005	Dec 21, 2015	May CTEC
N207947	006	Dec 21, 2015	May CTEC
N207947	007	Dec 21, 2015	May CTEC
N207947	008	Dec 21, 2015	May CTEC

SERTACONAZOLE NITRATE

CREAM;TOPICAL
ERTACZO

>D>	+! BAUSCH	2%	N021385	001	Dec 10, 2003	Aug CAHN
>A>	+! LACER PHARMA	2%	N021385	001	Dec 10, 2003	Aug CAHN

SERTRALINE HYDROCHLORIDE

TABLET;ORAL
SERTRALINE HYDROCHLORIDE
AB HERITAGE PHARMA AVET EQ 25MG BASE
AB EQ 50MG BASE
AB EQ 100MG BASE
@ ZYDUS EQ 25MG BASE
@ EQ 50MG BASE
@ EQ 100MG BASE

A076465	001	Aug 11, 2006	Mar CMFD
A076465	002	Aug 11, 2006	Mar CMFD
A076465	003	Aug 11, 2006	Mar CMFD
A077106	001	Feb 06, 2007	May CAHN
A077106	002	Feb 06, 2007	May CAHN
A077106	003	Feb 06, 2007	May CAHN

SETMELANOTIDE ACETATE

SOLUTION;SUBCUTANEOUS
IMCIVREE

>D>	+! RHYTHM	EQ 10MG/ML BASE (EQ 10MG/ML BASE)	N213793	001	Nov 25, 2020	Aug CPOT
>A>	+!	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N213793	001	Nov 25, 2020	Aug CPOT

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL
SEVELAMER CARBONATE

>A> AB	CHARTWELL RX	800MG/PACKET	A217319	001	Mar 02, 2023	Aug CAHN
>A> AB		2.4GM/PACKET	A217319	002	Mar 02, 2023	Aug CAHN
>D> AB	HANGZHOU ANPRIME	800MG/PACKET	A217319	001	Mar 02, 2023	Aug CAHN
AB		800MG/PACKET	A217319	001	Mar 02, 2023	Feb NEWA
>D> AB		2.4GM/PACKET	A217319	002	Mar 02, 2023	Aug CAHN
AB		2.4GM/PACKET	A217319	002	Mar 02, 2023	Feb NEWA

	TABLET;ORAL SEVELAMER CARBONATE AB MACLEODS PHARMS LTD	800MG	A206100 001 Apr 19, 2023	Apr NEWA
<u>SEVELAMER HYDROCHLORIDE</u>				
	TABLET;ORAL SEVELAMER HYDROCHLORIDE AB AUROBINDO PHARMA LTD	400MG	A212599 001 Jul 11, 2023	Jun NEWA
		800MG	A212599 002 Jul 11, 2023	Jun NEWA
	AB MACLEODS PHARMS LTD	400MG	A206883 001 May 26, 2023	May NEWA
		800MG	A206883 002 May 26, 2023	May NEWA
<u>SEVOFLURANE</u>				
	LIQUID;INHALATION SEVOFLURANE >A> AN SHANDONG	100%	A214382 001 Aug 18, 2023	Aug NEWA
<u>SILDENAFIL CITRATE</u>				
	SUSPENSION;ORAL LIQREV +! CMP DEV LLC	EQ 10MG BASE/ML	N214952 001 Apr 28, 2023	Apr NEWA
	TABLET;ORAL SILDENAFIL CITRATE AB MACLEODS PHARMS LTD	EQ 25MG BASE	A202255 001 Apr 19, 2023	Apr NEWA
		EQ 50MG BASE	A202255 002 Apr 19, 2023	Apr NEWA
		EQ 100MG BASE	A202255 003 Apr 19, 2023	Apr NEWA
>A> AB	NOVITIUM PHARMA	EQ 25MG BASE	A216383 001 Aug 29, 2023	Aug NEWA
>A> AB		EQ 50MG BASE	A216383 002 Aug 29, 2023	Aug NEWA
>A> AB		EQ 100MG BASE	A216383 003 Aug 29, 2023	Aug NEWA
<u>SILODOSIN</u>				
	CAPSULE;ORAL SILODOSIN @ ZYDUS PHARMS	4MG	A204816 001 Dec 08, 2022	May DISC
	@	8MG	A204816 002 Dec 08, 2022	May DISC
<u>SIPONIMOD</u>				
	TABLET;ORAL MAYZENT + NOVARTIS	EQ 0.25MG BASE	N209884 001 Mar 26, 2019	May CAIN
	+	EQ 1MG BASE	N209884 003 Aug 24, 2021	May CAIN
	+!	EQ 2MG BASE	N209884 002 Mar 26, 2019	May CAIN
<u>SIROLIMUS</u>				
	SOLUTION;ORAL SIROLIMUS AA MSN	1MG/ML	A216728 001 Jan 19, 2023	Jan NEWA
	TABLET;ORAL SIROLIMUS AB ZYDUS PHARMS	1MG	A201676 001 Feb 15, 2023	Feb NEWA
		2MG	A201676 002 Feb 15, 2023	Feb NEWA
<u>SODIUM ACETATE</u>				
	INJECTABLE;INJECTION SODIUM ACETATE >D> FRESENIUS KABI USA	4MEQ/ML	A206687 001 Oct 30, 2017	Aug CTEC
>A> AP		4MEQ/ML	A206687 001 Oct 30, 2017	Aug CTEC
>A> AP	MILLA PHARMS	4MEQ/ML	A214805 002 Aug 25, 2023	Aug NEWA
<u>SODIUM BENZOATE; SODIUM PHENYLACETATE</u>				
	SOLUTION;INTRAVENOUS SODIUM PHENYLACETATE AND SODIUM BENZOATE AP +! MAIA PHARMS INC	10%;10% (2GM/20ML;2GM/20ML)	N215025 001 Jun 10, 2021	Jul CFTG
	AP NAVINTA LLC	10%;10% (2GM/20ML; 2GM/20ML)	A217526 001 Jul 14, 2023	Jul NFTG
<u>SODIUM BICARBONATE</u>				
	INJECTABLE;INJECTION SODIUM BICARBONATE AP OMNIVIUM PHARMS	1MEQ/ML	A216364 001 Jun 15, 2023	Jun NEWA
	AP STERISCIENCE	1MEQ/ML	A217594 001 Jun 28, 2023	Jun NEWA

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

+ B BRAUN	9MG/ML	N019635	005	Aug 08, 2016	Mar CPOT
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
+ @ LIEBEL-FLARSHEIM	450MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Mar CPOT
+ @	1.125GM/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Mar CPOT
SODIUM CHLORIDE 0.9% IN PLASTIC THERMOJECT KIT FOR CARDIAC OUTPUT USE					
+ @ ICU MEDICAL INC	9MG/ML	N019217	001	Jul 13, 1984	Jun CTNA
SODIUM CHLORIDE 23.4%					
AP FRESENIUS KABI USA	234MG/ML	A212248	001	Apr 28, 2021	Jun CTEC
AP	234MG/ML	A217796	001	Jul 11, 2023	Jun NEWA
SOLUTION; INJECTION					
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
@ ABRAXIS PHARM	9MG/ML	A088909	001	Feb 07, 1985	Jun CDFR
@	90MG/10ML (9MG/ML)	A088909	002	May 15, 1985	Jun CMS1
@	270MG/30ML (9MG/ML)	A088909	001	Feb 07, 1985	Jun CPOT
AP FRESENIUS KABI USA	9MG/ML	A088911	001	Feb 07, 1985	Jun CDFR
AP	90MG/10ML (9MG/ML)	A088911	002	May 17, 1985	Jun CMS1
AP	270MG/30ML (9MG/ML)	A088911	001	Feb 07, 1985	Jun CPOT
AP +! HOSPIRA	9MG/ML	N018800	001	Oct 29, 1982	Jun CDFR
AP +!	90MG/10ML (9MG/ML)	N018800	001	Oct 29, 1982	Jun CPOT
AP +!	180MG/20ML (9MG/ML)	N018800	002	Oct 29, 1982	Jun CMS1
AP +!	270MG/30ML (9MG/ML)	N018800	003	Oct 29, 1982	Jun CMS1
SODIUM CHLORIDE 0.9%					
+ B BRAUN	9MG/ML	N019635	005	Aug 08, 2016	Jun CDFR
+ @	90MG/10ML (9MG/ML)	N019635	005	Aug 08, 2016	Jun CPOT
HIKMA	9MG/ML	A201833	001	Sep 24, 2013	Jun CDFR
AP	9MG/ML	A201850	001	Jan 20, 2012	Jun CDFR
	18MG/2ML (9MG/ML)	A201833	001	Sep 24, 2013	Jun CPOT
AP	90MG/10ML (9MG/ML)	A201833	002	Jan 07, 2015	Jun CMS1
AP	90MG/10ML (9MG/ML)	A201850	001	Jan 20, 2012	Jun CPOT
>A >A AP NEXUS PHARMS	90MG/10ML (9MG/ML)	A217535	001	Aug 23, 2023	Aug NEWA
>A >A AP	180MG/20ML (9MG/ML)	A217535	002	Aug 23, 2023	Aug NEWA
AP SPECTRA MDCL DEVICES	9MG/ML	A206171	001	Jul 21, 2017	Jun CDFR
AP	45MG/5ML (9MG/ML)	A206171	001	Jul 21, 2017	Jun CPOT
AP	90MG/10ML (9MG/ML)	A206171	002	Jul 21, 2017	Jun CMS1
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
@ ABBOTT	9MG/ML	N019218	001	Jul 13, 1984	Jun CDFR
@	90MG/10ML (9MG/ML)	N019218	001	Jul 13, 1984	Jun CPOT
@	180MG/20ML (9MG/ML)	N019218	002	Apr 30, 1985	Jun CMS1
AP +! BAXTER HLTHCARE	9MG/ML	N016677	004	Oct 30, 1985	Jun CDFR
AP +	9MG/ML	N020178	002	Dec 07, 1992	Jun CDFR
+!	225MG/25ML (9MG/ML)	N016677	004	Oct 30, 1985	Jun CTEC
AP +!	225MG/25ML (9MG/ML)	N016677	004	Oct 30, 1985	Jun CPOT
AP +!	450MG/50ML (9MG/ML)	N016677	003		Jun CMS1
AP +	450MG/50ML (9MG/ML)	N020178	002	Dec 07, 1992	Jun CPOT
AP +!	900MG/100ML	N016677	001		Jun CDFR
AP +!	900MG/100ML	N020178	001	Dec 07, 1992	Jun CDFR
AP ! FRESENIUS KABI USA	9MG/ML	A088912	001	Jan 10, 1985	Jun CDFR
AP !	18MG/2ML (9MG/ML)	A088912	004	Nov 29, 1985	Jun CMS1
AP !	90MG/10ML (9MG/ML)	A088912	001	Jan 10, 1985	Jun CPOT
AP !	180MG/20ML (9MG/ML)	A088912	002	Jan 10, 1985	Jun CMS1
AP !	270MG/30ML (9MG/ML)	A088912	003	Jan 10, 1985	Jun CMS1
AP +! HOSPIRA	90MG/10ML (9MG/ML)	N018803	001	Oct 29, 1982	Jun CPOT
AP +!	9MG/ML	N018803	001	Oct 29, 1982	Jun CDFR
AP +	9MG/ML	N019465	002	Jul 15, 1985	Jun CDFR
+ @	18MG/2ML (9MG/ML)	N018803	004	Jan 22, 2015	Jun CMS1
+ @	27MG/3ML (9MG/ML)	N018803	005	Jan 22, 2015	Jun CMS1
+ @	45MG/5ML (9MG/ML)	N018803	006	Jan 22, 2015	Jun CMS1
AP +!	180MG/20ML (9MG/ML)	N018803	002	Oct 29, 1982	Jun CMS1
AP +!	450MG/50ML (9MG/ML)	N018803	003	Oct 29, 1982	Jun CMS1
AP +	450MG/50ML (9MG/ML)	N019465	002	Jul 15, 1985	Jun CPOT
AP +!	900MG/100ML	N019465	001	Jul 15, 1985	Jun CDFR
+ @ ICU MEDICAL INC	45MG/5ML (9MG/ML)	N019217	002	Nov 18, 1998	Jun CMS1
+ @	90MG/10ML (9MG/ML)	N019217	003	Nov 18, 1998	Jun CMS1
+ @	360MG/40ML (9MG/ML)	N019217	004	Apr 01, 1999	Jun CMS1
@ JUBILANT CADISTA	9MG/ML	A203352	001	May 18, 2016	Jun CDFR
@	27MG/3ML (9MG/ML)	A203352	002	May 18, 2016	Jun CMS1
@	90MG/10ML (9MG/ML)	A203352	001	May 18, 2016	Jun CPOT
@ MILES	450MG/50ML (9MG/ML)	N018502	002		Jun CMS1
@	900MG/100ML	N018502	001		Jun CDFR

SOLUTION; INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	NEPHRON	9MG/ML	A211968	001	Apr 23, 2020	Jun CDFR
AP		450MG/50ML (9MG/ML)	A211968	001	Apr 23, 2020	Jun CPOT
AP		900MG/100ML	A211968	002	Apr 23, 2020	Jun CMS1
AP	! TARO	9MG/ML	A077407	001	Aug 11, 2006	Jun CDFR
AP	!	45MG/5ML (9MG/ML)	A077407	001	Aug 11, 2006	Jun CPOT
AP	!	90MG/10ML (9MG/ML)	A077407	002	Aug 11, 2006	Jun CMS1
	SODIUM CHLORIDE 0.9% IN PLASTIC THERMOJECT KIT FOR CARDIAC OUTPUT USE					
+ @ ICU MEDICAL INC	9MG/ML	N019217	001	Jul 13, 1984	Jun CDFR	
+ @	90MG/10ML (9MG/ML)	N019217	001	Jul 13, 1984	Jun CPOT	

SODIUM OXYBATE

FOR SUSPENSION, EXTENDED RELEASE; ORAL

LUMRYZ

+! AVADEL CNS	4.5GM/PACKET	N214755	001	May 01, 2023	Jun CHRS
+	4.5GM/PACKET	N214755	001	May 01, 2023	May NEWA
+	6GM/PACKET	N214755	002	May 01, 2023	May NEWA
+	7.5GM/PACKET	N214755	003	May 01, 2023	May NEWA
+	9GM/PACKET	N214755	004	May 01, 2023	May NEWA

SODIUM PHENYLBUTYRATE

POWDER; ORAL

BUPHENYL

AB	+! HORIZON THERAP US	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Jan CAHN
	TABLET; ORAL	BUPHENYL				

AB	+! HORIZON THERAP US	500MG	N020572	001	May 13, 1996	Jan CAHN
----	----------------------	-------	---------	-----	--------------	----------

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

AB	! NOVEL LABS INC	0.398GM;1.102GM	A079247	001	Dec 30, 2011	Jul CTEC
	!	0.398GM;1.102GM	A079247	001	Dec 30, 2011	Jul CHRS
	OSMOPREP					
+ @ SALIX PHARMS	0.398GM;1.102GM	N021892	001	Mar 16, 2006	Jul DISC	

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

SODIUM PHOSPHATES

AP	! FRESENIUS KABI USA	142MG/ML;276MG/ML	A209997	001	Mar 30, 2022	Mar CHRS
----	----------------------	-------------------	---------	-----	--------------	----------

SOLIFENACIN SUCCINATE

TABLET; ORAL

SOLIFENACIN SUCCINATE

AB	CHARTWELL RX	5MG	A210582	001	May 20, 2019	May CAHN
AB		10MG	A210582	002	May 20, 2019	May CAHN
	@ CIPLA	5MG	A209839	001	May 20, 2019	Jul DISC
	@	10MG	A209839	002	May 20, 2019	Jul DISC
>D> AB	GRAVITI PHARMS	5MG	A211423	001	Dec 11, 2019	Aug CAHN
>D> AB		10MG	A211423	002	Dec 11, 2019	Aug CAHN
AB	LANNETT CO INC	5MG	A211622	001	Jun 06, 2023	May NEWA
AB		10MG	A211622	002	Jun 06, 2023	May NEWA
>A> AB	RISING	5MG	A211423	001	Dec 11, 2019	Aug CAHN
>A> AB		10MG	A211423	002	Dec 11, 2019	Aug CAHN

SORAFENIB TOSYLATE

TABLET; ORAL

SORAFENIB TOSYLATE

AB	TORRENT	EQ 200MG BASE	A217095	001	Apr 12, 2023	Mar NEWA
----	---------	---------------	---------	-----	--------------	----------

SOTAGLIFLOZIN

TABLET; ORAL

INPEFA

+ LEXICON PHARMS INC	200MG	N216203	001	May 26, 2023	May NEWA
+!	400MG	N216203	002	May 26, 2023	May NEWA

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

AB	AUROBINDO PHARMA USA	80MG	A077616	001	Feb 07, 2007	Jul CMFD
AB		120MG	A077616	002	Feb 07, 2007	Jul CMFD
AB		160MG	A077616	003	Feb 07, 2007	Jul CMFD
>D>	@ MYLAN	80MG	A075237	001	May 01, 2000	Aug CAHN
>D>	@	120MG	A075237	002	May 01, 2000	Aug CAHN
>D>	@	160MG	A075237	003	May 01, 2000	Aug CAHN
>D>	@	240MG	A075237	004	May 01, 2000	Aug CAHN
>A>	@ NATCO PHARMA USA	80MG	A075237	001	May 01, 2000	Aug CAHN
>A>	@	120MG	A075237	002	May 01, 2000	Aug CAHN
>A>	@	160MG	A075237	003	May 01, 2000	Aug CAHN
>A>	@	240MG	A075237	004	May 01, 2000	Aug CAHN

SOTORASIB

TABLET; ORAL

LUMAKRAS

+ AMGEN INC

120MG

N214665 001 May 28, 2021 Mar CHRS

+!

320MG

N214665 002 Jan 20, 2023 Mar CHRS

+

320MG

N214665 002 Jan 20, 2023 Feb NEWA

SPARENTEAN

TABLET; ORAL

FILSPARI

+ TRAVERE

200MG

N216403 001 Feb 17, 2023 Feb NEWA

+!

400MG

N216403 002 Feb 17, 2023 Feb NEWA

SPIRONOLACTONESUSPENSION; ORAL
CAROSPIR

>D>	+! CMP DEV LLC	25MG/5ML	N209478	001	Aug 04, 2017	Aug CFTG
>A> AB	+!	25MG/5ML	N209478	001	Aug 04, 2017	Aug CFTG
>A>	SPIRONOLACTONE					
>A> AB	AMNEAL	25MG/5ML	A215572	001	Sep 05, 2023	Aug NFTG

STERILE WATER FOR INJECTION

LIQUID; N/A

STERILE WATER FOR INJECTION

>A> AP	AM REGENT	100% (10ML)	A217341	001	Aug 29, 2023	Aug NEWA
>A> AP		100% (20ML)	A217341	002	Aug 29, 2023	Aug NEWA
AP	HIKMA	100%	A212735	001	Jan 31, 2023	Jan NEWA
AP	+! HOSPIRA	100% (20ML)	N018801	003	Oct 27, 1982	Jun CFTG
	+ @	100% (5.2ML)	N018801	006	May 02, 2023	Jun DISC
	+!	100% (5.2ML)	N018801	006	May 02, 2023	May NEWA

SUCCINYLCHOLINE CHLORIDEINJECTABLE; INJECTION
SUCCINYLCHOLINE CHLORIDE

>D> AP	@ BRECKENRIDGE	20MG/ML	A212638	001	Oct 09, 2019	Apr DISC
>A> AP	MANKIND PHARMA	20MG/ML	A216127	001	Feb 02, 2023	Aug DISC
>A> AP	@	20MG/ML	A216127	001	Feb 02, 2023	Aug DISC
		20MG/ML	A216127	001	Feb 02, 2023	Jan NEWA

SUCRALFATE

TABLET; ORAL

SUCRALFATE

AB	ZYDUS LIFESCIENCES	1GM	A215705	001	May 03, 2023	Apr NEWA
----	--------------------	-----	---------	-----	--------------	----------

SUFENTANIL CITRATETABLET; SUBLINGUAL
DSUVIA

+! VERTICAL PHARMS

EQ 0.03MG BASE

N209128 001 Nov 02, 2018 Apr CAHN

SUGAMMADEX SODIUMSOLUTION; INTRAVENOUS
BRIDION

AP	+ MSD SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015	Jul CAHN
AP	+!	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225	001	Dec 15, 2015	Jul CAHN
AP	+ ORGANON SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG	N022225	002	Dec 15, 2015	Jun CFTG

**SOLUTION; INTRAVENOUS
BRIDION**

AP	+!	BASE/ML) EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N 022225 001 Dec 15, 2015	Jun CFTG
AP	SUGAMMADEX SODIUM			
AP	ASPIRO	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A 214337 001 Jun 09, 2023	Jun NFTG
AP		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A 214337 002 Jun 09, 2023	Jun NFTG
AP	MYLAN	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A 213915 001 Jun 15, 2023	Jun NEWA
AP		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A 213915 002 Jun 15, 2023	Jun NEWA
AP	SANDOZ	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A 214311 001 Jun 23, 2023	Jun NEWA
AP		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A 214311 002 Jun 23, 2023	Jun NEWA

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM

@ AKORN 10%

A 040215 001 May 25, 1999

Jan DISC

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	CHARTWELL MOLECULAR	200MG/5ML; 40MG/5ML	A 077785 001 Jan 24, 2007	Jul CAHN
----	---------------------	---------------------	---------------------------	----------

SULINDAC

TABLET; ORAL

SULINDAC

@ CHARTWELL RX 150MG

A 072712 001 Aug 30, 1991

Jan CAHN

@ 200MG

A 072713 001 Aug 30, 1991

Jan CAHN

SUMATRIPTAN

SPRAY; NASAL

TOSYMR A

+! TONIX MEDS

10MG/SPRAY

N 210884 001 Jan 25, 2019

Jul CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

>D> AP	BAXTER HLTHCARE CORP	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A 207101 001 Jan 19, 2023	Aug DISC
--------	----------------------	--	---------------------------	----------

>A>	@	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A 207101 001 Jan 19, 2023	Aug DISC
-----	---	--	---------------------------	----------

AP		EQ 6MG BASE/0.5ML EQ 12MG BASE/ML	A 207101 001 Jan 19, 2023	Jan NEWA
----	--	-----------------------------------	---------------------------	----------

SOLUTION; SUBCUTANEOUS

ZEMBRACE SYMTOUCH

+ TONIX MEDS

EQ 3MG BASE/0.5ML (EQ 3MG
BASE/0.5ML)

N 208223 001 Jan 28, 2016

Jul CAHN

TABLET; ORAL

SUMATRIPTAN SUCCINATE

>D> AB	SUN PHARM IND S LTD	EQ 25MG BASE	A 076554 001 Aug 10, 2009	Aug DISC
--------	---------------------	--------------	---------------------------	----------

@

EQ 25MG BASE

A 076554 001 Aug 10, 2009

Aug DISC

>D> AB		EQ 50MG BASE	A 076554 002 Aug 10, 2009	Aug DISC
--------	--	--------------	---------------------------	----------

@

EQ 50MG BASE

A 076554 002 Aug 10, 2009

Aug DISC

>A> AB		EQ 100MG BASE	A 076572 001 Feb 09, 2009	Aug DISC
--------	--	---------------	---------------------------	----------

@

EQ 100MG BASE

A 076572 001 Feb 09, 2009

Aug DISC

>A> AB		EQ 100MG BASE	A 076572 001 Feb 09, 2009	Aug DISC
--------	--	---------------	---------------------------	----------

SUNITINIB MALATE

CAPSULE; ORAL

SUNITINIB MALATE

>A> AB	NOVUGEN	EQ 12.5MG BASE	A 218012 001 Aug 21, 2023	Aug NEWA
--------	---------	----------------	---------------------------	----------

@

EQ 25MG BASE

A 218012 002 Aug 21, 2023

Aug NEWA

>A> AB		EQ 37.5MG BASE	A 218012 003 Aug 21, 2023	Aug NEWA
--------	--	----------------	---------------------------	----------

@

EQ 50MG BASE

A 218012 004 Aug 21, 2023

Aug NEWA

>A> AB		EQ 50MG BASE	A 218012 004 Aug 21, 2023	Aug NEWA
--------	--	--------------	---------------------------	----------

TACROLIMUS

	CAPSULE;ORAL TACROLIMUS						
AB	HANGZHOU ZHONGMEI	EQ 0.5MG BASE	A210929	001	Apr 17, 2023	Apr NEWA	
AB		EQ 1MG BASE	A210929	002	Apr 17, 2023	Apr NEWA	
AB		EQ 5MG BASE	A210929	003	Apr 17, 2023	Apr NEWA	
	OINTMENT;TOPICAL TACROLIMUS						
>A> AB	GLENMARK PHARMS LTD	0.03%	A210393	002	Aug 16, 2023	Aug NEWA	

TADALAFIL

	TABLET;ORAL ALYQ						
	@ TEVA PHARMS INC	20MG	A216932	001	Oct 12, 2022	Apr DISC	
	TADALAFIL						
AB2	CHARTWELL RX	20MG	A210572	001	Feb 05, 2019	May CAHN	
AB1	NOVITIUM PHARMA	5MG	A215949	001	Mar 03, 2023	Feb NEWA	
AB1		10MG	A215949	002	Mar 03, 2023	Feb NEWA	
AB1		20MG	A215949	003	Mar 03, 2023	Feb NEWA	
AB1	UNICHEM	2.5MG	A209250	001	Mar 26, 2019	Jan CTEC	
AB1		5MG	A209250	002	Mar 26, 2019	Jan CTEC	
AB1		10MG	A209250	003	Mar 26, 2019	Jan CTEC	
AB1		20MG	A209250	004	Mar 26, 2019	Jan CTEC	
AB2	ZYDUS PHARMS	20MG	A212515	001	Jun 06, 2023	May NEWA	

TALAZOPARIB TOSYLATE

	CAPSULE;ORAL TALZENNA						
+	PFIZER	EQ 0.1MG BASE	N211651	005	Jun 20, 2023	Jul NEWA	
+		EQ 0.35MG BASE	N211651	006	Jun 20, 2023	Jul NEWA	

TAMOXIFEN CITRATE

	SOLUTION;ORAL SOLTAMOX						
+	MAYNE PHARMA COMMRCI	EQ 20MG BASE/10ML	N021807	001	Oct 29, 2005	Feb CAHN	

TASIMELTEON

	CAPSULE;ORAL TASIMELTEON						
AB	APOTEX	20MG	A211607	001	Dec 20, 2022	Jan CAHN	
AB	MSN	20MG	A211654	001	Jan 12, 2023	Jan NEWA	

TAVABOROLE

	SOLUTION;TOPICAL TAVABOROLE						
AB	ZYDUS LIFESCIENCES	5%	A212294	001	Apr 10, 2023	Mar NEWA	

TAZAROTENE

	GEL;TOPICAL TAZAROTENE						
AB	PADAGIS ISRAEL	0.05%	A213079	001	Apr 25, 2023	Apr NEWA	
AB		0.1%	A213079	002	Apr 25, 2023	Apr NEWA	
AB	SOLARIS PHARMA CORP	0.05%	A213644	001	Mar 20, 2023	Mar NEWA	
AB		0.1%	A213644	002	Mar 20, 2023	Mar NEWA	

TECHNETIUM TC-99M MERTIATIDE KIT

	POWDER;INTRAVENOUS TECHNETIUM TC 99M MERTIATIDE KIT						
+	JUBILANT DRAXIMAGE	N/A	N216820	001	Jan 30, 2023	Jan NEWA	

TELMISARTAN

	TABLET;ORAL TELMISARTAN						
AB	CHARTWELL RX	20MG	A078710	001	Jan 08, 2014	May CAHN	
AB		40MG	A078710	002	Jan 08, 2014	May CAHN	
AB		80MG	A078710	003	Jan 08, 2014	May CAHN	

TEMAZEPAM

CAPSULE;ORAL						
TEMAZEPAM						
>A> AB	ALKEM LABS LTD	7.5MG	A217875	001	Aug 24, 2023	Aug NEWA
>A> AB		15MG	A217875	002	Aug 24, 2023	Aug NEWA
>A> AB		22.5MG	A217875	003	Aug 24, 2023	Aug NEWA
>A> AB		30MG	A217875	004	Aug 24, 2023	Aug NEWA

TEMOZOLOMIDE

CAPSULE;ORAL						
TEMOZOLOMIDE						
@ CHARTWELL MOLECULAR	5MG	A203898	001	Feb 10, 2016	Jul CAHN	
@	20MG	A203898	002	Feb 10, 2016	Jul CAHN	
@	100MG	A203898	003	Feb 10, 2016	Jul CAHN	
@	140MG	A203898	004	Feb 10, 2016	Jul CAHN	
@	180MG	A203898	005	Feb 10, 2016	Jul CAHN	
@	250MG	A203898	006	Feb 10, 2016	Jul CAHN	
>D> AB	HERITAGE	5MG	A078879	001	Mar 01, 2010	Aug DISC
>A>	@	5MG	A078879	001	Mar 01, 2010	Aug DISC
>D> AB		20MG	A078879	002	Mar 01, 2010	Aug DISC
>A>	@	20MG	A078879	002	Mar 01, 2010	Aug DISC
>D> AB		100MG	A078879	003	Mar 01, 2010	Aug DISC
>A>	@	100MG	A078879	003	Mar 01, 2010	Aug DISC
>D> AB		140MG	A078879	005	Mar 01, 2010	Aug DISC
>A>	@	140MG	A078879	005	Mar 01, 2010	Aug DISC
>D> AB		180MG	A078879	006	Mar 01, 2010	Aug DISC
>A>	@	180MG	A078879	006	Mar 01, 2010	Aug DISC
>D> AB		250MG	A078879	004	Mar 01, 2010	Aug DISC
>A>	@	250MG	A078879	004	Mar 01, 2010	Aug DISC

TENOFOVIR ALAFENAMIDE FUMARATE

CAPSULE;ORAL						
TENOFOVIR ALAFENAMIDE						
AB	LUPIN LTD	EQ 25MG BASE	A214226	001	Mar 30, 2023	Mar NFTG
	VEMILIDY					
AB	+! GILEAD SCIENCES INC	EQ 25MG BASE	N208464	001	Nov 10, 2016	Mar CFTG

TENOFOVIR DISOPROXIL FUMARATE

CAPSULE;ORAL						
TENOFOVIR DISOPROXIL FUMARATE						
>A> AB	REYOUNG	300MG	A211337	001	Mar 02, 2023	Aug CAHN
>D> AB	REYOUNG PHARM	300MG	A211337	001	Mar 02, 2023	Aug CAHN
AB		300MG	A211337	001	Mar 02, 2023	Feb NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL						
TERAZOSIN HYDROCHLORIDE						
@ BIONPHARMA	EQ 1MG BASE	A075667	001	Jul 28, 2000	Apr CAHN	
@	EQ 2MG BASE	A075667	002	Jul 28, 2000	Apr CAHN	
@	EQ 5MG BASE	A075667	003	Jul 28, 2000	Apr CAHN	
@	EQ 10MG BASE	A075667	004	Jul 28, 2000	Apr CAHN	
CAPSULE;ORAL						
TERAZOSIN HYDROCHLORIDE						
@ CHARTWELL RX	EQ 1MG BASE	A074657	001	Apr 28, 2000	May CAHN	
@	EQ 2MG BASE	A074657	002	Apr 28, 2000	May CAHN	
@	EQ 5MG BASE	A074657	003	Apr 28, 2000	May CAHN	
@	EQ 10MG BASE	A074657	004	Apr 28, 2000	May CAHN	

TERIFLUONIMIDE

CAPSULE;ORAL						
TERIFLUONIMIDE						
AB	AMNEAL PHARMS CO	7MG	A209613	001	Sep 28, 2018	Feb CMFD
AB		14MG	A209613	002	Sep 28, 2018	Feb CMFD
AB	APOTEX	7MG	A209601	001	Nov 02, 2018	Jan CMFD
AB		14MG	A209601	002	Nov 02, 2018	Jan CMFD
AB	AUROBINDO PHARMA	7MG	A209638	001	Oct 26, 2018	Jan CMFD
AB		14MG	A209638	002	Oct 26, 2018	Jan CMFD
AB	BIOCON PHARMA	7MG	A209639	001	Mar 13, 2023	Mar NEWA
AB		14MG	A209639	002	Mar 13, 2023	Mar NEWA
AB	HETERO LABS LTD V	7MG	A209598	001	Mar 13, 2023	Mar NEWA
AB		14MG	A209598	002	Mar 13, 2023	Mar NEWA
AB	MSN	7MG	A209623	001	Apr 24, 2019	Feb CMFD

TABLET;ORAL
TERIFLUNOMIDE

AB		14MG	A209623	002	Apr 24, 2019	Feb CMFD
AB	MYLAN	7MG	A209702	001	Feb 28, 2020	Feb CMFD
AB		14MG	A209702	002	Feb 28, 2020	Feb CMFD
AB	NATCO	7MG	A209555	001	May 15, 2023	May NEWA
AB		14MG	A209555	002	May 15, 2023	May NEWA
AB	SOLA PHARMS	14MG	A209677	001	Jun 17, 2020	Feb CMFD
AB	TEVA PHARMS USA	7MG	A209700	001	Sep 04, 2018	Feb CMFD
AB		14MG	A209700	002	Sep 04, 2018	Feb CMFD
AB	ZYDUS PHARMS	7MG	A209668	001	Nov 30, 2018	Jan CMFD
AB		14MG	A209668	002	Nov 30, 2018	Jan CMFD

TESTOSTERONE

	GEL, METERED;NASAL NATESTO					
+!	ACERUS	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jan CHRS
+		5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jan CRLD
	GEL, METERED;TRANSDERMAL ANDROGEL					
AB	+! BESINS HLTHCARE	1.62% (20.25MG/1.25GM ACTUATION)	N022309	001	Apr 29, 2011	Feb CAHN
+ @		12.5MG/1.25GM ACTUATION	N021015	003	Sep 26, 2003	Feb CAHN
	TESTOSTERONE					
AB	ENCUBE	1.62% (20.25MG/1.25GM ACTUATION)	A208620	001	Apr 10, 2019	Jan CAHN

TESTOSTERONE CYPIONATE

	INJECTABLE;INJECTION TESTOSTERONE CYPIONATE					
AO	XIROMED	100MG/ML	A215351	001	Apr 13, 2023	Mar NEWA
AO		200MG/ML	A215351	002	Apr 13, 2023	Mar NEWA

TETRABENAZINE

	TABLET;ORAL TETRABENAZINE					
AB	CHARTWELL RX	12.5MG	A210544	001	Apr 20, 2018	May CAHN
AB		25MG	A210544	002	Apr 20, 2018	May CAHN
@	SUN PHARM	12.5MG	A206129	001	Aug 17, 2015	Jan DISC
@		25MG	A206129	002	Aug 17, 2015	Jan DISC

TETRACYCLINE HYDROCHLORIDE

	CAPSULE;ORAL TETRACYCLINE HYDROCHLORIDE					
@	AUROBINDO PHARMA USA	250MG	A060783	001		Apr CAHN
@		500MG	A060783	002		Apr CAHN

THALIDOMIDE

	CAPSULE;ORAL THALIDOMIDE					
AB	NATCO	150MG	A213267	001	Apr 27, 2023	Apr NFTG

THALLOUS CHLORIDE TL-201

	INJECTABLE;INJECTION THALLOUS CHLORIDE TL 201					
>D> AP	+! CURIUM	1mCi/ML	N018150	001		Aug CTEC
>A>	+!	1mCi/ML	N018150	001		Aug CTEC
>D> AP	+! LANTHEUS MEDCL	1mCi/ML	N017806	001		Aug DISC
>A>	+ @	1mCi/ML	N017806	001		Aug DISC

THEOPHYLLINE

	TABLET, EXTENDED RELEASE;ORAL THEOCHRON					
>D>	@ NOSTRUM PHARMS LLC	100MG	A087400	003	Feb 21, 1985	Aug CMFD
>A>		100MG	A087400	003	Feb 21, 1985	Aug CMFD
>D>	@	200MG	A087400	004	Feb 21, 1985	Aug CMFD
>A>		200MG	A087400	004	Feb 21, 1985	Aug CMFD
>D>	@	300MG	A087400	002	Jan 11, 1983	Aug CMFD
>A> AB		300MG	A087400	002	Jan 11, 1983	Aug CMFD
>A> AB		450MG	A087400	005	Aug 09, 2023	Aug NEWA
	THEOPHYLLINE					
AB	AMNEAL	300MG	A216276	001	Mar 20, 2023	Mar NEWA
AB		450MG	A216276	002	Mar 20, 2023	Mar NEWA
AB	BIONPHARMA	300MG	A216300	001	Apr 26, 2023	Apr NEWA

**TABLET, EXTENDED RELEASE;ORAL
THEOPHYLLINE**

AB		450MG	A216300	002	Apr 26, 2023	Apr NEWA
AB	LEADING	300MG	A214950	001	Jan 30, 2023	Jan NEWA
AB		450MG	A214950	002	Jan 30, 2023	Jan NEWA
AB	RHODES PHARMS	300MG	A214113	001	May 11, 2023	May NEWA

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
THIAMINE HYDROCHLORIDE

AP	CAPLIN	100MG/ML	A215692	001	Mar 06, 2023	Feb NEWA
AP	DR REDDYS	100MG/ML	A080571	001		Mar CMFD
	!	200MG/ML	A080571	002		Mar CMFD

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL
THIORIDAZINE HYDROCHLORIDE

@	CHARTWELL RX	10MG	A088131	001	Aug 30, 1983	Jan CAHN
@		15MG	A088132	001	Aug 30, 1983	Jan CAHN
@		25MG	A088133	001	Aug 30, 1983	Jan CAHN
@		50MG	A088134	001	Aug 30, 1983	Jan CAHN
@		100MG	A088135	001	Nov 20, 1984	Jan CAHN
@		150MG	A088136	001	Sep 17, 1986	Jan CAHN
@		200MG	A088137	001	Sep 17, 1986	Jan CAHN

THIOTEP A

INJECTABLE; INJECTION
THIOTEP A

AP	PENN LIFE	15MG/VIAL	A208242	001	Jan 10, 2020	May CAHN
	POWDER; INTRACAVITARY, INTRAVENOUS, INTRAVESICAL THIOTEP A					
>A> AP	HIKMA	100MG/VIAL	A211755	001	Sep 05, 2023	Aug NEWA

THIOTHIXENE

CAPSULE;ORAL
THIOTHIXENE

AB	RISING	1MG	A071093	002	Jun 23, 1987	Feb CAHN
AB		2MG	A071093	003	Jun 23, 1987	Feb CAHN
AB		5MG	A071093	004	Jun 23, 1987	Feb CAHN
AB		10MG	A071093	001	Jun 23, 1987	Feb CAHN

TICAGRELOR

TABLET;ORAL
TICAGRELOR

AB	ALKEM LABS LTD	90MG	A208567	001	Apr 21, 2023	Apr NEWA
----	----------------	------	---------	-----	--------------	----------

TIMOLOL

SOLUTION/DROPS;OPHTHALMIC
BETIMOL

+!	THEA PHARMA	EQ 0.25% BASE	N020439	001	Mar 31, 1995	Jan CTEC
+!		EQ 0.5% BASE	N020439	002	Mar 31, 1995	Jan CTEC
	TIMOLOL					
@	AKORN	EQ 0.25% BASE	A205309	001	Sep 30, 2016	Jan DISC
@		EQ 0.5% BASE	A205309	002	Sep 30, 2016	Jan DISC

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS;OPHTHALMIC
TIMOLOL MALEATE

AB	EUGIA PHARMA	EQ 0.5% BASE	A213540	001	Mar 23, 2023	Mar NEWA
AB	GLAND PHARMA LTD	EQ 0.5% BASE	A214645	002	Feb 14, 2023	Feb NEWA

SOLUTION/DROPS;OPHTHALMIC
TIMOLOL MALEATE

AT1	AKORN	EQ 0.5% BASE	A074466	001	Mar 25, 1997	Jan DISC
AT1	MICRO LABS	EQ 0.25% BASE	A217343	001	May 26, 2023	May NEWA
AT1		EQ 0.5% BASE	A217343	002	May 26, 2023	May NEWA
AT3	SENTISS PHARMA	EQ 0.5% BASE	A217195	001	May 08, 2023	Apr NEWA

TABLET;ORAL
TIMOLOL MALEATE

>D> AB	ELYSIUM	5MG	A207556	001	May 02, 2019	Aug CAHN
>D> AB		10MG	A207556	002	May 02, 2019	Aug CAHN
>D> AB		20MG	A207556	003	May 02, 2019	Aug CAHN
>A> AB	RISING	5MG	A207556	001	May 02, 2019	Aug CAHN

TABLET;ORAL
TIMOLOL MALEATE

>A> AB		10MG	A207556	002	May 02, 2019	Aug CAHN
>A> AB		20MG	A207556	003	May 02, 2019	Aug CAHN

TINIDAZOLE

TABLET;ORAL
TINIDAZOLE

AB	CHARTWELL RX	250MG	A202044	001	Apr 30, 2012	Apr CAHN
AB		500MG	A202044	002	Apr 30, 2012	Apr CAHN

TIOPRONIN

TABLET, DELAYED RELEASE;ORAL
THIOLA EC

>A> AB	+ MISSION PHARMACAL	100MG	N211843	001	Jun 28, 2019	Apr CTEC
	+!	300MG	N211843	002	Jun 28, 2019	Aug CTEC
AB	+ MISSION PHARMACAL CO	100MG	N211843	001	Jun 28, 2019	Feb CFTG
>D>	+!	300MG	N211843	002	Jun 28, 2019	Aug CTEC
	+!	300MG	N211843	002	Jun 28, 2019	Apr CTEC
AB	+!	300MG	N211843	002	Jun 28, 2019	Feb CFTG
	TIOPRONIN					
>A> AB	AMNEAL	300MG	A216278	001	Aug 15, 2023	Aug NEWA
	@ PAR PHARM	100MG	A217219	001	Feb 24, 2023	Apr DISC
AB		100MG	A217219	001	Feb 24, 2023	Feb NFTG
	@	300MG	A217219	002	Feb 24, 2023	Apr DISC
AB		300MG	A217219	002	Feb 24, 2023	Feb NFTG

TIOTROPIUM BROMIDE

POWDER;INHALATION
SPIRIVA

AB	+! BOEHRINGER INGELHEIM	EQ 0.018MG BASE/INH	N021395	001	Jan 30, 2004	Jun CFTG
	TIOTROPIUM BROMIDE					
AB	LUPIN	EQ 0.018MG BASE/INH	A211287	001	Jun 20, 2023	Jun NFTG

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE

TABLET;ORAL
LONSURF

AB	+ TAIHO ONCOLOGY	EQ 6.14MG BASE;15MG	N207981	001	Sep 22, 2015	Jun CFTG
AB	+!	EQ 8.19MG BASE;20MG	N207981	002	Sep 22, 2015	Jun CFTG
	TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE					
AB	NATCO	EQ 6.14MG BASE;15MG	A214008	001	Jun 13, 2023	Jun NFTG
AB		EQ 8.19MG BASE;20MG	A214008	002	Jun 13, 2023	Jun NFTG

TIROFIBAN HYDROCHLORIDE

SOLUTION;INTRAVENOUS
AGGRASTAT

AP	+ MEDICURE	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N020913	002	May 17, 2002	Jan CFTG
	TIROFIBAN HYDROCHLORIDE					
AP	EUGIA PHARMA	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	A216379	001	May 01, 2023	Apr NEWA
AP		EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)	A216379	002	May 01, 2023	Apr NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL
ZANAFLEX

AB	+ LEGACY PHARMA USA	EQ 2MG BASE	N021447	001	Aug 29, 2002	Jul CAHN
AB	+!	EQ 4MG BASE	N021447	002	Aug 29, 2002	Jul CAHN
AB	+!	EQ 6MG BASE	N021447	003	Aug 29, 2002	Jul CAHN

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

	@ AUROBINDO PHARMA USA	EQ 2MG BASE	A076282	001	Dec 16, 2003	Apr CAHN
	@	EQ 4MG BASE	A076282	002	Dec 16, 2003	Apr CAHN
	ZANAFLEX					
AB	+ @ LEGACY PHARMA USA	EQ 2MG BASE	N020397	002	Feb 04, 2000	Jul CAHN
AB	+!	EQ 4MG BASE	N020397	001	Nov 27, 1996	Jul CAHN

TOBRAMYCIN

SOLUTION; INHALATION

TOBRAMYCIN

AN	MANKIND PHARMA	300MG/5ML	A214478	001	Jun 30, 2023	Jun NEWA
AN	MICRO LABS	300MG/5ML	A217344	001	Jul 27, 2023	Jul NEWA
SOLUTION/DROPS; OPHTHALMIC						
	AKTOB					
	@ AKORN	0.3%	A064096	001	Jan 31, 1996	Feb DISC

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

AP	EUGIA PHARMA	EQ 1.2GM BASE/VIAL	A217519	001	Jun 21, 2023	Jun NEWA
AP	HAINAN POLY	EQ 1.2GM BASE/VIAL	A217029	001	Feb 01, 2023	Jan NEWA

TOFACITINIB CITRATE

SOLUTION; ORAL

XELJANZ

>D>	+! PFIZER	EQ 1MG/ML BASE	N213082	001	Sep 25, 2020	Aug CPOT
>A>	+!	EQ 1MG BASE/ML	N213082	001	Sep 25, 2020	Aug CPOT
TABLET; ORAL						
	TOFACITINIB CITRATE					
	@ MICRO LABS	EQ 5MG BASE	A209738	001	Mar 13, 2023	Mar DISC
AB		EQ 5MG BASE	A209738	001	Mar 13, 2023	Mar NFTG

TOFERSEN

SOLUTION; INTRATHECAL

QALSODY

+! BIOGEN MA

100MG/15ML (6.7MG/ML)

N215887 001 Apr 25, 2023 Apr NEWA

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

RISING

EQ 400MG BASE

A073393 001 May 27, 1993 Jul CMFD

TABLET; ORAL

TOLMETIN SODIUM

! RISING

EQ 600MG BASE

A074473 001 Aug 30, 1994 May CMFD

TOLVAPTAN

TABLET; ORAL

TOLVAPTAN

AB	MSN	15MG	A216949	001	Jun 21, 2023	Jun NEWA
AB		30MG	A216949	002	Jun 21, 2023	Jun NEWA

TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL

TOPIRAMATE

AB1	ACTAVIS LABS FL	25MG	A206210	001	Mar 10, 2023	Mar NEWA
AB1		50MG	A206210	002	Mar 10, 2023	Mar NEWA
AB1		100MG	A206210	003	Mar 10, 2023	Mar NEWA
AB1		200MG	A206210	004	Mar 10, 2023	Mar NEWA
>A> AB1	AJANTA PHARMA LTD	25MG	A215663	001	Aug 15, 2023	Aug NEWA
>A> AB1		50MG	A215663	002	Aug 15, 2023	Aug NEWA
>A> AB1		100MG	A215663	003	Aug 15, 2023	Aug NEWA
>A> AB1		200MG	A215663	004	Aug 15, 2023	Aug NEWA
AB1	ALKEM LABS LTD	25MG	A217248	001	Jun 20, 2023	Jun NEWA
AB1		50MG	A217248	002	Jun 20, 2023	Jun NEWA
AB1		100MG	A217248	003	Jun 20, 2023	Jun NEWA
AB1		200MG	A217248	004	Jun 20, 2023	Jun NEWA
AB1	PAR PHARM	25MG	A205976	002	May 04, 2023	Apr NEWA
AB1		50MG	A205976	003	May 04, 2023	Apr NEWA
AB1		100MG	A205976	004	May 04, 2023	Apr NEWA
AB1		200MG	A205976	001	Mar 01, 2023	Feb NEWA
AB1	ZYDUS	25MG	A207382	001	Nov 24, 2017	Jan CAHN
AB2		25MG	A208949	001	Nov 29, 2022	Jan CAHN
AB1		50MG	A207382	002	Nov 24, 2017	Jan CAHN
AB2		50MG	A208949	002	Nov 29, 2022	Jan CAHN
AB1		100MG	A207382	003	Nov 24, 2017	Jan CAHN
AB2		100MG	A208949	003	Nov 29, 2022	Jan CAHN
AB2		150MG	A208949	004	Nov 29, 2022	Jan CAHN
AB2		200MG	A208949	005	Nov 29, 2022	Jan CAHN

CAPSULE, EXTENDED RELEASE;ORAL

TOPIRAMATE

>D> AB1	ZYDUS PHARMS	200MG	A216167	001	Feb 09, 2023	Aug DISC
>A> AB1	@	200MG	A216167	001	Feb 09, 2023	Aug DISC
		200MG	A216167	001	Feb 09, 2023	Jan NFTG
	TROKENDI XR					
AB1	+! SUPERNUS PHARMS	200MG	N201635	004	Aug 16, 2013	Jan CFTG

TOPOTECAN HYDROCHLORIDE

CAPSULE;ORAL

HYCAMTIN

+ SANDOZ	EQ 0.25MG BASE	N020981	001	Oct 11, 2007	May CAHN
+!	EQ 1MG BASE	N020981	002	Oct 11, 2007	May CAHN

INJECTABLE; INJECTION
HYCAMTIN

AP	+! SANDOZ	EQ 4MG BASE/VIAL	N020671	001	May 28, 1996	May CAHN
	SOLUTION; INTRAVENOUS					
	TOPOTECAN HYDROCHLORIDE					

@ DASH PHARMS EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

A206074 001 Nov 24, 2017 Mar CAHN

TORSEMIDE

TABLET;ORAL

SOAANZ

+ @ SARFE PHARMS	20MG	N213218	001	Jun 14, 2021	Jun DISC
+ @	60MG	N213218	002	Jun 14, 2021	Jun DISC

TRAMETINIB DIMETHYL SULFOXIDE

SOLUTION;ORAL

MEKINIST

+! NOVARTIS	EQ 0.05MG BASE/ML	N217513	001	Mar 16, 2023	Mar NEWA
-------------	-------------------	---------	-----	--------------	----------

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

AB	AUROBINDO PHARMA	50MG	A204852	001	Feb 05, 2020	Jan CAHN
AB		100MG	A204852	002	Feb 05, 2020	Jan CAHN
AB		150MG	A204852	003	Feb 05, 2020	Jan CAHN
AB		300MG	A204852	004	Feb 05, 2020	Jan CAHN

TREPROSTINILINJECTABLE;IV (INFUSION), SUBCUTANEOUS
TREPROSTINIL

AP	DR REDDYS	1MG/ML	A210214	001	May 22, 2020	Feb CMFD
AP		2.5MG/ML	A210214	002	May 22, 2020	Feb CMFD
AP		5MG/ML	A210214	003	May 22, 2020	Feb CMFD
AP		10MG/ML	A210214	004	May 22, 2020	Feb CMFD

TRETINOIN

CREAM;TOPICAL

RETIN-A

AB	+! BAUSCH	0.025%	N019049	001	Sep 16, 1988	Jan CAHN
	GEL;TOPICAL					
	AVITA					
	@ MYLAN	0.025%	N020400	001	Jan 29, 1998	May DISC
	RETIN-A-MICRO					
>D>	+! VALEANT INTL	0.08%	N020475	003	Jan 28, 2014	Aug CFTG
>A> AB	+!	0.08%	N020475	003	Jan 28, 2014	Aug CFTG
>A>	TRETINOIN MICROSPHERE					
>A> AB	ENCUBE	0.08%	A215609	001	Aug 22, 2023	Aug NFTG

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

AT	CHARTWELL RX	0.025%	A208763	001	Feb 01, 2017	May CAHN
AT		0.1%	A208763	002	Feb 01, 2017	May CAHN
AT		0.5%	A208763	003	Feb 01, 2017	May CAHN
	LOTION;TOPICAL					
	TRIAMCINOLONE ACETONIDE					
>D> AT	PAI HOLDINGS PHARM	0.025%	A204608	001	Jul 07, 2016	Aug DISC
>A> AT	@	0.025%	A204608	001	Jul 07, 2016	Aug DISC
>D> AT		0.1%	A204606	001	Jul 07, 2016	Aug DISC

<u>LOTION;TOPICAL</u>							
TRIAMCINOLONE ACETONIDE							
>A>	@	0.1%		A204606	001	Jul 07, 2016	Aug DISC
<u>OINTMENT;TOPICAL</u>							
TRIAMCINOLONE ACETONIDE							
AT	CHARTWELL RX	0.05%		A214532	001	Jan 27, 2023	May CAHN
AT		0.1%		A207365	001	Oct 12, 2018	Apr CAHN
AT	GLASSHOUSE PHARMS	0.05%		A214532	001	Jan 27, 2023	Jan NEWA
>A> AT	MACLEODS PHARMS LTD	0.05%		A216625	001	Aug 18, 2023	Aug NEWA
>D> AT	PAI HOLDINGS PHARM	0.5%		A208590	001	Mar 03, 2017	Aug DISC
>A>	@	0.5%		A208590	001	Mar 03, 2017	Aug DISC
<u>SPRAY;TOPICAL</u>							
KENALOG							
+ @	SUN PHARM INDNS INC	0.147MG/GM		N012104	001		Jun DISC
TRIAMCINOLONE ACETONIDE							
AT	! PADAGIS ISRAEL	0.147MG/GM		A205782	001	Apr 13, 2015	Jun CHRS
<u>TRIAMTERENE</u>							
CAPSULE;ORAL							
TRIAMTERENE							
@ EYWA		50MG		A214768	001	Jul 06, 2022	Jan DISC
@		100MG		A214768	002	Jul 06, 2022	Jan DISC
<u>TRIENTINE HYDROCHLORIDE</u>							
CAPSULE;ORAL							
TRIENTINE HYDROCHLORIDE							
AB	MSN	250MG		A211134	001	May 22, 2019	Mar CTEC
<u>TROFINETIDE</u>							
SOLUTION;ORAL							
DAYBUE							
+!	ACADIA PHARMS INC	200MG/ML		N217026	001	Mar 10, 2023	Mar NEWA
<u>UBROGEPANT</u>							
TABLET;ORAL							
UBRELVY							
+!	ABBVIE	50MG		N211765	001	Dec 23, 2019	Jan CAHN
+!		100MG		N211765	002	Dec 23, 2019	Jan CAHN
<u>URIDINE TRIACETATE</u>							
GRANULE;ORAL							
VISTOGARD							
+!	BTG INTL	10GM/PACKET		N208159	001	Dec 11, 2015	Jul CAHN
XURIDEN							
+!	BTG INTL	2GM/PACKET		N208169	001	Sep 04, 2015	Jul CAHN
<u>URSODIOL</u>							
CAPSULE;ORAL							
URSODIOL							
@ MYLAN		300MG		A090530	001	Feb 17, 2010	Jan DISC
AB	RK PHARMA	300MG		A214329	001	Jul 28, 2021	Jun CAHN
AB	VGYAAN	300MG		A214329	001	Jul 28, 2021	Apr CMFD
<u>VALACYCLOVIR HYDROCHLORIDE</u>							
TABLET;ORAL							
VALACYCLOVIR HYDROCHLORIDE							
AB	CHARTWELL RX	EQ 500MG BASE		A090216	001	May 24, 2010	Jan CAHN
AB		EQ 1GM BASE		A090216	002	May 24, 2010	Jan CAHN
<u>VALGANCICLOVIR HYDROCHLORIDE</u>							
FOR SOLUTION;ORAL							
VALCYTE							
AB	+! CHEPLAPHARM	50MG/ML		N022257	001	Aug 28, 2009	Mar CAHN
VALGANCICLOVIR HYDROCHLORIDE							
AB	APPCO	50MG/ML		A216317	001	Apr 11, 2023	Mar NEWA
TABLET;ORAL							
VALCYTE							
AB	+! CHEPLAPHARM	EQ 450MG BASE		N021304	001	Mar 29, 2001	Mar CAHN
VALGANCICLOVIR HYDROCHLORIDE							
>D> AB	CIPLA	EQ 450MG BASE		A209672	001	Nov 09, 2018	Aug DISC
>A>	@	EQ 450MG BASE		A209672	001	Nov 09, 2018	Aug DISC

VALPROATE SODIUM

INJECTABLE; INJECTION

VALPROATE SODIUM

>D>	AP	ATHENEX INC	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Aug CAHN
>A>	AP	SAGENT	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Aug CAHN

VALPROIC ACID

SYRUP; ORAL

VALPROIC ACID

AA	QUAGEN	250MG/5ML	A090517	001	May 28, 2010	Apr CAHN
	@ XTTRIUM LABS INC	250MG/5ML	A070868	001	Jul 01, 1986	Mar CAHN

VALSARTAN

SOLUTION; ORAL

VALSARTAN

! NOVITIUM PHARMA

20MG/5ML

A214102 001 Nov 02, 2021 Jan CHRS

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION; ORAL

VANCOCIN HYDROCHLORIDE

AA	! ANJ PHARMS	EQ 250MG BASE/5ML	A061667	002	Jul 13, 1983	Jun CTEC
AA	AMNEAL	EQ 250MG BASE/5ML	A215338	001	Jun 23, 2023	Jun NEWA

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

AP	GLAND PHARMA LTD	EQ 5GM BASE/VIAL	A205694	003	Jun 06, 2023	May NEWA
AP		EQ 10GM BASE/VIAL	A205694	004	Jun 06, 2023	May NEWA
AP	HIKMA	EQ 1GM BASE/VIAL	A203300	002	Aug 11, 2020	Jan CMFD

POWDER; INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

AP	EUGIA PHARMA	EQ 1.25GM BASE/VIAL	A217401	001	Aug 04, 2023	Jul NEWA
AP		EQ 1.5GM BASE/VIAL	A217401	002	Aug 04, 2023	Jul NEWA
AP	HIKMA	EQ 1.25GM BASE/VIAL	A217489	001	Jun 29, 2023	Jun NFTG
AP		EQ 1.5GM BASE/VIAL	A217489	002	Jun 29, 2023	Jun NFTG
AP	+! MYLAN LABS LTD	EQ 1.25GM BASE/VIAL	N209481	003	Jul 10, 2018	Jun CFTG
AP	+!	EQ 1.5GM BASE/VIAL	N209481	004	Jul 10, 2018	Jun CFTG
	POWDER; INTRAVENOUS, ORAL					
	VANCOMYCIN HYDROCHLORIDE					
+!	ZHEJIANG NOVUS PHARM	EQ 500MG BASE/VIAL	N210274	001	Jan 20, 2023	Jan NEWA
+!		EQ 1GM BASE/VIAL	N210274	002	Jan 20, 2023	Jan NEWA
+!		EQ 5GM BASE/VIAL	N210274	003	Jan 20, 2023	Jan NEWA
+!		EQ 10GM BASE/VIAL	N210274	004	Jan 20, 2023	Jan NEWA

VARENICLINE TARTRATE

TABLET; ORAL

VARENICLINE TARTRATE

>A>	AB	ALKEM LABS LTD	EQ 0.5MG BASE	A214557	001	Aug 23, 2023	Aug NEWA
>A>	AB		EQ 1MG BASE	A214557	002	Aug 23, 2023	Aug NEWA
	AB	APOTEX	EQ 0.5MG BASE	A201962	001	Jan 25, 2023	Jan NEWA
	AB		EQ 1MG BASE	A201962	002	Jan 25, 2023	Jan NEWA
	AB	MANKIND PHARMA	EQ 0.5MG BASE	A214255	001	Aug 01, 2023	Jul NEWA
	AB		EQ 1MG BASE	A214255	002	Aug 01, 2023	Jul NEWA
	AB	MEDLEY PHARMS	EQ 0.5MG BASE	A217151	001	Jul 25, 2023	Jul NEWA
	AB		EQ 1MG BASE	A217151	002	Jul 25, 2023	Jul NEWA
	AB	PAR PHARM INC	EQ 0.5MG BASE	A201785	001	Aug 11, 2021	Jan CTEC
	AB	!	EQ 1MG BASE	A201785	002	Aug 11, 2021	Jan CTEC
	AB	ZYDUS	EQ 0.5MG BASE	A216723	001	Jun 12, 2023	Jun CAHN
	AB		EQ 1MG BASE	A216723	002	Jun 12, 2023	Jun CAHN
	AB	ZYDUS PHARMS	EQ 0.5MG BASE	A216723	001	Jun 12, 2023	Jun NEWA
	AB		EQ 1MG BASE	A216723	002	Jun 12, 2023	Jun NEWA

VASOPRESSIN

SOLUTION; INTRAVENOUS

VASOPRESSIN

AP	+!	AM REGENT	200UNITS/10ML (20UNITS/ML)	N212593	002	Jun 09, 2023	Jul NEWA
		FRESENIUS KABI USA	20UNITS/ML (20UNITS/ML)	A213206	001	May 26, 2023	May NEWA
		VASOSTRICT					
	+!	PAR STERILE PRODUCTS	50UNITS/50ML (1UNITS/ML)	N204485	006	Apr 12, 2023	Apr NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB	GRANULES	EQ 37.5MG BASE	A217390	001	May 18, 2023	May NEWA
AB		EQ 75MG BASE	A217390	002	May 18, 2023	May NEWA
AB		EQ 150MG BASE	A217390	003	May 18, 2023	May NEWA
AB	NOSTRUM PHARMS LLC	EQ 37.5MG BASE	A200430	001	Apr 04, 2023	Mar NEWA
AB		EQ 75MG BASE	A200430	002	Apr 04, 2023	Mar NEWA
AB		EQ 150MG BASE	A200430	003	Apr 04, 2023	Mar NEWA
>D> AB	TORRENT	EQ 37.5MG BASE	A090899	001	Jun 01, 2011	Aug DISC
>A>	@	EQ 37.5MG BASE	A090899	001	Jun 01, 2011	Aug DISC
>D> AB		EQ 75MG BASE	A090899	002	Jun 01, 2011	Aug DISC
>A>	@	EQ 75MG BASE	A090899	002	Jun 01, 2011	Aug DISC
>D> AB		EQ 150MG BASE	A090899	003	Jun 01, 2011	Aug DISC
>A>	@	EQ 150MG BASE	A090899	003	Jun 01, 2011	Aug DISC
TABLET;ORAL						
VENLAFAXINE HYDROCHLORIDE						
	@ CHARTWELL RX	EQ 25MG BASE	A077515	001	Jun 13, 2008	Jan CAHN
	@	EQ 37.5MG BASE	A077515	002	Jun 13, 2008	Jan CAHN
	@	EQ 50MG BASE	A077515	003	Jun 13, 2008	Jan CAHN
	@	EQ 75MG BASE	A077515	004	Jun 13, 2008	Jan CAHN
	@	EQ 100MG BASE	A077515	005	Jun 13, 2008	Jan CAHN
TABLET, EXTENDED RELEASE;ORAL						
VENLAFAXINE HYDROCHLORIDE						
AB	AJANTA PHARMA LTD	EQ 37.5MG BASE	A214691	001	Apr 12, 2023	Mar NEWA
AB		EQ 75MG BASE	A214691	002	Apr 12, 2023	Mar NEWA
AB		EQ 150MG BASE	A214691	003	Apr 12, 2023	Mar NEWA
AB		EQ 225MG BASE	A214691	004	Apr 12, 2023	Mar NEWA

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CALAN SR

+ @ PFIZER	120MG	N019152	003	Mar 06, 1991	Mar DISC
+ @	240MG	N019152	001	Dec 16, 1986	Mar DISC

VERAPAMIL HYDROCHLORIDE

AB	CADILA PHARMS LTD	120MG	A206173	003	Nov 14, 2022	Mar NEWA
AB	! GLENMARK GENERICS	120MG	A090700	001	Aug 03, 2011	Mar CHRS
AB	!	240MG	A078906	001	Sep 17, 2009	Mar CHRS

VIGABATRIN

FOR SOLUTION;ORAL

VIGABATRIN

@ ACCORD HLTHCARE	500MG/PACKET	A214425	001	Nov 13, 2020	Mar DISC	
@ CHARTWELL RX	500MG/PACKET	A211790	001	Mar 10, 2022	May CAHN	
@ ZYDUS	500MG/PACKET	A214671	001	Mar 02, 2023	Jul DISC	
AA		500MG/PACKET	A214671	001	Mar 02, 2023	Feb NEWA

TABLET;ORAL

VIGABATRIN

AB	PROPEL PHARMA	500MG	A215519	001	Apr 28, 2023	Apr NEWA
AB	ZENARA	500MG	A214749	001	Jun 29, 2023	Jun NEWA

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VIIBRYD

AB	+! ABBVIE	10MG	N022567	001	Jan 21, 2011	Jan CAHN
AB	+	20MG	N022567	002	Jan 21, 2011	Jan CAHN
AB	+	40MG	N022567	003	Jan 21, 2011	Jan CAHN

VILAZODONE HYDROCHLORIDE

AB	APOTEX	10MG	A208228	001	Jul 07, 2023	Jun NEWA
AB		20MG	A208228	002	Jul 07, 2023	Jun NEWA
AB		40MG	A208228	003	Jul 07, 2023	Jun NEWA

VORICONAZOLE

INJECTABLE;INTRAVENOUS

VORICONAZOLE

>D> AP	EUGIA PHARMA	200MG/VIAL	A212162	001	Feb 02, 2023	Aug DISC
>A>	@	200MG/VIAL	A212162	001	Feb 02, 2023	Aug DISC
AP		200MG/VIAL	A212162	001	Feb 02, 2023	Jan NEWA
AP	UBI	200MG/VIAL	A211264	001	Mar 09, 2023	Mar NEWA
AP	XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	Mar CDFR

TABLET;ORAL
VORICONAZOLE

AB	CHARTWELL RX	50MG	A207371	001	May 24, 2016	Apr CAHN
AB		200MG	A207371	002	May 24, 2016	Apr CAHN

VUTRISIRAN SODIUM

SOLUTION;SUBCUTANEOUS
AMVUTTRA

+!	ALNYLAM PHARMS INC	EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML)	N215515	001	Jun 13, 2022	Feb CPOT
+!		25MG/0.5ML (25MG/0.5ML)	N215515	001	Jun 13, 2022	Feb CAIN

WARFARIN SODIUM

TABLET;ORAL
WARFARIN SODIUM

@	AUROBINDO PHARMA USA	1MG	A040415	001	Sep 27, 2004	May CAHN
@		2MG	A040415	002	Sep 27, 2004	May CAHN
@		2.5MG	A040415	003	Sep 29, 2004	May CAHN
@		3MG	A040415	004	Sep 27, 2004	May CAHN
@		4MG	A040415	005	Sep 27, 2004	May CAHN
@		5MG	A040415	006	Sep 27, 2004	May CAHN
@		6MG	A040415	007	Sep 27, 2004	May CAHN
@		7.5MG	A040415	008	Sep 27, 2004	May CAHN
@		10MG	A040415	009	Sep 27, 2004	May CAHN

XENON XE-129 HYPERPOLARIZED

GAS;INHALATION
XENOVIEW

+!	POLAREAN	N/A	N214375	001	Dec 23, 2022	Jan NEWA
----	----------	-----	---------	-----	--------------	----------

ZAVEGEPAINT HYDROCHLORIDE

SPRAY, METERED;NASAL
ZAVZPRET

+!	Pfizer	EQ 10MG BASE/SPRAY	N216386	001	Mar 09, 2023	Mar NEWA
----	--------	--------------------	---------	-----	--------------	----------

ZILEUTON

TABLET, EXTENDED RELEASE;ORAL
ZILEUTON

>A> AB	AIZANT	600MG	A211390	001	Oct 23, 2020	Aug CAHN
>D> AB	DASH PHARMS	600MG	A211390	001	Oct 23, 2020	Aug CAHN
AB	! RISING ZYFLO CR	600MG	A204929	001	Mar 17, 2017	Jan CHRS
+ @	CHIESI	600MG	N022052	001	May 30, 2007	Jan DISC

ZINC SULFATE

SOLUTION;INTRAVENOUS
ZINC SULFATE

AP	FRESENIUS KABI USA	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A216145	001	Dec 27, 2022	May CAIN
AP		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A216145	002	Dec 27, 2022	May CAIN
AP		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A216145	003	Dec 27, 2022	May CAIN
>A> AP	GLAND PHARMA LTD	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A216249	003	Sep 01, 2023	Aug NEWA
>A> AP	ZYDUS PHARMS	EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A217074	003	Aug 22, 2023	Aug NEWA
>A> AP		EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A217074	001	Aug 22, 2023	Aug NEWA
>A> AP		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A217074	002	Aug 22, 2023	Aug NEWA

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS
RECLAST

AP	+! SANDOZ ZOLEDRONIC ACID	EQ 5MG BASE/100ML	N021817	001	Apr 16, 2007	May CAHN
>A> AP	CHARTWELL RX	EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Aug CAHN
>A> AP		EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Aug CAHN
>D> AP	HONG KONG	EQ 5MG BASE/100ML	A213371	001	Jun 05, 2023	Aug CAHN
AP		EQ 5MG BASE/100ML	A213371	001	Jun 05, 2023	May NEWA
AP	+ INFORLIFE @ INGENUS PHARMS LLC	EQ 4MG BASE/100ML EQ 4MG BASE/5ML	N203231	001	Aug 02, 2013	Jul CRLD
>A> AP	MEITHEAL	EQ 5MG BASE/100ML	A208968	001	Feb 19, 2020	Jun DISC
>D> AP	PII	EQ 4MG BASE/5ML	A213371	001	Jun 05, 2023	Aug CAHN
AP		EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Aug CAHN
>D> AP		EQ 5MG BASE/100ML	A202571	001	May 07, 2013	Jul CAHN
AP		EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Aug CAHN
AP		EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Jul CAHN

ZOLMITRIPTAN

	SPRAY;NASAL					
	ZOMIG					
AB	+ AMNEAL	2.5MG/SPRAY	N021450	003	Sep 16, 2013	Jan CAHN
AB	+!	5MG/SPRAY	N021450	004	Sep 30, 2003	Jan CAHN
	TABLET;ORAL					
	ZOLMITRIPTAN					
AB	! AJANTA PHARMA LTD	5MG	A204041	002	May 20, 2016	Jun CHRS
	ZOMIG					
	+ @ IPR	2.5MG	N020768	001	Nov 25, 1997	Jun DISC
	+ @	5MG	N020768	002	Nov 25, 1997	Jun DISC
	TABLET, ORALLY DISINTEGRATING;ORAL					
	ZOLMITRIPTAN					
AB	! ZYDUS PHARMS USA INC	5MG	A202890	002	May 15, 2013	Jun CHRS
	ZOMIG-ZMT					
	+ @ ASTRAZENECA	2.5MG	N021231	001	Feb 13, 2001	Jun DISC
	+ @	5MG	N021231	002	Sep 17, 2001	Jun DISC

ZOLPIDEM TARTRATE

	CAPSULE;ORAL					
	ZOLPIDEM TARTRATE					
	+! ALMATICHA	7.5MG	N215721	001	May 09, 2023	May NEWA
	TABLET, EXTENDED RELEASE;ORAL					
	ZOLPIDEM TARTRATE					
	@ ANCHEN PHARMS	6.25MG	A078148	002	Apr 14, 2011	May DISC
	@	12.5MG	A078148	001	Dec 03, 2010	May DISC
>D> AB	BRECKENRIDGE	6.25MG	A213592	001	Jun 04, 2020	Aug DISC
>A>	@	6.25MG	A213592	001	Jun 04, 2020	Aug DISC
>D> AB		12.5MG	A213592	002	Jun 04, 2020	Aug DISC
>A>	@	12.5MG	A213592	002	Jun 04, 2020	Aug DISC

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL

EXCEDRIN (MIGRAINE RELIEF)

+! GLAXOSMITHKLINE CONS 250MG;250MG;65MG

N020802 001 Jan 14, 1998 Apr CTNA

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

ACETAMINOPHEN AND IBUPROFEN

BIONPHARMA 250MG;125MG

A216999 001 Aug 01, 2023 Jul NEWA

GRANULES 250MG;125MG

A216592 001 Jul 13, 2023 Jul NEWA

L PERRIGO CO 250MG;125MG

A214836 001 Feb 28, 2023 Feb NEWA

MARKSANS PHARMA 250MG;125MG

A216994 001 Jul 10, 2023 Jun NEWA

ALCAFTADINE

SOLUTION/DROPS;OPHTHALMIC

ALCAFTADINE

EUGIA PHARMA 0.25%

A210659 001 Jun 23, 2023 Jun NEWA

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE;ORAL

FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE

>D> PERRIGO R AND D 800MG;10MG;165MG

A204782 001 Aug 29, 2016 Aug DISC

>A> @ 800MG;10MG;165MG

A204782 001 Aug 29, 2016 Aug DISC

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

>D> APOTEX 10MG

A207235 001 Aug 12, 2016 Aug DISC

>A> @ 10MG

A207235 001 Aug 12, 2016 Aug DISC

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SOLUTION;TOPICAL

SOLUPREP S

+! 3M HEALTH CARE 2%;70%

N208288 001 Aug 08, 2018 Mar CTNA

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

DR REDDYS 30MG;600MG

A217340 001 Aug 01, 2023 Jul NEWA

60MG;1.2GM

A217340 002 Aug 01, 2023 Jul NEWA

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

COREPHARMA 25MG;220MG

A211830 001 Aug 22, 2019 Feb CAHN

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

>D> GUARDIAN DRUG EQ 20MG BASE

A216149 001 Mar 15, 2023 Mar NEWA

HETERO LABS LTD III EQ 20MG BASE

A208939 001 May 28, 2020 Aug DISC

>A> @ EQ 20MG BASE

A208939 001 May 28, 2020 Aug DISC

TABLET, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

AUROBINDO PHARMA LTD EQ 20MG BASE

A214473 001 Jul 12, 2023 Jun NEWA

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

MARKSANS PHARMA 10MG

A217543 001 Mar 08, 2023 Feb NEWA

20MG

A217543 002 Mar 08, 2023 Feb NEWA

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL

FEXOFENADINE HYDROCHLORIDE

AUROBINDO PHARMA LTD 30MG/5ML

A213466 001 May 23, 2023 May NEWA

TABLET;ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

AUROBINDO PHARMA USA 30MG

A202039 001 Nov 19, 2014 Apr CAHN

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE ALLERGY
AUROBINDO PHARMA USA 60MG
180MG

A202039 002 Nov 19, 2014 Apr CAHN
A202039 003 Nov 19, 2014 Apr CAHN

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL
GUAIFENESIN

>A> MARKSANS PHARMA 600MG A217780 001 Aug 21, 2023 Aug NEWA
>A> 1.2GM A217780 002 Aug 21, 2023 Aug NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE
@ GRANULES 600MG;60MG A216082 001 Aug 22, 2022 Feb DISC
@ 1.2GM;120MG A216082 002 Aug 22, 2022 Feb DISC

IBUPROFEN

SUSPENSION;ORAL
IBUPROFEN
@ ARISE 100MG/5ML A200457 001 Aug 18, 2011 Jun DISC
SUSPENSION/DROPS;ORAL
IBUPROFEN
TARO PHARMS 40MG/ML A217261 001 Aug 08, 2023 Jul NEWA

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC
KETOTIFEN FUMARATE
>D> AKORN EQ 0.025% BASE A077958 001 Jul 26, 2007 Aug CAHN
>A> SENTISS EQ 0.025% BASE A077958 001 Jul 26, 2007 Aug CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE
>D> MYLAN 15MG A203187 001 Jun 01, 2016 Aug DISC
>A> @ 15MG A203187 001 Jun 01, 2016 Aug DISC

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE
@ GRANULES 2MG;125MG A215981 001 Aug 29, 2022 Feb DISC

LORATADINE

TABLET;ORAL
LORATADINE
HETERO LABS LTD V 10MG A211718 001 Jul 28, 2023 Jul NEWA

MOMETASONE FUROATE

SPRAY, METERED;NASAL
MOMETASONE FUROATE
AMNEAL 0.05MG/SPRAY A217460 001 Jun 14, 2023 Jun NFTG

NALOXONE HYDROCHLORIDE

SPRAY, METERED;NASAL
NALOXONE HYDROCHLORIDE
PADAGIS ISRAEL 4MG/SPRAY A211951 001 Jun 21, 2022 Jul CMKT
NARCAN
+! EMERGENT 4MG/SPRAY N208411 001 Nov 18, 2015 Mar CMKT
RIVIVE
+! HARM REDUCTION THERP 3MG/SPRAY N217722 001 Jul 28, 2023 Jul NEWA

NAPROXEN SODIUM

CAPSULE;ORAL
NAPROXEN SODIUM
@ STRIDES PHARMA EQ 200MG BASE A215472 001 Aug 17, 2022 Feb DISC

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL
NICOTINE POLACRILEX
@ FERTIN PHARMA

EQ 4MG BASE

A214354 001 Dec 21, 2022 Jun DISC

NORGESTREL

TABLET;ORAL
OPILL
+ @ LABORATOIRE HRA

0.075MG

N017031 001

Jul CMKT

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE
@ AKORN EQ 0.1% BASE
@ EQ 0.2% BASE

A204532 001 Jan 10, 2017 Jan DISC
A204723 001 Dec 05, 2017 Jan DISC

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL
OMEPRAZOLE MAGNESIUM
AUROBINDO PHARMA LTD EQ 20MG BASE

A213201 001 Apr 28, 2023 Apr NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL
OMEPRAZOLE AND SODIUM BICARBONATE
AUROBINDO PHARMA 20MG;1.1GM
ZYDUS 20MG;1.1GM

A204923 001 Nov 07, 2016 Jun CAHN
A203345 001 Mar 16, 2018 May CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 8 AUGUST 2023

NO AUGUST 2023 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO AUGUST 2023 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551 001	8129385	Oct 05, 2027	DS DP		M-294	Jun 15, 2026
	8129385*PED	Apr 05, 2028			PED	Dec 15, 2026
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ PD</u>						
N 215413 001	8129385	Oct 05, 2027	DS DP		NPP	Jun 15, 2026
	8129385*PED	Apr 05, 2028			PED	Dec 15, 2026
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	11680942	Jan 10, 2040	U-3322		I-907	Dec 19, 2025
	8748382	Oct 03, 2027	U-2009			
	8748382	Oct 03, 2027	U-3543			
	RE49444	Apr 28, 2031	U-2009			
	RE49444	Apr 28, 2031	U-3543			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	7855211	Dec 15, 2029	DS DP U-2132			
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
	7855211	Dec 15, 2029	DS DP U-3265			
	7855211	Dec 15, 2029	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	7855211	Dec 15, 2029	DS DP U-2132			
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
	7855211	Dec 15, 2029	DS DP U-3265			
	7855211	Dec 15, 2029	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 003	7855211	Dec 15, 2029	DS DP U-2132			
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
	7855211	Dec 15, 2029	DS DP U-3265			
	7855211	Dec 15, 2029	DS DP U-3546			
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 001	>A> 11091459	Mar 27, 2038	DS DP			
	>A> 11673877	Mar 27, 2038	DS DP			
	>A> 8071623	Mar 27, 2031	DS DP			
	>A> 8436185	Apr 24, 2029	DS DP			
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 002	>A> 11091459	Mar 27, 2038	DS DP			
	>A> 11673877	Mar 27, 2038	DS DP			
	>A> 8071623	Mar 27, 2031	DS DP			
	>A> 8436185	Apr 24, 2029	DS DP			
<u>ABROCITINIB - CIBINOO</u>						
N 213871 001					NPP	Feb 09, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABROCITINIB - CIBINOO</u>						
N 213871 002					NPP	Feb 09, 2026
<u>ABROCITINIB - CIBINOO</u>						
N 213871 003					NPP	Feb 09, 2026
<u>ACETAMINOPHEN; IBUPROFEN - COMBOGESIC</u>						
N 209471 001	10532036	Sep 22, 2025	U-3553		NP	Mar 01, 2026
	11197830	Feb 27, 2039	DP U-3553			
	11534407	Feb 27, 2039	DP U-3553			
<u>ADAGRASIB - KRAZATI</u>						
N 216340 001					NCE ODE-352	Dec 12, 2027 Dec 12, 2029
<u>ALBUTEROL SULFATE; BUDESONIDE - AIRSUPRA</u>						
N 214070 001	9415009	May 28, 2030	U-3509		NP	Jan 10, 2026
<u>ALENDRONATE SODIUM - ALENDRONATE SODIUM</u>						
A 214512 001					CGT	Nov 20, 2023
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001					>A> M-300	Jul 27, 2026
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002					>A> M-300	Jul 27, 2026
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003					>A> M-300	Jul 27, 2026
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001					>A> M-300	Jul 27, 2026
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002					>A> M-300	Jul 27, 2026
<u>ALPELISIB - PIORAY</u>						
N 212526 001	8227462	Apr 29, 2033	DS DP U-2539			
<u>ALPELISIB - PIORAY</u>						
N 212526 002	8227462	Apr 29, 2033	DS DP U-2539			
<u>ALPELISIB - PIORAY</u>						
N 212526 003	8227462	Apr 29, 2033	DS DP U-2539			
<u>ALPELISIB - VIJOICE</u>						
N 215039 001	8227462	Apr 29, 2033	DS DP		ODE-396	Apr 05, 2029
<u>ALPELISIB - VIJOICE</u>						
N 215039 002	8227462	Apr 29, 2033	DS DP		ODE-396	Apr 05, 2029
<u>ALPELISIB - VIJOICE</u>						
N 215039 003	8227462	Apr 29, 2033	DS DP		ODE-396	Apr 05, 2029
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001	11571478	Jan 12, 2038	U-3163			
	11690914	Jan 12, 2038	U-3163			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081 001	11540981	Feb 07, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	11701326	Oct 06, 2037	DP			
<u>AMLODIPINE BESYLATE - NORLIQVA</u>						
N 214439 001	>A> 11723866	Feb 24, 2041	DP U-3309			
	>A> 11723866	Feb 24, 2041	DP U-3310			
	>A> 11723866	Feb 24, 2041	DP U-3311			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR</u>						
N 208147 001	11590228	Sep 07, 2036	DP U-3538			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 5</u>						
N 210526 001	11590081	Sep 24, 2038	DP U-3538			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 10</u>						
N 210526 002	11590081	Sep 24, 2038	DP U-3538			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 15</u>						
N 210526 003	11590081	Sep 24, 2038	DP U-3538			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 20</u>						
N 210526 004	11590081	Sep 24, 2038	DP U-3538			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001	11559559	Dec 18, 2034	U-3514			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002	11559559	Dec 18, 2034	U-3514			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 003	11559559	Dec 18, 2034	U-3514			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	10052314	Sep 23, 2033	U-2381	Y		
	10052314	Sep 23, 2033	U-2382	Y		
	9481663	Jun 04, 2033	DS DP U-2237			
	9481663	Jun 04, 2033	DS DP U-2624			
	RE49353	Sep 23, 2033	U-2381			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 002	10702508	Apr 30, 2038	U-3012			
	10849888	Sep 23, 2033	U-3013			
	8445507	Sep 15, 2030	DS DP U-2237			
	8445507	Sep 15, 2030	DS DP U-2624			
	8802689	Mar 27, 2027	U-2237			
	8802689	Mar 27, 2027	U-2624			
	9388159	Mar 27, 2027	DS DP			
	9481663	Jun 04, 2033	DS DP U-2237			
	9481663	Jun 04, 2033	DS DP U-2624			
	9884054	Sep 23, 2033	U-2237			
	9987261	Mar 27, 2027	DP			
	RE49353	Sep 23, 2033	U-2381			
<u>APREMILAST - OTEZLA</u>						
N 205437 001				>A> M-299		Jul 20, 2026
<u>APREMILAST - OTEZLA</u>						
N 205437 002				>A> M-299		Jul 20, 2026
<u>APREMILAST - OTEZLA</u>						
N 205437 003				>A> M-299		Jul 20, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	11648347	Apr 06, 2034	DP			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	11648347	Apr 06, 2034	DP			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	11648347	Apr 06, 2034	DP			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	11648347	Apr 06, 2034	DP			
<u>ARIPIPRAZOLE - ABILIFY ASIMTUFII</u>						
N 217006 001	10517951	Apr 23, 2033	DP U-3245			
	10517951	Apr 23, 2033	DP U-814			
	11097007	Apr 23, 2033	DP U-3245			
	11097007	Apr 23, 2033	DP U-814			
	11638757	Apr 23, 2033	DP U-3245			
	11638757	Apr 23, 2033	DP U-814			
	8338427	Mar 15, 2025	DP U-1530			
	8338428	Aug 06, 2023	DP U-1530			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
<u>ARIPIPRAZOLE - ABILIFY ASIMTUFII</u>						
N 217006 002	10517951	Apr 23, 2033	DP U-3245			
	10517951	Apr 23, 2033	DP U-814			
	11097007	Apr 23, 2033	DP U-3245			
	11097007	Apr 23, 2033	DP U-814			
	11638757	Apr 23, 2033	DP U-3245			
	11638757	Apr 23, 2033	DP U-814			
	8338427	Mar 15, 2025	DP U-1530			
	8338428	Aug 06, 2023	DP U-1530			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
<u>ASPIRIN - VAZALORE</u>						
N 203697 001	10646431	Sep 29, 2032	DP			
	10786444	Sep 29, 2032	U-3559			
<u>ASPIRIN - VAZALORE</u>						
N 203697 002	10646431	Sep 29, 2032	DP			
	10786444	Sep 29, 2032	U-3559			
<u>ATOGEPANT - OULIPTA</u>						
N 215206 001	8754096	Jul 19, 2032	DS DP U-3534	I-909	Apr 17, 2026	
	9499545	Nov 10, 2031	DS DP U-3534			
<u>ATOGEPANT - OULIPTA</u>						
N 215206 002	8754096	Jul 19, 2032	DS DP U-3534	I-909	Apr 17, 2026	
	9499545	Nov 10, 2031	DS DP U-3534			
<u>ATOGEPANT - OULIPTA</u>						
N 215206 003	8754096	Jul 19, 2032	DS DP U-3534	I-909	Apr 17, 2026	
	9499545	Nov 10, 2031	DS DP U-3534			
<u>ATORVASTATIN CALCIUM - ATORVALTO</u>						
N 213260 001	11369567	Jun 07, 2037	DP			
	11654106	Jun 07, 2037	DP U-3612			
	11654106	Jun 07, 2037	DP U-3613			
<u>AVACINCAPTAD PEGOL SODIUM - IZERVAY</u>						
N 217225 001	>A> 10947544	Feb 14, 2025	DS	U-3673		
	>A> 11273171	Jul 11, 2034		U-3673		
	>A> 11491176	Jul 11, 2034		U-3673		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVACINCAPTAD PEGOL SODIUM - IZERVAY</u>						
N 217225 001	>A> 7538211	Feb 14, 2025	DS			
	>A> 7579456	Feb 14, 2025	DS			
	>A> 7803931	Feb 14, 2025	DS			
	>A> 8236773	Nov 11, 2026	U-3673			
	>A> 9617546	Feb 14, 2025	DS	U-3673		
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001	11603356	May 29, 2041	DS DP U-3558			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 001					ODE-434	May 22, 2030
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 002					ODE-434	May 22, 2030
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 003					ODE-434	May 22, 2030
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 004	9200002	Oct 15, 2034	DS DP U-3168		I-912	May 22, 2026
	9200002	Oct 15, 2034	DS DP U-3506		ODE-434	May 22, 2030
	9944651	Oct 15, 2034	DS DP U-3168			
	9944651	Oct 15, 2034	DS DP U-3506			
	9994575	Oct 15, 2034	DS DP U-3168			
	9994575	Oct 15, 2034	DS DP U-3506			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 005					ODE-434	May 22, 2030
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001					NPP	Dec 20, 2025
<u>AZACITIDINE - VIDAZA</u>						
N 050794 001					ODE-399	May 20, 2029
<u>AZACITIDINE - ONUREG</u>						
N 214120 001	11571436	May 14, 2029	DP			
<u>AZACITIDINE - ONUREG</u>						
N 214120 002	11571436	May 14, 2029	DP			
<u>BACLOFEN - BACLOFEN</u>						
A 217252 001					PC	Dec 16, 2023
<u>BACLOFEN - LYVISPAH</u>						
N 215422 001	11654124	Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 002	11654124	Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 003	11654124	Jul 29, 2039	DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001	9737469	Nov 02, 2031	U-3500			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 002	9737469	Nov 02, 2031	U-3500			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BARICITINIB - OLUMIANT</u>						
N 207924 003	9737469	Nov 02, 2031		U-3500		
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 001	11559637	Jul 21, 2039		DP		
	11583643	Aug 19, 2041		DP		
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 002	11559637	Jul 21, 2039		DP		
	11583643	Aug 19, 2041		DP		
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	11613511	Jun 19, 2040		DS		
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	11613511	Jun 19, 2040		DS		
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	9533955	Mar 26, 2029		DP U-1949		
	9533955	Mar 26, 2029		DP U-1952		
	9533955*PED	Sep 26, 2029				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	9533955	Mar 26, 2029		DP U-1949		
	9533955	Mar 26, 2029		DP U-1952		
	9533955*PED	Sep 26, 2029				
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	11541026	Feb 19, 2040		U-3356		
	11628155	Dec 27, 2040		U-3356		
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYQ</u>						
N 214094 001	11618733	Nov 01, 2039		U-3300		
>A>	11708333	Mar 09, 2035		U-3300		
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 002	11618733	Nov 01, 2039		U-3300		
>A>	11708333	Mar 09, 2035		U-3300		
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - WYNZORA</u>						
N 213422 001 >A>	11696919	Mar 18, 2039		DP		
<u>BEXAGLIFLOZIN - BRENZAVVY</u>						
N 214373 001	10533032	Jul 03, 2031		U-2214		
	10981942	Jun 13, 2031	DS DP			
	7838499	Jan 30, 2029	DS DP	U-2214		
	8106021	Aug 22, 2028		U-2214		
	8802637	Aug 22, 2028	DS DP	U-2214		
	8987323	May 14, 2032	DS DP			
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	7777050	Mar 13, 2024	DS DP			
<u>BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE - BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE</u>						
A 217511 001					CGT	Dec 29, 2023
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 215331 001	11679119	Sep 23, 2042		U-3632		
	11679119	Sep 23, 2042		U-3633		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 215331 002	11679119	Sep 23, 2042	U-3632			
	11679119	Sep 23, 2042	U-3633			
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557 001	11590209	Apr 29, 2041	U-3539			
<u>BREXPIPRAZOLE - REXULTI</u>						
N 205422 001				I-913		May 10, 2026
<u>BREXPIPRAZOLE - REXULTI</u>						
N 205422 002				I-913		May 10, 2026
<u>BREXPIPRAZOLE - REXULTI</u>						
N 205422 003				I-913		May 10, 2026
<u>BREXPIPRAZOLE - REXULTI</u>						
N 205422 004				I-913		May 10, 2026
<u>BREXPIPRAZOLE - REXULTI</u>						
N 205422 005				I-913		May 10, 2026
<u>BREXPIPRAZOLE - REXULTI</u>						
N 205422 006				I-913		May 10, 2026
<u>BRIMONIDINE TARTRATE - LUMIFY</u>						
N 208144 001	11596600	Jul 27, 2029	U-2222			
<u>BUDESONIDE - BUDESONIDE</u>						
A 215328 001				CGT		Oct 24, 2023
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001				ODE-389		Dec 15, 2028
<u>BUDESONIDE; FORMOTEROL FUMARATE - SYMBICORT AEROSPHERE</u>						
N 216579 001	10716753	May 28, 2030	DP U-3203			
	9415009	May 28, 2030	U-3203			
<u>BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - BREZTRI AEROSPHERE</u>						
N 212122 001	>A> 11331442	Oct 05, 2038	DP			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 001	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 002	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 003	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 003	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 004	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 005	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 006	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	11534414	Nov 05, 2034	DP U-3419		NP	May 23, 2026
	11541021	Nov 05, 2034	U-3419			
	11541048	Nov 05, 2034	U-3419			
	11596627	Nov 05, 2034	U-3419			
	11617728	Nov 05, 2034	U-3419			
	11617747	Nov 05, 2034	U-3563			
>A>	11717518	Jan 20, 2043	U-3662			
>A>	11730706	Jan 23, 2043	U-3419			
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	11554102	Jan 11, 2033	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	11576894	Jul 06, 2030	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	11576894	Jul 06, 2030	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	11576894	Jul 06, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	11576894	Jul 06, 2030	DP			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	11633369	Jun 17, 2035	DP U-2780			
	11633369	Jun 17, 2035	DP U-2781			
	11633369	Jun 17, 2035	DP U-3071			
>A>	11701330	Jun 17, 2035	U-2780			
>A>	11701330	Jun 17, 2035	U-2781			
<u>CANTHARIDIN - YCANTH</u>						
N 212905 001	>A> 11052064	May 28, 2035	DP U-3663			
	>A> 11052064	May 28, 2035	DP U-3665			
	>A> 11147790	Aug 22, 2038	DP U-3663			
	>A> 11147790	Aug 22, 2038	DP U-3664			
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030 001	11529357	Jan 31, 2040	DP			
<u>CARBIDOPA; LEVODOPA - DHIVY</u>						
N 214869 001	11439613	Mar 28, 2039	U-3557			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	7737142	Sep 17, 2029	DS DP U-1750	I-904	Dec 16, 2025	
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142	Sep 17, 2029	DS DP U-2545			
	7737142	Sep 17, 2029	DS DP U-3503			
	RE47350	Jul 16, 2029	U-1750			
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
	RE47350	Jul 16, 2029	U-3503			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7737142	Sep 17, 2029	DS DP U-1750	I-904	Dec 16, 2025	
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142	Sep 17, 2029	DS DP U-2545			
	7737142	Sep 17, 2029	DS DP U-3503			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	RE49302	Jul 16, 2029	U-2543	I-904	Dec 16, 2025	
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	RE49302	Jul 16, 2029	U-2543	I-904	Dec 16, 2025	
	RE49302	Jul 16, 2029	U-2544			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CENOBAKATE - XCOPRI</u>						
N 212839 001	11654133	Jun 16, 2039	U-3610			
<u>CENOBAKATE - XCOPRI</u>						
N 212839 002	11654133	Jun 16, 2039	U-3610			
<u>CENOBAKATE - XCOPRI</u>						
N 212839 003	11654133	Jun 16, 2039	U-3610			
<u>CENOBAKATE - XCOPRI</u>						
N 212839 004	11654133	Jun 16, 2039	U-3610			
<u>CENOBAKATE - XCOPRI</u>						
N 212839 005	11654133	Jun 16, 2039	U-3610			
<u>CENOBAKATE - XCOPRI</u>						
N 212839 006	11654133	Jun 16, 2039	U-3610			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - SOLUPREP S</u>						
N 208288 001					M-292	Jan 20, 2026
<u>CHLOROPROCAINE HYDROCHLORIDE - IHEEZO</u>						
N 216227 001					NP	Sep 27, 2025
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001 >A> 6706276		Mar 06, 2024	DP			
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001	8143240	Jan 12, 2024	U-2942			
	8865690	Jul 24, 2024	U-2942			
	9211295	Jul 24, 2024	DP			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 001	11541002	Jan 31, 2040	DP U-724			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 002	11541002	Jan 31, 2040	DP U-724			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 003	11541002	Jan 31, 2040	DP U-724			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	11597699	Oct 05, 2026	U-3554		ODE-416	Oct 28, 2029
<u>COCAINE HYDROCHLORIDE - NUMBRINO</u>						
N 209575 001 >A> 10016407		Feb 07, 2037	U-2225			
>A> 10016407		Feb 07, 2037	U-2226			
>A> 10016407		Feb 07, 2037	U-2329			
>A> 10149843		Feb 07, 2037	U-2478			
>A> 10149843		Feb 07, 2037	U-2479			
>A> 10231961		Feb 07, 2037	DP			
>A> 10413505		Feb 07, 2037	U-3014			
>A> 10420760		Feb 07, 2037	U-2478			
>A> 10857095		Feb 07, 2037	U-3014			
>A> 10894012		Feb 07, 2037	U-3014			
>A> 10933060		Feb 07, 2037	U-2478			
>A> 10933060		Feb 07, 2037	U-3014			
>A> 10973811		Feb 07, 2037	U-3680			
>A> 11040032		Feb 07, 2037	DP			
>A> 9867815		Feb 07, 2037	U-2225			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COCAINE HYDROCHLORIDE - NUMBRINO</u>						
N 209575 001	>A> 9867815	Feb 07, 2037	U-2226			
	>A> 9867815	Feb 07, 2037	U-2227			
	>A> 9867815	Feb 07, 2037	U-2329			
<u>COLCHICINE - LODOCO</u>						
N 215727 001	10130585	Dec 31, 2034	U-3642			
	10206891	Jan 22, 2035	U-3641			
	10265281	Jan 22, 2035	U-3639			
	10842762	Jan 22, 2035	U-3640			
	11026899	Jan 22, 2035	U-3639			
	11026900	Jan 22, 2035	U-3639			
	11026901	Jan 22, 2035	U-3638			
	9744144	Jan 22, 2035	U-3643			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001				ODE-407		Jul 14, 2029
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002				ODE-407		Jul 14, 2029
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 210852 001	10849916	Jul 13, 2035	DP			
	11382923	Dec 01, 2035	DP			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 210852 002	10849916	Jul 13, 2035	DP			
	11382923	Dec 01, 2035	DP			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 210852 003	10849916	Jul 13, 2035	DP			
	11382923	Dec 01, 2035	DP			
<u>CYCLOSPORINE - VERKAZIA</u>						
N 214965 001	11612658	Jan 27, 2026	U-3560		NP	Jun 23, 2024
<u>CYCLOSPORINE - VEVYEE</u>						
N 217469 001	10813976	Sep 22, 2037	DP		NP	May 30, 2026
	11154513	Nov 20, 2038	DP U-1900			
	11413323	Oct 11, 2039	U-3627			
	8614178	Dec 13, 2030	DP			
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	11642370	Jan 15, 2039	DP			
	11648262	Jan 15, 2039	DP			
	11679125	Jan 15, 2039	DP			
	11684636	Jan 15, 2039	DP			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	11510941	Mar 02, 2039	DP			
	11510942	Jan 15, 2039	DP U-2752			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10028912	Oct 15, 2032	DP U-3149			
	10028912	Oct 15, 2032	DP U-3150			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	10869869	Aug 30, 2033	U-3185		I-894	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7994185	Jan 20, 2030	DS DP U-1406		ODE-147	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2031		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2032		ODE-183	May 04, 2025
	7994185	Jan 20, 2030	DS DP U-2296		ODE-428	Mar 16, 2030
	7994185*PED	Jul 20, 2030			PED	Dec 22, 2024
	8415345	Jan 20, 2030	DS DP U-1406		PED	Oct 30, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 001	8415345	Jan 20, 2030	DS DP U-2031		PED	Nov 04, 2025
	8415345	Jan 20, 2030	DS DP U-2032		PED	Dec 22, 2025
	8415345	Jan 20, 2030	DS DP U-2296			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2027			
	8952018*PED	Apr 15, 2031				
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956*PED	Nov 04, 2029				
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 002	10869869	Aug 30, 2033	U-3185		I-894	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7994185	Jan 20, 2030	DS DP U-1406		ODE-147	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2031		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2032		ODE-183	May 04, 2025
	7994185	Jan 20, 2030	DS DP U-2296		ODE-428	Mar 16, 2030
	7994185*PED	Jul 20, 2030			PED	Dec 22, 2024
	8415345	Jan 20, 2030	DS DP U-1406		PED	Oct 30, 2025
	8415345	Jan 20, 2030	DS DP U-2031		PED	Nov 04, 2025
	8415345	Jan 20, 2030	DS DP U-2032		PED	Dec 22, 2025
	8415345	Jan 20, 2030	DS DP U-2296			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2027			
	8952018*PED	Apr 15, 2031				
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956*PED	Nov 04, 2029				
DABRAFENIB MESYLATE - TAFINLAR						
N 217514 001	11504333	Jun 29, 2038	DP		NP	Mar 16, 2026
	7994185	Jan 20, 2030	DS DP		ODE-428	Mar 16, 2030
	8415345	Jan 20, 2030	DS DP			
	8703781	Oct 15, 2030	DS DP U-3565			
	8835443	Jun 10, 2025	U-3565			
DALBAVANCIN HYDROCHLORIDE - DALVANCE						
N 021883 001	6900175	May 23, 2028	U-3499			
DAPAGLIFLOZIN - FARXIGA						
N 202293 001					M-298	May 08, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002					M-298	May 08, 2026
<u>DAPRODUSTAT - JESDUVROQ</u>						
N 216951 001	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 27, 2023	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROQ</u>						
N 216951 002	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 27, 2023	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROQ</u>						
N 216951 003	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 27, 2023	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROQ</u>						
N 216951 004	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 27, 2023	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROQ</u>						
N 216951 005	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 27, 2023	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	8975254	Mar 25, 2033	DS DP U-2605			
<u>DARUNAVIR - DARUNAVIR</u>						
A 202073 002					PC	Nov 28, 2023
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 001				ODE-417	Apr 30, 2028	
				ODE-420	Apr 30, 2028	
				ODE-421	Apr 30, 2028	
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 002				ODE-417	Apr 30, 2028	
				ODE-420	Apr 30, 2028	
				ODE-421	Apr 30, 2028	
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 001				ODE-417	Apr 30, 2028	
				ODE-418	Apr 30, 2028	
				ODE-419	Apr 30, 2028	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 002					ODE-417 ODE-418 ODE-419	Apr 30, 2028 Apr 30, 2028 Apr 30, 2028
<u>DEFERIPRONE - FERRIPROX</u>						
N 212269 001					ODE-417 ODE-420 ODE-421	Apr 30, 2028 Apr 30, 2028 Apr 30, 2028
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	11446291 11446291*PED 11564917 11564917*PED 11648244 11648244*PED 11666566	Mar 07, 2036 Sep 07, 2036 Mar 07, 2036 Sep 07, 2036 Mar 07, 2036 Sep 07, 2036 Sep 18, 2033	U-1995	DP		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	11446291 11446291*PED 11564917 11564917*PED 11648244 11648244*PED 11666566	Mar 07, 2036 Sep 07, 2036 Mar 07, 2036 Sep 07, 2036 Mar 07, 2036 Sep 07, 2036 Sep 18, 2033	U-1995	DP		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	11446291 11446291*PED 11564917 11564917*PED 11648244 11648244*PED 11666566	Mar 07, 2036 Sep 07, 2036 Mar 07, 2036 Sep 07, 2036 Mar 07, 2036 Sep 07, 2036 Sep 18, 2033	U-1995	DP		
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 001	10959996 10959996*PED 11179386 11179386 11179386*PED 11311488 11311488 11357772 11357772 11357772*PED 11446291 11446291*PED 11564917 11564917*PED 11648244 11648244*PED 8524733 8524733*PED 9550780 9550780 9550780*PED	Mar 07, 2036 Sep 07, 2036 Mar 15, 2038 Mar 15, 2038 Sep 15, 2038 Jun 10, 2041 Jun 10, 2041 Mar 07, 2036 Mar 07, 2036 Sep 07, 2036 Mar 07, 2036 Sep 07, 2036 Mar 07, 2036 Sep 07, 2036 Apr 03, 2031 Oct 03, 2031 Sep 18, 2033 Sep 18, 2033 Mar 18, 2034	U-3055	DP U-1995 DP U-3055 DP U-1995 DP U-3055 DP U-1995 DP U-3055 U-1995 U-1995 U-1995 U-1995 U-1995 U-1995 U-1995 DS DP DS DP U-1995 DS DP U-3055		
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 002	10959996 10959996*PED 11179386 11179386 11179386*PED 11311488	Mar 07, 2036 Sep 07, 2036 Mar 15, 2038 Mar 15, 2038 Sep 15, 2038 Jun 10, 2041	U-3055	DP U-1995 DP U-3055 DP U-1995 DP U-3055		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 002	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 003	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001					NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002					NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003					NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004					NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 005					NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 001	11497711	Jun 26, 2039	DP U-3645			
	11517524	Jun 26, 2039	DP U-3645			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 002	11497711	Jun 26, 2039	DP U-3645			
	11517524	Jun 26, 2039	DP U-3645			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 001	11559501	Jan 06, 2042	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 002	11559501	Jan 06, 2042	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 003	11559501	Jan 06, 2042	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 004	11559501	Jan 06, 2042	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 215813 001	10398785	Mar 14, 2036	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 215813 002	10398785	Mar 14, 2036	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 215813 003	10398785	Mar 14, 2036	DP			
<u>DONEPEZIL HYDROCHLORIDE - ADILARITY</u>						
N 212304 001	11648214	Sep 23, 2037	DP U-3334			
	11679086	May 26, 2037	U-3334			
<u>DONEPEZIL HYDROCHLORIDE - ADILARITY</u>						
N 212304 002	11648214	Sep 23, 2037	DP U-3334			
	11679086	May 26, 2037	U-3334			
<u>DOXEPIN HYDROCHLORIDE - DOXEPIN HYDROCHLORIDE</u>						
A 215408 001				CGT		Aug 16, 2023
<u>DROSPIRENONE; ETHINYLOestradiol; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532 001	11617751	Jul 17, 2030	DP U-1			
	11617751	Jul 17, 2030	DP U-3572			
	11617751	Jul 17, 2030	DP U-3573			
	11617751	Jul 17, 2030	DP U-3574			
<u>DROSPIRENONE; ETHINYLOestradiol; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N 022574 001	11617751	Jul 17, 2030	DP U-1			
	11617751	Jul 17, 2030	DP U-3572			
<u>DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM - XACDURO (COPACKAGED)</u>						
N 216974 001	10376499	Nov 17, 2035	DP U-2840		NCE	May 23, 2028
	9309245	Apr 02, 2033	DS		GAIN	May 23, 2033
	9623014	Apr 02, 2033	U-2840			
	9968593	Nov 17, 2035	DP U-2840			
<u>EDETA TE CALCIUM DISODIUM - EDETA TE CALCIUM DISODIUM</u>						
A 216435 001				CGT		Jan 08, 2024
<u>EFINAConazole - JUBLIA</u>						
N 203567 001	11654139	Oct 02, 2034	U-1969			
<u>ELACESTRANT DIHYDROCHLORIDE - ORSERDU</u>						
N 217639 001	10071066	Oct 10, 2034	U-3524		NCE	Jan 27, 2028
	10385008	Jan 05, 2038	DS DP			
	10420734	Oct 10, 2034	U-3524			
	10745343	Jan 05, 2038	U-3523			
	7612114	Aug 18, 2026	DS DP U-3523			
	8399520	Dec 25, 2023	DS DP U-3523			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELACESTRANT DIHYDROCHLORIDE - ORSERDU</u>						
N 217639 002	10071066	Oct 10, 2034	U-3524		NCE	Jan 27, 2028
	10385008	Jan 05, 2038	DS DP			
	10420734	Oct 10, 2034	U-3524			
	10745343	Jan 05, 2038	U-3523			
	7612114	Aug 18, 2026	DS DP U-3523			
	8399520	Dec 25, 2023	DS DP U-3523			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	11542239	Jul 23, 2039	DS DP			
	11690845	Aug 27, 2040	U-3654			
	11690854	Apr 19, 2038	U-3653			
>A>	11707464	Mar 14, 2034	U-3672			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 002	11542239	Jul 23, 2039	DS DP			
	11690845	Aug 27, 2040	U-3654			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	11542239	Jul 23, 2039	DS DP			
	11690845	Aug 27, 2040	U-3655			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	11564916	Aug 13, 2029	U-3525			
	11578062	Mar 25, 2031	DP U-3544			
	11639347	Apr 09, 2027	DS DP U-3587			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	11564916	Aug 13, 2029	U-3525			
	11578062	Mar 25, 2031	DP U-3544			
	11639347	Apr 09, 2027	DS DP U-3587			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 001	10022352	Apr 09, 2027	DP U-3596		NCE	Oct 21, 2024
	10081621	Mar 25, 2031	DP U-3600		NP	Apr 26, 2026
	10239867	Apr 09, 2027	DS DP U-3590		ODE-433	Apr 26, 2030
	10272046	Feb 27, 2033	DP U-3599			
	10646481	Aug 13, 2029	DP			
	10758534	Oct 06, 2035	DS DP U-3589			
	10793547	Dec 08, 2037	DS DP U-3588			
	11147770	Feb 27, 2033	DP U-3598			
	11179367	Dec 08, 2037	DP U-3597			
	11426407	Oct 06, 2035	DS DP U-3595			
	11453655	Dec 08, 2037	DS DP			
	11517564	Dec 08, 2037	DP U-3586			
	11564916	Aug 13, 2029	U-3585			
	11578062	Mar 25, 2031	DP U-3584			
	11639347	Apr 09, 2027	DS DP U-3583			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-3589			
	8354427	Jul 06, 2026	U-3593			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-3589			
	8598181	May 01, 2027	U-3589			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-3592			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-3591			
	9974781	Apr 09, 2027	DP U-3589			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 217660 002	10022352	Apr 09, 2027	DP U-3596		NCE	Oct 21, 2024
	10081621	Mar 25, 2031	DP U-3600		NP	Apr 26, 2026
	10239867	Apr 09, 2027	DS DP U-3590		ODE-433	Apr 26, 2030
	10272046	Feb 27, 2033	DP U-3599			
	10646481	Aug 13, 2029	DP			
	10758534	Oct 06, 2035	DS DP U-3589			
	10793547	Dec 08, 2037	DS DP U-3588			
	11147770	Feb 27, 2033	DP U-3598			
	11179367	Dec 08, 2037	DP U-3597			
	11426407	Oct 06, 2035	DS DP U-3595			
	11453655	Dec 08, 2037	DS DP			
	11517564	Dec 08, 2037	DP U-3586			
	11564916	Aug 13, 2029	U-3585			
	11578062	Mar 25, 2031	DP U-3584			
	11639347	Apr 09, 2027	DS DP U-3583			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-3589			
	8354427	Jul 06, 2026	U-3593			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-3589			
	8598181	May 01, 2027	U-3589			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-3592			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-3591			
	9974781	Apr 09, 2027	DP U-3589			
EMPAGLIFLOZIN - JARDIANCE						
N 204629 001	10258637	Apr 03, 2034	U-2290		I-869	Aug 18, 2024
	10258637*PED	Oct 03, 2034			M-82	Feb 24, 2025
	11090323	Apr 03, 2034	U-3191		NPP	Jun 20, 2026
	11090323*PED	Oct 03, 2034			PED	Aug 24, 2025
	7579449	Aug 01, 2028	DS		PED	Dec 20, 2026
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	U-1651			
	8551957*PED	Apr 14, 2030				
	9949997	May 17, 2034	U-2292			
	9949997	May 17, 2034	U-3199			
	9949997	May 17, 2034	U-3325			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN - JARDIANCE						
N 204629 002	10258637	Apr 03, 2034	U-2290		NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	11090323	Apr 03, 2034	U-3191			
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	U-1651			
	8551957*PED	Apr 14, 2030				
	9949997	May 17, 2034	U-2292			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	10258637	Apr 03, 2034	U-2290			
	10258637*PED	Oct 03, 2034				
	11033552	May 04, 2027	DP			
	11033552*PED	Nov 04, 2027				
	11090323	Apr 03, 2034	U-3191			
	11090323*PED	Oct 03, 2034				
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP U-1651			
	8551957*PED	Apr 14, 2030				
	8673927	May 04, 2027	U-1652	Y		
	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	10258637	Apr 03, 2034	U-2290			
	10258637*PED	Oct 03, 2034				
	11033552	May 04, 2027	DP			
	11033552*PED	Nov 04, 2027				
	11090323	Apr 03, 2034	U-3191			
	11090323*PED	Oct 03, 2034				
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP U-1651			
	8551957*PED	Apr 14, 2030				
	8673927	May 04, 2027	U-1652	Y		
	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001	10258637	Apr 03, 2034	U-2731			
	10258637*PED	Oct 03, 2034				
	11090323	Apr 03, 2034	U-3192			
	11090323*PED	Oct 03, 2034				
	11564886	Mar 07, 2032	DP U-3531			
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP U-2730			
	8551957*PED	Apr 14, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9949998	Jun 11, 2034	U-2731			
	9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	10258637	Apr 03, 2034	U-2731			
	10258637*PED	Oct 03, 2034				
	11090323	Apr 03, 2034	U-3192			
	11090323*PED	Oct 03, 2034				
	11564886	Mar 07, 2032	DP U-3531			
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP U-2730			
	8551957*PED	Apr 14, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9949998	Jun 11, 2034	U-2731			
	9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 003	10258637	Apr 03, 2034	U-2731			
	10258637*PED	Oct 03, 2034				
	11090323	Apr 03, 2034	U-3192			
	11090323*PED	Oct 03, 2034				
	11564886	Mar 07, 2032	DP U-3531			
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP U-2730			
	8551957*PED	Apr 14, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9949998	Jun 11, 2034	U-2731			
	9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 004	10258637	Apr 03, 2034	U-2731			
	10258637*PED	Oct 03, 2034				
	11090323	Apr 03, 2034	U-3192			
	11090323*PED	Oct 03, 2034				
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP U-2730			
	8551957*PED	Apr 14, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9949998	Jun 11, 2034	U-2731			
	9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	10258637	Apr 03, 2034	U-2290		NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10610489	Sep 30, 2030	DP			
	10610489*PED	Mar 30, 2031				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	10258637	Apr 03, 2034	U-2290		NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10610489	Sep 30, 2030	DP			
	10610489*PED	Mar 30, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	10258637	Apr 03, 2034	U-2290			
	10258637*PED	Oct 03, 2034			NPP	Jun 20, 2026
	10610489	Sep 30, 2030	DP		PED	Dec 20, 2026
	10610489*PED	Mar 30, 2031				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	10258637	Apr 03, 2034	U-2290			
	10258637*PED	Oct 03, 2034			NPP	Jun 20, 2026
	10610489	Sep 30, 2030	DP		PED	Dec 20, 2026
	10610489*PED	Mar 30, 2031				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	10258637	Apr 03, 2034	U-2290			
	10258637*PED	Oct 03, 2034			M-296	Jun 20, 2026
	10596120	Mar 07, 2032	DP U-2775		PED	Dec 20, 2026
	10596120	Mar 07, 2032	DP U-2792			
	10596120*PED	Sep 07, 2032				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	10258637	Apr 03, 2034	U-2290			
	10258637*PED	Oct 03, 2034			M-296	Jun 20, 2026
	10596120	Mar 07, 2032	DP U-2775		PED	Dec 20, 2026
	10596120	Mar 07, 2032	DP U-2792			
	10596120*PED	Sep 07, 2032				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	10258637	Apr 03, 2034	U-2290		M-296	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	10596120*PED	Sep 07, 2032				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	10258637	Apr 03, 2034	U-2290		M-296	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	10596120*PED	Sep 07, 2032				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	8501758	Aug 27, 2030	DS DP			
	RE49556	Feb 27, 2030	DS DP			
<u>EPHEDRINE SULFATE - EMERPHED</u>						
N 213407 001	11571398	May 16, 2040		U-3183		
<u>EPHEDRINE SULFATE - EMERPHED</u>						
N 213407 002	11464752	May 16, 2040	DP			
	11571398	May 16, 2040	U-3183			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	11590286	Dec 12, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	11590286	Dec 12, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 003	11590286	Dec 12, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - EPINEPHRINE IN 0.9% SODIUM CHLORIDE</u>						
N 215875 001	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039		U-3567		
	11207280	Mar 21, 2039	DP			
<u>EPINEPHRINE - EPINEPHRINE IN 0.9% SODIUM CHLORIDE</u>						
N 215875 002	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039		U-3567		
	11207280	Mar 21, 2039	DP			
<u>EPINEPHRINE - EPINEPHRINE IN 0.9% SODIUM CHLORIDE</u>						
N 215875 003	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039		U-3567		
	11207280	Mar 21, 2039	DP			
<u>EPINEPHRINE - EPINEPHRINE IN 0.9% SODIUM CHLORIDE</u>						
N 215875 004	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039		U-3567		
	11207280	Mar 21, 2039	DP			
<u>EPINEPHRINE - EPINEPHRINE IN 0.9% SODIUM CHLORIDE</u>						
N 215875 005	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039		U-3567		
	11207280	Mar 21, 2039	DP			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 001	11578044	Oct 19, 2037	DS			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 002	11578044	Oct 19, 2037	DS			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	11684620	Feb 09, 2036	U-2518			
	11684620	Feb 09, 2036	U-3065			
	11684620	Feb 09, 2036	U-3066			
	11684620	Feb 09, 2036	U-3067			
	8895601	Apr 12, 2033	DS DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	11684620	Feb 09, 2036	U-2518			
	11684620	Feb 09, 2036	U-3065			
	11684620	Feb 09, 2036	U-3066			
	11684620	Feb 09, 2036	U-3067			
	8895601	Apr 12, 2033	DS DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	11684620	Feb 09, 2036	U-2518			
	11684620	Feb 09, 2036	U-3065			
	11684620	Feb 09, 2036	U-3066			
	11684620	Feb 09, 2036	U-3067			
	8895601	Apr 12, 2033	DS DP			
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 001					NPP	May 12, 2026
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 002					NPP	May 12, 2026
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 003					NPP	May 12, 2026
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021365 001					NPP	May 12, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	11173134	Sep 10, 2035	U-3257			
	11173134	Sep 10, 2035	U-3536			
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001				M-289		Jan 27, 2026
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001				ODE-393		Mar 25, 2029
				PED		Sep 25, 2029
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	11364260	Jan 08, 2027	U-3637		I-915	May 31, 2026
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11433091	Jan 08, 2027	U-3634			
	11590097	Oct 20, 2023	DS DP U-3312			
	11590097	Oct 20, 2023	DS DP U-3313			
	7754702	Feb 15, 2028	U-1432			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	7754702	Feb 15, 2028	U-3636			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	8895612	Jan 08, 2027	U-3635			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	11364260	Jan 08, 2027	U-3637		I-915	May 31, 2026
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11433091	Jan 08, 2027	U-3634			
	11590097	Oct 20, 2023	DS DP U-3312			
	11590097	Oct 20, 2023	DS DP U-3313			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	7754702	Feb 15, 2028	U-3636			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	8895612	Jan 08, 2027	U-3635			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	11364260	Jan 08, 2027	U-3637		I-915	May 31, 2026
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	11433091	Jan 08, 2027	U-3634			
	11590097	Oct 20, 2023	DS DP U-3312			
	11590097	Oct 20, 2023	DS DP U-3313			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	7754702	Feb 15, 2028	U-3636			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	8895612	Jan 08, 2027	U-3635			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	11364260	Jan 08, 2027	U-3637	I-915	May 31, 2026	
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11433091	Jan 08, 2027	U-3634			
	11590097	Oct 20, 2023	DS DP U-3312			
	11590097	Oct 20, 2023	DS DP U-3313			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	7754702	Feb 15, 2028	U-3636			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	8895612	Jan 08, 2027	U-3635			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 001	11633489	Jun 22, 2036	U-3594			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 002	11633489	Jun 22, 2036	U-3594			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 003	11633489	Jun 22, 2036	U-3594			
<u>FEZOLINETANT - VEOZAH</u>						
N 216578 001	10836768	Mar 28, 2034	U-3621	NCE	May 12, 2028	
	8871761	Apr 04, 2031	DS			
	9422299	Mar 28, 2034	DS DP U-3622			
	9987274	Mar 28, 2034	U-3622			
<u>FLOTUFOLASTAT F-18 GALLIUM - POSLUMA</u>						
N 216023 001	11413360	Nov 22, 2038	DS	U-3614	NCE	May 25, 2028
	11413360	Nov 22, 2038	DS	U-3615		
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 003	8113199	Oct 23, 2027	DP		M-290	Mar 01, 2026
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	11116721	Feb 26, 2029	DP U-1401		NPP	May 13, 2026
	11116721	Feb 26, 2029	DP U-1691			
	11116721	Feb 26, 2029	DP U-3623			
	11116721*PED	Aug 26, 2029				
	7439393	May 21, 2025	DS DP U-1401			
	7439393	May 21, 2025	DS DP U-1691			
	7439393	May 21, 2025	DS DP U-2099			
	7439393	May 21, 2025	DS DP U-2100			
	7439393	May 21, 2025	DS DP U-3623			
	7439393*PED	Nov 21, 2025				
	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8511304	Jun 14, 2027	DP U-1424			
	8511304	Jun 14, 2027	DP U-1691			
	8511304	Jun 14, 2027	DP U-3623			
	8511304*PED	Dec 14, 2027				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	11116721	Feb 26, 2029	DP U-1691			
	11116721	Feb 26, 2029	DP U-3623			
	11116721*PED	Aug 26, 2029				
	7439393	May 21, 2025	DS DP U-1691			
	7439393	May 21, 2025	DS DP U-2099			
	7439393	May 21, 2025	DS DP U-2100			
	7439393	May 21, 2025	DS DP U-3623			
	7439393*PED	Nov 21, 2025				
	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8511304	Jun 14, 2027	DP U-1691			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE: VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	8511304	Jun 14, 2027	DP U-3623			
	8511304*PED	Dec 14, 2027				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE: VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 003	11116721	Feb 26, 2029	DP U-3623		NS	May 13, 2026
	7439393	May 21, 2025	DS DP U-3623			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8511304	Jun 14, 2027	DP U-3623			
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGITALER</u>						
N 208798 004	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGITALER</u>						
N 208798 005	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGITALER</u>						
N 208798 006	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGITALER</u>						
N 208798 008	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	11554229	Feb 23, 2036	U-2133			
	11602603	Oct 27, 2028	DP U-2133			
	8327844	Oct 24, 2023	U-2133			
	8522778	Apr 20, 2024	DP			
<u>FOSDENOPTERIN HYDROBROMIDE - NULIBRY</u>						
N 214018 001					M-286	Oct 27, 2025
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	11529362	Jun 02, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 002	11529362	Jun 02, 2037	DP			
<u>FUTIBATINIB - LYTGOBI</u>						
N 214801 001					ODE-410	Sep 30, 2029
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 001	11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 002	11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 003	11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 004	11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 005	11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 006	11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 007	11590246	Jan 17, 2040	DP			
<u>GANAXOLONE - ZTALMY</u>						
N 215904 001					ODE-395	Jun 01, 2029
<u>GIVOSIRAN SODIUM - GIVLAARI</u>						
N 212194 001	9133461	Nov 30, 2033	DS DP U-2672			
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 001	11590205	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 002	11590205	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYPOPEN</u>						
N 212097 003	11590205	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYPOPEN</u>						
N 212097 004	11590205	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE KIT</u>						
N 212097 005	11590205	Apr 22, 2036	DP U-2742			
<u>GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE - PREVDUO</u>						
N 216903 001	10456354	Oct 25, 2038	DP			
	11110054	Oct 25, 2038	DP			
<u>HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII</u>						
N 209354 001	11648256	Jun 06, 2036	DP U-2625			
	11679115	Jun 06, 2036	DP U-2625			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 006	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBREXAFUNGERP CITRATE - BREXA FEMME</u>						
N 214900 001	11534433	Jun 10, 2039	U-3159		I-903	Nov 30, 2025
	11534433	Jun 10, 2039	U-3508			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	10478439	Jun 03, 2031	U-1650		ODE-109	Mar 04, 2023
	10478439	Jun 03, 2031	U-1684		ODE-117	May 06, 2023
	10478439	Jun 03, 2031	U-1946		ODE-152	Aug 02, 2024
	10478439	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	10478439	Jun 03, 2031	U-2242		PED	Feb 02, 2025
	10478439	Jun 03, 2031	U-2665		PED	Feb 24, 2030
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	11672803	Jun 03, 2031	U-1684			
	11672803	Jun 03, 2031	U-1946			
	11672803	Jun 03, 2031	U-2241			
	11672803	Jun 03, 2031	U-2242			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015*PED	Jun 28, 2027				
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9540382*PED	Feb 18, 2034				
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	10478439	Jun 03, 2031	U-1650		ODE*	Mar 04, 2023
	10478439	Jun 03, 2031	U-1684		ODE*	May 06, 2023
	10478439	Jun 03, 2031	U-1946		ODE*	Aug 02, 2024
	10478439	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	10478439	Jun 03, 2031	U-2242		PED	Feb 24, 2030
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	11672803	Jun 03, 2031	U-1684			
	11672803	Jun 03, 2031	U-1946			
	11672803	Jun 03, 2031	U-2241			
	11672803	Jun 03, 2031	U-2242			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015*PED	Jun 28, 2027				
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1491			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382*PED	Feb 18, 2034				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10478439	Jun 03, 2031	U-1650	ODE*	Mar 04, 2023	
	10478439	Jun 03, 2031	U-1684	ODE*	May 06, 2023	
	10478439	Jun 03, 2031	U-1946	ODE*	Aug 02, 2024	
	10478439	Jun 03, 2031	U-2241	ODE-405	Aug 24, 2029	
	10478439	Jun 03, 2031	U-2242	PED	Feb 24, 2030	
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	11672803	Jun 03, 2031	U-1684			
	11672803	Jun 03, 2031	U-1946			
	11672803	Jun 03, 2031	U-2241			
	11672803	Jun 03, 2031	U-2242			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10478439	Jun 03, 2031	U-1650	ODE*	Mar 04, 2023	
	10478439	Jun 03, 2031	U-1684	ODE*	May 06, 2023	
	10478439	Jun 03, 2031	U-1946	ODE*	Aug 02, 2024	
	10478439	Jun 03, 2031	U-2241	ODE-405	Aug 24, 2029	
	10478439	Jun 03, 2031	U-2242	PED	Feb 24, 2030	
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	11672803	Jun 03, 2031	U-1684			
	11672803	Jun 03, 2031	U-1946			
	11672803	Jun 03, 2031	U-2241			
	11672803	Jun 03, 2031	U-2242			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	10478439	Jun 03, 2031	U-1650		ODE*	Mar 04, 2023
	10478439	Jun 03, 2031	U-1684		ODE*	May 06, 2023
	10478439	Jun 03, 2031	U-1946		ODE*	Aug 02, 2024
	10478439	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	10478439	Jun 03, 2031	U-2242		PED	Feb 24, 2030
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	11672803	Jun 03, 2031	U-1684			
	11672803	Jun 03, 2031	U-1946			
	11672803	Jun 03, 2031	U-2241			
	11672803	Jun 03, 2031	U-2242			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004					ODE*	Mar 04, 2023
					ODE*	May 06, 2023
					ODE*	Aug 02, 2024
					ODE-405	Aug 24, 2029
					PED	Feb 24, 2030
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	10106548	Jun 03, 2033	DS DP		ODE-405	Aug 24, 2029
	10106548*PED	Dec 03, 2033			PED	Feb 24, 2030
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034		U-3422		
	9795604*PED	Apr 24, 2035				
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001 >A> 11717504		Apr 29, 2030		U-3669		
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002 >A> 11717504		Apr 29, 2030		U-3669		
<u>INCLISIRAN SODIUM - LEOVIO</u>						
N 214012 001	10125369	Aug 18, 2034	DS DP	U-3652		
	10131907	Aug 24, 2028	DS DP	U-3652		
	10266825	Nov 04, 2023		U-3652		
	10851377	Aug 25, 2036		U-3652		
	11078485	Nov 04, 2023	DS	U-3652		
	8106022	Dec 12, 2029	DS DP	U-3652		
	8222222	Dec 29, 2027		U-3652		
	8809292	May 10, 2027	DS DP	U-3652		
	8828956	Dec 04, 2028	DS DP	U-3652		
	9370582	Dec 04, 2028	DS DP	U-3652		
	9708610	Jan 01, 2024	DS DP	U-3652		
<u>INDOCYANINE GREEN - SPY AGENT GREEN KIT</u>						
N 211580 001 >A> 11712320		Jul 14, 2039	DP		I-911	Jun 05, 2026
<u>INDOMETHACIN - INDOMETHACIN</u>						
A 216184 001				>A> CGT		Jan 30, 2024
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 002	6812238	Oct 31, 2025	DS			
<u>ISTRADERFYLLINE - NOURIANZ</u>						
N 022075 001 >A> 7727993		Jan 28, 2028	DP U-2623			
<u>ISTRADERFYLLINE - NOURIANZ</u>						
N 022075 002 >A> 7727993		Jan 28, 2028	DP U-2623			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	11564916	Aug 13, 2029		U-3530		
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	11564916	Aug 13, 2029		U-3528	ODE-435	May 03, 2030
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	11564916	Aug 13, 2029		U-3528	ODE-435	May 03, 2030
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003	11564916	Aug 13, 2029		U-3528	ODE-435	May 03, 2030

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 004	10272046	Feb 27, 2033	DP U-3605		NPP	May 03, 2026
	10646481	Aug 13, 2029	DP		ODE-435	May 03, 2030
	11147770	Feb 27, 2033	DP U-3604			
	11564916	Aug 13, 2029	U-3603			
	7495103	May 20, 2027	DS DP			
	8324242	Aug 05, 2027	U-3609			
	8354427	Jul 06, 2026	U-3608			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-3607			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-3606			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 005	10272046	Feb 27, 2033	DP U-3605		NPP	May 03, 2026
	10646481	Aug 13, 2029	DP		ODE-435	May 03, 2030
	11147770	Feb 27, 2033	DP U-3604			
	11564916	Aug 13, 2029	U-3603			
	7495103	May 20, 2027	DS DP			
	8324242	Aug 05, 2027	U-3609			
	8354427	Jul 06, 2026	U-3608			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-3607			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-3606			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	11564916	Aug 13, 2029	U-3527			
	11578062	Mar 25, 2031	DP U-3545			
	11639347	Apr 09, 2027	DS DP U-2569			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	11564916	Aug 13, 2029	U-3527			
	11578062	Mar 25, 2031	DP U-3545			
	11639347	Apr 09, 2027	DS DP U-2569			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	11564916	Aug 13, 2029	U-3529			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	11564916	Aug 13, 2029	U-3529			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	11564916	Aug 13, 2029	U-3526		ODE-408	Sep 02, 2029
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	11564916	Aug 13, 2029	U-3526		ODE-408	Sep 02, 2029
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 003	11564916	Aug 13, 2029	U-3526		ODE-408	Sep 02, 2029
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185 001	11337943	Jun 05, 2040	DP U-3660			
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185 002	11337943	Jun 05, 2040	DP U-3660			
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185 003	11337943	Jun 05, 2040	DP U-3660			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
LAROTRECTINIB SULFATE - VITRAKVI						
N 211710 001	11191766 11484535	Apr 04, 2037 Apr 04, 2037		U-2471 U-2470		
LASMIDITAN SUCCINATE - REYVOW						
N 211280 001	7423050	Feb 17, 2028	DS DP	U-1719		
LASMIDITAN SUCCINATE - REYVOW						
N 211280 002	7423050	Feb 17, 2028	DS DP	U-1719		
LASMIDITAN SUCCINATE - REYVOW						
N 211280 003	7423050	Feb 17, 2028	DS DP	U-1719		
LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN						
N 208259 001	11618748	Jan 27, 2030		U-1524		
LEDIPASVIR; SOFOBUVIR - HARVONI						
N 205834 001					ODE*	Aug 28, 2026
LEDIPASVIR; SOFOBUVIR - HARVONI						
N 205834 002					ODE*	Apr 07, 2024
					ODE*	Aug 28, 2026
					PED	Oct 07, 2024
LEMBOREXANT - DAYVIGO						
N 212028 001					M-293	Apr 20, 2026
LEMBOREXANT - DAYVIGO						
N 212028 002					M-293	Apr 20, 2026
LENACAPAVIR SODIUM - SUNLENCA						
N 215973 001	10071985 10654827 11267799 9951043	Aug 17, 2037 Aug 17, 2037 Aug 16, 2038 Feb 28, 2034	DS DP U-3507 DS DS DP U-3507		NCE	Dec 22, 2027
LENACAPAVIR SODIUM - SUNLENCA						
N 215974 001	10071985 10654827 11267799 9951043	Aug 17, 2037 Aug 17, 2037 Aug 16, 2038 Feb 28, 2034	DS DP U-3507 DS DS DP U-3507		NCE	Dec 22, 2027
LENIOLISIB PHOSPHATE - JOENJA						
N 217759 001	8653092	Feb 19, 2032	DS DP		NCE ODE-430	Mar 24, 2028 Mar 24, 2030
LENVATINIB MESYLATE - LENVIMA						
N 206947 001	11090386	Feb 23, 2036		U-3519		
LENVATINIB MESYLATE - LENVIMA						
N 206947 002	11090386	Feb 23, 2036		U-3519		
LETTERMOVIR - PREVYMIS						
N 209939 001					I-916 ODE-423	Jun 05, 2026 Jun 05, 2030
LETTERMOVIR - PREVYMIS						
N 209939 002					I-916 ODE-423	Jun 05, 2026 Jun 05, 2030
LETTERMOVIR - PREVYMIS						
N 209940 001					I-916 ODE-423	Jun 05, 2026 Jun 05, 2030

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LETTERMOVIR - PREVYMIS</u>						
N 209940 001					I-916 ODE-423	Jun 05, 2026 Jun 05, 2030
<u>LETTERMOVIR - PREVYMIS</u>						
N 209940 002					I-916 ODE-423	Jun 05, 2026 Jun 05, 2030
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED KIT</u>						
N 020263 009	8921326	Feb 05, 2031	DP		NS	Apr 14, 2026
	9617303	Mar 22, 2028		U-3611		
<u>LEUPROLIDE MESYLATE - CAMCEVI KIT</u>						
N 211488 001 >A> 11717555		Jan 01, 2039	DP			
<u>LEVKETOCONAZOLE - RECORLEV</u>						
N 214133 001					ODE-385	Dec 30, 2028
<u>LEVOLEUCOVORIN - KHAPZORY</u>						
N 211226 001	11541012	Mar 25, 2039	DP			
<u>LEVOLEUCOVORIN - KHAPZORY</u>						
N 211226 002	11541012	Mar 25, 2039	DP			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001 >A> 11628088		Feb 07, 2027	DP			
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001	11571328	Sep 07, 2040	DP		I-917	Jun 29, 2026
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001 >A> 11628088		Feb 07, 2027	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	10702576	Aug 11, 2031	U-1516			
	10702576	Aug 11, 2031	U-3644			
	7304036	Aug 30, 2026	DS DP U-1516			
	7304036	Aug 30, 2026	DS DP U-3644			
	8110553	Jan 28, 2024	U-1516			
	8110553	Jan 28, 2024	U-3644			
	8933030	Feb 17, 2031	DP U-1516			
	8933030	Feb 17, 2031	DP U-3644			
	9708371	Aug 16, 2033	DP U-1516			
	9708371	Aug 16, 2033	DP U-3644			
<u>LINAGLITZTIN - TRADJENTA</u>						
N 201280 001	10034877	Aug 05, 2029	U-2347		M-295	Jun 20, 2026
	10034877*PED	Feb 05, 2030			PED	Dec 20, 2026
	11033552	May 04, 2027	DP			
	11033552*PED	Nov 04, 2027				
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8846695	Jun 04, 2030	U-1503	Y		
	8846695*PED	Dec 04, 2030				
	8853156	Mar 05, 2031	DP U-1642			
	8853156*PED	Sep 05, 2031				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9486526	Aug 05, 2029	U-1915			
	9486526*PED	Feb 05, 2030				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
LINAGLIPITIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 001	10022379	Apr 02, 2029	U-2339		M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029		DP	PED	Dec 20, 2026
	10973827	Apr 02, 2029		DS DP		
	10973827*PED	Oct 02, 2029				
	7407955	May 02, 2025		DS DP		
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503		Y	
	8673927*PED	Nov 04, 2027				
	8846695	Jun 04, 2030	U-1503			
	8846695*PED	Dec 04, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
LINAGLIPITIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 002	10022379	Apr 02, 2029	U-2339		M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029		DP	PED	Dec 20, 2026
	10973827	Apr 02, 2029		DS DP		
	10973827*PED	Oct 02, 2029				
	7407955	May 02, 2025		DS DP		
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503		Y	
	8673927*PED	Nov 04, 2027				
	8846695	Jun 04, 2030	U-1503			
	8846695*PED	Dec 04, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
LINAGLIPITIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR						
N 208026 001	10022379	Apr 02, 2029	U-2339		M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029		DS DP	PED	Dec 20, 2026
	7407955	May 02, 2025				
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503		Y	
	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9173859	May 04, 2027	DP U-1503		Y	
	9173859*PED	Nov 04, 2027				
	9415016	Apr 02, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	9415016*PED	Oct 02, 2029				
	9555001	Mar 06, 2033		DP U-1967		
	9555001	Mar 06, 2033		DP U-1968		
	9555001*PED	Sep 06, 2033				
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	10022379	Apr 02, 2029	U-2339		M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029			PED	Dec 20, 2026
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503		Y	
	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9173859	May 04, 2027	DP U-1503		Y	
	9173859*PED	Nov 04, 2027				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
	9555001*PED	Sep 06, 2033				
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219 001	11534395	Jan 26, 2036	DP U-2764			
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	11642317	May 03, 2033	DP			
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	11596599	May 03, 2033	U-2985			
	11642317	May 03, 2033	DP			
<u>LOTILANER - XDEMVY</u>						
N 217603 001	>A> 10835517	Dec 14, 2038	U-3674			
	>A> 11197847	Dec 14, 2038	U-3674			
	>A> 11690826	Dec 14, 2038	U-3674			
	>A> 11690827	Dec 14, 2038	U-3674			
	>A> 8383659	Jan 17, 2030	DS DP			
<u>LUMASIRAN SODIUM - OXLUMO</u>						
N 214103 001					ODE-415	Oct 06, 2029
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	11690842	Aug 30, 2039	DP U-3362			
	11690842	Aug 30, 2039	DP U-3363			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 002	11690842	Aug 30, 2039	DP U-3362			
	11690842	Aug 30, 2039	DP U-3363			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 003	11690842	Aug 30, 2039	DP U-3362			
	11690842	Aug 30, 2039	DP U-3363			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9907794 9907794*PED	May 26, 2026 Nov 26, 2026		DP		
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9907794 9907794*PED	May 26, 2026 Nov 26, 2026		DP		
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9907794 9907794*PED	May 26, 2026 Nov 26, 2026		DP		
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE - SUFLAVE</u>						
N 215344 001					NP	Jun 15, 2026
<u>MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE - SUTAB</u>						
N 213135 001	11638697	Aug 04, 2037		DP		
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001					NPP ODE-429	Mar 13, 2026 Mar 13, 2030
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596 001	11684632	Jan 04, 2032		U-3650		ODE-388
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 001					M-297 ODE-398	Jun 15, 2026 Apr 28, 2029
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 002					M-297 ODE-398	Jun 15, 2026 Apr 28, 2029
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 003					M-297 ODE-398	Jun 15, 2026 Apr 28, 2029
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 004					M-297 ODE-398	Jun 15, 2026 Apr 28, 2029
<u>MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO</u>						
N 214383 001	6992207	Jun 25, 2024		DS DP U-3093		
<u>MELPHALAN HYDROCHLORIDE - HEPZATO</u>						
N 201848 001	>A> 10098997 >A> 10195334 >A> 10369264 >A> 11083831 >A> 11241522 >A> 11633528 >A> 9314561 >A> 9707331	Nov 07, 2032 Jan 16, 2033 Nov 07, 2032 Dec 30, 2032 Nov 07, 2032 Nov 07, 2032 Feb 07, 2034 Sep 17, 2034	DP DP DP DP DP DP DP DP		>A> ODE-438	Aug 14, 2030
<u>MELPHALAN HYDROCHLORIDE - MELPHALAN HYDROCHLORIDE</u>						
N 217110 001	>A> 10537520	Jun 29, 2036		DP		
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	11684723	Mar 10, 2029		DP		
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	11684723	Mar 10, 2029		DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	11684723	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	11684723	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	11684723	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	11684723	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	11684723	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	11684723	Mar 10, 2029	DP			
<u>METHOTREXATE - JYLAMVO</u>						
N 212479 001	>A> 11129833	Oct 28, 2035	DP			
<u>METHSUXIMIDE - MENTSUXIMIDE</u>						
A 217213 001				CGT		Oct 28, 2023
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	11633389	Aug 14, 2033	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	11633389	Aug 14, 2033	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	11633389	Aug 14, 2033	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388 001	11628150	Dec 22, 2029	DP U-2843			
<u>MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE</u>						
A 216159 001				PC		Jan 02, 2024
<u>MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE</u>						
A 216159 002				PC		Jan 02, 2024
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	11612593	May 30, 2038	DS			
	11612594	May 30, 2038	DS			
	11622962	Mar 17, 2039	DS			
	11633387	May 30, 2038	DS			
	11633388	Mar 25, 2039	U-2371			
	11642334	Feb 20, 2039	U-2371			
	11666564	May 30, 2038	U-2371			
<u>MIRABEGRON - MYRBETRIQ</u>						
N 202611 001	>A> 10842780	Sep 28, 2029	DP U-2996			
	>A> 10842780	Sep 28, 2029	DP U-3670			
	>A> 10842780*PED	Mar 28, 2030				
	>A> 11707451	Sep 28, 2029	U-2996			
	>A> 11707451	Sep 28, 2029	U-3670			
	>A> 11707451*PED	Mar 28, 2030				
<u>MIRABEGRON - MYRBETRIQ</u>						
N 202611 002	>A> 10842780	Sep 28, 2029	DP U-2996			
	>A> 10842780	Sep 28, 2029	DP U-3670			
	>A> 10842780*PED	Mar 28, 2030				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
MIRABEGRON - MYRBETRIO						
N 202611 002	>A> 11707451	Sep 28, 2029		U-2996		
	>A> 11707451	Sep 28, 2029		U-3670		
	>A> 11707451*PED	Mar 28, 2030				
MITAPIVAT SULFATE - PYRUKYND						
N 216196 001	RE49582	Feb 24, 2031	DS DP		ODE-392	Feb 17, 2029
MITAPIVAT SULFATE - PYRUKYND						
N 216196 002	RE49582	Feb 24, 2031	DS DP		ODE-392	Feb 17, 2029
MITAPIVAT SULFATE - PYRUKYND						
N 216196 003	RE49582	Feb 24, 2031	DS DP		ODE-392	Feb 17, 2029
MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS						
N 211746 001	11679210	Sep 03, 2038	DP			
MONOMETHYL FUMARATE - BAFIERTAM						
N 210296 001	11590095	Mar 18, 2036		U-1384		
NALMEFENE HYDROCHLORIDE - OPVEE						
N 217470 001	11458091	Jul 10, 2038	DP U-3630		NP	May 22, 2026
NALOXONE HYDROCHLORIDE - EVZIO						
N 205787 001	11590286	Dec 12, 2026	DP			
NALOXONE HYDROCHLORIDE - REXTOVY						
N 208969 001					NP	Mar 07, 2026
NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)						
N 209862 001	11590286	Dec 12, 2026	DP			
NALOXONE HYDROCHLORIDE - KLOXXADO						
N 212045 001	11617713	Aug 26, 2034	DP U-3110			
	11628139	Aug 26, 2034	DP U-3110			
NALOXONE HYDROCHLORIDE - ZIMHI						
N 212854 001	11571518	Jun 14, 2041	DP U-3515			
	11571518	Jun 14, 2041	DP U-3516			
	11571518	Jun 14, 2041	DP U-3517			
NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE (AUTOINJECTOR)						
N 215457 001	11590286	Dec 12, 2026	DP			
NALOXONE HYDROCHLORIDE - RIVIVE						
N 217722 001	>A> 11020343	May 11, 2032		U-3671		
NETARSUDIL MESYLATE - RHOPRESSA						
N 208254 001	11618748	Jan 27, 2030		U-1524		
NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO						
N 205718 001	11559523	Nov 18, 2030	DP U-3522			
NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER						
N 019734 002	11547758	Apr 18, 2027		U-1029		
NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER						
N 019734 003	11547758	Apr 18, 2027		U-1029		
NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER						
N 019734 004	11547758	Apr 18, 2027		U-1029		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 002	11517563	Apr 16, 2038	DP		Y	
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	10154990	Jan 08, 2026		U-2620		
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	10154990	Jan 08, 2026		U-2620		
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447 001	11673877	Mar 27, 2038	DP	U-3646		
	11673877	Mar 27, 2038	DP	U-3647		
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 001	11091459	Mar 27, 2038	DP			
	11673877	Mar 27, 2038	DP	U-3646		
	11673877	Mar 27, 2038	DP	U-3647		
	8071579	Aug 12, 2027		U-2655		
	8071623	Mar 27, 2031	DS	DP		
	8143241	Aug 12, 2027		U-2655		
	8436185	Apr 24, 2029	DS			
	8859562	Aug 04, 2031		U-2655		
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 002	11091459	Mar 27, 2038	DP			
	11673877	Mar 27, 2038	DP	U-3646		
	11673877	Mar 27, 2038	DP	U-3647		
	8071579	Aug 12, 2027		U-2655		
	8071623	Mar 27, 2031	DS	DP		
	8143241	Aug 12, 2027		U-2655		
	8436185	Apr 24, 2029	DS			
	8859562	Aug 04, 2031		U-2655		
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 003	11091459	Mar 27, 2038	DP			
	11673877	Mar 27, 2038	DP	U-3646		
	11673877	Mar 27, 2038	DP	U-3647		
	8071579	Aug 12, 2027		U-2655		
	8071623	Mar 27, 2031	DS	DP		
	8143241	Aug 12, 2027		U-2655		
	8436185	Apr 24, 2029	DS			
	8859562	Aug 04, 2031		U-2655		
<u>NIRMATRELVIR; RITONAVIR - PAXLOVID (COPACKAGED)</u>						
N 217188 001	11351149	Aug 05, 2041	DS	DP	U-3629	
	11541034	Oct 31, 2041			U-3629	
<u>NIRMATRELVIR; RITONAVIR - PAXLOVID (COPACKAGED)</u>						
N 217188 002						NCE May 25, 2028
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860 001	11511252	Sep 21, 2029	DP			
	11554241	Aug 18, 2025		U-3037		
	11672938	Jul 22, 2040		U-3037		
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 001	11602508	Jan 30, 2038	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 002	11602508	Jan 30, 2038	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 003	11602508	Jan 30, 2038	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	10011633	Nov 08, 2031	U-3186	I-918	Jun 13, 2026	
	10011633	Nov 08, 2031	U-3187	ODE-436	Jun 13, 2030	
	10011633	Nov 08, 2031	U-3648			
	10011633	Nov 08, 2031	U-3649			
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3187			
	10093697	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3649			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10487111	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3649			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	10981952	Nov 08, 2031	U-3648			
	10981952	Nov 08, 2031	U-3649			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
	11365182	Jun 20, 2039	U-3648			
	11365182	Jun 20, 2039	U-3649			
	11583539	Nov 12, 2041	U-3186			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3187			
	9694018	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3649			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 002	10011633	Nov 08, 2031	U-3186	I-918	Jun 13, 2026	
	10011633	Nov 08, 2031	U-3187	ODE-436	Jun 13, 2030	
	10011633	Nov 08, 2031	U-3648			
	10011633	Nov 08, 2031	U-3649			
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3187			
	10093697	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3649			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10487111	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3649			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	10981952	Nov 08, 2031	U-3648			
	10981952	Nov 08, 2031	U-3649			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
	11365182	Jun 20, 2039	U-3648			
	11365182	Jun 20, 2039	U-3649			
	11583539	Nov 12, 2041	U-3186			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3187			
	9694018	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3649			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	10011633	Nov 08, 2031	U-3186	I-918	Jun 13, 2026	
	10011633	Nov 08, 2031	U-3187	ODE-436	Jun 13, 2030	
	10011633	Nov 08, 2031	U-3648			
	10011633	Nov 08, 2031	U-3649			
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3187			
	10093697	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3649			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10487111	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3649			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	10981952	Nov 08, 2031	U-3648			
	10981952	Nov 08, 2031	U-3649			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
	11365182	Jun 20, 2039	U-3648			
	11365182	Jun 20, 2039	U-3649			
	11583539	Nov 12, 2041	U-3186			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3187			
	9694018	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3649			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	10011633	Nov 08, 2031	U-3186	I-918	Jun 13, 2026	
	10011633	Nov 08, 2031	U-3187	ODE-436	Jun 13, 2030	
	10011633	Nov 08, 2031	U-3648			
	10011633	Nov 08, 2031	U-3649			
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3187			
	10093697	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3649			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10487111	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3649			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	10981952	Nov 08, 2031	U-3648			
	10981952	Nov 08, 2031	U-3649			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
	11365182	Jun 20, 2039	U-3648			
	11365182	Jun 20, 2039	U-3649			
	11583539	Nov 12, 2041	U-3186			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3187			
	9694018	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3649			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001 >A> 11707466		Nov 12, 2041	DP			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002 >A> 11707466		Nov 12, 2041	DP			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003 >A> 11707466		Nov 12, 2041	DP			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004 >A> 11707466		Nov 12, 2041	DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	11633396	Oct 07, 2029	DP	I-914	May 31, 2026	
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8071579	Aug 12, 2027	U-2833			
	8071579	Aug 12, 2027	U-3333			
	8071579	Aug 12, 2027	U-3631			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-3333			
	8143241	Aug 12, 2027	U-3631			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
	8859562	Aug 04, 2031	U-3333			
	8859562	Aug 04, 2031	U-3631			
	9169235	Mar 12, 2024	U-2832			
	9169235	Mar 12, 2024	U-2833			
	9169235	Mar 12, 2024	U-3631			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	11633396	Oct 07, 2029	DP		I-914	May 31, 2026
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8071579	Aug 12, 2027	U-3333			
	8071579	Aug 12, 2027	U-3631			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-3333			
	8143241	Aug 12, 2027	U-3631			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
	8859562	Aug 04, 2031	U-3333			
	8859562	Aug 04, 2031	U-3631			
	9169235	Mar 12, 2024	U-2832			
	9169235	Mar 12, 2024	U-2833			
	9169235	Mar 12, 2024	U-3631			
<u>OLUTASIDENIB - REZLIDHIA</u>						
N 215814 001					NCE	Dec 01, 2027
					ODE-413	Dec 01, 2029
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	7553828	Jun 02, 2024	DS			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	7553828	Jun 02, 2024	DS			
<u>OMAVELOXOLONE - SKYCLARYS</u>						
N 216718 001	11091430	Apr 20, 2029	U-3552		NCE	Feb 28, 2028
	8124799	Dec 03, 2029	DS		ODE-427	Feb 28, 2030
	8440854	Apr 20, 2029	DP			
	8993640	Apr 24, 2033	DS DP			
	9670147	Apr 20, 2029	DS			
	9701709	Apr 24, 2033	DS DP			
<u>OMEPRAZOLE: SODIUM BICARBONATE - KONVOMEP</u>						
N 213593 001	11633478	Jul 16, 2039	DP			
<u>OMIDENEPAK ISOPROPYL - OMLONTI</u>						
N 215092 001	11666563	Jul 16, 2039	U-3454			
<u>PACRITINIB CITRATE - VONJO</u>						
N 208712 001					ODE-397	Feb 28, 2029
<u>PAFOOLACIANINE SODIUM - CYTALUX</u>						
N 214907 001					I-905	Dec 16, 2025
					ODE-390	Nov 29, 2028
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001 >A> 11065250		Aug 19, 2036	DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 002 >A> 11065250		Aug 19, 2036	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALBOCICLIB - TBRANCE</u>						
N 212436 003	>A> 11065250	Aug 19, 2036		DP		
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 005	11666697	Nov 24, 2041		U-3626		
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 006	11666697	Nov 24, 2041		U-3626		
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 001					>A> NCE	Aug 16, 2028
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 002					>A> NCE	Aug 16, 2028
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 003					>A> NCE	Aug 16, 2028
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 004					>A> NCE	Aug 16, 2028
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 005					>A> NCE	Aug 16, 2028
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	11661441	Jan 13, 2033	DS	U-3124	M-288	Feb 08, 2026
<u>PEGCETACOPLAN - SYFOVRE</u>						
N 217171 001	10035822	Nov 15, 2033	DS		NCE	May 14, 2026
	10125171	Aug 02, 2033	DS		NP	Feb 22, 2026
	10875893	Nov 15, 2033	DS	U-3540		
	11292815	Nov 15, 2033	DS DP	U-3540		
	11661441	Jan 13, 2033	DS	U-3540		
	7888323	Dec 04, 2027	DS			
	7989589	Dec 04, 2027	DS			
	8168584	Apr 07, 2027		U-3540		
	8168584	Apr 07, 2027		U-3542		
	9056076	Oct 25, 2026		U-3540		
	9169307	Nov 18, 2027	DS	U-3541		
<u>PEMETREXED DISODIUM - PEMETREXED</u>						
N 215179 001	11147817	Mar 26, 2035		DP		
<u>PEMETREXED DISODIUM - PEMETREXED</u>						
N 215179 002	11147817	Mar 26, 2035		DP		
<u>PEMETREXED DISODIUM - PEMETREXED</u>						
N 215179 003	11147817	Mar 26, 2035		DP		
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 001	11628162	Aug 30, 2040		U-3568	ODE-404	Aug 26, 2029
	11628162	Aug 30, 2040		U-3569		
	11628162	Aug 30, 2040		U-3570		
	11628162	Aug 30, 2040		U-3571		
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 002	11628162	Aug 30, 2040		U-3568	ODE-404	Aug 26, 2029
	11628162	Aug 30, 2040		U-3569		
	11628162	Aug 30, 2040		U-3570		
	11628162	Aug 30, 2040		U-3571		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 003	11628162	Aug 30, 2040	U-3568		ODE-404	Aug 26, 2029
	11628162	Aug 30, 2040	U-3569			
	11628162	Aug 30, 2040	U-3570			
	11628162	Aug 30, 2040	U-3571			
<u>PENCICLOVIR - PENCICLOVIR</u>						
A 216981 001				>A> CGT		Feb 28, 2024
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
<u>PERFLUOROHEXYLOCTANE - MIEBO</u>						
N 216675 001	10058615	Sep 12, 2033	U-1900		NCE	May 18, 2028
	10369117	Sep 12, 2033	U-1900			
	10449164	Sep 12, 2033	U-1900			
	10507132	Jun 21, 2037	U-1900			
	10576154	Sep 12, 2033	U-1900			
	11357738	Sep 29, 2036	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PHENOBARBITAL SODIUM - SEZABY</u>						
N 215910 001					ODE-414	Nov 17, 2029
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159 001	7229630	Jul 31, 2023	DP			
	7575757	Jul 31, 2023	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
A 216496 001					CGT	Jul 17, 2023
<u>PHENYLEPHRINE HYDROCHLORIDE - IMMPEHNTIV</u>						
N 203826 004	11213480	Sep 26, 2036	DP			
	11471400	Aug 05, 2036	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE - IMMPEHNTIV</u>						
N 203826 005	11213480	Sep 26, 2036	DP			
	11471400	Aug 05, 2036	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE - MYDCOMBI</u>						
N 215352 001					NP	May 05, 2026
<u>PILOCARPINE HYDROCHLORIDE - VUITY</u>						
N 214028 001	10610518	Apr 24, 2039	U-3252		D-187	Mar 28, 2026
	10610518	Apr 24, 2039	U-3561			
	10610518	Apr 24, 2039	U-3562			
	11285134	Apr 24, 2039	U-3252			
	11285134	Apr 24, 2039	U-3561			
	11285134	Apr 24, 2039	U-3562			
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001	10342780	Dec 16, 2036	DS DP		NCE	Jan 27, 2028
	10464905	Dec 16, 2036	U-3518		ODE-424	Jan 27, 2030
	10695323	Dec 16, 2036	DS DP U-3518			
	10918622	Dec 16, 2036	U-3518			
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002	10342780	Dec 16, 2036	DS DP		NCE	Jan 27, 2028
	10464905	Dec 16, 2036	U-3518		ODE-424	Jan 27, 2030
	10695323	Dec 16, 2036	DS DP U-3518			
	10918622	Dec 16, 2036	U-3518			
<u>POSACONAZOLE - POSACONAZOLE</u>						
A 208768 001					PC	Dec 26, 2023
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001	>A> 10030005	Nov 01, 2036	DS DP U-2952			
	>A> 10030005	Nov 01, 2036	DS DP U-3002			
<u>PREDNISOLONE - PREDNISOLONE</u>						
A 215673 001					CGT	Nov 18, 2023
<u>QUIZARTINIB DIHYDROCHLORIDE - VANFLYTA</u>						
N 216993 001	>A> 7820657	Sep 26, 2028	DS		>A> NCE	Jul 20, 2028
	>A> 7968543	Aug 15, 2029	DP U-3661		ODE-437	Jul 20, 2030
	>A> 8129374	Mar 16, 2027	U-3661			
	>A> 8357690	Feb 26, 2031	U-3661			
	>A> 8557810	Mar 16, 2027	DP			
	>A> 8836218	Mar 23, 2030	U-3661			
	>A> 8865710	Aug 15, 2029	DP			
	>A> 8883783	Mar 16, 2027	DS			
	>A> 9555040	May 14, 2030	U-3661			
	>A> 9585892	Mar 16, 2027	U-3661			
	>A> 9675549	Sep 30, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>QUIZARTINIB DIHYDROCHLORIDE - VANFLYTA</u>						
N 216993 002	>A> 7820657	Sep 26, 2028	DS		>A> NCE	Jul 20, 2028
	>A> 7968543	Aug 15, 2029	DP U-3661		ODE-437	Jul 20, 2030
	>A> 8129374	Mar 16, 2027	U-3661			
	>A> 8357690	Feb 26, 2031	U-3661			
	>A> 8557810	Mar 16, 2027	DP			
	>A> 8836218	Mar 23, 2030	U-3661			
	>A> 8865710	Aug 15, 2029	DP			
	>A> 8883783	Mar 16, 2027	DS			
	>A> 9555040	May 14, 2030	U-3661			
	>A> 9585892	Mar 16, 2027	U-3661			
	>A> 9675549	Sep 30, 2033	DP			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 022145 001	8771733	Jun 02, 2030	DS DP U-257			
	8852632	Jan 28, 2028	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS HD</u>						
N 022145 002	8771733	Jun 02, 2030	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 002	8771733	Jun 02, 2030	DS DP U-257			
<u>RELUGOLIX - ORGOVYX</u>						
N 214621 001	11583526	Sep 29, 2037		U-3020		
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	11691948	Jul 14, 2030		DP		
<u>REZAFUNGIN ACETATE - REZZAYO</u>						
N 217417 001	10702573	Mar 14, 2033	DS DP U-3566		NCE	Mar 22, 2028
	11197909	Jul 14, 2038	DS DP U-3566		ODE-426	Mar 22, 2030
	11654196	Mar 02, 2032	DS DP U-3566		GAIN	Mar 22, 2033
	>A> 11712459	Mar 15, 2037	DP U-3566		GAIN	Mar 22, 2035
	8722619	Mar 02, 2032	DS DP U-3566			
	9526835	Mar 14, 2033	DS DP U-3566			
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 002	11564912	Feb 26, 2029		U-3511		
	11564912	Feb 26, 2029		U-3512		
<u>RIPRETTINIB - QINLOCK</u>						
N 213973 001	11529336	Aug 12, 2040		U-3382		
	11534432	Aug 12, 2040		U-3442		
	11576903	Dec 30, 2040	DP			
	11576904	Aug 12, 2040		U-3537		
	11612591	Dec 30, 2040	DP			
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001	11534444	Oct 04, 2038		U-1943		
					ODE-400	May 27, 2029
<u>RISPERIDONE - RYKINDO</u>						
N 212849 001	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
<u>RISPERIDONE - RYKINDO</u>						
N 212849 002	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
RISPERIDONE - RYKINDO						
N 212849 003	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
RISPERIDONE - RYKINDO						
N 212849 004	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
RISPERIDONE - UZEDY						
N 213586 001	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 002	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 003	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 004	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 005	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
RISPERIDONE - UZEDY						
N 213586 005	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 006	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 007	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RITTLECITINIB TOSYLATE - LITFULO						
N 215830 001	9617258	Dec 03, 2034	DS DP		NCE	Jun 23, 2028
RIZATRIPTAN BENZOATE - RIZAFILM						
N 205394 001	9301948	Jul 30, 2034	DS DP			
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 001					M-285 PED	Dec 19, 2025 Jun 19, 2026
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 002					M-285 PED	Dec 19, 2025 Jun 19, 2026
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 003					M-285 PED	Dec 19, 2025 Jun 19, 2026
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 004					M-285 PED	Dec 19, 2025 Jun 19, 2026
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 005					M-285 PED	Dec 19, 2025 Jun 19, 2026
RUXOLITINIB PHOSPHATE - OPZELURA						
N 215309 001	11510923	Sep 04, 2040	U-3505			
	11571425	May 20, 2031	DP			
	11590136	May 20, 2031	U-3229			
	11590136	May 20, 2031	U-3404			
	11590137	Sep 04, 2040	U-3505			
	11590138	Jun 10, 2040	U-3551			
	11602536	May 05, 2041	U-3550			
SAXAGLIPTIN HYDROCHLORIDE - SAXAGLIPTIN						
A 205941 001					>A> PC	Jan 27, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SAXAGLIPTIN HYDROCHLORIDE - SAXAGLIPTIN</u>						
A 205941 002				>A> PC		Jan 27, 2024
<u>SAXAGLIPTIN HYDROCHLORIDE - SAXAGLIPTIN</u>						
A 205972 001				>A> PC		Jan 27, 2024
<u>SAXAGLIPTIN HYDROCHLORIDE - SAXAGLIPTIN</u>						
A 205972 002				>A> PC		Jan 27, 2024
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	11602522	Sep 04, 2035	DP U-3169			
	11602522	Sep 04, 2035	DP U-3302			
	11684607	Sep 16, 2035	DP U-2583			
	11684607	Sep 16, 2035	DP U-3169			
	11684607	Sep 16, 2035	DP U-3270			
	11684607	Sep 16, 2035	DP U-3302			
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	8999996	Jul 03, 2033	DS DP			
<u>SELINEXOR - XPOVIO</u>						
N 212306 002	8999996	Jul 03, 2033	DS DP			
<u>SELINEXOR - XPOVIO</u>						
N 212306 003	8999996	Jul 03, 2033	DS DP			
<u>SELINEXOR - XPOVIO</u>						
N 212306 004	8999996	Jul 03, 2033	DS DP			
<u>SEPERCATINIB - RETEVMO</u>						
N 213246 001				ODE-409	Sep 21, 2029	
				ODE-412	Sep 21, 2029	
<u>SEPERCATINIB - RETEVMO</u>						
N 213246 002				ODE-409	Sep 21, 2029	
				ODE-412	Sep 21, 2029	
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001	7425637	Mar 13, 2024	DS			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002	7425637	Mar 13, 2024	DS			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001				NPP	Dec 23, 2025	
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002				NPP	Dec 23, 2025	
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003				NPP	Dec 23, 2025	
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004				NPP	Dec 23, 2025	
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005				NPP	Dec 23, 2025	
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793 001				ODE-402	Jun 16, 2029	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845 001					M-287	Jan 31, 2026
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 022473 001					M-287	Jan 31, 2026
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 203109 001					M-287	Jan 31, 2026
<u>SILDENAFIL CITRATE - LIOREV</u>						
N 214952 001	11337979	Dec 24, 2038	DP U-3582			
	11464778	Dec 24, 2038	DP U-3582			
<u>SIROLIMUS - FYARRO</u>						
N 213312 001					ODE-386	Nov 22, 2028
<u>SIROLIMUS - HYFTOR</u>						
N 213478 001					ODE-391	Mar 22, 2029
<u>SODIUM CHLORIDE - SODIUM CHLORIDE 23.4%</u>						
A 217796 001					CGT	Jan 23, 2024
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 001	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	10925844	Feb 28, 2040	DP			
	10952986	Jul 21, 2037	U-3601			
	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP U-3580			
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037	U-3579			
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042	U-3578			
	11602512	Jul 21, 2037	U-3577			
	11602513	Jul 21, 2037	U-3576			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 002	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	10925844	Feb 28, 2040	DP			
	10952986	Jul 21, 2037	U-3601			
	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP U-3580			
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037	U-3579			
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042	U-3578			
	11602512	Jul 21, 2037	U-3577			
	11602513	Jul 21, 2037	U-3576			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 003	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	10925844	Feb 28, 2040	DP			
	10952986	Jul 21, 2037	U-3601			
	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP U-3580			
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037	U-3579			
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042	U-3578			
	11602512	Jul 21, 2037	U-3577			
	11602513	Jul 21, 2037	U-3576			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 003	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	10925844	Feb 28, 2040	DP			
	10952986	Jul 21, 2037		U-3601		
	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP	U-3580		
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037		U-3579		
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042		U-3578		
	11602512	Jul 21, 2037		U-3577		
	11602513	Jul 21, 2037		U-3576		
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 004	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	10925844	Feb 28, 2040	DP			
	10952986	Jul 21, 2037		U-3601		
	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP	U-3580		
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037		U-3579		
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042		U-3578		
	11602512	Jul 21, 2037		U-3577		
	11602513	Jul 21, 2037		U-3576		
<u>SODIUM PHENYLBUTYRATE - OLPRUVA</u>						
N 214860 001	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036		U-3502		
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYLBUTYRATE - OLPRUVA</u>						
N 214860 002	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036		U-3502		
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYLBUTYRATE - OLPRUVA</u>						
N 214860 003	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036		U-3502		
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYLBUTYRATE - OLPRUVA</u>						
N 214860 004	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036		U-3502		
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYLBUTYRATE - OLPRUVA</u>						
N 214860 005	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036		U-3502		
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYLBUTYRATE - OLPRUVA</u>						
N 214860 006	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036		U-3502		
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYLBUTYRATE; TAURURSODIOL - RELYVRIO</u>						
N 216660 001	11583542	Jul 27, 2040	DP		ODE-411	Sep 29, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
SODIUM THIOSULFATE - PEDMARK						
N 212937 001	10596190 11617793	Jan 05, 2038 Jul 01, 2039	U-3443 DP	Y	ODE-384	Sep 20, 2029
SOFOSBUVIR; VELPATASVIR - EPCLUSA						
N 214187 001	>A> 11707479 >A> 11707479*PED	Jan 30, 2034 Jul 30, 2034	DP U-1470			
SOFOSBUVIR; VELPATASVIR - EPCLUSA						
N 214187 002	>A> 11707479 >A> 11707479*PED	Jan 30, 2034 Jul 30, 2034	DP U-1470			
SOLRIAMFETOL HYDROCHLORIDE - SUNOSI						
N 211230 001	11160779 11439597 11560354 11648232 8440715	Mar 19, 2040 Sep 05, 2037 Mar 06, 2039 Jun 01, 2038 Jun 11, 2031	U-3521 DP DP U-3520 U-3602 U-2548			
SOLRIAMFETOL HYDROCHLORIDE - SUNOSI						
N 211230 002	11160779 11439597 11560354 11648232 8440715	Mar 19, 2040 Sep 05, 2037 Mar 06, 2039 Jun 01, 2038 Jun 11, 2031	U-3521 DP DP U-3520 U-3602 U-2548			
SOTAGLIFLOZIN - INPEFA						
N 216203 001	7781577 8217156 8476413	May 04, 2028 Oct 07, 2030 May 29, 2028	DS DP U-3628 DS DP DS DP U-3628		NCE	May 26, 2028
SOTAGLIFLOZIN - INPEFA						
N 216203 002	7781577 8217156 8476413	May 04, 2028 Oct 07, 2030 May 29, 2028	DS DP U-3628 DS DP DS DP U-3628		NCE	May 26, 2028
SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE						
N 022306 001	10512620 10512620 10799138 10799138 11583216 11696902	Aug 14, 2038 Aug 14, 2038 Apr 05, 2039 Apr 05, 2039 Aug 21, 2039 Aug 14, 2038	U-2769 U-3547 U-3125 U-3549 U-3549 U-2769			
SOTORASIB - LUMAKRAS						
N 214665 001	11426404	Sep 15, 2040	U-3306			
SOTORASIB - LUMAKRAS						
N 214665 002	10519146 11236091 11426404	May 21, 2038 May 20, 2040 Sep 15, 2040	DS DP DS DP U-3306 U-3306		NCE ODE-352	May 28, 2026 May 28, 2028
SPARENTEAN - FILSPARI						
N 216403 001	9993461	Mar 29, 2030	U-3269		NCE ODE-389	Feb 17, 2028 Feb 17, 2030
SPARENTEAN - FILSPARI						
N 216403 002	9993461	Mar 29, 2030	U-3269		NCE ODE-389	Feb 17, 2028 Feb 17, 2030
STIRIPENTOL - DIACOMIT						
N 206709 001					ODE-403	Jul 14, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>STIRIPENTOL - DIACOMIT</u>						
N 206709 002					ODE-403	Jul 14, 2029
<u>STIRIPENTOL - DIACOMIT</u>						
N 207223 001					ODE-403	Jul 14, 2029
<u>STIRIPENTOL - DIACOMIT</u>						
N 207223 002					ODE-403	Jul 14, 2029
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128 001	11672738	Feb 02, 2038	DP			
	11676691	Mar 16, 2030	DP			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001					M-291	Jan 22, 2024
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002					M-291	Jan 22, 2024
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001	>A> 11723869	May 15, 2039	DP U-3666			
	>A> 11723869	May 15, 2039	DP U-3667			
	>A> 11723869	May 15, 2039	DP U-3668			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	11571531	Feb 23, 2026	U-1809			
<u>TADALAFIL - TADLIO</u>						
N 214522 001	11666576	Dec 24, 2038	DP U-3397			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 001	10780088	Jul 27, 2029	U-3651		>A> I-920	Jun 20, 2026
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 003	10780088	Jul 27, 2029	U-3651		>A> I-920	Jun 20, 2026
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 005	10189837	Oct 20, 2031	DS DP		>A> I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651		NCE	Oct 16, 2023
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 006	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 001					NPP	Jul 03, 2026
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 002					NPP	Jul 03, 2026
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 003					NPP	Jul 03, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTadol HYDROCHLORIDE - NUCYNTA</u>						
N 203794 001					NPP	Jul 03, 2026
<u>TAPINAROF - VTAMA</u>						
N 215272 001	11590088	Nov 13, 2039		U-2625		
	11597692	Nov 13, 2038	DS DP			
	11612573	May 19, 2036		U-2625		
	11617724	May 19, 2036		DP		
	11622945	May 19, 2036		DP		
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	11566011	Feb 12, 2035	DS DP			
	11633377	Jan 25, 2033		U-2149		
	11633377	Jan 25, 2033		U-3003		
<u>TASIMELTEON - HETLIOZ LO</u>						
N 214517 001	11566011	Feb 12, 2035	DS DP			
	11633377	Jan 25, 2033		U-3003		
<u>TAZAROTENE - ARAZLO</u>						
N 211882 001	11679116	Jun 06, 2036		DP		
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	8410088	Jan 23, 2034	DS DP			
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209549 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209549 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209601 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209601 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209613 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209613 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209638 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209638 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209663 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209663 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209668 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209668 002					PC	Sep 08, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209690 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209690 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209700 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209700 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209710 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209710 002					PC	Sep 08, 2023
<u>TERLIPRESSIN ACETATE - TERLIVAZ</u>						
N 022231 001					ODE-406	Sep 14, 2029
<u>TESTOSTERONE CYPIONATE - TESTOSTERONE CYPIONATE</u>						
N 216318 001	11642355	Mar 25, 2039		DP		
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	11564933	Apr 12, 2039		U-1103		
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	11564933	Apr 12, 2039		U-1103		
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	11564933	Apr 12, 2039		U-1103		
<u>TESTOSTERONE UNDECANOATE - TLANDO</u>						
N 208088 001	11559530	Nov 28, 2037		U-1500		
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u>						
N 213953 001	11590146	Dec 31, 2030		DP		
	11617758	Mar 15, 2033		DP U-2506		
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u>						
N 213953 002	11590146	Dec 31, 2030		DP		
	11617758	Mar 15, 2033		DP U-2506		
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u>						
N 213953 003	11590146	Dec 31, 2030		DP		
	11617758	Mar 15, 2033		DP U-2506		
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	>A> 10456399	Feb 03, 2037		U-3657		
	>A> 10456399	Feb 03, 2037		U-3658		
	>A> 10960004	Feb 03, 2037		U-3657		
	>A> 10960004	Feb 03, 2037		U-3658		
	9943537	Sep 05, 2034		U-3659		
	>A> RE46284	Sep 22, 2029		U-1751		
	>A> RE46284	Sep 22, 2029		U-2503		
	>A> RE46284	Sep 22, 2029		U-3656		
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	>A> 10456399	Feb 03, 2037		U-3657		
	>A> 10456399	Feb 03, 2037		U-3658		
	>A> 10960004	Feb 03, 2037		U-3657		
	>A> 10960004	Feb 03, 2037		U-3658		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF						
N 207981 002	9943537	Sep 05, 2034	U-3659			
>A>	RE46284	Sep 22, 2029	U-1751			
>A>	RE46284	Sep 22, 2029	U-2503			
>A>	RE46284	Sep 22, 2029	U-3656			
TIVOZANIB HYDROCHLORIDE - FOTIVDA						
N 212904 001	6821987	Apr 26, 2024	DS DP U-3100			
TIVOZANIB HYDROCHLORIDE - FOTIVDA						
N 212904 002	6821987	Apr 26, 2024	DS DP U-3100			
TOFERSEN - QALSYDY						
N 215887 001	10385341	Apr 01, 2035	DS DP		NCE	Apr 25, 2028
	10669546	Apr 01, 2035	U-3575		ODE-432	Apr 25, 2030
	10968453	Apr 01, 2035	U-3575			
TOPIRAMATE - EPRONTIA						
N 214679 001	11633374	Aug 21, 2040	DP			
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 001	10869869	Aug 30, 2033	U-3184		I-895	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	7378423*PED	Nov 29, 2027			ODE-182	Apr 30, 2025
	8580304	Jan 28, 2032	DP		ODE-183	May 04, 2025
	8580304*PED	Jul 28, 2032			ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP U-1712		PED	Dec 22, 2024
	8703781	Oct 15, 2030	DS DP U-2020		PED	Oct 30, 2025
	8703781	Oct 15, 2030	DS DP U-2037		PED	Nov 04, 2025
	8703781	Oct 15, 2030	DS DP U-2302		PED	Dec 22, 2025
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 002	10869869	Aug 30, 2033	U-3184		I-895	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	7378423*PED	Nov 29, 2027			ODE-182	Apr 30, 2025
	8580304	Jan 28, 2032	DP		ODE-183	May 04, 2025
	8580304*PED	Jul 28, 2032			ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP U-1712		PED	Dec 22, 2024
	8703781	Oct 15, 2030	DS DP U-2020		PED	Oct 30, 2025
	8703781	Oct 15, 2030	DS DP U-2037		PED	Nov 04, 2025
	8703781	Oct 15, 2030	DS DP U-2302		PED	Dec 22, 2025
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	8835443	Jun 10, 2025	U-2305			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	10869869	Aug 30, 2033	U-3184		I-895	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	7378423*PED	Nov 29, 2027			ODE-182	Apr 30, 2025
	8580304	Jan 28, 2032	DP		ODE-183	May 04, 2025
	8580304*PED	Jul 28, 2032			ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP U-1712		PED	Dec 22, 2024
	8703781	Oct 15, 2030	DS DP U-2020		PED	Oct 30, 2025
	8703781	Oct 15, 2030	DS DP U-2037		PED	Nov 04, 2025
	8703781	Oct 15, 2030	DS DP U-2302		PED	Dec 22, 2025
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 217513 001	7378423	May 29, 2027	DS DP		NP	Mar 16, 2026
	8703781	Oct 15, 2030	DS DP U-3564		ODE-428	Mar 16, 2030
	8835443	Jun 10, 2025	U-3564			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001 >A> 11723887		Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002 >A> 11723887		Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003 >A> 11723887		Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004 >A> 11723887		Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 005 >A> 11723887		Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001 >A> 11723887		Dec 15, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 001 >A> 11723887		Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 002 >A> 11723887		Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 003 >A> 11723887		Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 004 >A> 11723887		Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001 >A> 11723887		Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002 >A> 11723887		Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003 >A> 11723887		Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004 >A> 11723887		Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005 >A> 11723887		Dec 15, 2028	DS			
<u>TRIENTINE TETRAHYDROCHLORIDE - CUVRIOR</u>						
N 215760 001					ODE-401	Apr 28, 2029
<u>TRIFAROTENE - AKLIEF</u>						
N 211527 001	7807708	Jul 19, 2031	DS DP			
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	11529352	Jul 23, 2039	U-3504			
>A> 11717523		Mar 14, 2034	U-3678			
>A> 11717523		Mar 14, 2034	U-3679			
<u>TROFINETIDE - DAYBUE</u>						
N 217026 001	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	9212204	Jan 27, 2032	U-3556		ODE-425	Mar 10, 2030
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	11207324	Apr 27, 2038	U-3510		I-906	Jan 19, 2026
					ODE-422	Jan 19, 2030
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	11207324	Apr 27, 2038	U-3510		I-906	Jan 19, 2026
					ODE-422	Jan 19, 2030
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	11524964	Oct 17, 2036	U-3371		I-919	May 18, 2026
	11535624	Oct 17, 2036	U-3255			
	11535625	Oct 17, 2036	U-3298			
	11564922	Mar 09, 2038	U-3624			
	11607411	Mar 09, 2038	U-3341			
	11661425	Oct 17, 2036	DS DP			
	11680069	Oct 17, 2036	DS DP			
>A> 11718627		Oct 17, 2036	DS DP			
	8962629	Jan 15, 2031	DS	U-3255		
	8962629	Jan 15, 2031	DS	U-3275		
	8962629	Jan 15, 2031	DS	U-3341		
	8962629	Jan 15, 2031	DS	U-3371		
	8962629	Jan 15, 2031	DS	U-3624		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	11524964	Oct 17, 2036	U-3371		I-919	May 18, 2026
	11535624	Oct 17, 2036	U-3255			
	11535625	Oct 17, 2036	U-3298			
	11564922	Mar 09, 2038	U-3624			
	11607411	Mar 09, 2038	U-3341			
	11661425	Oct 17, 2036	DS DP			
	11680069	Oct 17, 2036	DS DP			
>A>	11718627	Oct 17, 2036	DS DP			
	8962629	Jan 15, 2031	DS U-3255			
	8962629	Jan 15, 2031	DS U-3275			
	8962629	Jan 15, 2031	DS U-3341			
	8962629	Jan 15, 2031	DS U-3371			
	8962629	Jan 15, 2031	DS U-3624			
<u>UPADACITINIB - RINVOO</u>						
N 211675 002	11535626	Oct 17, 2036	U-3298		I-919	May 18, 2026
>A>	11564922	Mar 09, 2038	U-3624			
>A>	11607411	Mar 09, 2038	U-3341			
	11661425	Oct 17, 2036	DS DP			
	11680069	Oct 17, 2036	DS DP			
>A>	11718627	Oct 17, 2036	DS DP			
	8962629	Jan 15, 2031	DS U-3341			
	8962629	Jan 15, 2031	DS U-3624			
<u>UPADACITINIB - RINVOO</u>						
N 211675 003	11564922	Mar 09, 2038	U-3624		I-919	May 18, 2026
	11607411	Mar 09, 2038	U-3341			
	11661425	Oct 17, 2036	DS DP			
	11680069	Oct 17, 2036	DS DP			
>A>	11718627	Oct 17, 2036	DS DP			
	8962629	Jan 15, 2031	DS U-3341			
	8962629	Jan 15, 2031	DS U-3624			
<u>VANCOMYCIN - VANCOMYCIN</u>						
N 213895 001	11517609	Nov 06, 2035	U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
A 215338 001					CGT	Dec 20, 2023
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
A 217489 001				>A>	CGT	Feb 12, 2024
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
A 217489 002				>A>	CGT	Feb 12, 2024
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 001	11638692	Mar 13, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 002	11638692	Mar 13, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 001	11628200	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 002	11628200	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 003	11628200	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 004	11628200	Nov 06, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 005	11628200	Nov 06, 2035		DP		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 006	11628200	Nov 06, 2035		DP		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 007	11628200	Nov 06, 2035		DP		
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 006	10010575	Jan 30, 2035		U-1857		
	9919026	Jan 30, 2035		DP		
	9925233	Jan 30, 2035		U-1857		
	9925234	Jan 30, 2035		U-1857		
	9962422	Jan 30, 2035		U-1857		
	9968649	Jan 30, 2035		U-1857		
	9974827	Jan 30, 2035		U-1857		
	9981006	Jan 30, 2035		U-1857		
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	11590128	Sep 06, 2033		U-3548		
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	11590128	Sep 06, 2033		U-3548		
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	11590128	Sep 06, 2033		U-3548		
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	11622991	Dec 07, 2037		U-3056		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	>A> 11458134	Jun 15, 2027		DP U-3463		
	>A> 11458134*PED	Dec 15, 2027				
	>A> 7144884	Jun 17, 2026	DS	DP U-1439		
	>A> 7144884*PED	Dec 17, 2026				
	>A> 8722684	Jun 30, 2031	DS	DP		
	>A> 8722684*PED	Dec 30, 2031				
	>A> 8969355	Jun 15, 2027		U-1668		
	>A> 8969355*PED	Dec 15, 2027				
	>A> 9125908	Jun 15, 2027		U-2309		
	>A> 9125908*PED	Dec 15, 2027				
	>A> 9125909	Jun 15, 2027		U-2309		
	>A> 9125909*PED	Dec 15, 2027				
	>A> 9125910	Jun 15, 2027		U-2309		
	>A> 9125910*PED	Dec 15, 2027				
	>A> 9227946	Jun 15, 2027		U-1668		
	>A> 9227946*PED	Dec 15, 2027				
	>A> 9278096	Mar 21, 2032		U-2436		
	>A> 9278096*PED	Sep 21, 2032				
	>A> 9861630	Jun 15, 2027		U-1668		
	>A> 9861630*PED	Dec 15, 2027				
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	>A> 11458134	Jun 15, 2027		DP U-3463		
	>A> 11458134*PED	Dec 15, 2027				
	>A> 7144884	Jun 17, 2026	DS	DP U-1439		
	>A> 7144884*PED	Dec 17, 2026				
	>A> 8722684	Jun 30, 2031	DS	DP		
	>A> 8722684*PED	Dec 30, 2031				
	>A> 8969355	Jun 15, 2027		U-1668		
	>A> 8969355*PED	Dec 15, 2027				
	>A> 9125908	Jun 15, 2027		U-2309		
	>A> 9125908*PED	Dec 15, 2027				
	>A> 9125909	Jun 15, 2027		U-2309		
	>A> 9125909*PED	Dec 15, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	>A> 9125910	Jun 15, 2027		U-2309		
	>A> 9125910*PED	Dec 15, 2027				
	>A> 9227946	Jun 15, 2027		U-1668		
	>A> 9227946*PED	Dec 15, 2027				
	>A> 9278096	Mar 21, 2032		U-2436		
	>A> 9278096*PED	Sep 21, 2032				
	>A> 9861630	Jun 15, 2027		U-1668		
	>A> 9861630*PED	Dec 15, 2027				
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	>A> 11458134	Jun 15, 2027	DP	U-3463		
	>A> 11458134*PED	Dec 15, 2027				
	>A> 7144884	Jun 17, 2026	DS	DP U-1439		
	>A> 7144884*PED	Dec 17, 2026				
	>A> 8722684	Jun 30, 2031	DS	DP		
	>A> 8722684*PED	Dec 30, 2031				
	>A> 8969355	Jun 15, 2027		U-1668		
	>A> 8969355*PED	Dec 15, 2027				
	>A> 9125908	Jun 15, 2027		U-2309		
	>A> 9125908*PED	Dec 15, 2027				
	>A> 9125909	Jun 15, 2027		U-2309		
	>A> 9125909*PED	Dec 15, 2027				
	>A> 9125910	Jun 15, 2027		U-2309		
	>A> 9125910*PED	Dec 15, 2027				
	>A> 9227946	Jun 15, 2027		U-1668		
	>A> 9227946*PED	Dec 15, 2027				
	>A> 9278096	Mar 21, 2032		U-2436		
	>A> 9278096*PED	Sep 21, 2032				
	>A> 9861630	Jun 15, 2027		U-1668		
	>A> 9861630*PED	Dec 15, 2027				
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	>A> 11458134	Jun 15, 2027	DP	U-3463		
	>A> 11458134*PED	Dec 15, 2027				
	>A> 7144884	Jun 17, 2026	DS	DP U-1439		
	>A> 7144884*PED	Dec 17, 2026				
	>A> 8722684	Jun 30, 2031	DS	DP		
	>A> 8722684*PED	Dec 30, 2031				
	>A> 8969355	Jun 15, 2027		U-1668		
	>A> 8969355*PED	Dec 15, 2027				
	>A> 9125908	Jun 15, 2027		U-2309		
	>A> 9125908*PED	Dec 15, 2027				
	>A> 9125909	Jun 15, 2027		U-2309		
	>A> 9125909*PED	Dec 15, 2027				
	>A> 9125910	Jun 15, 2027		U-2309		
	>A> 9125910*PED	Dec 15, 2027				
	>A> 9227946	Jun 15, 2027		U-1668		
	>A> 9227946*PED	Dec 15, 2027				
	>A> 9278096	Mar 21, 2032		U-2436		
	>A> 9278096*PED	Sep 21, 2032				
	>A> 9861630	Jun 15, 2027		U-1668		
	>A> 9861630*PED	Dec 15, 2027				
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001					ODE-387	Nov 19, 2028
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002					ODE-387	Nov 19, 2028
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003					ODE-387	Nov 19, 2028
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001					ODE-394	Dec 17, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 002					ODE-394	Dec 17, 2028
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001					ODE-394	Dec 17, 2028
<u>VUTRISIRAN SODIUM - AMVUTTRA</u>						
N 215515 001					ODE-212	Jun 13, 2029
<u>XENON XE-129 HYPERPOLARIZED - XENOVIEW</u>						
N 214375 001	10583205	Feb 20, 2035	DP		NCE	Dec 23, 2027
	11052161	Dec 29, 2035	DP			
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10570139	Apr 22, 2034	U-1745		I-817	Jan 19, 2026
	10570139	Apr 22, 2034	U-2145		ODE-274	Jan 19, 2030
	10570139	Apr 22, 2034	U-2537			
	10570139	Apr 22, 2034	U-2666			
	10570139	Apr 22, 2034	U-3063			
	10570139	Apr 22, 2034	U-3486			
	11142528	Apr 22, 2034	DP U-1745			
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-2537			
	11142528	Apr 22, 2034	DP U-2666			
	11142528	Apr 22, 2034	DP U-3063			
	11142528	Apr 22, 2034	DP U-3486			
	11591340	Aug 15, 2037	U-1745			
	11591340	Aug 15, 2037	U-2145			
	11591340	Aug 15, 2037	U-2537			
	11591340	Aug 15, 2037	U-2666			
	11591340	Aug 15, 2037	U-3063			
	11591340	Aug 15, 2037	U-3486			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-2537			
	9447106	Apr 22, 2034	DS DP U-2666			
	9447106	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-3486			
<u>ZAVEGEPANT HYDROCHLORIDE - ZAVZPRET</u>						
N 216386 001	7220862	Jan 21, 2024	DS DP		NCE	Mar 09, 2028
	7314883	Dec 05, 2023		U-3555		
	8481546	Oct 07, 2031	DS DP	U-3555		
<u>ZINC SULFATE - ZINC SULFATE</u>						
A 216145 001					CGT	Aug 14, 2023

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 43rd Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm